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Introduction
Abstract
Judith Strobl:
Use of Databases for Drug Effectiveness Studies
Background:
Health policy decisions need to be based on effectiveness estimates of interventions which are 
representative of normal clinical practice, in order to determine their likely impact on 
outcomes and costs in real life. Clinical or claims databases may provide a potential source of 
relevant unselected data for research. However, effectiveness studies based on such 
databases experience threats to internal and external validity.
This thesis draws methodological lessons from an attempted effectiveness study of dornase 
alfa for cystic fibrosis, and expands those with a subsequent comprehensive review of 
comparable published database studies in order to describe current practice and identify 
useful approaches. Case study comparisons of observational database effectiveness studies 
with randomised controlled trials seek to add to our knowledge on the comparability of these 
two study types and their contribution to an evidence base.
Aims:
1. Describe in depth the process of and lessons from conducting a drug effectiveness case 
study using an existing database (the Dornase Alfa Case Study);
2. Review comparable published studies and explore the features relevant to their
internal and external validity;
3. Assess whether drug “Effectiveness Studies based on Databases” (ESDs) show
comparable results to those of RCTs when selection criteria are the same and when
baseline differences in ESDs have been adjusted for.
Main findings and conclusions:
The internal validity of ESDs depends on the valid and reliable measurement and reporting of 
key variables. The Dornase Alfa Case Study encountered many practical as well as 
methodological pitfalls. There were significant variations in clinical and recording practices 
between centres. A detailed data validation exercise highlighted considerable data quality 
problems relating to key outcome variables (exacerbations and deaths). The sample was too 
small and the data too imbalanced in terms of enrolment and follow-up to be able to subject 
them to further multivariate analysis.
The potential strengths of ESDs include greater generalisability, better representativeness of 
the target population, and a more naturalistic setting. The review of published ESDs showed 
that these strengths have seldom been demonstrated or exploited in published reports, and 
hypotheses are not always clearly stated. Also, existing drug ESDs tend not to report issues of 
data access, management, or quality, and many do not comment on data protection and 
ethical issues. Significant publication bias is likely. Thus, even ESDs published in high-quality 
journals fall considerably short of expected quality standards.
Four case study comparisons of drug ESDs and RCTs were hampered because key study 
characteristics differed between study types. There was no indication that ESDs 
systematically over-estimated effects compared to RCTs, but different biases left scope for 
diverging results. Robust implemention of now available guidance on the conduct of ESDs, and 
of the recommendations arisng from this thesis, as well as further methodological research are 
vital before ESDs can be more confidently used for effectiveness evidence.
20 Use of Databases for Drug Effectiveness Studies
Introduction
1 Introduction
Use of Databases for Drug Effectiveness Studies 21
Introduction
The assessment of the effectiveness of health care interventions relies heavily 
on evidence generated through randomised controlled trials (RCTs). Over 
recent years, the values and shortcomings of randomised and non-randomised 
studies have been debated (Peto et ai. 1995; Black 1996; Anonymous 2000c; 
Collins & MacMahon 2001), and methodological research, including several 
systematic reviews comparing both types of study designs, has been published 
(Gray-Donald 6 Kramer 1988; Britton et al. 1998; Kunz & Oxman 1998; Benson 
Et Hartz 2000; Concato et ai. 2000; MacLehose et ai. 2000; loannidis et al. 
2001).
A random allocation of treatment ensures that treated and untreated patients 
in sufficient numbers are likely to be very similar in all characteristics other 
than the treatment intervention. Thus randomisation permits the assumption 
that any observed differences in measured outcomes are principally due to the 
intervention, as long as the study is properly blinded and measurements are 
rigorous (Britton et al. 1998). It is generally held that alternative study 
designs without randomisation (such as cohort, case-control, cross-sectional 
studies, or non-randomised trials) cannot provide the same degree of 
assurance in the observed effectiveness results, because any known or 
unknown differences between patient groups at baseline may influence the 
observed outcomes.
On the other hand, the validity of randomised studies may also be limited, for 
example, if blinding of patients and assessors is insufficient or indeed not 
possible. Randomised studies may be unrepresentative of patient groups not 
included in such studies. They are also not always possible or practical (Black 
1996). The artificial research conditions imposed by a typical randomised trial 
are unrepresentative of normal clinical practice and care, which has 
implications for the generalisability of trial results to a wider population. 
Nevertheless, whereas the advantages of randomisation over no randomisation
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are not disputed, the value of non-randomised studies particularly in 
effectiveness research is hotly debated. Recent reviews showed no clear 
indication that such studies systematically over-estimate the effects of 
treatments.
A particular type of non-randomised study, namely those using routinely 
collected data to evaluate treatments (“ Effectiveness Studies using 
Databases” , from hereon abbreviated to “ ESDs” ), is increasingly used to 
“ complement or supplement^ (Lewsey et aL 2000 p.1) RCTs. This may be 
used where there is no RCT evidence, because either an RCT would be 
unsuitable or has not yet been undertaken (to aid the design of a future RCT), 
or to assess whether the findings from an RCT can be translated into clinical 
practice. The ready availability of routinely collected data sources, their 
large and increasing size and comparatively low cost, as well as the 
availability of increasingly sophisticated analysis methods, make such ESDs 
attractive as alternatives to RCTs. In addition, ESDs may be considered to 
have higher external validity than RCTs (GAO 1992). However, the criticisms 
levelled against non-randomised studies still apply, and data quality and 
applicability pose additional problems, although these may not be 
insurmountable. The value of ESDs as a sub-type of non-randomised studies 
therefore requires further assessment.
The increasing computerisation of healthcare records encourages a wider 
interest in the use of databases in effectiveness research. This would have 
the advantage that effectiveness studies could be based on clinical realities, 
rather than settings which are constrained and distorted by research- 
conditions. Importantly also, the range and nature of researchable 
effectiveness questions could expand towards more population health relevant 
questions. Current evidence - particularly in the pharmaceutical field - is 
dominated by efficacy questions formulated and investigated by primarily 
industry-funded RCTs.
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There is some guidance on conducting and reporting ESDs (Huston & Naylor
1996; Motheral & Fairman 1997, and more recently von Elm et al. 2007,
Gliklich fit Dreyer 2007, and Berger et al. 2008); however, there is a lack of in- 
depth accounts of the experiences of undertaking such studies, as well as of 
systematic reviews of such studies. This thesis explores the potential value 
and methodological strengths and weaknesses of drug ESDs, by reporting the 
in-depth experiences gathered during an attempted ESD, as well as a 
comprehensive review of ESDs. The importance of this work is underlined by 
the fact that there is increasing interest in such studies (Rawlins 2008) and the 
opportunities presented by pre-existing data are rapidly growing - as is the
temptation by clinicians and researchers to use pre-existing data for
effectiveness studies. Existing reviews include only very few, if  any, drug 
ESDs, and there has so far not been a review dedicated to these studies.
The aims of the thesis are as follows:
1. Describe in depth the process of and lessons from conducting a drug 
effectiveness case study using an existing database (the Dornase Alfa 
Case Study);
2. Review comparable published studies and explore the features relevant 
to their internal and external validity;
3. Assess whether drug “ Effectiveness Studies based on Databases” (ESDs) 
show comparable results to those of RCTs when selection criteria are 
the same and when baseline differences in ESDs have been adjusted for.
The work began in 1999 with the intention to evaluate the long-term cost- 
effectiveness of dornase alfa for cystic fibrosis (CF). Dornase alfa is 
recombinant human deoxyribonuclease (rhDNase), a genetically engineered 
version of a human enzyme which cleaves extra cellular deoxyribonuclease 
(DNA). The drug is administered by inhalation and cleaves DNA in the sputum,
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thereby reducing its viscoelasticity. Clearing the lungs of the viscous sputum 
(usually through physiotherapy) is one of the most important interventions in 
CF, and dornase alfa is intended to facilitate that process.
At the planning stage for this study, there was evidence for the short-term 
effectiveness of the drug from randomised controlled trials (RCTs) of up to six 
months, but the long-term effectiveness, and particularly cost-effectiveness, 
was under question. Many patients were already using the drug, but clinicians 
still fe lt uncertain about the continued benefit of one of the most expensive 
elements of their treatment regimen.
Given that most eligible patients had already at least tried dornase alfa 
treatment, future long-term RCTs are prohibitively difficult to initiate in a 
patient population no longer naïve to the drug. Any potential RCT would have 
to recruit from a small number of newly diagnosed patients meeting certain 
eligibility criteria. The loss of equipoise would have been a further reason not 
to initiate another RCT. It was therefore decided to analyse a subset of data 
from a large post-marketing surveillance database, the Epidemiologic Registry 
of CF (ERCF), in an attempt to shed light on the long-term effectiveness of 
dornase alfa.
In this thesis, I describe the practical experiences of conducting this study in 
detail. At an early stage, the consideration of then recent UK data protection 
legislation and guidance posed an unexpected challenge. The process of 
reaching decisions on access to the secondary data source, and the conflicting 
guidance and legislation which were available at the time to inform these 
decisions, are discussed. Based on this experience, I highlighted the 
problematic implications of the Data Protection Act for medical research in an 
article in the British Medical Journal (Strobl et al. 2000 - see Appendix A). 
Secondly, the study incorporated a verification of database records against 
original patient records in order to assess data quality. This represents the
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only direct (and published) verification of data from the ERCF (see Appendix A 
for a copy of the peer-reviewed publication (Strobl et al. 2003)). Thirdly, an 
attempt to establish the generalisability of the study is described, and finally 
the data and initial analyses and analytical challenges are presented and 
discussed.
The dornase alfa study ran into significant difficulties, not only from a point of 
view of access to records and data. The detailed considerations of the quality 
of the available data highlighted more methodological problems in relation to 
the set up and operation of databases, as well as the use of data derived from 
them. This resulted in the desire to examine how, if at all, other investigators 
have managed these problems and what can be learnt from that.
I therefore undertook a comprehensive review of other published drug 
effectiveness studies based on databases with the intention to examine and 
describe these studies, their data sources, design, objectives, funding, 
outcomes, methods, and results, in order to identify design-specific problems 
and possible solutions. This is the first review focussed on drug effectiveness 
studies based on databases and its findings are reported here in detail.
Of the ESDs identified in this review, four lent themselves to direct 
comparisons with RCTs which have addressed the same question. Other 
investigators have reported systematic comparisons of RCTs and observational 
study designs, but a systematic approach to such reviews is hampered not 
least by the comparatively poorer bibliographic indexing of observational 
studies compared to RCTs. This thesis adds four case studies specifically on 
ESDs of drug treatments to this body of knowledge. The case studies were 
selected on the basis of the availability of a Cochrane review having assessed 
the same question. Study quality was assessed for both ESDs and RCTs, and 
studies were described in detail before comparisons of results were 
attempted.
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The thesis begins with a detailed review of relevant literature on health 
technology assessment methods, focusing on RCTs and ESDs (Chapter 2). Much 
of the empirical work reported in this thesis is exploratory. Both the Dornase 
Alfa Case Study (Chapters 3-5), as well as the review (Chapters 6) and 
comparison case studies (Chapter 7) are used to gather insights into the use of 
ESDs, their intentions, problems, and the value which they may add to a body 
of effectiveness evidence. Chapters 8 and 9 bring together the findings from 
these pieces of work and draw out specific lessons for ESD as well as database 
design, and further areas in need of research. The temptation to use database 
studies as alternatives to resource-intensive RCTs which ultimately may not be 
sufficiently generalisable is persistent, as recent debates indicate (Rawlins 
2008). This thesis aims to contribute to and further inform this debate.
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2 Literature Review
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2.1 Introduction
This chapter provides the context of existing knowledge for the thesis. The 
relevant fields are charted out, beginning with health technology assessment 
(HTA) methods, with a particular focus on RCTs and ESDs. It presents a 
critical review of RCTs as a gold standard for effectiveness evaluations, as well 
as methodological developments which have moved beyond RCTs, in an 
attempt to cope with their limitations. In later sections, I review the state of 
the debate about the value of non-randomised studies for effectiveness 
research, of which ESDs are an example.
As is customary in multi-topic literature reviews preceding research reports, 
this chapter organises the material in a “ funnel” approach. Hence, it takes 
the reader from the general to the specific, from health technology 
assessment in general to the specific open question about the value of ESDs 
for effectiveness evidence. The identification of relevant literature 
consequently varied for the different sub-sections of this chapter. Earlier 
sections are mostly narrative, based on standard texts. The subsequent 
sections on critiquing RCTs and methodological developments beyond RCTs 
include increasingly more methodological research and discussion papers 
identified through a range of Medline searches as well as through “ snow­
balling” (i.e. texts identified by other authors). The intention is to provide a 
critical narrative and not necessarily a comprehensive systematic review. 
Similarly, section 2.5 (Effectiveness studies using databases) aims to be 
descriptive and illustrative and therefore again uses a limited range of 
methodological texts. Section 2.6 on previously published systematic 
comparisons of randomised and non-randomised studies is the most 
comprehensive and the search strategy is described there.
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2.2 Health Technology Assessment
2.3 Critique of RCTs
2.4 Developments beyond RCTs
2.5 Effectiveness studies using databases
2.6 Published systematic comparisons of randomised and non-randomised
studies
2.7 Comparisons between RCTs and ESDs
2.8 Summary
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2.2 Health Technology Assessment (HTA)
This section provides the reader with a brief introduction to Health 
Technology Assessment and describes the study designs used for determining 
treatment effect. This section does not lend itself to a systematic review and 
therefore uses a traditional narrative style. Methodological texts referred to 
are to a large extent standard textbooks.
The UK HTA Programme defines a health technology as follows:
“Health Technology Assessment asks important questions about [health] 
technologies such as:
• When is counselling better than drug treatment fo r depression?
• What is the best operation fo r aortic aneurysms?
• Should we screen fo r human papilloma virus when doing cervical 
smears?
• Should aspirin be used fo r the primary prevention o f cardiovascular 
disease?
It answers these questions by investigating four main factors:
• whether the technology works
• fo r whom
• at what cost
• how i t  compares with alternatives”
(National Coordinating Centre for Health Technology Assessment 2009)
HTA thus includes the assessment of clinical effects, as well as economic 
evaluations and other non-clinical assessments of, for example, legal, ethical, 
and social implications of health technologies. For the last group, a large 
array of study methods may be appropriate, including qualitative interviewing
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or observational methods (Mowatt et al. 1997). Thus, HTA - like many areas of 
health-related research - is a field where fundamentally different scientific 
paradigms meet (chiefly the positivistic paradigm of the natural sciences, and 
the ethnographic and anthropological tradition of social sciences) and are 
challenged to integrate conceptually and practically their respective 
methodological tools. Similarly, the use of epidemiological methods and study 
designs in HTA is an issue of ongoing debate and development.
2.2.1 “Effectiveness”
It is noteworthy that the UK HTA Programme speaks of “ effectiveness” rather 
than “efficacy” (National Institute for Health Research 2009). Thus, HTA is 
concerned with whether an intervention is effective in practice 
(“ effectiveness” ), rather than the mere potential of an intervention to be 
effective (“efficacy” ). The efficacy of a treatment concerns its ability to 
improve or cure certain conditions under optimal conditions (rather than cause 
harm). By contrast, the effectiveness of an intervention concerns its actual 
effect on patients using or being offered it  under real life conditions. Thus 
effectiveness also considers broader aspects of use in practice, such as the 
acceptance of the treatment, including compliance (Drummond et al. 1997). 
Related issues of interest to health service planners are access to and 
availability of the treatment for those patients who are able to benefit from 
it.
The United States General Accounting Office (GAO 1992) has described three 
dimensions of the “effectiveness domain” : various types of patients and forms 
of the disease, varying implementations of the treatment in question, and 
varying outcome criteria. The effectiveness of any treatment thus depends on 
all these three dimensions, whereby for many treatments, the size of the 
effectiveness domain is not known. Thus if  a study evaluates a treatment in a
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particular respondent group in a particular way, it  may be unknown how 
effective the treatment is in other groups or under different conditions.
Effectiveness information may feed into the evaluation of efficiency, or 
economic evaluation, of health interventions. Such evaluations address the 
relative value of interventions, i.e. the question of whether they are worth 
doing compared to other options. The evaluation of different aspects of 
effectiveness should ideally precede any economic evaluations (Drummond et 
al. 1997). In reality, health economists often draw on a number of studies of 
different design, using their results to model decision options because of many 
uncertainties.
2.2.2 Study designs for determining effects of treatments
The focus of this thesis is on research designs relevant to the assessment of 
the clinical effects of health technologies. It is recognized, however, that 
qualitative and other social research methods can directly inform 
effectiveness evaluations, for example by exploring aspects of medication use 
in practice (e.g. dissemination of new technologies, their acceptability to 
practitioners and patients, patients’ motivation to seek or comply with a 
particular treatment). Before considering the main designs for estimating 
treatment effects, two important concepts need to be introduced, by which 
the adequacy of a research design can be assessed: internal and external 
validity.
2.2.2.1 Internal and external validity
Internal validity of a study is attained if  the change in the dependent 
variable(s) can be said to arise from only the effect of the independent 
variable of interest (Polit fit Hungler 1991). The intention of a study's analysis 
is to demonstrate that an observed association between independent and 
dependent variables is not due to either chance, systematic error (“ bias” ), or
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confounding, i.e. an association of any factor with both the independent and 
dependent variables (Hennekens & Buring 1987).
A range of possible biases may threaten internal validity and can influence 
study results in both directions (Elwood 1998). Testing and instrumentation 
effects can be a problem in any before-after study, e.g. if patients are 
sensitised or there are learning effects. Selection bias is a serious possibility 
where study subjects in the comparison groups differ in significant factors. In 
epidemiological studies in particular, recall and observation bias may play a 
role, where the recall by patients of significant information or the observation 
methods applied differ between comparison groups (Hennekens & Buring 
1987). A further problem may be the misclassification of exposure or 
outcomes through inaccuracies in data collection.
Confounding - and to some extent selection bias - can be controlled through 
either study design or analysis by stratification, restriction of the sample, 
matching, randomisation, or multivariate analysis (Hennekens & Buring 1987; 
Rothman & Greenland 1998). Of course, this is only possible where the 
confounding variable(s) are known and measured. Observation bias may be 
controlled by the blinding of patients and observers, if  that is possible. Biases 
are difficult to control post-hoc, and assessments of biases can often only be 
undertaken qualitatively and subjectively (Elwood 1998).
External validity refers to the generalisability of a study's findings to other 
settings or samples. Strictly speaking, this is only possible where a study 
sample has been randomly drawn from a target population to which findings 
are then generalisable (provided the study was internally valid). In many 
cases, studies rely on an accessible patient population, e.g. of patients of 
particular hospitals or clinicians interested in participating in the study, and 
authors need to demonstrate the similarity of both the target and accessible 
populations in terms of their characteristics (Polit & Hungler 1991).
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Restrictive exclusion criteria over patient entry into a study, as well as low 
participation rates can jeopardise external validity (Elwood 1998).
Apart from sample characteristics, the characteristics of the environment or 
research situation can affect external validity (Polit & Hungler 1991). The 
Hawthorne effect describes situations where subjects behave differently in a 
research context from normal life; similarly, subjects may behave differently 
because the treatment is new, but the effect would not last equally over time. 
External events may influence the success of treatment, as may the behaviour 
of the experimenter. Finally, measurement effects may occur which may 
mean that findings are not replicable in settings where the same set of 
measurements are not performed. Also, it  has to be stressed that external 
validity without internal validity is meaningless. RCTs should have high 
internal validity but often suffer from limited external validity.
2.2.2 2 Clinical trials
Bowling (1997) defines an experiment as follows:
“A scientific method used to establish cause and effect relationships 
between the independent and dependent variables. At its most basic, 
the experiment is a situation in which the independent (experimental) 
variable is fixed by manipulation by the investigator or by natural 
occurrence. The true experimental method involves the random 
allocation o f participants to experimental and control groups. Ideally, 
participants are assessed before and a fte r the manipulation o f the 
independent variable in order to measure its effects on the dependent 
variable” , (p.388)
“A clinical trial is an experiment with patients as subjects." (Rothman & 
Greenland 1998, p.69). The independent variable in a clinical trial is the 
clinical intervention whose effectiveness is to be assessed. Subjects in the
Use of Databases in Drug Effectiveness Studies 35
Literature Review
experimental group(s) receive the intervention^ of interest; subjects in the 
control groups may receive placebo, standard or no specific care.
The key to accomplishing comparability between subjects in different groups 
with respect to underlying “ baseline" characteristics and ensuring that causal 
inferences can be drawn with a minimum of assumptions, is randomisation. 
Randomised trials have first been used in agriculture and have been applied to 
medical research for the first time in the 1940s (Elwood 1998). Random 
allocation of subjects to the different comparison groups and their resulting 
comparability with respect to even unmeasured factors ultimately safeguards 
the validity of the trial.
in addition, many clinical trials are designed to minimise bias through 
“ blinding" (to the assigned treatment) those administering the intervention, 
patients, as well as those assessing the outcomes of interest. Keeping all 
these participants in ignorance over the treatment assignment minimised 
biases introduced through the knowledge of being treated or not. Blinding 
demands that any real differences between the treatment of subjects in 
different groups must not be detectable. This can be achieved by identical- 
looking forms of administration.
Peto and colleagues (1995) argue that randomisation ensures negligible biases 
and small random errors - both requirements for the detection or refutation of 
moderate differences in outcomes. By contrast, non-randomised studies 
frequently have to undertake mathematical adjustments to control for 
differences between comparison groups. It is often argued that important 
prognostic factors may be unrecorded or the quality of their recording may 
vary, and thus an analysis free of bias can never be guaranteed in non­
randomised studies (Peto et al. 1995).
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Peto and colleagues (1995) present four requirements for reliable assessment 
of moderate treatment effects: “ properly randomised evidence, an “ intent- 
to -trea t”  analysis o f all randomised patients, no unduly data-derived 
emphasis on particular subgroups, and, fina lly, an overview o f all the 
relevant randomised trials (w ithout unduly data-derived emphasis on the 
results from particular studies)”  (p.33). Only large trials are seen as able to 
avoid moderate random errors. Collins and MacMahon (2001 ) echo this set of 
criteria and go as far as claiming that already many premature deaths have 
been caused by a failure to produce such evidence.
In relation to the fourth stated requirement, much effort has gone into the 
development of methods for systematic reviews and meta-analyses of RCTs, 
not least through the international Cochrane Collaboration. Typically, the 
assessment of the quality of RCTs (and thus their ability to minimise potential 
biases) plays a central role in systematic reviews, as do assessments of 
heterogeneity (i.e. impact of potential effect modifiers) and possible 
publication bias. Non-RCTs are increasingly considered in systematic reviews, 
but many available reviews and certainly meta-analyses are still exclusively 
based on RCTs or at least quasi-randomised trials.
2.2.2.3 Observational study designs
Observational studies do not involve experimentation ("non-experimental 
studies” ); they are, however, also hypothesis-testing studies. Some writers 
consider both trials as well as observational studies as “ epidemiologic studies” 
(Rothman St Greenland 1998). The two main types of observational study 
design are cohort studies and case control studies. Either of these could be 
applied in database studies, so they are briefly described below:
Cohort studies
A cohort study is a direct analogue of the experiment (Rothman St Greenland 
1998), but the investigator does not assign the exposure/intervention. Rather,
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groups are defined (by the investigator) according to their exposure to a 
potential causative agent; hence in a cohort study there is at least one group 
of subjects who are exposed and one group of unexposed subjects.
Case-controI studies
A case-control study defines study groups according to the outcome, rather 
than an exposure of interest. Only cases and exposure status are identified, 
but denominators in each group are not measured. Hence, only relative 
effects can be estimated by case-control studies. These studies are also more 
prone to bias (Rothman & Greenland 1998).
The lack of randomisation in observational study designs used for the 
evaluation of intended treatment effects means that there is always a 
potential for bias due to the non-random allocation of treatment. Several 
study design features and analytical methods have been proposed and used to 
control for potential bias (Klungel et al. 2004). They include stratification, or 
matching on certain variables, multivariable statistical techniques, such as 
linear or logistic regression, or Cox proportional hazards regression (survival 
analysis), and propensity score adjustment. Klungel and colleagues also 
review other methods more commonly used in statistics and econometrics. 
However, there is little  empirical evaluation of the validity of such methods.
For database studies in particular, confounding by indication is a considerable 
problem, whereby patients treated differ in some systematic way from those 
not treated. This is difficult to overcome in analysis, not least because the 
basis for the doctor’s decision to treat is not always clear and rarely 
documented systematically in databases.
2.2.2.4 Considerations in choice of study design
Observational study designs are most often used by epidemiologists for 
estimating the degree of harm caused by an agent. For ethical reasons as well
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as issues of study size, trials could not be used to answer such research 
questions, and trials of beneficial effects are often too small to detect 
sufficient numbers of adverse events. In health technology assessment, the 
use of these methods is still controversial. There is a broad consensus, that 
randomised controlled trials are the “ gold standard” at least in that context 
(Carné & Arnaiz 2000). Other study designs used for efficacy/effectiveness 
evaluations are allocated “ lower” rungs on the quality of evidence hierarchical 
ladder. Table 2.1 presents an example of such a hierarchy of levels of 
evidence for therapy/prevention, aetiology/harm, developed at the Oxford 
Centre for Evidence-Based Medicine (Phillips et aL 2001a).
Table 2.1: Oxford Centre for Evidence-Based Medicine Levels of Evidence
for therapy/prevention, aetiology/harm (Phillips et al. 2001a)
Level 1a Systematic review (with homogeneity) of RCTs
(i.e. no “worrisome” variations in directions and degrees of results 
between individual studies; studies with worrisome heterogeneity should 
be tagged with a “minus" at the end of their designated level)
Level 1b Individual RCT (with narrow confidence interval)
Level 1c “All or none” (i.e. either all patients died before the treatment became
available, but now some survive on it, or some patients died before 
treatment became available, but now none die on it)
Level 2a Systematic review (with homogeneity) of cohort studies
Level 2b Individual cohort study (including low quality RCTs, e.g. <80% follow-up)
Level 2c “Outcomes” research, ecological studies
Level 3a Systematic review (with homogeneity) of case-control studies
Level 3b Individual case-control studies
Level 4 Case series (and poor quality cohort and case control studies)*
Level 5 Expert opinion without explicit critical appraisal, or based on physiology,
 ______ bench research, or “first principles” ______________________________
* Poor quality study: failed to define clearly comparison groups and/or measure exposures and 
outcomes in the same (preferably blinded), objective way in both groups, and/or failed to 
identify or appropriately control known confounders (for cohort studies also: and/or failed 
to carry out a sufficiently long and complete follow-up of patients).
As is implied in the above table, the main shortcoming of observational studies 
is their proneness to various biases. It has been argued that observational 
studies therefore have no place in evaluating moderate treatment effects, but 
are best used for identifying adverse effects or rare outcomes, provided that 
there are no obvious sources of bias in operation (MacMahon & Collins 2001).
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However, from the issues raised above it  becomes clear that the choice of 
study design depends on several issues. For example, a temporal dimension 
underlies the evaluation of a particular drug; the evaluation questions alter 
with each phase of drug development and licensing, as well as in the post­
licensing period and long-term. Further, the questions different parties need 
to have answered to inform their decisions vary; for example, licensing 
authorities require efficacy and safety data relating to the primary effect and 
licensed use of a drug, whereas physicians may have a range of questions 
relating to the use of the drug for different conditions, co-morbidities, patient 
subgroups, durations or dosages. Thus Strom and colleagues (Strom et al. 
1984; 1985) highlighted that clinicians need more information about the 
relative efficacy of drugs (relative to other available alternatives) than may be 
demanded by licensing authorities. The authors demonstrated also that 
licensed drugs are used for several different indications, often despite a lack 
of supporting trial evidence.
In a small review Strom and his colleagues (1984) showed that relatively few 
post-marketing efficacy questions needed to be addressed by experimental 
techniques. For a sample of 131 potential uses of 100 recently approved 
drugs, the authors judged (1) whether formal comparative efficacy evaluation 
was required or whether instead the intended effect would be dramatic 
enough to be observed from an uncontrolled case series or even a single 
patient, and (2) whether a non-experimental formal study would involve 
problems of confounding by indication, and (3) if  this was the case, whether 
the indication could be sufficiently characterised to provide control of 
confounding through conventional techniques. The judgement was that the 
absolute efficacy of 89 potential drug uses (68%) could be evaluated from 
clinical observations alone, and only 6 (5%) required an experimental study 
design (22% could not be addressed by either design). Even for relative 
efficacy questions, 94 (72%) were judged to be able to be addressed validly in
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a non-experimental study design, i.e. where allocation to treatment occurs for 
a purpose other than the scientific inquiry. This study is now rather dated, 
and the authors themselves concede that their theoretical statements that a 
question would be “ studiable”  does not prove that a valid study could be 
performed. More recent experience casts doubts over these assertions on the 
basis of observational findings having been refuted by subsequent trials 
(MacMahon and Collins 2001).
Similarly, Black (1996) is frequently quoted in defence of observational studies 
to evaluate effectiveness of healthcare. He argues that experimental studies 
may be, (1) unnecessary (e.g. where the effect of an intervention is 
dramatic), (2) inappropriate (e.g. for rare events, for long-term future 
outcomes, or where randomisation influences the effectiveness of the 
intervention), (3) impossible (e.g. when clinicians refuse to participate, 
ethical objections exist, legal or political obstacles are posed, where 
contamination is unavoidable, or simply the limits of research capacity are 
exceeded), or (4) inadequate particularly where generalisability of a trial 
would be poor.
In the evaluation process of new drug treatments, trial designs play an 
important role, particularly in early phases, up to what is termed "Phase III” 
studies. These are large-scale RCTs on patients (rather than healthy 
volunteers) and are usually sponsored by the manufacturers. These trials form 
the basis of licensing decisions concerning the new drug. Once the drug is 
licensed, there may be an obligation on the side of the manufacturer to 
monitor drug safety, particularly given recent high-profile cases of drug 
withdrawals from the market (e.g. Vioxx). However, companies’ incentives to 
sponsor more effectiveness research may be severely curtailed, unless 
commercial interests are at stake. It is thus often left to public and research 
funding bodies to sponsor studies evaluating the new drug in clinical practice.
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At the “ post-marketing" phase, key questions on long-term effectiveness, or 
the effectiveness of the new treatment in particular patient groups not 
included in Phase HI trials (e.g. children, older people, and those with co­
morbidities) usually remain unanswered. Thus - apart from methodological 
criticisms mentioned above - these open questions provide further incentives 
to look for alternative study designs, not least because of the high cost 
involved in conducting multiple RCTs of the same treatment. Costs may be an 
even stronger argument, where long-term effectiveness is to be evaluated, or 
where a substantial proportion of the patient population have already 
received the new drug and would no longer be available for recruitment into a 
trial.
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2.3 Critique of RCTs
I have already indicated that RCTs also present methodological limitations, 
and this section provides an overview of these.
2.3.1 Threats to internal validity
The importance of internal validity to the potential value of a study has 
already been stressed, and it  is a main concern of any study design to 
safeguard this. As the main sources of alternative explanations of study 
findings are chance, bias, and confounding, RCTs are in a strong position: 
randomisation minimises confounding, and blinding minimises bias (Elwood
1998); a typical RCT involves both.
However, Kaptchuk (2001 ) points out that randomisation eliminates 
preference, which is a key element of treatment choice. Particularly where a 
study is un-blinded, “ preference bias" may change the observed treatment 
effect. Cook and Campbell (1979) describe several threats to internal validity, 
which may occur despite successful randomisation, particularly in cases where 
blinding is not possible or not maintained. Many of these result from the 
inevitable inequity due to only some subjects receiving a possibly desirable 
intervention. Information intended for only one group may “ leak” to another 
group. The authors term this “ diffusion or imitation of treatments” . Where 
the comparison group receives no treatment, there is a temptation on behalf 
of administrators to compensate for their lack of treatment in other ways 
(“compensatory equalisation of treatments” ). Similarly, “ compensatory 
rivalry” by respondents receiving the less desirable treatment is equally 
possible; these subjects may thus strive to reverse the expected difference. 
The same respondents may also respond with “ resentful demoralisation” ,
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which could impact on the post-test difference in a way that cannot be 
attributed to the intervention alone.
In drug trials, blinding is relatively more easily achieved and maintained, but 
there are several reasons why blinding may still fail despite a concealment of 
the allocation of subjects to different groups and despite the use of placebos. 
Clinicians or patients may be able to guess the treatment patients are 
receiving because of the occurrence of particular effects or side effects. 
Similarly, blinding may be difficult to maintain during treatment withdrawal 
phases, if  experienced clinicians - or indeed patients - are familiar with the 
typical duration of a trial.
Randomisation as a probabilistic technique relies on chance; thus it  is still 
possible that even substantial differences between groups remain, despite 
successful randomisation (Elwood 1998). There are analytic techniques to 
deal with such unequal distributions, but in some cases such unequal 
distribution may not be known. It is good practice to report the achieved 
distribution of all factors between the groups.
2.3.2 Threats to external validity
Measures which increase internal validity often potentially jeopardise external 
validity. Thus the RCT with its potentially high internal validity is often 
criticised for low external validity. Strict criteria may be applied to RCTs to 
lim it the influence of extraneous variation in outcomes and thus ensure that 
any observed differences between groups are most likely due to the 
intervention (Simon et al. 1994). Such criteria include patient selection 
criteria, placebo washout phases, or specific treatment and investigational 
protocols. They result in a homogeneous patient sample with a minimum of 
co-morbid conditions, maximum compliance, and homogeneous treatment 
across participating centres, which all reduce variability and may thus
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increase the power of the study and decrease the potential for bias (Simon et 
al. 1994). However, the generalisability of such RCTs may be restricted, and 
examples have been highlighted in many studies (Brown et al. 1999; Stegmayr 
et al. 1999; Roy et al. 2000; Magee et al. 2001).
Others have described cases where an RCT includes a different patient 
spectrum from that seen in clinical practice as "nonconsent bias” (Kaptchuk 
2001). This can arise not only because of restricted sampling, but also 
because patients participating in an RCT are by default volunteers and may 
thus be different from the normal patient population. Britton et al. (1998) 
have reviewed the evidence on the external validity of randomised trials and 
have found that excluded subjects tended to have a worse prognosis than 
included subjects. Also, less affluent subjects were more likely to be included 
in treatment trials, but less likely to be participants in a trial of a preventive 
intervention.
Quite apart from patient selection, intensive treatment protocols pursued in 
RCTs also jeopardise the external validity of such studies. Similarly, the 
timeframe of studies may impinge on the ability to project results to other 
time points. For example, retention rates in short-term studies were found 
not to be representative of long-term results in clinical practice (Hawley fit 
Wolfe 1991).
2.3.3 Threats to validity inherent to features of the RCT
“Randomly subjecting a person to a m ilieu o f hidden exposures and then 
spotlighting him or her w ith relentless observation does not nurture 
normalcy, nor does i t  isolate humans from their mental processes. ”
(Kaptchuk 2001 p.543)
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Kaptchuk (2001 ) summarises several ways in which the gold-standard design of 
the RCT can itself give rise to biased results. Firstly, the masking of the 
treatment may introduce bias by causing feelings of uncertainty which may 
decrease any real effect; conversely, heightened vigilance may increase the 
response. Participation in a blinded RCT may cause a range of emotional 
responses which could influence results. At times these may have differential 
impacts on treatments and controls (Bergmann et al. 1994) and produce what 
Kaptchuk (2001 ) describes as a “ masking bias” .
Similarly, the need to inform patients of possible side effects may significantly 
increase the likelihood of detecting and reporting them (“ consent bias” ). 
Another possible bias is referred to by Kaptchuk (2001) as “ investigator self­
selection" bias, and he quotes evidence of the possibility of investigators 
having differential impacts on patients and observed treatment outcomes.
2.3.4 Limits to economic evaluations
Health economic evaluations of treatments are based not on the theoretical 
possibility of the treatment working, but on its likely performance in clinical 
practice (Rittenhouse 1995; Rittenhouse fit O'Brien 1996; Revicki fit Frank
1999). These evaluations can be severely misleading, if  they are based on 
RCTs which were limited to a certain patient group or which involved 
treatment and investigative protocols not normally followed in everyday 
practice. Critically also, health economic evaluations require data on long­
term outcomes, when they examine the discounted costs and benefits, e.g. in 
estimating cost per life-year saved (Nuijten 1998). Such outcomes are rarely 
gleaned from resource-in tensive and thus time-limited RCTs.
Critics would argue that cost-effectiveness evaluations based on RCT data 
provide “ a very precise answer to the wrong question” , and would not 
represent the effect of a new treatment on costs, healthcare use, and
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outcomes in clinical practice (Revicki & Frank 1999). It has been argued that 
the use of blinding and randomisation distorts the reality which an economic 
evaluation needs to capture, and that the way treatments are applied in RCTs 
differs from normal practice (Revicki & Frank 1999).
Thus, even the RCT as the “ gold standard” design for effectiveness evaluations 
shows considerable scope for threats to its validity. The next section explores 
study designs which may offer options for overcoming some of the limitations 
of RCTs; in many cases, these design variations allow for preferences of 
patients and/or clinicians to be taken into account.
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2.4 Developments beyond RCTs
Several variations of the RCT design have been suggested in the literature in 
order to overcome some of its criticisms.
2.4.1 RCT variants
Mac Le hose and colleagues offer a helpful overview and discussion of variants 
of RCTs (MacLehose et al. 2000). The first example is the single randomised 
consent design (Zelen 1979), which randomises patients to either a new 
treatment, or current or no treatment options. Patients are only told about 
randomisation if they are randomised to the new treatment group. Others are 
followed up and their data analysed (in an intention-to-treat analysis) without 
information or consent. Whereas the avoidance of discussing randomisation 
with patients may sound methodologically attractive, such conduct is now 
unacceptable in research involving human subjects.
The same author suggests a double randomised consent design for situations 
where there is no control or best standard therapy (Zelen 1981). In this case, 
patients are randomised to experimental or standard therapy prior to consent. 
In both groups, patients are then permitted to choose which treatment they 
wish to receive, but the analysis is again performed by intention-to-treat. 
Whereas this design is ethically less repugnant, it  shares some shortcomings 
with the single randomised consent design; firstly, double-blinding is not 
possible, and there may be substantial loss of efficiency due to patients 
choosing the alternative treatment.
Response adaptive designs adjust the likelihood of newly recruited patients 
being allocated to a particular treatment group depending on how successful
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the treatment currently appears. Likelihoods are adjusted in favour of 
treatments appearing more successful, and the exposure to less effective 
treatments is minimised (MacLehose et al. 2000). The complexities in 
determining likelihoods are, however, substantial, particularly where long 
follow-ups are required or multiple outcomes are to be assessed.
A further variation of the RCT gives patients the option to change onto open 
treatment at any point in the study, and analyses the time until this is 
requested (Hogel et al. 1994). One of the advantages seen in the change-to- 
open-label design is that patients might more readily agree to participate, 
thus making the trial more generalisable. However, for several types of 
treatment this design seems inappropriate, e.g. where beneficial outcomes 
are not expected for some time.
Feldman and colleagues (Feldman et al. 2001) suggest a randomised study 
design for situations where it  is unacceptable for patients to be allocated to a 
control group. In the randomised placebo-phase design, all patients are 
randomised to a placebo-phase duration (any number of days), after which 
treatment begins. The design can thus only assess whether patients treated 
sooner respond to treatment sooner than those patients commenced later on 
treatment.
Other variants of RCTs aim to exclude patients who are likely not to comply 
with treatment through placebo run-in phases (thus increasing the efficiency 
of the trial), or to minimise the exposure to placebo of patients who are not 
responding to treatment by eliminating non-responders after a treatment run- 
in phase (MacLehose et al. 2000).
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2.4.2 Pragmatic or naturalistic trial designs
Over thirty years ago, Lasagna (1974) argued for what he called a 
"naturalistic”  evaluation of medicines. Naturalistic trials aim to utilise the 
strengths of randomisation and simultaneously to improve generalisability 
through broad patient selection criteria, long follow-up periods (not least in 
order to be able to measure clinical endpoints instead of surrogate variables), 
and substantial flexibility in dosing, prescribing, and care practices. These 
demands tend to make the trials more expensive, time-consuming and difficult 
to implement (Carné Et Arnaiz 2000) than standard efficacy trials.
Sacristan and colleagues (1998) have described a design which includes 
randomisation modules into computer-based patient record systems. This 
method should thus eliminate selection bias and also utilise the strength of 
large database systems in collecting “ naturalistic” data from clinical practice 
for larger samples and longer study periods. However, the high demands on 
the degree of computerisation and level of data quality implicit in this 
proposed design seem to have contributed to its so far limited success. The 
authors themselves point out possible methodological problems such as cross­
over bias, and what Kaptchuk (2001) called investigator self-selection bias.
2.4.3 Hybrid study designs
MacLehose and colleagues have as part of their systematic review provided an 
overview of study designs which provide both RCT and non-randomised effect 
estimates. An overview of the designs is provided in Table 2.2.
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Table 2.2: Hybrid designs with RCT and non-randomised components
Design
Comprehensive 
cohort study
Patient
preference trial
Ctinician- 
preferred- 
treatment trial
Two-stage trial 
design
Description
Patients who refuse randomisation may choose 
any comparison treatment and are also followed 
up so that generalisability of the RCT can be 
tested
Patients with strong preferences for one of the 
comparison treatments (for whatever reasons) 
are allocated the preferred treatment, 
indifferent patients are randomised; effects in 
randomised and non-randomised groups are 
compared.
Patients for whom either comparison treatment 
is clearly indicated receive the appropriate 
treatment; where the indication is less clear, a 
panel of clinicians can either agree on a 
preferred drug for each individual patient, or if 
the panel does not agree, patients are offered 
randomisation to either treatment and then 
treated by a clinician with a preference for the 
randomly allocated treatment; effects in 
randomised and non-randomised cohorts are 
compared.
Patients are randomised to a patient-preference 
trial or to a further randomisation into an RCT
Reference
(Olschewski fit
Scheurlen
1985)
(Brewin fit 
Bradley 1989)
(Korn fit
Baumrind 1991)
(Rucker 1989)
Source: MacLehose et al. (2000).
2.4.4 Research syntheses
The need to summarise the available evidence for decision making in 
healthcare and medicine has given rise to new quantitative synthesis 
techniques (Petitti 1994; Labin 2007). The evidence-based practice movement 
and HTA programmes in several countries have contributed much to the 
development of research synthesis techniques in HTA. In particular, the 
review work of the international Cochrane Collaboration centres on meta- 
analytic techniques. National and international programmes and 
collaborations exist to coordinate and undertake systematic and 
comprehensive syntheses.
Research syntheses depend firstly on a comprehensive search and 
identification of all relevant available studies. Without such systematic
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literature reviews, bias is almost inevitable. Search criteria and data 
extraction and handling procedures are to be defined a priori, based on a 
clinical question, rather than previous knowledge of the available literature. 
Manipulating inclusion criteria can bias a review (Jüni et al. 2001). The 
identification of RCTs has recently been made easier through concerted 
efforts in registering trials and coding trial publications (Thompson 2001 ), but 
search strategies for identifying non-randomised studies are much more 
difficult to design (MacLehose et al. 2000).
Despite systematic searches, potential biases remain. Firstly, publication bias 
poses considerable problems, not only where industry-sponsored trials are 
predominant, but also where researchers fail to submit or editors fail to select 
for publication those trials which do not show statistically significant results. 
This means that published studies may differ systematically from unpublished 
studies, and both should therefore be included in a systematic review 
(Thompson 2001). Similarly, the identification of studies published in less 
widely-used languages is difficult, but more importantly, such studies may
differ systematically from studies published in English (Jüni et al. 2001). Trial
authors may jeopardise the validity of a subsequent review through their 
choice of outcomes reported, other studies they cite, and even number of 
publications they produce based on the same study.
The quality of evidence from any research synthesis is only as good as the
quality of the studies and information on which it  is based. The quality of 
evidence is difficult to define, and may address the design, implementation, 
and/or reporting of a study (Jüni et al. 2001). Again, the methodological 
developments for assessing the quality of studies are most advanced in the 
case of RCTs, for which validated quality assessment instruments exist (Jadad 
et al. 1996). Whereas a number of tools for assessing the quality of 
observational studies are available, many are not fully developed, and a 
consensus on the critical elements for assessing the susceptibility to bias is
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still outstanding (Sanderson et al. 2007). The CONSORT group guidelines for 
the reporting of observational studies (von Elm et al. 2007) could be a starting 
point.
2.4.4.1 Meta-analysis
A meta-analysis is a statistical method for combining results from a number of 
studies. Apparently the term was coined by Glass in 1976, but appropriate 
statistical methods had already been developed in the 1930 (work by Tippett, 
Fisher, Cochrane, and Pearson), before being widely used in the social 
sciences in the 1970s (Petitti 1994). Whereas most meta-analyses are limited 
to RCTs, there are increasingly attempts to include non-experimental data in 
meta-analyses.
The result of a meta-analysis is an overall estimate of effect of an 
intervention, based on a number of trials. However, different trials included 
may be heterogeneous, and an overall result of the meta-analysis may not 
apply to particular subgroups of patients or treatment practices. An 
exploration of any potential sources of heterogeneity in a meta-analysis is 
therefore important and can be very informative. Meta-regressions can assess 
how trial or patient characteristics can influence treatment effects (Petitti 
1994).
The limitations of meta-analyses in terms of their contribution to healthcare 
decision-making relate to the reliance on predominantly RCTs. Meta-analyses 
thus suffer from the shortcomings of RCTs, mainly in terms of their lack of 
generalisability. Poor reporting of trials poses an additional limiting factor, as 
many older trials do not provide the necessary detail (point estimate plus 
standard error or confidence limits) to be included in a meta-analysis 
(Greenland 1987). As researchers retire, this information w ill be increasingly 
difficult to retrieve retrospectively.
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Evidence-based decision-making does not exclusively rely on meta-analyses, as 
(clinical) experience, contextual knowledge, and other types of information 
are taken into account. Thus, there is probably more readiness on the part of 
decision-makers than statisticians to ignore the findings of a meta-analysis 
whose main outcome is a recommendation for further research.
It is possible in meta-analyses to examine subgroups of patients for differential 
responses. However, it  has been suggested that such probing effectiveness 
analyses can be misleading and therefore are to be seen as exploratory 
(Temple 1999). Such analyses need to account for multiple comparisons by 
specifying a-priori hypotheses and correcting p-values accordingly in order to 
avoid spuriously significant findings.
Berlin and Cotditz (1999) suggest that meta-analyses could be pre-planned by 
specifically developing a series of trials on different patient groups; the final 
meta-analysis of such trials should thus provide better generalisability as well 
as the possibility to identify variations between subgroups of patients. Temple 
(1999) argues that, multi-centre trials might serve this purpose. Further, he 
suggests that if such meta-analyses were to examine defined differences 
between settings, each individual trial would have to be large enough to show 
an independent effect. A meta-analysis would be valuable for such a case 
only if  individual studies are not large enough to examine further effects or 
outcomes of interest (Temple 1999).
2.4A.2 Broader-based synthesis methods
There is a growing methodological literature on statistical methods to include 
evidence from other study designs (Eddy et al. 1992; Sutton et al. 1998). In 
the 1980 and 1990s, the United States Government Accountability Office 
(formerly General Accounting Office) has developed several synthesis methods 
with a view to integrating different research methods to answer broader-based 
policy questions (see Labin 2007).
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With particular relevance to ESDs, the then General Accounting Office (GAO 
1992) proposed “ cross-design synthesis” as a means for improving knowledge 
about the effectiveness of interventions by synthesising findings from 
complementary research designs. Labin (2007) describes this as a “ bridge 
between meta-analysis and the evaluation and prospective synthesis 
methodologies from the GAO.” Results from studies with designs of 
complementary strengths and weaknesses are to be combined, after a 
systematic and detailed assessment and taking account of different studies’ 
weaknesses in the synthesis of the results.
The GAO (1992) describes the steps for the example of a synthesis of results 
from randomised studies and database analyses, which are considered 
complementary designs insofar as they have opposite strengths and 
weaknesses in terms of their internal and external validity. Whereas RCTs 
have the potential to ensure high internal validity, they often sacrifice 
external validity. The opposite may be true of ESDs which may be criticised 
for their potential selection and other biases, but can have significantly higher 
generalisability due to their inclusiveness and large patient numbers. The four 
major steps of cross-design synthesis of these study designs have been 
described as:
• assessing randomised studies for their generalisability to all relevant 
patients
• assessing ESDs for “ imbalanced comparison groups”
• adjusting individual studies’ results compensating for biases if necessary
• synthesising adjusted results within and across design categories.
(GAO 1992)
This approach has since been built on in further developments of broad-based 
syntheses (Greenhouse & Kelleher 2005; Sutton et al. 2000).
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2.4.4.3 Decision analysis
Decision analysis uses quantitative methods to compare the values of different 
decision options. The method originates in game theory, and in the medical 
context is used to assist either decisions about the management of individual 
patients, or - increasingly - the development of health(care) policies (Petitti 
1994). The identified “ problem” has to be structured and broken down into 
components and decision options, represented in a decision tree. Outcomes 
are defined, and uncertainties identified. Values of outcomes are measured 
or inferred, and uncertainties estimated on the basis of literature reviews and 
expert opinions, before the decision tree is analysed statistically to estimate 
the relative net value of the decision options (Pauker 6t Kassirer 1987).
While intuitively appealing, the methods can be complex and based on many 
assumptions. For example, Markov modelling, which is used to represent 
transitions in and out of various states of health, assumes independence of 
subsequent transitions from previous ones. Also, data to estimate transition 
probabilities may not be available. Clear descriptions of methods and 
assumptions as well as sensitivity analyses are thus vital.
2.4.4.4 Cost-effectiveness analysis and other economic evaluations
Ultimately, HTA informs not only decisions at individual patient level but also 
at the level of entire patient populations and finally whole populations for 
whom healthcare options are chosen. Economic evaluations are thus an 
increasingly important part of HTA. It has already been mentioned that health 
economists have voiced reservations about basing their evaluations on clinical 
trials alone (Rittenhouse Et O'Brien 1996). In order to provide decision-makers 
with the necessary evidence on the economic consequences of possible 
decision options, health economists build on effectiveness evidence from an 
increasing variety of study designs.
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In summary, alternative methods to RCTs focus in part on a combination of 
strengths from various study designs, as well as methods for synthesising 
evidence to answer questions to support individual or population treatment 
decisions in practice. Experience with some of these study designs however is 
still limited. I will now focus on ESDs and their use in effectiveness research.
Use of Databases in Drug Effectiveness Studies 57
Literature Review
2.5 Effectiveness studies using databases
2.5.1 Introduction
Secondary data sources have increasingly been used for health services 
research, including effectiveness research (Antczak-Bouckoms et al. 1991a), 
despite continued controversy about the quality and validity of evidence so 
derived (Byar 1980; Shapiro 1989; Antczak-Bouckoms et al. 1991a). This 
section reviews more closely the different types of secondary data sources 
used for effectiveness research, as well as the challenges and problems 
associated with such analyses.
2.5.2 Secondary data sources
Huston and Naylor (1996) identify two types of secondary data. Firstly, there 
are databases designed for ongoing surveillance of care. Examples of such 
databases are post-marketing surveillance databases, but also clinical 
databases or disease registries, which are focussed on a particular patient 
population, often those suffering from a chronic condition. Secondly, 
databases may be designed for administrative purposes, such as hospital 
databases, or claims databases of insurance companies or health care 
maintenance organisations. Similarly, administrative databases may have as 
their subject matter the long-term care of a patient population (Berlowitz et 
al. 1997). Both types of data sources are described further below. Any of 
these data sources may be used for the evaluation of health interventions. In 
addition, vital statistics and demographic data (Blais 1991) and also databases 
generated from large RCTs (Canto et al. 1999) have been identified as possible 
data sources used in health technology assessment and outcomes research.
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2.5.2.1 Surveillance databases
Surveillance has been defined as “ a continuous and systematic process of 
collection, analysis, interpretation, and dissemination of descriptive 
information for monitoring health problems" (Buehler 1998). This definition 
implies that the main objective of surveillance is health monitoring. There is 
no consistent use of terminology regarding different types of surveillance data 
sources. What some describe as a disease registry, others may term a 
database, a post-marketing surveillance programme or system, or loosely a 
cohort study.
Buehler defines registries as “ listings of all occurrences of a disease, or 
category of disease (e.g., cancer, birth defects), within a defined area” 
(Buehler 1998, p.450). Prime examples of such registries are the regional and 
national cancer registries where all occurrences of malignant neoplasms are 
registered in the UK, or the Surveillance, Epidemiology, and End Result (SEER) 
project of the National Cancer Institute (NCI) in the USA (Klawansky et al. 
1991b; Wyshak et at. 1991).
Disease-specific registries may vary depending on their prime intention. They 
often go far beyond listing disease occurrences. Some registries are designed 
to follow a patient group over time, usually with the aim to determine the 
incidence and natural course of a disease, their survival, or incidence of 
adverse events, as in the case of post-marketing surveillance. Patients are 
registered on first entry to the database and follow-up information can be 
entered either periodically (e.g. on regular review visits of patients) or on the 
occurrence of specific events. Patients are usually identified through clinics 
or hospitals on the basis of their specified diagnosis, e.g. rheumatoid arthritis 
(Singh 2001), cystic fibrosis (Anonymous 1994), acute myocardial infarction 
(Every et at. 1999), human immunodeficiency virus (Ledergerber et at. 1994; 
Tassie et at. 1999) or a particular intervention, for which follow-up data is
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collected (e.g. International Bone Marrow Transplant Registry (Rimm et at. 
1991).
Disease-specific surveillance systems include the ARAMIS (Arthritis, 
Rheumatism and Aging Medical Information System) programme, which is 
intended as a post-marketing surveillance system to explore effectiveness, as 
well as safety of therapies for rheumatic diseases (Singh 2001). ARAMIS is 
sponsored by the US National Institutes of Health, with supplemental funding 
from a range of pharmaceutical companies and the Food and Drug 
Administration.
A further example of a post-marketing surveillance database is the 
Epidemiologic Registry of Cystic Fibrosis (ERCF), which provided the data for 
the Dornase Alfa Case Study presented as part of this thesis (see section 4.1 
for more details). The stated aims of this registry include the assessment of 
effectiveness of a particular treatment (dornase alfa) marketed by the 
pharmaceutical company funding the registry (Anonymous 1994). A sister 
database to this exists in North America, the Epidemiological Survey of CF 
(ESCF).
Some post-marketing surveillance involves very short follow-up. An example 
of a cross-sectional registry practically without follow-up is the National 
Registry of Myocardial Infarction (NRMI-2) in the US. It has multiple aims, 
including descriptive epidemiology as well as safety monitoring of alteplase, a 
thrombolytic agent (Every et at. 1999). This registry collects cross-sectional 
data on patients admitted with myocardial infarction in the USA and is also 
funded by a pharmaceutical company (Genentech). A similar database is the 
Cooperative Cardiovascular Project by the Health Care Financing Agency, 
albeit that patients discharged from hospital after an acute myocardial 
infarction are identified centrally for this database (Every et at. 1999).
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In some cases, healthy volunteers may be recruited to longitudinal cohort 
studies. The data from these cohorts of individuals may be used to examine 
several hypotheses relating to normal changes occurring with age, or the 
development of risk factors. For example, the Framingham Heart Study 
selected a random population sample of adults (to which further volunteers 
were added later) beginning in 1949, to examine the development of risk 
factors for coronary heart disease (Roberts et al. 1991). The Veterans Affairs 
Normative Aging Study was initiated in 1963 to observe health changes through 
the aging process in healthy men, who are followed up with examinations and 
tests every five years (Antczak-Bouckoms et al. 1991b).
Researchers at the London School of Hygiene and Tropical Medicine have 
systematically gathered detailed background information on clinical databases 
existing in the UK. This Directory of Clinical Databases (“ DoCDat” ) is available 
to be reviewed online (now through the MHS Information Centre). The 
intention is to provide details on coverage, variables, as well as data accuracy 
to potential data users. In 2002, 44 clinical databases were registered (the 
ERCF was not among them); in March 2009 the DoCDat website listed 158 
databases.
2.5.2.2 Administrative databases
Databases compiled for administrative - often billing - purposes have also been 
used for research, including effectiveness and outcomes research; they can of 
course also be used for surveillance purposes (Buehler 1998). They are, 
however, not designed for this purpose. Typically, such databases hold 
information relating to resource use of individual patients, e.g. investigations, 
treatments, hospital admissions and discharges, diagnoses, operations, and 
reimbursed prescriptions.
Information technology has enabled the increasing computerisation of health 
records, and hospital and health service administration systems. In the UK,
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VAMP and AAH-Meditel were the two main commercial organisations 
responsible for computerisation of general practices (Currie 6t MacDonald 
2000). They have fed into two large datasets, which were widely used for 
post-marketing research: the UK General Practice Research Database, and 
MediPlus, a commercial database of Intercontinental Medical Statistics (IMS, 
UK and Ireland). Both also include clinical data.
Compared with many surveillance databases, administrative data sources may 
contain less detailed clinical data, making effectiveness evaluations more 
difficult. Thus the opportunities for record linkage between data sources is 
particularly important, given that datasets tend to be subject-specific and by 
themselves rarely contain sufficient information to examine effectiveness- 
related hypotheses (Klawansky et al. 1991b). In the UK, a small number of 
record-linkage systems exist, e.g. the Oxford Record Linkage Study, the 
Scottish Medical Record Linkage System, and the database of the Medicines 
Monitoring Unit at Dundee University (Currie fit MacDonald 2000). In other 
countries, more extensive systems are available (Currie & MacDonald 2000).
Some Health Maintenance Organisations, as well as the USA Department of 
Veterans Affairs hold particularly comprehensive health information systems 
relating to subscribed individuals. One of the most impressive initiatives, 
however, is the healthcare information system for the province of 
Saskatchewan in Canada, which covers the entire population of 1 million 
inhabitants. Several separate databases on e.g. hospital discharges, 
prescriptions, birth and death certificates etc. can be linked for drug 
surveillance, health outcomes research and other health services research. 
These databases are regularly used for epidemiological research 
(Saskatchewan Health 2005).
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2.5.3 The use of databases for effectiveness evaluations
Alpert (2000) lists several possible uses of clinical registries, including the 
provision of comparative pictures of the progress of a disease and its 
management, or information on the outcomes or resource utilisation 
associated with the disease. Effectiveness analyses do not feature on this list. 
However, secondary data sources are being used for health technology 
assessment, despite this not being their (main) objective (Blais 1991). 
Effectiveness evaluations thus constitute only a minor, albeit growing, 
proportion of the analytical output of clinical or administrative databases 
(Wyshak et aL 1991).
Work on the use of secondary data in effectiveness analysis published in a 
special section of the international Journal of Technology Assessment in 
Health Care in 1991 (“The contribution of medical registries to technology 
assessment” ) highlighted several ways in which secondary data can contribute 
to technology assessment (Klawansky et aL 1991a; Roberts et al. 1991):
• Evaluate technologies reported there and received by registered 
individuals to a varying degree;
• Evaluate technologies not reported there or used in clinical practice, but 
administered to registered individuals (or their data or stored serum) for 
research or evaluation purposes;
• Evaluate technologies unrelated to the registered population sample 
(e.g. applying risk predicted by logistic regression equations from the 
database to other samples);
• Use of registered individuals as control group in comparison with various 
experimental groups;
• Assessing selection bias in clinical trials;
• Facilitating evaluations of classification and coding systems.
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Sorensen and colleagues (1996) provide a useful summary of factors affecting 
the value of secondary data in epidemiological research (Table 2.3). Whereas 
this provides a guide for ESD researchers, it  can also support the evaluation of 
published ESD reports.
Table 2.3: Factors affecting the value of secondary data in
epidemiological research (Sorensen e t a l. 1996, p.436):
1. Completeness of registration of individuals
a. comparing the data source with one or more 
independent reference sources
b. comprehensive records review
c. aggregated methods
2. Accuracy and degree of completeness of variables
a. Precision
b. Validity
3. Size of the data sources
4. Registration period
5. Data accessibility, availability and cost
6. Data format
 7. Record linkage____________________________________
Several recent reviews funded by the UK HTA Programme have explored the 
use of routinely available data in HTA, with only few of them addressing 
effectiveness research. One of the first (Lewsey et al. 2000) was dedicated to 
exploring the use of routine data to complement or supplement RCTs. Three 
case studies of surgical interventions were presented to illustrate the use of 
routine data in situations where (1) an RCT was not feasible, (2) two 
established surgical interventions were compared, and (3) trial results were 
compared with those achieved in routine practice. Although the first case 
study did not attempt to provide an alternative to an RCT, its findings are 
relevant: namely that neither scope nor quality of routine data were sufficient 
to allow such studies, but that changes to data collection could make them 
possible at least in theory. For example, the lack of data on complexity and 
severity of a condition of interest should be remediable. This finding was
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echoed in the two other case studies, which more directly investigated 
effectiveness questions, albeit that the scope and quality of the data varied 
depending on the clinical topics studied.
A review by Williams et al. (2003) set out to estimate the feasibility, utility 
and resource implications of electronically captured routine data for HTA by 
RCTs. This was done by replicating the analysis of four RCTs by simulating 
them using routine data. For each RCT, analyses based on designed data were 
compared with an analysis based on routine data. The research team 
concluded that routine data could answer the questions posed in RCTs, as well 
as clinical effectiveness questions by using available proxy measures. Despite 
this encouraging finding, the authors point out that the validity of routine data 
and the practicalities of using them still pose considerable problems in reality. 
The authors recommended prospective testing of the use of routine data in 
HTA RCTs.
Raftery et al. (2005) examined the use of 270 known English databases more 
generally and assessed their potential use in HTA (examined were those 
existing by the year 2000). Twelve of them were reported to have been used 
for effectiveness research, and a further 10 for comparative audit. However, 
only very few of the referenced studies were drug effectiveness studies. The 
authors reported that key aspects of the validity of these databases were 
often difficult to assess (e.g. completeness of variables or registration of 
individuals, and that validations of data accuracy was very uncommon), and 
concluded that few existing databases met the required criteria for 
effectiveness studies.
In May 2007, the American Agency for Healthcare Research and Quality 
published a guide to the use of registry data in evaluating patient outcomes. 
The guide describes what is considered good practice in creating, operating, 
and evaluating registries, and using them in research (including effectiveness
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research); it  does not review the quality of such studies (Gliklich 6t Dreyer 
2007).
Increasing numbers of database or registry analyses are being published from a 
variety of clinical fields and data sources, and the debate about the use of 
registries or databases for the evaluation of treatment effectiveness is still 
very much alive (Rawlins 2008), albeit that there are few recent 
methodological publications evaluating or critiquing such research in practice.
2.5.4 Advantages and disadvantages of effectiveness analyses 
using databases
Firstly, a greater generalisability of ESDs is often held up as one of the 
advantages over randomised controlled trials, as large databases can cover a 
more diverse patient sample (GAO 1992). RCTs tend to apply strict and 
narrowly defined inclusion and exclusion criteria, which limits the ability to 
generalise findings. For example, Pincus (1988) notes that fewer than 25% of 
consecutive patients with rheumatoid arthritis are eligible for participation in 
most clinical trials.
However, claims databases in particular may be limited to a particular 
(insured, treated) patient group, which may not be representative of the 
overall patient population (Motheral & Fairman 1997). Similarly, regional 
practice patterns may vary. Lewis (2001 ) has criticised cystic fibrosis (CF) 
registries for a lack of representativeness of the target population, as 
incomplete and poorly defined sub-populations are covered in such registries. 
Moreover, there is a strong cohort effect in cystic fibrosis, as previously few 
cases survived to adulthood. Thus, adult “ survivors” currently registered will 
be different from future adults with CF.
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However, the desirability of a more comprehensive population coverage and 
thus better generalisability of many databases compared to available 
randomised studies is for many unquestioned (GAO 1992). The 
representativeness of a database analysis of course depends on inclusion and 
exclusion criteria applied to data on individuals in the database, as well as 
those applied for the ESD itself. If too many cases are excluded, the results of 
an ESD may be no more representative than those of a randomised controlled 
trial (or may just represent a different sub-population).
A second potential advantage of ESDs is the long duration of patient follow-up 
in administrative and disease databases. This is comparatively difficult and 
costly to achieve in randomised controlled studies. Researchers investigating 
a particular hypothesis do not have to plan and execute complex data 
collection operations, but can use readily available data and thus arrive at 
results - even for longitudinal evaluations - much faster which of course makes 
an individual study much less costly (Lewis et al. 1993). A further advantage 
of ESDs is the possibility to link data from different datasets for investigating a 
range of different hypotheses not necessarily anticipated at the initiation of 
the data sources.
Researchers of interventions for chronic diseases have been particularly keen 
on disease database analyses. The lack of follow-up and real-life context is 
often criticised in RCTs. Starmer and Lee (1982) note that the emphasis of 
RCTs is on patient groups rather than individuals, whereas clinicians are drawn 
towards more detailed subgroup analyses in order to inform individual patient 
decisions. Crucially, they note that "once one embarks on multiple  
comparisons outside the design hypothesis, accurate estimation o f inferential 
error rates is lost in a randomised design”  (Starmer & Lee 1982, P.1079). 
RCTs are usually too small and too brief to handle this problem, or indeed the 
issue of periodic changes relevant to HTAs in chronic disease areas.
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One of the strongest arguments in favour of ESDs is the claim to a real-life 
naturalistic environment in which patients receive their treatment, regardless 
of and even oblivious to any treatment evaluation undertaken on the collected 
data (Lewis et al. 1993). Thus the use of routine data sources can eliminate 
or at least reduce certain biases such as patient selection bias, recall bias, or 
volunteer bias (Sackett 1979).
However, substantial room for bias and confounding remains in ESDs. The 
main dangers to the validity of an effectiveness study are very similar to those 
faced in non-randomised studies, particularly confounding by indication, which 
may leave even experienced analysts unable to draw sensible conclusions from 
the data (Byar 1980). Motheral and Fairman (1997) provide a comprehensive 
overview of possible limitations of the use of claims databases in outcomes 
research. As threats to internal validity, they mention problems with coding 
diagnostic information, poor reporting of compliance, misclassification of 
exposure, referral bias, protopathic bias (i.e. change in treatment because of 
the baseline manifestation caused by a disease or other event), and 
confounding by risk factor, severity, or indication.
In order to control for confounding by indication, the data source needs to 
contain sufficient detail to allow an assessment of the possible confounding 
variables at baseline in those exposed and those not exposed to the 
intervention of interest (Roberts et al. 1991). Propensity score analysis 
methods have been suggested to assess a database's ability to address a 
particular hypothesis of causal effects (Rubin 1997), and other statistical 
modelling techniques can be used to adjust for confounders (e.g. Cox 
proportional hazards model). However, it  can be argued that it  is impossible 
to rule out residual confounding by unobserved variables (Green & Byar 1984).
Other more practical - and theoretically at least partly avoidable - problems 
include inconsistent reporting or coding of information in databases, changes
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of definitions over time, and a lack of information about those changes, 
missing data, and defining “ time zero” , particularly for patients with chronic 
diseases (Byar 1980; Shapiro 1989; Byar 1991). Even more problems arise in 
prescription databases which often contain limited if  any diagnostic 
information, e.g. of chronic and secondary conditions or the timing of a 
diagnosis (Lewis et at. 1993). Drug prescriptions alone are not a sufficiently 
rigorous definition of exposure (Shapiro 1989) and may pose a threat to 
construct validity, e.g. where a drug can be used for more than one indication 
(Motheral St Fairman 1997).
2.5.4.1 Recommendations for ESDs
Against the background of continued controversy about the validity and 
usefulness of database analyses, some authors have published helpful 
suggestions and recommendations for conducting and interpreting ESDs 
(Huston St Naylor 1996; Motheral St Fairman 1997; von Elm et al. 2007; Gliklich 
St Dreyer 2007):
The paper by Huston St Naylor (1996) in the Canadian Medical Association 
Journal provided an early helpful set of guidance on reporting studies based on 
secondary data analyses. Study authors are advised to pay particularly close 
attention to the assessment of any possible random and systematic errors. In 
addition, the level of detail in the description of the manipulation of the 
database should be such as to allow replication of the reported study. It is 
suggested that authors need to defend their choice of data source by clearly 
demonstrating that it  does indeed capture the variables of interest to the 
study.
This advice is echoed by Motheral and Fairman (1997) in their paper on the use 
of claims databases in outcomes research. Their advice is more 
methodological and comments on the need for a comparative study design, 
and for ensuring that study design and objectives need to be compatible with
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the database. The authors also advise researchers to assess carefully, which 
variables their study needs to have available, and whether these are valid, 
reliable, and complete in the database; relationships between variables need 
to make clinical sense. For example, if  a confounding factor is known, its 
assessment and adjustment must be built into the study. Lastly, the authors 
recommend sensitivity analyses to assess the impact of methodological 
decision, and the reporting of all relevant information important for the 
interpretation of the study and its generalisability to a particular context.
More recently, von Elm et al. (2007) have published a consensus guidelines on 
the reporting of observational studies more generally, which is eminently 
applicable to ESDs. In the same year, the US Agency for Healthcare Research 
and Quality has published its guidance on “ Registries for Evaluating Patient 
Outcomes". In over 200 pages, this publication covers everything from 
planning and design of registries to data collection and quality assurance 
(Gliklich 6t Dreyer 2007).
Thus, plenty of advice exists now for ESD researchers, but I am not aware of 
any reviews of whether published ESDs heed this advice and how they 
overcome potential methodological pitfalls.
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2.6 Published systematic comparisons of randomised 
and non-randomised studies
This section reviews the current literature on systematic comparisons between 
randomised and non-randomised studies of the same intervention. 
Comparisons of RCTs and non-randomised effectiveness studies of single 
interventions were excluded. Reviews were identified from a Medline search 
including relevant methodological terms describing both RCTs and 
observational studies (previously used by Britton et aL 1998). The search was 
undertaken in 2001, a time when the key studies by Benson and Hartz (2000) 
and loannidis et ai. (2001) had just been published. The references of these 
studies and several others discussing them at the time were examined. In 
addition, the electronic table of contents of key journals has been scanned for 
further studies until August 2007 (International Journal of Epidemiology, The 
Lancet, Journal of the American Medical Association, New England Journal of 
Medicine, Journal of Clinical Epidemiology, Journal of Epidemiology and 
Community Health, and British Medical Journal). Given the lack of 
appropriate indexing of relevant reports in bibliographic databases, this 
review cannot be entirely systematic, but it  draws on the key papers available 
at the time and since.
The underlying assumption in such comparisons is that observational studies 
are to be validated against the randomised controlled trial. This may not be 
entirely justified. Kaptchuk (2001 ) argues that the appeal of the randomised 
controlled trial was never based on empirical evidence. He gives a historical 
overview of the development of the widely held view that non-randomised 
methods produce higher estimates of outcomes and favour new treatments. 
However, recent systematic reviews have seriously undermined this 
assumption.
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Kunz and Oxman (1998) have examined the relationship between 
randomisation and effect estimates in a systematic review of four types of 
comparisons: RCTs versus non-RCTs of the same interventions, RCTs versus 
non-RCTs across different interventions, adequately concealed versus 
inadequately concealed random allocation in trials, and high quality trials 
versus low quality trials in which the effect of randomisation could not be 
separated from the effects of other methodological manoeuvres. No 
comparisons between RCTs and observational study designs were made.
In the first comparison, eight identified comparisons represented both under­
and over-estimations of effects in non-RCTs compared to RCTs. In the second 
type of comparisons, which included three reviews, substantial heterogeneity 
and other potentially distorting factors made the interpretation difficult. No 
consistent relationship between study design and effect size were found. The 
third comparison group only included two studies, both of which showed an 
over-estimation of effect in studies with inadequately concealed allocation. 
The fourth comparison (high versus low quality trials) found considerable 
differences in effect estimates with distortion in both directions. The authors 
conclude that “ the unpredictability o f randomisation is the best protection 
asainst the unpredictability o f the extent and direction o f bias in clinical 
trials that are not properly randomised”  (Kunz 6t Oxman 1998, p.1189).
Two reviews undertaken through the UK HTA programme have examined the 
issue (Britton et al. 1998; MacLehose et al. 2000). Reeves and colleagues 
(1998) hold that “ the perception that non-randomised estimates consistently 
favour new treatments has led to the assumption that discrepancies arise 
from bias”  (p.73). Thus the first review (Britton et al. 1998) focussed on 
issues of external validity, whereas the second (MacLehose et al. 2000) 
addressed issues of internal validity.
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Britton et at. (1998) identified 18 papers reporting evaluations of the same 
intervention by non-randomised studies and RCTs. Overall, there was no 
consistent discrepancy between the effect estimates of studies of both 
designs. The authors identify several reasons for discrepancies in either 
direction, which could be due to chance, differences in study populations, 
timing, or the nature of the intervention. The review found that the results of 
both designs concur best if  the same exclusion criteria are applied and 
potential confounders controlled for in non-randomised studies.
The second HTA programme review (MacLehose et al. 2000) compared 
randomised and non-randomised studies of the same intervention reported in 
the same paper. In a second comparison, two interventions were compared, 
regardless of the source of their reports. These interventions were 
mammography screening to reduce breast cancer mortality, and folic acid 
supplementation for women trying to conceive to prevent neural tube defects 
in babies. These interventions were chosen on the basis that the nature of the 
intervention, the populations, and outcomes studied would be similar across 
studies.
For the fourteen papers reporting direct comparisons (38 comparisons), 
MacLehose et al, (2000) judged the fairness of these comparisons based on the 
comparability of the studies and the susceptibility of the comparisons to bias. 
For comparisons judged as “ fa ir” , discrepancies between the results of both 
designs were found to be not significant and were much smaller than for 
“ unfair” comparisons. For the latter there was a tendency in non-randomised 
studies to show more extreme results than randomised studies, particularly for 
large sample sizes.
In the comparisons of studies on mammography screening and folic acid 
supplementation, effect size estimates of RCTs and cohort studies were 
similar, but case-control studies gave significantly different effects estimates.
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However, the direction of the discrepancy could not be predicted, and the 
authors suggest that it  could be specific to the type of intervention.
In June 2000, the New England Journal of Medicine carried two further reviews 
of randomised versus observational studies. Concato and colleagues (2000) 
identified RCTs and observational studies from published meta-analyses and 
were able to perform comparisons of the original studies on five topics (99 
reports). For each topic and study design, summary estimates and confidence 
intervals were determined. This review found that well-designed 
observational studies showed very similar results to RCTs and also showed less 
variability in point estimates than RCTs. The authors challenge the often 
awarded higher status of RCTs in the hierarchy of research designs.
Benson and Hartz (2000) searched first for observational studies comparing 
two or more interventions for the same condition. Subsequently, trials and 
further observational studies of the same research question were searched for. 
Results were pooled by research design (randomised or observational) for each 
of 19 treatment comparisons (total of 53 observational studies and 83 RCTs). 
The combined effect size of observational studies lay outside the confidence 
interval of that of the RCTs in only 2 of the 19 comparisons. However, in most 
cases the possibility of a clinically important difference could not be 
excluded.
A further comparison between effect sizes of randomised and non-randomised 
studies identified as many as 45 medical interventions for which 240 RCTs and 
168 non-randomised studies previously included in meta-analyses of binary 
data were available for comparisons (loannidis et al. 2001). Despite a very 
strong correlation between the synthesised results of both study types (r=0.75, 
p<0.001), non-randomised studies tended to show larger treatment effects (28 
vs. 11, p-O.OO9). Prospective observational studies tended to fare better than 
retrospective ones.
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A more recent methodological study has been undertaken by Deeks et al. 
(2003) as part of the UK HTA programme. The work included the generation 
of non-randomised studies based on re-analysis of data from two large multi­
centre RCTs. The researchers re-sampled the data to generate several 
thousand historically and concurrently controlled non-randomised studies and 
the same number of RCTs for direct comparisons of results. Distributions of 
results for each design could thus be compared. The authors concluded that 
individual non-randomised studies can seriously bias results and mask even 
moderate treatment effects by reporting significant results in the opposite 
direction.
A review by Hartz et aL (2005) considered that issues of validity are not the 
only characteristics of a study which can influence its results. In addition, 
they specified issues of applicability, such as treatment specifics, outcome, 
and patient characteristics. Unfortunately, these issues were not considered 
in the previous comparison studies.
In summary, there is some evidence against the assumption that observational 
studies always arrive at more extreme results than randomised studies. 
However, given the disparate findings of the available reviews and their own 
methodological limitations, it is impossible to predict when observational 
studies might be safe alternatives to RCTs. To that effect, prospective study 
designs seem to be more promising, as do attention to exclusion criteria and 
control of confounders.
Despite their systematic approach, the above reviews effectively constitute a 
series of case studies. Most authors have reported difficulties in identifying 
studies for inclusion. Thus, the generalisability of their findings cannot be 
assumed. It is also not possible to draw general conclusions as to whether 
there are intervention-, patient-, or disease-specific trends in terms of the
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validity of non-randomised studies. Further case studies and methodological 
research will thus be needed.
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2.7 Comparisons between RCTs and ESDs
The reviews reported in the previous section did not focus on ESDs. I 
therefore attempted to identify studies which compared RCTs with relevant 
ESDs. I undertook a Medline search for reviews comparing the findings of RCTs 
with those from ESDs, using the same search terms as for the review described 
in section 6.4 ("CHEMICALS AND DRUGS CATEGORY" [MESH] AND 
(EFFECTIVENESS OR EFFICACY OR OUTCOME OR EFFECT OR EFFECTS) AND 
(DATABASE OR DATABASES OR DATABASES OR DATABASE OR REGISTER OR 
REGISTRY OR REGISTERS OR REGISTRIES OR DATASET OR COHORT OR "CLAIMS 
DATA" OR "SECONDARY ANALYSIS") Limits: English, Human, Core clinical 
journals).
The search was undertaken on December 2001 and limited to reviews 
published in high quality English language journals referenced in the Index 
Medicus. However, this search was abandoned as published abstracts of 
reviews do not indicate clearly whether ESDs are included in the review. This 
section therefore only presents relevant studies known to me or encountered 
during the work on this thesis. This section therefore does not claim to be a 
systematic review of the subject, but a narrative review that does illustrate 
different approaches taken by researchers.
Some workers have provided reports of direct comparisons of results from 
RCTs with those from database analyses. The intentions of their papers vary. 
Pincus (1993) explored a discrepancy found between one of his earlier 
analyses of a clinical database (Pincus et al. 1992) and a randomised trial 
(Williams et a i  1992). The trial had found no difference between 
methotrexate, auranofin, and a combination of both in the treatment of 
rheumatoid arthritis over 48 weeks in days to normalise the creatinine
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phosphokinase muscle enzyme, change in muscle strength score, and change in 
inflammation on the muscle biopsy. The earlier ESD had found that the 
continuation of methotrexate over a minimum of 5 years was over 50%, that of 
auranofin less than 10%. When a subset of treatment courses was selected 
from the database in order to match the inclusion criteria of the trial (only 
courses representing the first second-line drug used in a patient), no 
significant differences were seen between the estimated continuation of both 
treatments after one year. The author concluded that whereas trial and 
database results concurred when selection criteria and timeframes were 
matched, the trial failed to highlight clinically important long-term 
differences (Pincus 1993).
Hlatky and colleagues (1988) have explicitly set out to test whether database 
analyses could arrive at similar information to RCTs, if  the lack of 
randomisation can be corrected for statistically. The findings of three major 
RCTs of coronary bypass surgery (Veterans Administration Cooperative Study, 
European Cooperative Surgery Study, and Coronary Artery Surgery Study 
(CASS)), were compared with predictions based on statistical models using 
data from the Duke Cardiovascular Disease Databank. This longitudinal 
database of patients having undergone cardiac catheterisation is specifically 
aiming to provide prognostic factors in order to predict the prognosis of 
individuals. Since direct application of the prognostic model to trial patients 
was not possible, the authors selected individuals from their Databank who 
would have been eligible to participate in a particular trial. Their baseline 
information was then used to predict the results of therapy observed in the 
trial. In addition, there was an adjustment for the time period of each trial. 
Predicted 5-year survival was then compared to that observed for the arms of 
each trial.
The authors report a very close correlation between predicted and observed 
survivals (Spearman correlation coefficient: 0.73, p<0.0001). In five out of six
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trial arms, the predictions of the trial results were within the 95% confidence 
limits of the observed survival rates. It is unclear whether the one 
inconsistency (medically treated patients of the CASS) was due to a 
shortcoming of the model or differences between trial and database patient 
populations. It is suggested that prognostic models may assist in interpreting 
conflicting RCT results (Hlatky et al. 1988). The study considered outcomes 
after a surgical intervention, and the extent of concordance between 
predicted and observed effects may be quite different for long-term drug 
therapies.
There are instances where the conduct of an RCT is closely related to data 
collection for a patient registry. Feit and colleagues (1999) report for the 
Bypass Angioplasty Revascularisation Investigation (BARI) the results of a 
randomised trial (n=1829) of percutaneous transluminal coronary angioplasty 
(PTCA) and coronary artery bypass graft surgery (CABG). Eligible patients who 
did not consent to randomisation and for whom treatment was chosen by their 
physicians were followed-up in an accompanying registry (n=2010). Numerous 
differences were observed between both studies at baseline. Of 90% 
revascularised registry patients, 66% were selected for PTCA.
Randomised CABG patients had fewer grafts, fewer lesions, and shorter bypass 
times than registry patients receiving CABG (p<0.001). Patients randomised to 
PTCA had more significant lesions (p<0.001) and were more likely to need 
emergency CABG than registry patients receiving PTCA (p=0.027). Seven-year 
mortality did not differ significantly between RCT and registry patients (after 
CABG: 15.6% and 14.2% respectively, unadjusted relative risk: 1.08, p=0.57, 
adjusted relative risk: 0.94, p=0.66; after PTCA: 19.1% and 13.9% respectively, 
unadjusted relative risk: 1.43, p<0.01, adjusted relative risk: 1.17, p=0.16). 
The authors did not present a direct comparison of effect sizes of the two 
studies; rather the emphasis was on the successful selection of patients for 
PTCA without jeopardising long-term survival (Feit et at. 1999).
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The CASS of medical and surgical (CABG) interventions for coronary artery 
disease also operated an RCT and registry (Holloway & Schocken 1988). 
Chaitman and colleagues (1990) presented 10-year survival data for 
randomised and registry patients who were eligible but not randomised. No 
significant differences were found between survival rates of randomised and 
non-randomised patient groups (medical: 79% and 80% respectively, CABG: 82% 
and 81% respectively). However, apart from a large proportion of eligible 
patients who refused random assignment, the registry contained a large 
number of non-eligibte patients. The RCT sample was relatively healthy 
compared to the actual patient population (Holloway 6t Schocken 1988).
Feuer and colleagues (1994) have examined whether patients on cisplatin- 
based combination chemotherapy for advanced testicular cancer and 
registered in the SEER Programme have experienced the same survival benefit 
as participants in the Memorial Sloan-Kettering Cancer Centre trials (n=172 
and n=133 respectively). Multiple exclusion criteria ensured that both patient 
groups were comparable in terms of disease staging and prognostic 
characteristics. Despite most registry patients receiving chemotherapy, the 
survival of those categorised as having minimal/moderate extent of disease 
was significantly poorer than that of comparable trial patients (73% and 95% 3- 
year survival rate; p<0.001), for advanced stage patients the difference was 
less stark (40% and 52% respectively; p=0.56). After a range of sensitivity 
analyses to test the many assumptions involved in defining and comparing the 
samples, the authors concluded that, rather than the mere availability of 
effective chemotherapy, other health care delivery factors seemed to have a 
major impact on patient outcome.
In the area of HIV, several national and international patient databases exist. 
Phillips and colleagues (1999) have used data from three of these databases to 
estimate the effectiveness of antiretroviral regimens and compare these
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estimates to results of available randomised trials. Three treatment 
comparisons were identified for which data were available from both sources 
(trials and databases): (i) zidovudine monotherapy versus combination therapy 
of two nucleoside analogues; (ii) zidovudine in combination with either 
didanosine or zalcitabine; and (iii) dual combination versus triple therapy 
including a protease inhibitor. Cox proportional hazards models were used to 
analyse data from the three databases for each treatment comparison in an 
intention-to-treat analysis, adjusting for baseline differences and confounders.
The adjusted relative risk estimates for progression to AIDS or death were 
compared with corresponding trial results. For comparisons (i) [zidovudine 
monotherapy versus combination therapy of two nucleoside analogues] and (ii) 
[zidovudine in combination with either didanosine or zalcitabine], the 
estimates from the databases were similar to those resulting from the trials 
(comparison (i): between 0.61-0.84 compared with 0.57-0.63 respectively; 
comparison (ii): between 0.81-1.01 compared with 0.77-0.92 respectively). In 
comparison (iii) [dual combination versus triple therapy including a protease 
inhibitor], one of the cohorts contradicted the trial result (relative risk: 1.20 
(95%CI: 1-01-1.44) compared to 0.50 (95%CI: 0.33-0.76) respectively). The 
authors conclude that biases were present albeit small in eight out of nine 
comparisons. Given the inability of large-scale trials to keep up with the 
speed of development of HIV therapies, the consideration of a combination of 
several database analyses seems very useful, if prognostic factors are 
balanced.
In summary, these case study comparisons of RCTs and published ESDs show a 
similar picture to that presented by the reviews in section 2.6: patient 
selection appears to be an important issue in terms of comparability, as are 
other healthcare related factors which may not always be well described or 
controlled. It is difficult to search for such studies comprehensively, and 
hence to draw any methodological conclusions from these selected examples.
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2.8 Summary
Randomisation is the preferred method to assure internal validity of studies 
evaluating treatment effects. However, RCTs often only achieve poor external 
validity. Moreover, the trial environment and randomisation per se may 
introduce different biases and may therefore lim it a realistic evaluation of 
treatment effectiveness. Alternative randomised study designs have been 
proposed to address specific criticisms of RCTs, but experience with them is 
still limited.
Systematic comparisons of randomised and non-randomised studies have been 
inconclusive, but it  would appear that there is no systematic distortion of 
effect estimates stemming from non-randomised studies. It has been 
suggested that effect estimates from both study types are generally similar if 
baseline differences are adjusted for in the non-randomised studies, and the 
same selection criteria are used (Britton et al. 1998). None of the systematic 
comparisons focussed on ESDs specifically. Similarly, several reviews have 
assessed the potential contributions of database research to health technology 
assessment, but their focus is also not on ESDs, let alone ESDs of drug 
therapies.
ESDs of treatment effectiveness seem to offer potentially comparatively large- 
scale assessments with long follow-ups of treatment use and associated 
outcomes in naturalistic settings. Such studies have been much debated and 
criticised, particularly for their proneness to confounding by indication and 
poor internal validity. Whereas guidance on the conduct of such studies is 
increasingly becoming available, no systematic assessment or review of them 
has yet been undertaken. There are limited examples and limited experience 
with comparisons of non-randomised and randomised studies, particularly
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ESDs, and reviews or single comparative studies do not allow any firm 
conclusions on the validity or quality of ESDs in general.
The following three chapters describe a case study of an ESD (the Dornase Alfa 
Case Study), with particular focus on the methodological challenges arising in 
the process. This is followed by a comprehensive review of similar published 
studies and their methodological features relating to internal and external 
validity, as well as an attempt at comparing their results with those from 
RCTs.
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3 Dornase Alfa Case Study: Preparatory Issues
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3.1 Introduction
This and the subsequent two chapters report an attempt to undertake an ESD. 
The intention of this chapter is to describe the design and preparatory phases 
of the study and the challenges encountered there. The subsequent chapter 
illustrates in detail further methodological challenges encountered in 
examining the data source and the quality of its data. These chapters thereby 
demonstrate some of the difficulties and weaknesses of ESDs. The study itself 
has been reported previously to the funding body (the NHS Executive North 
West) by the principal investigator (Dr A Haycox), and the third chapter 
dedicated to the Dornase Alfa Case Study (Chapter 5) provides an overview of 
the descriptive analysis undertaken by an analyst at the time.
Cystic fibrosis (CF) is an inherited disease, affecting an estimated one in 2,500 
newborn babies in the UK (Dodge et al. 1997). The genetic defect is 
associated with abnormally high absorption of sodium between the cells, 
resulting in thickened, dehydrated secretions. The most serious manifestation 
is respiratory disease. Patients have abundant viscous sputum, which can 
become infected by bacteria. Inflammation of the airways contributes to 
progressive lung damage. The median life expectancy of people with CF has 
increased significantly over the past decades due to comprehensive treatment 
regimens. In 1991, the median life expectancy of a child born with CF has 
been estimated to be around 40 years (Elborn et al. 1991).
Recombinant human deoxyribonuclease (rhDNase) called dornase alfa is a 
genetically engineered version of a human enzyme which cleaves extra­
cellular deoxyribonuclease (DNA). It is marketed under the name 
Pulmozyme®. The drug is administered by inhalation and cleaves the DNA in 
the sputum, thereby reducing its viscoelasticity. Clearing the lungs of the 
viscous sputum (usually through physiotherapy) is one of the most important
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interventions in CF, and dornase alfa is intended to facilitate that process. 
The drug has been licensed since 1994 and the current UK licence is for use in 
CF patients who are over five years of age with a forced vital capacity (FVC) of 
greater than 40% of predicted, to improve pulmonary function.
The annual treatment costs in the UK for continuous dornase alfa therapy are 
currently approximately £6,800 per patient. There is evidence for the short­
term effectiveness of the drug, but the long-term effectiveness is still under 
question. It was clear that a long-term RCT was not feasible due to most 
existing patients no longer being naïve to the drug. Any new potential RCT 
would have had to recruit from a small number of newly diagnosed patients 
meeting certain eligibility criteria. Also, the loss of equipoise would have 
spoken against another RCT. The NHS Executive North West therefore 
provided funding for an observational study in 1999, to elicit evidence on the 
long-term cost-effectiveness of dornase alfa.
This and the subsequent chapter present the preparation phase and the 
methodological challenges encountered in the process. Subject-specific 
information, such as the complete literature review and more detailed 
descriptive Dornase Alfa Case Study results are presented in Appendix A to not 
deter from the methodological focus. This chapter describes how the original 
study design had to be adapted sequentially due to practical difficulties with 
the planned approaches. One of the main issues here was data protection, 
and this topic is covered in a separate section.
3.1.1 Summary of the literature review
Readers unfamiliar with the nature and epidemiology of CF, or the literature 
on the effectiveness of dornase alfa, may wish to refer to Appendix A for a 
detailed literature review undertaken for the Dornase Alfa Case Study. Below,
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the conclusions relevant to the rationale for an observational study approach 
are reproduced:
❖ There were indications that benefits of dornase alfa in CF in terms of a 
reduced lung function decline and a reduced risk of respiratory 
exacerbations may continue over the long term. Randomised controlled 
trial evidence of the efficacy of dornase alfa was available for a follow- 
up period of 2 years. In the longest (two-year) RCT, the treatment 
group exhibited a significantly reduced lung function decline vis-à-vis 
the control group. However, after one year, this difference was not 
significant (Quan et al. 2001).
❖ Longer-term RCTs do not exist and are very unlikely to be possible in 
future. Observational studies of more than two years follow-up are 
rare; they are so far of relatively small scale and frequently without 
comparison groups. The authors of a relatively recent four-year case- 
control study recommended further long-term studies involving larger 
cohorts (Shah et al. 2001).
❖ Considerable variations in the nature and extent of response between 
and probably also within individuals as well as practice variations 
between different CF centres add to the difficulties in evaluating the 
effectiveness of dornase alfa.
3.1.2 Aim and objectives
The aim of the original Dornase Alfa Case Study was to evaluate whether long­
term use of dornase alfa was associated with a delay in disease progression in 
CF patients and hence an extension in their survival, and to assess whether 
statistically significant changes in lung function measures demonstrated in the 
trials would translate into clinically relevant outcomes such as exacerbations, 
or disability /  quality of life.
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The objectives of the study were to:
1. undertake a long-term comparative analysis of homogenous groups of 
dornase alfa users employing a large scale longitudinal database;
2. analyse the mortality experience of the different dornase alfa user 
groups, as far as is possible within the sample;
3. analyse the rate of respiratory exacerbations experienced by patients 
from each group;
4. analyse the long-term decline in lung function experienced by each 
dornase alfa user group;
5. analyse the long-term anthropometric changes experienced by each 
dornase alfa user group.
As will be demonstrated, the analysis of the data was limited for a variety of 
reasons. Therefore, the intention of this and subsequent chapters describing 
the Dornase Alfa Case Study focuses on learning methodological lessons from 
the detailed process of preparing and conducting the study.
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3.2 Proposed and final study designs
The research question of the protocol approved for funding by the NHS 
Executive North West was “ to undertake a rigorous naturalistic multi-centre 
tria l to assess the impact o f DNase on disease progression, quality o f life  and 
resource consumption in patients with cystic fibrosis” . It was intended to 
exploit the difference in treatment protocols between centres, whereby some 
used dornase alfa, and others did not. Thus retrospective data collection 
should have first identified matched pairs of patients from seven Northern 
English CF centres (three adult and four children’s centres) - patients on and 
off dornase alfa. A retrospective study phase should have reviewed available 
data and thus permitted sample size calculation for a prospective study phase. 
In a 1 -year prospective phase data on relevant outcomes, specifically long­
term trends in lung function, and self-rated quality of life, would have been 
collected for comparative analysis of patients on and off the drug.
The project steering group included the principal investigator and all co­
applicants for the original proposal funded by the Department of Health, North 
West Regional Office.1 Prior to commencing the study, early discussions with 
the steering group revealed that the proposed prospective phase of the study 
in particular was considered not feasible in practice. Instead, a solely 
retrospective record review was suggested, covering a longer time period of
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10 years, and comparing the experiences of patients “ on" and “o ff” dornase 
alfa. Data from this period was to be collected from medical records and 
existing information systems in the participating seven CF centres, and thus 
avoided direct data collection involving patients.
A pilot phase sought to establish the availability of suitable data in the centres 
and to estimate the time necessary for data extraction. A question pro forma 
was developed to interview the centre clinicians about data availability and 
accessibility of key variables such as demographic data, lung function 
measurements, anthropometric measurements, dornase alfa use, and 
exacerbations. Clinicians and operational staff in the centres were 
interviewed by telephone to elicit this information.
The retrospective data collection was piloted in one centre which was 
considered to have relatively well-summarised and accessible paper-based 
records going back several years. Even there, records did not reach far 
enough back, and what was more important, the manual data extraction per 
patient took far longer than the estimated time available for the retrospective 
study phase. Whereas there was one other centre which had computerised 
data, this was rather limited in terms of available variables. In other centres, 
actual records would have had to be reviewed, which would have multiplied 
the time necessary.
The interviews and pilot work further identified that (1) data availability for 
key variables covering the period in question varied considerably between the 
units, and, given that I would have had to access and retrieve data from 
patient records, (2) further significant delays would have been inevitable 
because of the need for getting individual written consent from patients, 
parents, or guardians.
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The Steering Group therefore identified another option: members considered 
that all centres involved in the study had over a number of years contributed 
anonymised data on their patients to a Europe-wide database of CF patients, 
the European Registry of Cystic Fibrosis (ERCF). Many of the data items that 
were originally to be retrieved manually from patients’ records were collected 
in that database. The principal investigator therefore was tasked with 
approaching the chair of the ERCF Advisory Committee to seek access to the 
data.
The Europe-wide Advisory Committee for the ERCF was keen for researchers to 
use the data (not least as this was hoped to support the case for applying for 
public funding to continue the registry), but had not yet been approached by 
any outside institutions wanting to do so. Consequently, no formal process for 
gaining access to the data existed. The ERCF Advisory Committee controlled 
access to the data and considered the individual CF centres and patients to be 
the owners of the ERCF data. The Committee had to first explore and agree 
their approach for releasing the data. The process between the first 
application to the Advisory Committee for access to the ERCF data and the 
eventual receipt of the dataset took 6 months.
Agreements had to be reached on the proposed use of the dataset, as well as 
the potential restrictions on any future publications resulting from the 
analysis. However, a main concern of those developing the process for
granting the research team access to the data appeared to be the 
confidentiality of centres and clinicians, as much as patients. Between the 
Advisory Committee and the company managing the ERCF (NSPM), it  was 
decided that each CF centre should give written permission for its data to be 
made available for the current research study. In addition, principal 
investigators in the seven participating units had to give their written 
permission for the research team to receive the code which identified their
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respective centres (rather than patients). The process from my appointment 
to this study to the receipt of the first copy of the ERCF took one year.
Clinicians on the local Steering Group had expressed reservations about the 
quality and completeness of data in the ERCF, and therefore detailed data 
verification was planned against information existing in the centres. This 
meant that individual patients' data had to be decoded and checked. 
Quintiles, the company holding the ERCF data, was instructed to introduce an 
additional layer of coding for extra protection, so that only centres themselves 
were able to identify patients from the dataset. This meant that CF centres 
involved in the data verification exercise had to go through two steps of 
decoding to identify patients from the dataset.
However, the data verification also encountered data protection issues arising 
from new legislation at the time, as the Data Protection Act had only just 
been published and was not consistently understood and interpreted by 
relevant decision makers in participating centres. The following section 
considers the impact of this new legislation on research using patient records. 
It describes how I was forced to navigate and interpret the then very unclear 
and conflicting available guidance, at the same time as the research approach 
kept being adapted and therefore raised different data protection issues each 
time.
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3.3 Data protection and confidentiality issues
3.3.1 Introduction
As described above, the protocol for the research project underwent 
considerable changes. Each of them posed questions regarding applicable 
data protection and confidentiality rules. It is important to stress that this 
work was undertaken at a time of major changes in NHS governance, 
particularly research governance, around the year 2000, and against the 
background of inconsistent and unclear policy and guidance from various 
bodies. More guidance exists now, and this is referred to in the Discussion 
(Chapter 8).
This section describes in detail the data protection and confidentiality issues 
faced at the planning stage of the research project. Firstly, the section 
reports on the process of gaining approval by the Research Ethics Committees. 
Thereafter, the changing research approach and resulting data protection 
issues are mapped out for clarity, and the reader taken on a chronological 
journey of the decision-making processes involved, accompanied by summaries 
of the then existing guidance.
3.3.2 Research ethics committee approval
Before work on the research project began, approval for the initial protocol 
was sought and received from the North West Multi-Centre Research Ethics 
Committee (MREC), as well as the relevant Local Research Ethics Committees 
(LRECs) for seven participating centres. At the time, the latter worked 
independently of the MREC and could in theory reject a study approved by the 
MREC. In this case, only minor conditions were imposed, e.g. to use Trust­
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headed paper for correspondence with patients. A later protocol alteration 
was similarly approved by the MREC, and the required written notification of 
these alterations was sent to the relevant LRECs.
Research ethics committee approval is not synonymous with the fulfilment of 
data protection and confidentiality laws, but constitutes considered advice on 
the observance of ethical principles in research proposals. As soon as the first 
changes to the protocol were discussed, the MREC’s advice was sought on the 
need for consent of patients to permit the collection of data from their 
medical records by myself. The MREC advised us to check the proposal with 
data protection officers of the responsible hospital Trusts (now this is national 
guidance). This was the beginning of a lengthy exploratory journey through 
then current data protection legislation and guidance. The following section 
illustrates this alongside the changes in the research approach.
3.3.3 Changes in the research approach and resulting data 
protection issues
The initial research protocol envisaged the collection of original data from 
patients (e.g. quality of life measurements) as well as the access to patient 
record systems by myself as a University-employee to retrieve routinely 
collected clinical data. The second protocol involved only the retrieval of 
routine data.
The final protocol meant that routine data submitted to a clinical database, 
the Epidemiologic Registry of CF (ERCF), were to be used (see section 4.2.1). 
This database had been set up in 1994 by F. Hoffmann-La Roche across several 
European countries as a multi-centre, longitudinal, follow-up project of CF 
patients receiving routine care. The intention was to collect data on all 
patients of participating CF units and analyse progression of lung disease by 
pulmonary function and infection rates (Anonymous 1994). The data were
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anonymised, insofar as the CF centres reporting data relating to individual 
patients were able to decode the data and identify their patients. For the 
planned extensive data verification process as part of this research, however, 
this decoding was unavoidable.
The table below illustrates the relevant changes in research approach and the 
data protection issues arising from each. It is obvious that the issue of 
“ consent” (to accessing records or coded data) played a key role. The 
requirement for this was not clearly defined at the time, and subsequent 
questions arose from the available guidance, e.g. under which conditions 
might consent be implied, rather than explicit (e.g. written) consent be 
necessary, and under which conditions might a requirement for consent be 
waived? Another key question was this: whose role and responsibility should it  
be to decide upon the answers?
Table 3.1: Changes in research approach and data protection issues
Research approach Data protection issues
First protocol:
(1) Data collection from patient records, 
plus
(2) Prospective data collection from 
patients and records
(1) Is consent required for access to records by a
university-employee?
(2) Clear that consent was required for
prospective phase.
Second protocol:
(1) Longer retrospective data collection 
from patient records
As (1) above
Final protocol:
(1) Use of ERCF database for analysis
(2) Decoding of individual data in 
centres for data verification exercise
(1) Is consent required given that this is “coded” 
data, i.e. the decoding key still exists?
(2) Only staff ordinarily able to access patients’ 
data should be involved in this exercise
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This story cannot be told without equipping the reader with the basic concepts 
involved, and introducing him to the then available guidance and resulting 
issues. In doing so, I re-trace my steps in seeking clarification from available 
guidance, as I was increasingly becoming aware of the complexities involved. 
However, as will become more obvious, the guidance documents were 
inconsistent and confused the issues. I finally published part of our 
experience in a paper in the British Medical Journal - possibly the first having 
illustrated the implications of the then current state of the law for research 
involving patient records, and hence a major contribution to the debate at the 
time (Strobl et al. 2000). It is worth pointing out that further developments 
and debates have taken place since, and an update can be found in Chapter 8.
Before describing the sources of law and guidance at the time, I will introduce 
the reader to definitions of relevant concepts (and their lacking clarity): Table 
3.2 illustrates well the confusion already arising from merely attempting to 
clarify the concepts involved in answering the question of consent for 
accessing records.
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Table 3.2: Definitions and their inconsistencies at the time
Personal data
The EU Data Protection Directive 95/46/EC defines personal data as “any information 
relating to an identified or identifiable natural person” (European Parliament and 
Council 1995 p.42). A person may be identifiable directly or indirectly, also through 
the use of identification numbers or reference to specific items of information. The
UK Data Protection Act 1998 limits this to living individuals.____________________
Data processing
According to the Data Protection Act 1998, data processing means obtaining, 
recording, or holding data and includes any operation performed upon the data,
whether automated or not. Disclosure is a data processing operation.____________
Data controller
Legal person or agency who determines the purpose and means of processing 
(European Parliament and Council 1995). The data processor may be different from
the data controller.__________________________________________________
Common Law Duty of Confidentiality
The British Medical Association defines confidentiality as “ the principle of keeping 
secure and secret from others, information given by or about an individual in the 
course of a professional relationship” (Romano-Critchley & Sommerville 1999). This 
legal duty applies to information entrusted to someone in confidence. The duty of
confidentiality applies independently of the UK Data Protection Act._____________
Consent for data processing
The EU Directive 95/46/EC defines consent as “any freely given specific and informed 
indication of his wishes by which the data subject signifies his agreement to personal 
data relating to him being processed” (European Parliament and Council 1995 p.43). 
Rather unhelpfully, the UK Data Protection Act 1998 does not define consent at all.
However, the definition given by the Directive leaves uncertain the nature of the 
required consent. For example, there is uncertainty about whether consent can be 
implied if the patient knows that data will be shared but does not express any 
objection. Also, it remains unclear what constitutes information for “ informed” 
consent. Seemingly unrelated to the issue of consent, the Directive specifies 
information to be given to the data subject; this may be insufficient as a basis for 
his/her decision to permit their data to be processed in the first place.
According to the Directive, the “ unambiguous” consent of the data subject is one of 
several criteria for making data processing legitimate; but consent can be waived 
under certain conditions, such as the vital interest of the data subject, or if 
processing is in the public interest.
In relation to health data, the Directive - as well as the UK Data Protection Act 1998 - 
requires "explicit” consent of the data subject to the processing of such data, unless 
other conditions are met. Among these conditions are purposes of preventive 
medicine, medical diagnosis, provision of care or treatment, or health-care service 
management, as long as a health professional or person subject to obligations of 
secrecy processes the data. EU member states are permitted to lay down additional 
exemptions for reasons of “substantial” public interest, either by law or decision of 
the supervisory authority (in the UK, the Data Protection Commissioner, see below).
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Anonymisation
The EU Data Protection Directive concerns data which may identify individuals 
directly or indirectly. Many read this as including coded data, not least the UK Data 
Protection Commissioner, who uses the term “pseudonymised” in this case. Some 
guidance documents interpret anonymisation differently, however. For example, the 
Royal College of Physicians Committee on Ethical Issues in Medicine (1999) 
recommends early anonymisation of data for research using archived patient data. 
However, the authors must have been aware that longitudinal databases cannot do 
away with codes, otherwise updating of registers, or data verification would not be 
possible. Even where guidelines talk about a complete separation of the clinical or 
administrative information from anything which may identify an individual, it still 
remains unclear whether data can be called anonymous if the decoding information
remains in existence but inaccessible to e.g. a researcher.____________________
Public interest
The EU Directive 95/46/EC permits processing of personal data in the public interest 
(even without consent). It is noteworthy that in the context of health data, the 
Directive uses the expression "substantial public interest” . However, the concept of 
public interest (or for that matter, substantial public interest) is not defined. The 
BMA guidance (Romano-Critchley 6t Sommerville 1999) gives much attention to this
issue._________________________________________________ ____ ______
Audit or research
In the UK, audit does not require consent or ethical approval (Royal College of 
Physicians Committee on Ethical Issues in Medicine 1999), albeit that this view is not 
held unanimously, and that there is still some confusion as to the dividing line 
between audit and research (Wilson et al. 1999). The UK Department of Health 
acknowledges that at times the dividing line is blurred.
Whereas some hold that audit is part of the healthcare process and therefore does 
not need consent (R&D Office 2002), others view patients' consent for audit as 
necessary unless their data are effectively anonymised (CMC 1998).______________
Various professional and health sector bodies have addressed questions of 
consent, anonymisation of data for research, and access to medical notes for 
research purposes (rather than audit), and I have already drawn on existing 
guidance documents in defining the concepts above. At the time of protocol 
development for the Dornase Alfa Case Study project, some of these 
documents were in the process of being updated, some had already been 
published and met with criticism, not least for pre-empting others (Romano- 
Critchley & Sommerville 1999).
With few exceptions, broad debate about the implications of the then new 
Data Protection Act 1998 was lacking, particularly in the context of
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epidemiological research using patients' records. Thus, there was a dearth of 
up-to-date and clear policy guidance on which to base research protocols. 
This was not helped by the fact that the interpretation of the Act as well as of 
the common law duty of confidentiality were subject to debate, and no case 
law existed which might have clarified at least some of the interpretation.
This section summarises the relevant legislation and guidance available at the 
time of planning the research project, with an emphasis on the issues raised 
by the project. It is useful to revisit the relative hierarchical positions of the 
guidance and legal instruments. A Directive in European Union law is an 
instrument of primary legislation; it  is binding to all EU member states which 
have to implement it  in their national law. In the UK, constitutional law 
consists of statute law and case law, with the latter constituting judicial 
precedents as judges in the courts interpret statute law (Carter 2002). Public 
General Acts (such as the Data Protection Act 1998, or the Human Rights Act 
1998) and Local and Personal Acts are the two types of primary UK legislation.
Statutory instruments (Sis) are regulations made under the authority of an act 
and thus constitute secondary legislation. In contrast to the planning phases 
of the research study, there are now several statutory instruments relating to 
the Data Protection Act 1998 clarifying particular aspects of the Act. For 
example, statutory instruments have expanded on the access of data subjects 
to their own data, including an SI referring to health data (Anonymous 2000b), 
or on conditions under which sensitive personal data may be processed 
(Anonymous 2000b). However, no SI seems to clarify in particular any of the 
issues faced in the research project described in this thesis.
in the case of the Data Protection Act 1998 in particular, the views and 
guidance expressed by the UK’s Information Commissioner (formerly Data 
Protection Commissioner) interpreting the Act can be viewed as authoritative. 
The Commissioner has published two significant documents which became
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available only after the critical decision-making phase in the Dornase Alfa 
Case Study project (Information Commissioner 2001; Information 
Commissioner 2002).
Guidelines and codes of professional and public bodies do not constitute any 
legal instrument, but they may be taken into consideration in a court of law. 
One SI (Anonymous 2000a) has accepted certain codes published by agencies 
such as the British Broadcasting Corporation, Press Complaints Commission, or 
Independent Television Commission as relevant for interpreting the Act. 
Compliance with guidelines of a professional body may be looked upon 
favourably by a court of law, but it  does not guarantee legality of conduct.
European Directive 95/46/EC
The Directive 95146/EC o f the European Parliament and o f the Council o f 24 
October 1995 on the protection o f individuals with regard to the processing o f 
personal data and on the free movement o f such data (European Parliament 
and Council 1995) stresses the Member States’ responsibility to protect the 
right of natural persons to privacy with respect to the processing of personal 
data, whether automated or not.
A guiding principle of the Directive is that personal data must be processed 
“ fairly and lawfully” . Neither the Directive, nor the Data Protection Act 1998 
made clear the meaning of this phrase, and there was room for different 
opinions on its interpretation and thus implementation. In the context of 
health data, the phrase was generally interpreted as complying at least with 
the common law duty of confidentiality.
Whereas data must not be processed in a way incompatible with explicit and 
specified purposes, further processing for statistical and scientific purposes is 
permissible.
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Data Protection Act 1998
This brings into UK law the European Directive 95/46/EC on the processing of 
personal data. The Act came into effect on 1 March 2000, and in comparison 
with the 1984 Data Protection Act (which it  replaces) is concerned with both 
records on paper and records held on computers. The Act does not concern 
personal data relating to dead individuals, or anonymous data (which is no 
longer considered identifiable and thus not personal). The Act is based on 
eight principles (Table 3.3), the first of which stipulates that “personal data 
shall be processed fa ir ly  and law fu lly .”  Schedules 2 and 3 of the Act set out 
conditions applying for the purposes of this First Principle.
Table 3.3: Eight principles of the Data Protection Act 1998_____________
(1) Personal data shall be processed fairly and lawfully and, in particular, shall 
not be processed unless -
a. At least one of the conditions in Schedule 2 is met, and
b. In the case of sensitive personal data, at least one of the conditions in 
Schedule 3 is also met.
(2) Personal data shall be obtained only for one or more specified and lawful 
purposes, and shall not be further processed in any manner incompatible 
with that purpose or those purposes.
(3) Personal data shall be adequate, relevant, and not excessive in relation to 
the purpose or purposes for which they are processed.
(4) Personal data shall be accurate and, where necessary, kept up to date.
(5) Personal data processed for any purpose or purposes shall not be kept for
longer than is necessary for that purpose or those purposes.
(6) Personal data shall be processed in accordance with the rights of data 
subjects under this Act.
(7) Appropriate technical and organisational measures shall be taken against 
unauthorised or unlawful processing of personal data and against 
accidental loss or destruction of, or damage to, personal data.
(8) Personal data shall not be transferred to a country or territory outside the 
European Economic Area unless that country or territory ensures an 
adequate level of protection for the rights and freedoms of data subjects
________ in relation to the processing of personal data. _____________
Schedule 2 applies to the processing of any personal data and stipulates that 
data subjects have to have given “ consent”  to processing (which is not further 
defined), or the processing has to be necessary for a variety of stated reasons.
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Among these are the “exercise of any other functions of a public nature 
exercised in the public interest by any person” , and circumstances that the 
Secretary of State may specify as purposes of legitimate interest.
Schedule 3 applies to the processing of sensitive personal data (in addition to 
Schedule 2), which includes health data. For the processing of such data, 
“ explicit consent”  is required. Again several alternative conditions are listed. 
One of these relates to processing being necessary for medical purposes - 
which explicitly include medical research -, as long as a health professional or 
someone with a duty of confidentiality undertakes them. It is important to 
remember, that the First Principle of fair and lawful processing needs to still 
be met in medical research, but that this as well as confidentiality were 
poorly defined.
In Section 33, the Act makes an exemption for research with regard to the 
Second Principle. Accordingly, the further processing of personal data for 
research is not incompatible with the purposes for which they were obtained, 
provided the processing does not get used with respect to individuals or is 
likely to cause distress or damage to a data subject. This exemption comes 
into play where health professionals use for research the data they have 
collected “ fairly and lawfully” as part of their professional relationship with 
patients.
Human Rights Act (1998)
This Act formally incorporates into UK law the European Convention of Human 
Rights. This guarantees the right to respect of privacy. The Act enables 
people to enforce their Convention rights in the UK and makes it  illegal for 
public authorities to infringe these rights. It was thought that the impact of 
this Act on current practice would be small, as current ethical standards were 
seen as likely to be compliant with the Act (BMA 2000).
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Case law
Ultimately, the legality of using confidential data in research can only be 
determined on a case by case basis by the courts (Strobl et al. 2000). 
However, there are few court rulings to guide the interpretation of the 
common law of confidentiality (see next section).
Department of Health guidance
The Department of Health did acknowledge that there were conflicting legal 
views on applying the duty of confidentiality and was at the time trying to 
interpret it  for the health sector (NHS Executive 1999c). A previous 1996 
Health Service Guidance document (HSG(96)18) is quoted which holds that 
consent to sharing information for NHS purposes can be implied if a patient 
has been informed and does not object.
In For the Record (NHS Executive 1999b), it  is noted that the common law duty 
of confidentiality can be overridden by public interest. The document goes on 
to say that if data are anonymised (“ so that individual patients cannot be 
identified” ), it  can be used for epidemiological research (presumably without 
consent).
The Department of Health was involved in a court case brought by Source 
Informatics Inc. who sought to obtain and sell anonymous information from 
pharmacies (Anonymous 1999). The first ruling in the case raised the question 
of whether even the processing of fully anonymous data was in breach of 
confidentiality (Anonymous 1999). However, an appeal against this was 
upheld (Anonymous 2000d).
Thus at the time of the research proposal development, topical Department of 
Health guidance was lacking, albeit that it  had been announced and was 
imminent. In the meantime, UK professional and research bodies had
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developed their own (conflicting) guidance documents, which are summarised 
in Table 3.4. In summary, at the protocol development stage of the Dornase 
Alfa Case Study, there were significant gaps and uncertainties across the 
legislative and guidance documents in the definitions of key concepts, such as 
what constituted "fair and lawful” processing, the duty of confidentiality, 
consent, as well as “ public interest” . Professional bodies had issued guidance 
documents, which could be seen as incongruent with the Data Protection Act. 
It may be suspected that some incongruence was a deliberate challenge, as 
the medical and research community was becoming aware of the potential 
threats to the epidemiological research posed by the legislation. Only the 
resulting confusion was certain.
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Table 3.4: Guidance from UK professional and research organisations
General Medical Council (CMC)
The GMC guidance Seeking Patients’ Consent: the Ethical Considerations (GMC 1998) 
referred partly to research. The GMC demanded that doctors seek written consent 
for research from patients, but did not specifically refer to the use of anonymous
data for research.___________________________________________________
British Medical Association (BMA)
The BMA had published one of the most recent and most detailed guidance documents 
available at the time (Romano-Critchley Et Sommerville 1999). The guidance held 
that passing patient information from one health professional to another in the “NHS 
family" who is not involved in the care of the patient concerned constitutes a breach 
of confidentiality. The guidance made surprisingly few references to the Data 
Protection Act. Instead, the BMA took a clear stance on anonymisation, stating that 
the processing of fully anonymised data did not require consent, but advised 
clinicians to seek legal advice given the uncertainties.
Most critically, perhaps, this guideline defines personal health information as one 
from which a person can be identified. The guideline goes on to say that 
“ Information which does not permit the recipient to identify an individual is not 
contentious. Coded, encrypted, aggregated, or anonymised data can easily be used 
effectively for many health service or research purposes instead of identifiable data. 
... Use of minimal data identifying the patient's electoral ward, sex and year of birth 
is acceptable for administrative or research purposes” (Romano-Critchley & 
Sommerville 1999).
Anonymised information is defined as information which does not identify the data 
subject, either directly or indirectly. The text following this definition in the 
guideline, however, seems to imply that what matters is that the user of the data is 
unable to identify the data subject. This and the paragraph above indicate that the 
BMA's view of anonymisation differs from that of the Data Protection Commissioner, 
who holds that for truly anonymous data no decoding key should exist anywhere.
Lastly, the guidance seems to imply that patient records can be used for research 
(presumably by the treating clinicians), but health professionals must make a 
“ reasonable effort” to inform patients of this possible use of their data and give them
the opportunity to object._____________________________________________
Medical Research Council (MRC)
The MRC had published a draft guideline for consultation on Personal Information in 
Medical Research on 17 September 1999. It stated that “Most international and 
national ethical codes do not require explicit, informed, consent for research based 
only on records that will not directly affect the individual” (MRC 1999). The 
guideline was based on legal advice to the MRC and emphasized the responsibility of 
individual clinicians for safeguarding confidentiality, but also acknowledged that 
legality of any processing of personal data would have to be determined on a case-by- 
case basis.
The guideline put great emphasis on informing patients routinely about possible use 
of records for research in general; patients should be given the opportunity to object 
to the use of their data for research. It was thought that this would “go a long way 
towards meeting the legal principle of “fa ir processing” .”_____________________
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Regarding anonymisation, the guideline stated that personal information must be 
encoded or anonymised as far and as early as possible. Most importantly, in the 
MRC’s view, if consent was impractical, it was permissible to disclose personal 
information for research under certain conditions. These conditions are related to 
safe processing, except one: the importance of the study justifying the disclosure.
Research Ethics Committees were supposed to judge whether this was the case._____
United Kingdom Central Council fo r Nursingt Midwifery and Health Visiting 
(UKCC) (now: Nursing and Midwifery Council, NMC)
The UKCC’s guideline on records and record keeping stated that the principles of 
confidentiality apply to the use of records for research, and the right of the patient 
to refuse access should be respected (UKCC 1998). Whereas it clearly stated that 
explicit consent was needed for disclosing patient data (unless disclosure is required 
by law or is necessary in the public interest), the UKCC was less clear on what it 
meant by disclosure. No explicit consent was mentioned where the use of records for
research were discussed (UKCC 1996).____________________________________
The Royal College o f Physicians' Committee on Ethical Issues in Medicine (1999) 
had published recommendations relating to research based on archived information. 
The Committee expressed concerns over the severe restrictions the Data Protection 
Act placed upon non-intrusive record-based research and held the view that such 
research should be possible without the express consent of data subjects. A condition 
for such research should be the anonymisation of the data at the earliest opportunity 
and to a minimum level of precluding identification of individuals from the output of 
the research.
Significantly, the Committee specifically recommended the Department of Health not 
to subscribe to legislation which could impede such research. This was at the time 
when the Department of Health was preparing its own guidance on the Data 
Protection Act and had just lost its appeal in the Source Informatics case (Anonymous 
2000d). ______________________________
The above presented results of my enquiries into existing concepts, definitions 
and guidance meant that there would be no agreed authoritative answer. 
Before I go on to describing the next steps in decision-making, it  is worth 
considering the different potential participants involved in this process. These 
are described in Table 3.5.
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Table 3.5: Participants in the Decision-Making Process
Caldicott Guardians
In 1997 the Caldicott Committee reported on its review of information that identifies 
NHS patients (Caldicott Committee 1997). In keeping with the report’s main 
recommendations each health authority, Trust, and primary care group in the United 
Kingdom appointed a “Caldicott Guardian.” A key responsibility of these Guardians 
was to agree and review local protocols for the protection and use of identifiable 
information obtained from patients, including protocols governing disclosure across 
organisational boundaries (NHS Executive 1999a).___________________________
Data Protection Commissioner (now: Information Commissioner)
This office exists for the purposes of the Data Protection Act 1998 (the role had been 
established in the previous Data Protection Act 1984 as Data Protection Registrar).
The role of the Commissioner is to promote the observance of the Act. He or she may 
also assess any processing operation for good practice.________________________
Data Protection Officers
Data controllers, such as NHS Trusts, or universities, have appointed named 
individuals who lead on their organisation’s endeavours to comply with the 1998 Data 
Protection Act. They ensure the formal notification of all uses of personal data to 
the Data Protection Commissioner, and act as internal advisors and facilitators.____
Clinicians
Clinicians remain accountable for the confidential information they have received 
from their patients, regardless of authorisations by Research Ethics Committees or 
even Health Authorities (MRC 1999).___________________________________
Research Ethics Committees
The NHS has a system of Local and Multi-Centre Research Ethics Committees to which 
any proposal for research within the NHS has to be submitted for consideration. 
Department of Health guidance was very clear on the need for approval by a Research 
Ethics Committee for any research using patient records (NHS Executive 1999b). The 
Royal College of Physicians’ Committee on Ethical Issues in Medicine (1999) seemed 
less agreed on this issue.
Research Ethics Committees, however, cannot be asked to interpret the law on behalf 
of applicants or data controllers involved, and ethics committee approval of a 
research project is not necessarily an indication that it complies with the law. 
Although committee approval is necessary for research within the NHS, research 
ethics committee decisions have no legal standing (MRC 1999). Committees simply 
advise on whether a proposed project meets recognised ethical standards._________
Data controllers of the database
The ERCF arguably held pseudonymised data, whereby the decoding key was held by 
the respective CF centres. Apart from CF centres who contributed the data, several 
organisations were involved: funding came from a pharmaceutical company (Roche
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Pharmaceuticals), the management of the Registry was ultimately entrusted to a 
Swiss company (NSPM, Lucerne, Switzerland), whereas the data handling was 
contracted to Quintiles (Frankfurt, Germany), a pharmaceutical services company. 
The Steering Group was made up of an international group of clinicians, but individual 
clinicians in the participating centres had a key role in deciding over access to data 
from their own centres.
Patients
It is ultimately the patients' data which is sought to be protected. However, patients 
had little part in the discussion, and despite publications of the issues in high-profile 
journals, there was never any real public debate on data protection and 
epidemiological research. There are now surveys which suggest that patients are 
relaxed about such use of their data (Barrett et al. 2006), however, others show that 
the public clearly want to be asked for their permission (Clayton 2008).___________
Therefore, at the outset of the study, and following MREC approval and 
advice, I asked the Data Protection Officers of participating hospital Trusts for 
their advice on the need for consent from patients, given that I - a University 
employee - sought to access patient records for retrospective data collection. 
The responses to this request are shown in the Table 3.6. The Trusts' decisions 
varied considerably and usually involved discussions and consultation between 
Data Protection Officers, Caldicott Guardians, and at times executive 
directors; consequently, this led to delays.
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Table 3.6: Trusts' decisions on whether patients needed to give explicit
consent
Decision Time to 
decision
Trust 1 This Trust decided that the researcher could have access 
to patients' records without explicit consent from 
patients as long as no identifiable information was 
removed from the hospital (for example, the researcher 
could extract information from records and retain it in 
coded form but the key for decoding would be kept at 
the hospital).
< 3 weeks
Trust 2 The Caldicott guardian decided that consent from 
patients was required. This decision was later revised 
after the Trust sought legal advice, and the researcher 
was then permitted to have access to patients' records 
because the Data Protection Act 1998 only came into 
force after the start of the study (1 March 2000).
4-5 months
Trust 3 The data protection officer and the Caldicott guardian 
advised the researcher to obtain explicit consent from 
patients because the researcher was not a staff member 
of the Trust and no explicit consent exists from patients 
to permit the use of their data for research (for 
example, no agreements are signed by patients when 
they are first seen).
6 weeks
Trust 4 The data protection officer immediately decided that 
the proposed study required explicit consent from 
patients since only staff with a duty of care to the 
patient are permitted to have access to that patient's 
medical records, and, unlike audit, research is not seen 
as part of the healthcare process.
Immediate
Trust 5 The data protection officer made a formal decision only 
about records held on the computer. The outsider status 
of the researcher was problematic. The case of 
deceased patients (which is not covered by the Data 
Protection Act) would have to be decided by the 
research ethics committee.
No formal 
decision at 7 
weeks
Predictably, it  emerged that patient consent would be required (albeit that 
this view was not held unanimously). However, it  was already becoming clear 
that time restrictions would render the collection of data from medical 
records unfeasible, not least because the pilot phase had also demonstrated 
that the actual data collection process by myself would take an impossible 
amount of time (and in some centres, data might not even be available).
Hence, the final question to data protection officers resulting from the final 
protocol change was whether the use of ERCF data would be permissible in
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anonymised form, whereby the de coding key would be held in the centres. 
This would allow de coding and checking of the data by internal staff in the 
centres (see section 4.3.2 for detailed procedures). I addressed the same 
question to the MREC and to the UK Data Protection Commissioner's Office and 
their responses were made available to data protection officers. The ultimate 
decision was thus left with the participating NHS Trusts.
The response letter from the Data Protection Commissioner’s Office (Appendix 
A) emphasised her view on the nature of "pseudonymised” data, which she 
considered to be personal data and thus under the remit of the Data 
Protection Act 1998. Her reason for this was the existence of the practical 
means for identification of individuals, albeit that these means are not in the 
possession of the recipient of the data (in this case myself as the researcher).
Finally, four out of the five hospital Trusts concerned (covering five of the 
seven centres) decided that the study was permissible in the proposed form 
without further consent, given their reading of the data protection legislation 
and advice. One of these Trusts saw it necessary to request the University 
who employed the research team to indemnify the Trust in respect of any 
material risks in the event that the decision was ever challenged - a rare step 
at the time but now almost standard.
The fifth  Trust, after internal deliberations between the Data Protection 
Officer, Caldicott Guardian, REtD Director, and the Trust’s authorised data 
protection signatory, decided that the retention of a code was not acceptable 
without patients’ consent. The Data Protection Commissioner’s letter was 
interpreted as requiring specific information to data subjects on the particular 
research so that explicit consent could be obtained. Consequently the local 
clinician had to destroy the de coding key he had received from the ERCF 
operating company, and data quality checks could not be performed in that
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Trust. The use of the thus fully anonymous data from the database was seen 
as permissible.
Thus, four Trusts retained the decoding key in order to identify their patients 
for data checking. The staff to be involved in decoding the data were 
selected by the responsible clinicians on the basis that they would have access 
to the data in the course of their normal duties. Those members of staff 
signed a form committing them to observing patient confidentiality. I signed a 
declaration committing me to holding the data securely and not seeking access 
to the decoding key. On completion of the project, I specifically requested 
the involved Trust staff to destroy the decoding keys.
3.3.4 Concluding Remarks
The difficulties described above were to some extent time-dependant; further 
relevant guidance documents have been published since, but the debates on 
the implications of the Data Protection Act, the Human Rights Act, and the 
Common Law Duty of Confidentiality on medical research have continued in 
the medical literature (and the publication stemming from this work has 
frequently been referenced). Despite it  often being said that the matter is 
ultimately for the courts to decide, there has been no further relevant case 
law.
The Dornase Alfa Case Study itself was severely affected by the uncertainties 
around the interpretation of the - at times conflicting - legislation and 
available guidance. Suitable consent arrangements are unlikely to have been 
put into place at the initiation of many existing databases and registries, and 
researchers may therefore continue to risk inconsistent interpretation of the 
guidance by different participating organisations. Evidently, even researchers 
setting up new registries now are still overwhelmed by the complexity of the
Use of Databases in Drug Effectiveness Studies 111
Dornase Alfa Case Study: Preparatory Issues
relevant legislation (Haynes et al. 2007). However, this seems now inevitable, 
unless the legal framework is altered to enable important research to take 
place more easily.
Approval for the use of identifiable data without consent can be sought from 
the National Information Governance Board (NIGB) for England and Wales 
(formerly Patient Information Advisory Group, PIAG). However, this 
mechanism is itself complex and by its very nature intended to be temporary, 
as approval is conditional on efforts being made to obtain consent in future. 
Disease registries such as the ERCF need to adapt their procedures to obtain 
explicit consent from current and future patients in the long run. However, 
this does little  for making already existing databases available for research.
The issue of access to existing data is of significant importance for a vast 
range of health services research as well as health technology assessments. 
Patients and the public may still be largely unaware of the implications of the 
current laws, and it  has to be asked whether the current restrictive position 
serves the public interest. The Discussion chapter sets this issue into the 
current context.
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4 Dornase Alfa Case Study: Further
Methodological Issues
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4.1 Introduction
A main concern in ESDs centres around the quality of the available data. So 
it  was in this study. This chapter describes the work undertaken to assess the 
quality of the database and its data. It explores the dataset and variables 
within it, and reports the conduct and results of a detailed external 
verification of key variables. This was later published as the first such data 
verification of this data source (Strobl et al. 2003), and I was later asked to 
present this work at a subsequent international CF conference as an invited 
speaker. This underlines the great interest which the CF research and clinical 
community awarded to this work. In the last section in this chapter I present 
an assessment of the representativeness of the available sample from the 
database. This is in recognition of the oft-made claim that results from 
observational studies are more generalisable than trial results.
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4.2 Data Source and Data
4.2.1 The Epidemiologic Registry of Cystic Fibrosis (ERCF)
The Epidemiologic Registry of CF (ERCF) has been set up in 1994 by F. 
Hoffmann-La Roche across several European countries as a multi-centre, 
longitudinal, follow-up project of CF patients receiving routine care. The 
intention of the ERCF was to analyse progression of lung disease by pulmonary 
function and infection rates (Anonymous 1994). The database monitored lung 
function, respiratory infections, potential risk factors for lung function 
decline, and the safety of dornase alfa treatment.
The ERCF had over 13,600 patients enrolled and in 1999 reported a mean 
observational period of 2.3 years. Centres contributing data on their patients 
were paid for doing so and might have seen this as a welcome generation of a 
little  extra income. An Advisory Committee including clinicians from 
participating centres in different countries controlled the ERCF. The 
management of the Registry was entrusted to a Swiss company, NSPM 
(Lucerne), whereas the data were held in Frankfurt by Quintiles, a 
pharmaceutical services company. It received anonymised data on patients 
from participating CF centres by remote data entry (in the early years of its 
existence, it  received data via paper-based report forms). Only the units 
themselves could link codes used by the ERCF to individually identifiable 
patients. All patients of a participating centre were meant to be registered, 
both those on and o ff  dornase alfa.
The ERCF Advisory Committee controlled access to the data. Whereas 
previously no outside research team had sought access to the dataset, the 
Committee was keen to enable such access. The Committee had hoped to
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secure public funding to continue the ERCF after the financial support from 
Hoffmann-La Roche had ceased. Unfortunately no further funding was granted 
and the ERCF stopped collecting data in the year 2000.
Several journal papers, regular annual reports, as well as a number of 
conference abstracts had been published based on ERCF data. Some of the 
papers presented descriptive analyses (Delaisi et aL 1998), but many reported 
exploratory analyses on different topics: e.g. factors associated with lung 
function decline (Mastella et al. 1999; Navarro et al. 2001), practice patterns 
by age and severity of lung disease (Koch et al. 1997), or disease 
manifestations by different classes of mutations (Koch et al. 2001). 
Conference abstracts included exploratory analyses on the impact of dornase 
alfa on the frequency of exacerbations and FEVi decline (Hodson et al. 1998b; 
Hodson et al. 1999), and the impact of diabetes on lung function and 
nutritional status (Koch et al. 2000), and descriptive reports on centre and 
country differences (Harms et al. 1998b), and bacterial colonisation rates 
(Mastella et al. 2000).
4.2.1.1 ERCF objectives
The explicit objectives of the ERCF were as follows (Anonymous 1994):
❖ “ To collect information on the safety o f long-term treatment with 
dornase alfa and to examine trends in pulmonary function and rates o f 
pulmonary exacerbations that relate to the effectiveness o f long-term 
treatment w ith dornase alfa and in the patient population who are not 
receiving dornase alfa;
❖ To fu rthe r define the clinical course and natural history o f specific 
populations o f all subgroups o f CF patients using information on 
concurrent medical conditions, non-routine hospitalisations, deaths, 
and other data;
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❖ To describe practice patterns in the treatment o f pulmonary disease in 
diffe rent populations o f CF patients includin§ non-routine 
hospitalisations, clinic visits, routine medications, administration o f 
intravenous, inhaled, and oral antibiotics, and dornase alfa treatment 
information, i f  applicable, ”
4.2.2 Access to the dataset
One of the ERCF Advisory Committee’s concerns was the protection of the 
identity of individual centres/clinicians. Thus, it  was stipulated that the lead 
clinicians in participating CF centres had to give written permission for their 
data to be made available for the current research study. In order to 
facilitate the data quality review, lead clinicians in the seven participating 
centres permitted the research team to receive the code which identified 
their respective centres. Even though there may not be any legal reason for 
the centres to remain anonymous, the potential sensitivities arising from 
comparing clinical data of different centres warranted this cautious approach.
A second layer of anonymisation was added to the already coded patient data 
for security reasons. Thus each participating centre clinician received a new 
decoding key from Quintiles, in addition to the one already held routinely.
4.2.3 Data management
4.2.3.1 Outline of the dataset
The dataset received from Quintiles arrived as a set of 13 password-protected 
files in SAS format. Each of the 13 files related to a particular subject (e.g. 
diagnostic, demographic, clinical, medication, or transfer data), and 
contained a varying number of reports for individual patients. These were 
identified by a patient ID number, an enrolment or visit/reporting date, and
Use of Databases in Drug Effectiveness Studies 117
Dornase Alfa Case Study: Further Methodological Issues
numbers distinguishing the reporting and current centres. The dataset 
spanned the observation period from the beginning of the database in 1994 to 
the end of the year 1999. Participating centres had been requested to 
contribute data on all their patients to the ERCF.
4.2.3.2 Data handiing and documentation
Copies of the original files were converted into SPSS format; data cleaning and 
data quality review were undertaken using SPSS Version 9.0. For some 
auxiliary steps and for generating feedback forms for the data quality review, 
Microsoft Excel 2000 was used.
Log files were produced to document the data cleaning of each individual file; 
later, a set of summary log files was produced and finally a set of variable 
summaries for each file, detailing for each available variable the data origin, 
coding, data quality and any alterations or preliminary processing such as re­
coding.
4.2.3.3 Security
Data were stored on the original compact disc received from Quintiles and 
copies of ongoing working files at different stages were kept. Copies of this 
material were also saved regularly. On completing the data cleaning and data 
quality review (see subsequent section), a final full version of the dataset was 
saved, before reducing and merging files ready for the analysis.
The electronic transmission of files containing BPID numbers and centre codes 
between research staff was not permitted.
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4.2.4 Variables
The following list of main variables corresponds to 12 of the 13 files (the 
remaining file contained data on prompts for further responses from the main 
recording form):
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Table 4.1 : List of data files and variables available in the ERCF
Files Variables
Demographics: Month and year of birth
Sex
Race
Diagnostics: Year of CF diagnosis
Clinical indications of diagnosis
Sweat test
Genotype
Dornase alfa: Start and discontinuation dates
Dose per day
Timing of use in relation to physiotherapy
Nebuliser/ compressor
Doses missed in past 7 days
Lung function and spirometry (actual measured):
FVC, FEVi, FEF25.75X, RV, TLC (including test dates)
(including baseline measurements prior to dornase alfa initiation)
Antibiotic use: Drug name
Route of administration
Indication (exacerbation or prophylaxis)
Start and stop dates
Microbiology: Organisms present in respiratory cultures (with culture dates)
Medical history: Certain conditions /  illnesses occurring in the past and during the
observational period: e.g. asthma, haemoptysis, ABPA, MIE, gall bladder
disease, diabetes, nasal polyps, heart failure, organ transplants, etc.
Clinical status: Purpose of visit
Height
Weight
Cough frequency
Sputum productivity, volume, and colour
Physical findings (crepitations, wheezing, clubbing, hyperinflation)
Blood gases
Routine therapies: Scheduled medications and therapies: e.g. airway clearance,
bronchodilators, corticosteroids, diuretics, insulin, mucolytics, NSAIDs, oral
supplements, tube feeding, pancreatic enzymes, vitamins, etc.
Adverse events: Non-routine hospitalisations (causes, admission and discharge dates)
Deaths (causes and dates)
Transfers and discontinuations:
Dates of transfers and new centre number
Discontinuation dates and reasons
Blood tests: Dates and results for WBC (white blood count) and IgG tests.
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4.2.5 Definitions of key variables and their categorisation
4.2.5.1 Date of birth and age-related variables
Only the month and year of each patient's date of birth were available for 
security reasons. In the calculation of all age-related variables therefore the 
day was set to the 15th of the month (and year) of birth. Age-related variables 
have been categorised into 5-year age bands and into age bands comparable 
with those of other published studies. Unless stated otherwise, completed life 
years have been used as cut-off values for categories (e.g. category 5<10 
encompasses all cases between age 5.0 and 9.9, rather than 9.49).
4.2.5 2 Genotype
The categorisation of genotype has been undertaken in two ways: (1) into 
severe (“A” ), and less severe (“ B” ) categories, including a category “ U” for 
unknown genotypes, and (2) reporting specifically the occurrence of DF508, 
other, and unknown or unreported mutations. A geneticist on the project 
steering group undertook the first A-B-U categorisation. However, only some 
3% of the sample were categorised as “ B” , making a comparative analysis 
difficult.
4.2.5.3 CF Diagnosis
Everyone included in the ERCF was assumed to have CF. Data from four 
patients explicitly identified on the database as not suffering from the 
condition were removed from the dataset.
Only the year of diagnosis was collected by the ERCF, rather than the exact 
date. Hence, to calculate age at diagnosis the “ 1 July” of the year of 
diagnosis was used. Therefore, age at diagnosis has to be interpreted with a 
half-year margin of uncertainty.
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4.2.5.4 Predicted iung function
Lung function (forced expiratory volume in one second (FEVi), FVC, and other 
less frequently reported measures) was recorded on the ERCF as actual values 
in litres. However, since lung function is influenced by a number of factors 
such as age, gender, height, prediction formulae have been developed which 
use a combination of these factors to produce reference values of e.g. FEVi 
for a patient with a given set of values for the relevant influencing factors. 
Thus an individual’s predicted value can be used together with the actual 
value to calculate the “ per cent of predicted” value.
Two sets of prediction formulae were used in this study. The UK Cystic 
Fibrosis Foundation research centre based in Dundee uses different formulae 
for patients aged less than 18 years, and those aged 18+ years (with different 
sets for males and females). The US Cystic Fibrosis Foundation uses a 
different formula with separate child, adolescent and adult formulae for each 
sex (Knudson et al. 1983). These two types are referred to as “ Dundee” and 
“ Knudson” respectively (for details of formulae used see Appendix A). Unless 
stated otherwise, the predicted values are categorised into <40% of predicted, 
40-<70%, and 70% and over.
4.2.5.5 Height, weight, body mass index (BMI)
The ERCF recorded height in centimetres. If two reports were available from 
the same day, the mean value was used. In patients aged over 18 years, 
missing height readings were replaced by the most recently recorded reading, 
as long as the patient was over 18 years old at the time of that reading 
(referred to later as “ imputed” height values). Weight was reported in 
kilograms.
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Height and weight were summarised by calendar quarter. Body mass index 
was calculated on the conventional basis (weight in kilos divided by the square 
of the height in metres) on these averaged figures.
Anthropometric data were standardised to the UK Child Growth Foundation 
1990 references.
4.2.5.6 Dornase alfa use
Reported start and stop dates of dornase alfa use were used to categorise 
patients into “ never” , “ intermittent” and “ continuous” users. Intermittent 
users are those who have used dornase alfa intermittently since their first 
initiation or have since stopped, continuous users are reported to have 
received the treatment without interruption since their first indication of use. 
In addition, intermittent and continuous users were distinguished in the 
analysis depending on whether they started using dornase alfa before or after 
enrolment to the ERCF.
4.2.5.7 Exacerbations
A “ pulmonary exacerbation” was defined for the purposes of the ERCF as “o 
respiratory tract infection that is treated with intravenous, inhaled, or 
specific oral antibiotics and which excludes prophylactic use.”  (Anonymous 
1994).
However, exacerbation reports appeared in three different files (forms) in the 
ERCF (see section 4.3.4.3). All explicit indications of exacerbations were 
accepted as such and data from the three source files were merged by the 
start date of a hospital admission for exacerbation, or antibiotic treatment 
episode for exacerbation, or a clinic visit date for an exacerbation. The last 
available stop date (either end of course of medication or discharge date) for 
each start date was accepted as the end of an episode. On the advice of 
clinicians on the steering group, episodes thus generated which were
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separated by less than one week were treated as a continuous exacerbation 
episode.
4.2.6 Concluding Remarks
This brief section has described the data source, the ERCF, and the process for 
accessing the data, as well as the key variables relevant to the Dornase Alfa 
Case Study. There was an important political dimension to accessing the data. 
Whereas there was a clear intention to release data to outside researchers for 
analysis (not least in order to secure the future of the registry), the ERCF 
organisers did not have any existing mechanisms for doing so. This is 
understandable, given that the pharmaceutical company marketing the study 
drug was the original funder of the registry. It is likely that other industry- 
funded post-marketing surveillance registries would not be as willing to 
subject their data to outside researchers pursuing their own agendas - and to 
checking their quality as rigorously as I did as part of this work (which is the 
subject of the next section).
The registry collected several dozen variables. The key variables have been 
introduced here, and the following section is devoted to a detailed assessment 
of the quality of these variables.
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4.3 Data quality assurance processes
The ERCF itself had in place reputedly intensive validation processes which 
involved automated data checking of certain variables and requesting 
corrections from centres. However, on hearing the reservations of the local 
Steering Group about data quality, I decided to undertake detailed data 
cleaning and data quality review processes myself.
The main intention of the Dornase Alfa Case Study project was to use the 
available dataset for an economic evaluation; therefore, the data quality 
needed to be assessed and improved by correcting and amending data where 
necessary. Specifically, the completeness and accuracy of the data, and the 
comparability of cases across centres needed to be examined.
I used three processes to assess and improve the dataset: first, thorough data 
cleaning processes, secondly, a detailed data quality review (DQR) to verify 
the main variables against existing data sources in CF centres, and thirdly, I 
undertook semi-structured telephone interviews with clinical and clerical staff 
in the centres to identify relevant clinical and recording practices that may 
impinge on the comparability of records from different centres.
4.3.1 Data cleaning
I formulated the following steps for the data cleaning process. Some of these 
steps involved simple descriptions of the available data on each variable, 
others aimed at validating the data through cross-checks between variables, 
and others still involved more direct judgement by myself of the likely risk of 
inconsistently applied definitions for variables and hence bias or error in the 
data:
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1. Identification of variables in the data files vis-à-vis the original data 
entry forms
2. Assessment of:
a. Completeness of variables
b. Range and spread of values
c. Frequency of occurrences / numbers of readings
3. Judgment on potential reliability issues
4. Identification and deletion of duplicate reports
a. Genuine duplicates (which could be deleted without any loss of 
information)
b. Problematical duplicates (where discrepancies between reports 
exist)
5. Validity of values
Assessed against other variables in the same or different files of 
the dataset (e.g. age vs. height)
6. Coding
a. Previously un-coded text variables
b. Merging of different variables for easier data handling
7. Identification of questions to be addressed at local centres regarding 
their practice of recording the data as well as their normal clinical 
practice.
4.3.1.1 identification of variables
Quin tiles provided the following documentation:
(1 ) "Code lists" for all numerically coded variables;
(2) "Schemata” for each file, which contained the variable name, data
type, code list, a very brief description (i.e. full name of the
variable), the output format, database format, and an indication
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of whether the variable was derived and whether it was 
mandatory;
(3) Copies of all data entry forms denoted with the relevant variable 
names as well as the form-IDs found in the relevant files (see 
Appendix A).
Together with a copy of the folder containing all the instructions supplied to 
local staff entering data into the ERCF, this information enabled me to 
recognise the variables in the 13 files, link them to the original questions on 
the data entry forms, and to review the instructions given to staff at 
participating centres.
This initial assessment was complicated, as two different versions existed of 
most data entry forms, due to an earlier revision. For some variables, the 
questions on the forms had not changed. In some cases, data from both 
versions of the form had been entered into the same variable. In many cases, 
however, variables contained data from either one or the other form version.
4.3.1.2 Further assessments
Completeness of variables and frequency of occurrences
In each file, an overview had to be gained over the basic numbers of available 
reports and their completeness: broadly, this included an assessment in each 
file of the number of reports per individual, the number of reports from each 
centre, and the number of reports which were complete for each variable.
Range and spread of values
For each variable, the range of values and their frequency and spread was 
assessed. Impossible values had to be deleted and recorded, set as “ missing 
values” so they would be excluded from analysis. Values were also assessed 
against values from other variables (see below).
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4.3.1.3 Judgment on potential reliability issues
Issues which may have implications for data reliability include:
❖ Differences in question wording and question layout between the 
different forms, where data were coded into the same variable;
❖ Variables which were difficult to assess or allowed a significant 
degree of subjectivity in their interpretation (e.g. daily sputum 
volume);
❖ Variables for which no or no sufficiently unambiguous instructions 
existed for data entry staff;
❖ Variables which originated from a “ tick-box answer” (e.g. “ check 
if none” ).
4.3.1.4 Identification and deletion of duplicate reports 
Genuine duplicates
Most files contained duplicate reports, sometimes multiple reports, whereby 
BPID number, the date of the report and all variables (apart from 
administrative variables) were duplicated. These reports can be identified 
easily by using the “AGGREGATE” function in SPSS using the key variables. In 
most cases, duplicates were deleted manually; only for two very large files 
(reporting lung function and antibiotic use) with a great number of duplicates 
(often due to missing data), a “ MACRO” was written and applied in Excel for 
this purpose.
Problematical duplicates (where discrepancies between reports exist) 
Having used the “AGGREGATE” function for identifying duplicates and 
assessing them manually, it  emerged that not all duplicates were full clerical 
duplicates. In cases where there were discrepancies, rules for alterations and 
deletions of those duplicates had to be defined. Generally, where there was 
no other means of checking the true value of a numeric variable, data was 
considered to be missing. Discrepant entries in duplicate reports of a text
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variable were usually “ complementary” rather than contradictory and could 
therefore be merged.
4.3.1.5 Validity of vaiues
Wherever possible, values of individual variables were cross-tabulated or 
cross-referenced with those from other variables. Initially this cross- 
referencing was restricted to variables from the same file, e.g. variables 
representing subgroups of a particular variable, or reporting date vis-à-vis 
event date. In a later stage, cross-referencing was undertaken between 
variables of different files, allowing e.g. the comparison of clinical data such 
as height, weight, lung function with age and sex, the use of antibiotics in 
hospital vs. reports of hospital admissions, or the prescription of insulin or 
hypoglycaemics vs. the diagnosis of diabetes, or simply the matching of key 
dates (such as date of birth, diagnosis, enrolment, transfer, death, and 
discontinuation).
The assessment and alteration of any data followed documented rules. 
Incompatible values had to be logged and deleted, because in many cases, 
alterations could not be made with any degree of certainty. However, in 
cases where more than two variables could be expected to match, this was 
easier (e.g. if  height and age were compatible with each other, but not with 
the given weight, or if  a reporting date, admission and discharge date were all 
available and the admission date preceded the reporting date by exactly one 
year). Equally, the timely sequence of values for an individual could be used 
to make decisions on the likely correctness of individual entries.
4.3.1.6 Coding
Previously un-coded text variables
In many cases, text variables were already coded. For some free-text 
responses, coding still had to be undertaken. Coding schemes of clinical data
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were checked with clinicians and amended following their advice. Entries 
relating to “ other, please specify” -response options were coded also.
Merging of different variables for easier data handling
Some variables could be summarised into a smaller number of variables by re­
coding them.
4.3.1.7 identification of questions to be addressed at iocai centres
It became obvious that the interpretation of some data would depend on local 
recording conventions, as well as the clinical practice and case management in 
each centre. Relevant questions clarifying these were gathered during the 
data cleaning process and were raised with local clinicians and data entry 
personnel.
4.3.2 Data Quality Review (DQR)
Over and above the data cleaning process described in the previous section, a 
detailed data quality review (DQR) against original patient records in the 
centres was possible for five of the seven Northern UK centres (one Trust 
covering the remaining two centres did not permit the patient identification 
necessary for the DQR - see previous Chapter). Such data verification 
exercises are not the rule for database studies, as they involve considerable 
time and resource, but we saw it  as important here, given the doubts 
expressed by Steering Group members about the quality and completeness of 
the ERCF data. I was able to publish this work as the first external verification 
of this dataset (Strobl et al. 2003), and was later invited to present it  at in 
international CF conference (along with findings from the comprehensive 
Review reported in Chapter 6), underlining the contribution this work made to 
the scientific and clinical CF community.
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4.3.2.1 Seiection of variables
Because of the potential workload involved, the DQR had to be limited to a 
priority set of variables: some key variables were checked for the total patient 
population (“ population-DQR” ), and a further set of variables (demographic 
variables, genotype, use of dornase alfa, FEVi and FVC readings, 
hospitalisation) was checked for a sample of patients only (“ sample-DQR” ). 
The choice of variables for inclusion in the DQR derived from their inclusion in 
the objectives of the study, and also by judgments on the accessibility of data 
locally for comparison purposes.
Table 4.2: Variables included in data quality review
Key variables checked in the population-DQR:
Enrolment centre
Enrolment date {for orientation only)
Current centre
Discontinuation date
Death date
Cause of death
Transfer date
New centre after transfer
Last reporting date (only to be checked if  <1999)
Further variables checked in the sample-DQR:
Month and year of birth 
Sex
Year of diagnosis 
Genotype 
Enrolment date 
Discontinuation date 
Reason for discontinuation 
FEV1 and test date 
FVC and test date
Indication of whether spirometry was pre-dornase alfa baseline value 
Dornase alfa therapy (yes/no)
Dornase alfa therapy start and stop dates 
Adverse events 
Hospitalisations 
______ Admission and discharge dates
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4.3.2.2 Review process and pilot
The five participating centres had been supplied with decoding lists by 
Quin tiles, allowing them to identify their own individual patients. Thus a 
member of each centre's staff could be supplied with anonymised data by the 
research team and check their correctness against other existing in-house 
records and data sources.
Each reviewer received Summary Lists for the population-DClR. These 
Summary Lists were split into
1. Current patients;
2. Patients enrolled at the centre but transferred while on the ERCF.
The purpose of those lists was to assess the completeness of the database, 
with a view to transfer, discontinuation, and death data (see Appendix A for a 
sample of data feedback forms).
The sample-DClR comprised 4 forms for each patient record, one for once-only 
recorded items (demographic, diagnostic, and follow-up details), and one form 
each for spirometry readings, dornase alfa treatment details, and 
hospitalisations.
In addition to written guidance on how to check the data, I visited most 
reviewers on site to explain the process.
For a small p ilo t of the sample-DQR, six records were checked in each centre. 
These were chosen to represent a spread of different lengths of observation: 
one record of a patient "on” and one of a patient "o ff” dornase alfa of a 
length of follow-up of 1,3 and 5 years (or the next available record closest to 
these periods), avoiding transferred patients.
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4.3.2.3 Selection of records for sampie-DQR
The time taken for these 6 records was used to calculate an average length of 
time needed to review one record in a centre. Because of time and funding 
restrictions, a pragmatic decision was made to determine the size of the 
sample to be reviewed in each centre depending on the amount of time each 
person was able to commit to the process within the available 10 weeks.
The record samples were made up of (a) records for which discrepancies or 
queries regarding the key variables had been identified in the original data 
cleaning process, and, if this number did not already exceed the estimated 
possible number of records a local person could review, (b) a further number 
of randomly chosen records from each centre to make up the estimated 
manageable number.
4.3.2.4 Amending data fiies
Additions, deletions, and any amendments of the existing data files were 
undertaken manually according to the data reported back by the local DQR- 
reviewers. Their corrections were given preference over existing data. Each 
amendment was logged on a separate Excel spreadsheet. A separate Excel 
sheet was created later to collect detailed information on the nature of any 
necessary amendment or correction; at this stage, the first spreadsheet was 
double-checked.
4.3.3 Semi-structured interviews
The review of the dataset and data cleaning process identified a number of 
questions regarding recording and clinical practices in the different centres. 
These questions were collected and used to formulate a semi-structured 
schedule of questions, which were then addressed to clinicians and centre 
staff responsible for recording ERCF data via telephone.
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4.3.4 Results of data quality assurance processes
This section reports the results of the data quality assurance processes and 
discusses their implications for the Dornase Alfa Case Study.
4.3.4.1 Completeness of data 
Completeness of reports
Differences in reporting rates for key variables might be used as a crude 
indicator of problems with data completeness. In this regard, the proportion 
of each centre’s patients for whom reports existed in data files referring to 
clinical status, microbiology, and antibiotic use was similar across all centres 
(97-100%) (see Table 4.3). In contrast, the proportion of patients for whom 
entries existed in the file relating to non-routine hospitalisations/adverse 
events (25-74%) varied, as did the proportions in the file on blood tests (0- 
97%). This variation suggests that recording of these variables is unreliable; 
blood tests did not seem to be reported at all in some centres.
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Table 4.3: Proportion (%) of patients per reporting centre appearing in
each variable group (after data cleaning)
Centre and number of records associated with each centre
Variable group Centre Centre Centre Centre Centre Centre Centre
(file) 1 2 3 4 5 6 7
161 137 200 181 119 286 215 1299
Clinical status 100 100 100 100 100 99 100 100
Medical history 100 100 100 100 99 99 100 100
Routine
therapies 97 100 99 100 99 99 100 99
Dornase alfa use 100 100 100 100 99 99 100 100
Pulmonary
function 82 55 77 81 99 98 99 86
Microbiology 100 99 97 100 98 98 98 98
Blood tests 84 2 18 84 97 55 0 46
Adverse events 57 19 25 47 70 74 60 52
Antibiotics 99 100 100 100 97 98 97 99
Notes:
a) Individual patients may appear in more than one centre.
b) Centres 1-4 are children’s centres, centres 5-7 are adult centres.
c) Centre 2 only contributed to the ERCF for two-three years (other centres: six years).
d) Centres 4 and 7 did not take part in the DQR.
Interviews with centre staff highlighted that the frequency of routine clinic 
appointments varied between and within centres. Most centres saw patients 
every 2-3 months, but some operated a more flexible review system by 
inviting patients depending on their individual need and circumstances. Thus, 
the frequency and regularity of reports would have varied. Many centres 
conducted more or less standardised annual reviews of all patients, and most 
reported that there would be little  if any variations in practices between 
doctors of the same centre.
However, it was also elicited that the number of visits recorded on the ERCF 
does not represent the actual number of visits. Local ERCF coordinators 
reported that they tended to adhere to an upper lim it of four visits per patient 
per year which were entered into the ERCF. Some selected four visits
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arbitrarily, others tried to space them reasonably equally throughout a 
particular year. Overall, the number of reports for a patient did not 
correspond to the number of quarter-years under observation.
This indicates considerable differences in reporting frequency and practice 
between centres and considerable potential for bias through under-reporting 
certain key variables such as adverse events, i.e. a key outcome! This means 
that the dataset should not be analysed as one homogenous sample, but 
centre differences need to be taken into account in the analysis, at least of 
some if not all variables. More worryingly, there are reporting practices at 
play which the ERCF operators would most likely not have realised, but which 
would have a significant impact on the eventual quality of data and reliability 
of any subsequent analysis and interpretation.
Completeness of patient records
Some centres have provided overall numbers of their patient populations and 
information on how many of those patients are registered on the database. 
This information could be compared with the numbers of individuals found 
registered on the dataset. In three centres the numbers matched closely at 
the end of any particular calendar year (up to 8 patients missing in the ERCF 
dataset); different date points being chosen for the count may explain some of 
that variation. However, underreporting definitely affected one centre, 
where registration stopped after a certain number of patients were reached. 
In one other centre the ERCF dataset seems to contain more patients than 
were reported verbally for a particular year, probably due to shared care 
patients being included in the register. For two centres no comparison data 
existed, but local ERCF coordinators were confident in a total coverage of 
their patient population, except for 1999 when registration and reporting 
ceased.
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Of one of the centres not included in the DQR, summary data were available, 
which could be compared to the data held in the ERCF. This was particularly 
interesting, because this centre reported that only part of its patients were 
registered on the ERCF. Summary data and comparative values from the ERCF 
sample are presented in Table 4.4. Whereas some of the clinical data are well 
comparable between the two sources, the prevalence of bacterial 
colonisation, but also the use of dornase alfa seem under-reported in the ERCF 
data. It is unclear to what extent these differentials might be explained by 
non-registration of more severely affected patients, or incomplete reporting 
on recorded patients. However, the relevant clinician reported that the ERCF 
data relating to the centre was less reliable than data held in the centre’s own 
CF database (the source of the summary comparison data).
Table 4.4: Available summary data from one centre compared to data of
the same centre held in the ERCF sample
Summary data available Data available in ERCF 
elsewhere sample
Mean FEVi% of predicted 
between 1995 and 1999 
Mean body mass index (1999)
Prevalence of diabetes (%)
(1999)
Dornase alfa use (%) (1999)
Number of patients in 1999 
% of patients with FEV1<40% of 
predicted (1999)
% of patients reporting 
Pseudomonas aeruginosa (1999)
% of patients reporting 
Burkholderia cepacia (1999)
Mean age (years) (1999)
Includes all patients with any diabetic therapy recorded.
2) Cannot include patients who continue therapy during 1999 but have no report of use in 
1999.
3) 2 patients from that centre were amongst those excluded because of missing demographic 
data
4) Any reading of <40% predicted FEVi is included, not mean during entire year 1999.
5) Mean age (on 31.12.99) of patients on register at end of 1999.
55 50
21.2 20.9
28 271)
approx. 40 312)
262 1963)
27 324)
76 50
9 6
25 25.4%
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4.3.4.2 Records subjected to sample-DQR
A total of 230 case records were subjected to the Sample-DQR process in five 
centres; the number of records verified in each centre varied (Table 4.5).
Table 4.5: Numbers of patients in sample-DQR
Centre Total record 
number 
(last centre)
Sample for DQR
Records with 
queries for 
checking
Additional
randomly
selected
records
Total number of 
records in sample, 
including pilot *
1 127 21 14 41
2 115 19 0 2>6
3 179 35 0 40
5 130 27 13 46
6 282 81 20 106
Grand Total 833 183 47 3)239
This is not necessarily the sum of the previous two columns and the 6 pilot records, because 
the latter may have already included case records which contained queries for checking.
No further case records accepted for checking due to time pressure.
Nine actual patient records appear twice, e.g. if they were checked in different centres. 
Hence, a total of 230 case records have been subjected to DQR.
Not all records delivered to the units for checking could actually be reviewed; 
reasons were as follows:
(a) BPIDs were not recognisable from the de coding lists the centres 
had received, because the lists did not contain all the necessary 
number pairs (e.g. for very recent database entries);
(b) Only part of a patient's medical records were kept on site, either 
because the patient had been transferred, or was treated under 
a shared care arrangement and therefore records were kept in a 
peripheral hospital;
(c) Patients’ records were inaccessible;
(d) Variables were not recorded in the notes (e.g. start and stop 
dates of dornase alfa in one centre).
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Table 4.6 presents the completeness of checks undertaken on the sample of 
records. Of all 230 patients reviewed, 140 were users of dornase alfa at some 
point in time, but 24 of these were allocated to the centre which could not 
review the information on dornase alfa use. Thus, dornase alfa use could not 
be verified for a total of 64 records (45 in one centre), hospital admissions for 
23, and lung function tests for 19 records.
Table 4.6: Completeness of checks in sample-DQR
Extent of data verified* Number of records %
All data items 127 55%
75-99% 40 17%
50-74% 37 16%
1-49% 11 5%
None 15 7%
TOTAL 230 100%
*one item = either a lung function, dornase, or admissions follow-up report (including all 
relevant variables), or an item of fixed data (e.g. sex, genotype, discontinuation date)
4.3.4.3 Data quality of main variables
The following text summarises the findings on the data quality of key variables 
only resulting from the data quality assessments, preceded by an overview of 
data disagreements identified prior and through the DQR:
Disagreements identified in the data
Table 4.7 summarises the corrections of some key variables which were 
possible to be undertaken during data cleaning (i.e. without the DQR).
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Table 4.7: Corrections of key variables possible without DQR
Variable Corrections Total number 
of reports
Month and year of 10 (variable appeared in two files, on
birth multiple reports in one file)
Sex 1 (variable appeared in two files, on multiple 
reports in one file)
Year of diagnosis 1 deletion (impossible value)
FEY, Deleted 5 values <0.01 and >6, plus 1 severe  ^
outlier
13 discrepancies in duplicates replaced by 
mean reading for that test date
FVC Deleted 14 values <0.01 and >8, plus 4 severe
outliers 18,464
12 discrepancies in duplicates replaced by > lung function
mean reading for that test date reports
Lung function test 5 deleted (<1990, but were definite follow-
date up reports)
68 alterations (usually of YEAR in test date) 
following comparison with report date and 
other information in files j
Admission dates 4 corrections 2,766
admission
reports
Table 4.8 summarises the disagreements identified in the sample-DQR 
between the ERCF data and original patient records. The greatest area of 
disagreement was on hospital admissions. Both for this (21 additions, 18 in 
one centre) and for dornase alfa treatment (6 additions), additional reports 
were found on examining the patient case notes.
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Table 4.8: Disagreements between ERCF data and DQR
Variables Disagreements between 
ERCF data and DQR 
reports
Number of records 
verified
% of verified 
records with 
disagreements
Sample DQJR
Sex 2 (1 addition) 214 0.9%
Month and year of birth 6 (1 addition) 214 2.8%
Year of diagnosis 4 (1 addition) 213 1.9%
Number of relevant % of follow-up
follow-up reports1* reports with
disagreements
FEV, 45 3602 1.2%
FVC 47 3602 1.3%
Lung function test date 48 3602 1.3%
dornase alfa (yes/no) 11 2)2481 0.4%
Dornase alfa start dates 15 2)2481 2)0.6%
Dornase alfa stop dates 13 Z)2481 2,0.5%
Admission dates 34 925 3.7%
Population DQR
Death 8 (all additions)
Death date 18 (17 additions)
Cause of death 21 (all additions)
Transfers 12 (8 additions)
2) A minority of these reports contain actual start or stop date entries; there were a total of 189 
start and 99 stop dates concerned; using these figures as denominators would bring the 
disagreement rates for start and stop dates to 8% and 13% respectively.
This data demonstrates that relatively little  actual data correction could be 
achieved through routine data cleaning only; the majority of such corrections 
were of lung function test dates. The disagreement rates from the sample 
DQR ranged from under 1% to 3.7% for admission dates. This is globally 
speaking a satisfying result. However, it  is likely that the ERCF’s own data 
verification processes would have been focussed on similar key variables. 
Therefore, the relatively low rates may not be indicative of other variables 
not checked here or by the ERCF. The under-reporting of death - the easiest, 
memorable and reliable outcome measure of all - by contrast is a significant 
and rather disappointing finding. This is not unknown in databases, and 
without specific additional safeguards to ensure completeness of reporting, 
under-reporting of outcomes remains a significant risk.
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Demographic information
Both sex and date of birth were recorded twice in the ERCF, once in the 
demography file and again on each report in the file on adverse events and 
hospitalisations (for approximately half the patients on the database). 
Reports from those two files are unlikely to have been completed on the same 
day, so if  there was agreement between both files, then there is good reason 
to be confident about the reliability of these variables. Whereas there were 
some wrong entries on the multiple reports in the adverse events file, the 
majority of them matched the entries in the demography file (one “ female” 
entry against several “ male” entries for the same individual can be corrected 
with a good degree of confidence).
The DQR identified two disagreements on sex entries and six on month/year of 
birth (Table 4.8).
Five individuals were not recorded in any of the two files mentioned, but 
reported on in other files. Only one of the five BP IDs could be identified by 
the DQR-reviewers in the centres and the demographic information 
completed. The other four could not be included in the sample.
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Transfers and discontinuations
Twenty-four patients appeared on the database as registered in two different 
centres with two different ID numbers. In many cases, this dual registration 
was due to the fact that patients under “ shared care” arrangements between 
a specialist centre and a local hospital had been transferred to another 
specialist centre, which perceived the local hospital to have been the main 
treatment centre; whereas in transfers between specialist centres (who know 
of each other's participation in the ERCF) the ERCF ID numbers were routinely 
passed on, this clearly did not always happen in transfers of shared care 
patients. It would appear that there was overall an insufficient mechanism to 
ensure that links between patient episodes in different centres are made.
In the original dataset, 142 transfers had been indicated (with 141 transfer 
dates). The DQR revealed a further 8 transfers during the observation period. 
Four transfers indicated in the dataset were identified (in the DQR) as not 
having taken place.
Deaths
Similarly to demographic data, patients' deaths had been reported in two 
separate files of the original dataset: the transfer and discontinuation file 
(which contained a discontinuation date only and a variable to indicate the 
reason for discontinuation), and the adverse events and hospitalisations file 
(which contained the death date and cause of death).
Whereas the first file had reported 91 deaths, only 84 of these were reported 
in the latter file, where a definitive date and cause of death were recorded. 
All 91 deaths were confirmed in the DQR. The DQR revealed also an additional 
8 deaths having occurred during the observation period.
Only one date of death was corrected in the DQR. Twenty-one causes of 
death and 17 death dates were added during the verification, but several of
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the latter had already been recorded on the ERCF as discontinuation dates. 
The causes of three deaths remained missing, because these deaths occurred 
in a centre not taking part in the DQR.
This is now one of the most reliable variables, because (a) it  was part of the 
total population-DQR and (b) it  is likely that centre staff know which of their 
patients have died, even without checking their records. However, this 
conclusion does not apply to the two centres not participating in the DQR. 
Deaths were under-reported by 8%.
Exacerbations
Despite being a key outcome variable, exacerbations were reported at three 
different places in the dataset:
1. Adverse events and non-routine hospitalisations file:
Variables describing an adverse event were used to create a new 
dichotomous variable which identified all reports involving the term 
“ exacerbation” (but not merely “ exacerbation of symptoms” );
2. Clinical status file:
“ Exacerbation” was an answer option to indicate the purpose of a 
clinic visit;
3. Medications file  (i.e. antibiotic treatments for RTI):
“ Exacerbation” was an answer option to the question on indication 
of antibiotic treatment.
The majority of identified exacerbations (97%) were recorded in the 
medications file. Figure 4.1 gives on overview of the congruence of reporting 
of exacerbation episodes in the three files. In order to arrive at defined
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outcomes, an operational definition had to be agreed with clinical advisors 
(for the operational definition of exacerbation used see section 4.2.5.7)
Figure 4.1 : Congruence of different sources of data on exacerbations
Numbers of exacerbation reports in each file:
Medications file
Clinical status file
684
5,688
1121
783
1,563
123
Adverse events file
n=1184 patients Total: 8,973 exacerbations
The number of exacerbations reported per patient varied considerably 
between the centres, even leaving aside the centre which contributed to the 
ERCF for a shorter time. The variation is particularly gross between children's 
centres, but rates also vary about 2-fold between adult centres. It seems 
unlikely that all of this variation is accounted for by a real difference in 
exacerbation frequency, and differences in reporting practices, and 
particularly under-reporting by some centres seems likely. Note that a large 
number of reports were lost due to incomplete data on drug names, and 
treatment start- and stop dates.
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No centre seemed to have an agreed centre-specific definition of 
“ exacerbation” ; some local coordinators reported that they usually chose the 
response category “ exacerbation” if  an increase of respiratory symptoms was 
observed at the time of a hospital admission or when antibiotics were 
prescribed over and above the prophylactic regimens and regular treatment 
courses against Pseudomonas.
There were great variations between centres, patients, and also over time in 
the location of intravenous antibiotics administration (i.e. at home or in 
hospital). Patients in all centres were routinely on continuous oral antibiotic 
prophylaxis.
Hospitalisation
Similarly, to exacerbations, the database contained three different sources of 
information on hospitalisation events:
1. Adverse events and non-routine hospitalisations file:
“ Hospitalisation” as a dichotomous variable (specified as “ non- 
routine” in Version II of the form only);
2. Clinical status file:
a. “ Hospitalisation” as an answer option to the question on the 
occasion of enrolment (specified as “ non-routine” in Version II of 
the form only) on enrolment;
b. In answer options to the question on the purpose of a clinic visit: 
“ non-routine hospitalisation” on Version II of the follow-up form 
only, and “ planned hospitalisation" on Version II of both follow- 
up and enrolment forms;
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3. Medications f i le  (i.e. an tib io tic  treatm ents fo r  RTI):
"iv- in hospital” as answer option to the question on the route of 
administration.
In addition, the file on medical history of patients logged the year of an organ 
transplant; this is known for 24 out of 44 patients having received a 
transplant; if  the year falls into the observation period, the event may also be 
logged in the adverse events file, but since transplants may well not be seen 
as non-routine hospitalisation, they may not have been reported there.
In terms of congruence between the data sources, data from the clinical status 
file (point 2 above), which indicated hospitalisations other than planned 
hospitalisations, were confirmed by data from the adverse events file (point 1 
above): only 10 patients were not covered by adverse events data, 9 of whom 
are specifically reported to have attended for a “ non-routine hospitalisation” , 
and the tenth patient having attended as a “ new patient” . The agreement 
between hospitalisations reported in the adverse events file (point 1 above) 
and intravenous treatment in hospital (point 3 above) was far less satisfactory.
Dornase alfa therapy
The database contained a whole host of variables relating to the use of 
dornase alfa. Given that the daily dose and frequency of use were practically 
uniform across all users, the main interest from the point of view of this study 
lay in periods “o ff” and “on” dornase alfa and characteristics of “ never 
users” . Hence, the most important variables were start and stop dates for the 
treatment and any indications of patients being “o ff” or “ on” or continuing 
treatment at any given point in time. Therefore, only these variables were 
included in the sample DQR.
The DQR dealt with 140 patients ever having received dornase alfa, 24 of 
whom were from the centre unable to review dornase alfa information, and a
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further nine records were not or only minimally reviewed. The review 
reported seven wrong or missed start dates and four such discontinuation 
dates.
Some patients were on dornase alfa continuously, whereas others simply 
underwent short trial periods of some two weeks or receive dornase alfa for 
short treatment episodes only during a hospital admission. For many patients, 
the sequence of start and stop dates was compatible with supporting variables 
such as whether a patient was continuing treatment at the time of a report. 
In a few remaining cases, the sequence was obviously broken, e.g. where 
there was no stop date between two different start dates for a patient.
A key concern was the compliance of patients with the prescription; whereas 
one variable (doses missed in past 7 days) clearly aimed to elicit this 
information, the variable was far from complete. A small study in Manchester 
and Salford compared cost claims for dornase alfa prescriptions in primary 
care with expected costs from the start date of the prescriptions for 13 adults 
and 10 children. Based on this simple comparison, the estimated prescription 
uptake was 59% for adults and 78% for children (Talbot et at. 1998).
All centres reported the use of a protocol to select eligible patients for 
dornase alfa treatment. In many cases colonisation with P. aeruginosa and 
sputum production and/or cough were amongst the eligibility criteria. 
Sometimes lung function values (e.g. <70% predicted FEVi) were also 
considered; patients awaiting transplants may also have been selected for 
treatment. The duration of individual trial periods was mostly 2 weeks, but 
longer in some centres or for severe patients (up to 3 months) (Conway 1997; 
Ledson et at. 1998). Some centre protocols included a review after one year 
of treatment.
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Although a date of registration into the study could be identified by the date 
on the original enrolment form, the patient may well have been on dornase 
alfa treatment for some time. If a patient was not noted as using dornase alfa 
on enrolment, it  was not clear if  the patient had been using it  previously. 
There is evidence in the literature that cessation of treatment is followed by 
rapid diminution of effect, so there may not be any “ carry-over” effects. A 
more serious worry is a selection effect - cessation because of unsuccessful 
use may indicate that the patient has systematically different characteristics 
from one who simply has not had a trial of dornase alfa.
Some centres used dornase alfa for short-term symptom relief for in-patients. 
This typically resulted in (sometimes repeated) short treatment episodes of 
maybe two weeks. Whereas most centres recorded short-term use and 
initiation trial periods on the ERCF, two reported not to have recorded these 
at all. One of them also reported that the start date chosen was at the end of 
the trial period. These circumstances make it  practically impossible for 
analysts to select p re-treatment lung function values from the database.
Spirometry: FEVi and FVC
About one fifth  of individuals with spirometry reports (n=1040) were reviewed. 
The review reported low rates of discrepancies, and the difference between 
the original and corrected values was far below 1 litre (actual).
After the DQR, 12 (for FVC) and 13 (for FEVi) pairs of duplicate reports with 
discrepant readings for the same day had to be merged by using the mean of 
each pair of readings. Again, the differences were minor.
Predicted values of both variables have been compared with height and age; 
thus, gross outliers of actual values of spirometry measures could be 
highlighted and deleted.
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However, there were systematic centre-differences in lung function readings. 
This was confirmed by the findings from interviews: on each data entry form 
for the ERCF, there was space for two readings of FEVi and FVC from different 
test dates, but the selection of readings to be recorded was le ft up to the 
centres themselves. Whereas some centres selected any one or two 
measurements recorded since the previous visit, one centre chose to record 
the best and worst readings from the period since the previous visit. Another 
centre recorded the pre-lung function values and yet another centre selected 
a “ good” reading, and thus would have chosen a reading afte r a course of 
treatment rather than a reading preceding treatment.
Height
Height is needed to calculate predicted spirometry measures. It was recorded 
for all patients on enrolment, and for children under the age of 18 at every 
visit; for all but nine patients there existed at least one reading.
Height was recorded in two different files: the clinical status file and the lung 
function and spirometry file; hence, similarly to the demographic information, 
the two files allowed some collation of the reports. A merged file was 
created, merging all readings for the same date by their arithmetic mean. 
This method took care of any discrepancies between the two files, after 
having first assessed their size (after data cleaning, only one report had a 
remaining discrepancy of 4 cm in height between two reports of the same day, 
a further few reports recorded smaller differences). This variable was not 
part of the DQR.
Informal checks for height against weight and height against age as well as 
assessments of BMI extreme values (12 or less and 30 or more) helped in 
identifying outliers, which could then be assessed against the trend of 
consecutive reports for a particular patient and amended or deleted.
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Genotype
Genotype for both chromosomes was reported in 74% of patients (892); for a 
further 10% of patients, the genotype was known of only one chromosome. 
The DQR was very valuable in increasing the rate of known genotypes and 
added information on 51 patients (74 chromosomes). Presumably much of the 
added information was not previously available, or at least not on enrolment. 
Four entries were corrected during the DQR. The proportion of patients 
reported to have been genotyped varied between centres (from 73% to 98%).
Shared care
The interviews identified that some patients were subject to “ shared care” 
arrangements between a specialist and a peripheral hospital. Such 
arrangements varied greatly between centres in terms of frequency of contact 
with specialised CF clinicians, the degree of similarity of disease management 
practices between patients directly cared for by the centre and “ shared care 
patients” , and also their location (i.e. CF centre or peripheral clinic). In some 
instances, clinical guidelines may be shared with local non-CF clinicians to 
ensure a consistent approach; in other cases, local non-CF clinicians may 
consult CF clinicians only sporadically. Only some centres enrolled their 
shared care patients on the ERCF, others only entered patients for whom they 
were sole providers of care. This was not a variable in the database, but 
clinicians were concerned about its possible impact.
4.3.5 Discussion and concluding remarks
The ERCF had in place a detailed system of checking the data on key variables 
and requesting corrections by local centres, if missing or discrepant 
information was identified. Nevertheless, there are limits to the extent of 
checking which can be routinely undertaken and therefore further detailed 
data cleaning and quality checks were undertaken as part of this study.
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The Data Quality Review reported here is the only known (and published) such 
effort concerning the ERCF database. It provides insights into the quality of 
the key variables meant for inclusion in the analysis and more generally. Many 
of the problems and issues identified here may also apply to other multi­
centre disease databases, particularly those with less intensive routine 
verification processes than existed for the ERCF!
Even with this limited exercise, important information was gleaned, e.g. eight 
previously un-reported deaths (8%), much additional genotyping information, 
and the conclusion that spirometry was relatively well recorded, but outcomes 
data were badly defined and poorly recorded (deaths, exacerbations, 
hospitalisations). In addition, the processes for patient transfers missed a 
considerable number of “ shared care” patients.
The DQR generated low disagreement rates on a number of key variables in 
the ERCF (notably demographic variables, and lung function). Whereas this 
finding cannot be generalised to the entire ERCF, one may assume that the 
available subset contained reasonably reliable lung function data. Differences 
between centres in interpreting lung function reporting rules (i.e. whether a 
particularly good or poor result was selected for reporting), however, still 
caused systematic differences between centres.
Chronic disease databases depend heavily on the commitment as well as 
expertise of local data coordinators and collaborators. Allowing a degree of 
freedom in defining particular data fields for their own purposes and interests 
can provide an attractive incentive. Researchers using multi-centre data need 
to know local reporting rules in order to judge the comparability of data 
across centres.
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Similarly, interviews with centre staff indicated variations in clinical practice 
between centres which may not be well recorded in a disease registry (e.g. 
differences in treatment protocols). This risks misattributing variations in 
outcome to recorded variables when they may arise from unrecorded 
variables. At the planning of the Dornase Alfa Case Study, clinicians were 
concerned that outcomes of patients may be partly determined by whether 
they were looked after under “ shared care” arrangements with local non­
specialist clinicians. Such “ soft” issues may be ignored in large clinical 
databases.
The issue of motivation to participate in and report to a large clinical 
database is important. One centre operated its own database alongside the 
ERCF. It seems thus likely that contributing high quality data to the latter 
would have been of comparatively lower priority. CF clinicians may have seen 
the ERCF as a means of generating income for their centres, as they were 
reimbursed for contributing data. Only if a centre perceived its own purposes 
to be served by the data collection efforts, might staff be sufficiently 
encouraged to report complete data and focus on data quality locally.
incomplete outcomes data pose a problem for particularly economic 
evaluations, as neither resource use nor health outcomes per se can be 
estimated reliably unless the extent of under reporting is known. The ERCF 
had operated very detailed routine data quality assurance procedures, but 
under-reporting is difficult to address without reference to other data sources 
for verification. The DQR found that deaths and hospitalisations were under­
reported by some centres (overall by 8% and at least 2% respectively). A 
verification of data from the US Veterans Affairs’ HIV registry also identified 
underreporting of deaths and difficulties in routinely verifying such data 
without accessing other data sources (Rabeneck et a i  2001).
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Whereas only a detailed verification process can identify the extent of under­
reporting, comparisons of data from different centres could highlight a range 
of data quality problems. In the Case Study, centre comparisons could 
identify problems with under-reporting (e.g. of blood results, exacerbations), 
and point towards the possibility of reporting differences (e.g. lung function) 
or important differences in clinical practice (e.g. use of iv antibiotics in 
hospital).
For a pharmacoeconomic evaluation, compliance with drug treatment is an 
important issue, both from the point of view of categorising the intervention 
as well as the associated costs (Hughes et al. 2001). A categorical variable 
which could have estimated compliance (number of doses missed in last week) 
was poorly completed in the ERCF (over 80% of entries missing). Verification 
of such a variable would be very difficult, but the issue of measuring 
compliance is itself complex. Previous studies highlighted that patient self- 
reporting as a measure of compliance with dornase alfa can be highly 
unreliable, and compliance has been observed to vary considerably between 
patients (Dodd et at. 1998; Phillips et al, 2001b).
Researchers using secondary data have to be familiar with the objectives of 
the original data collection. For example, post-marketing databases tend to 
focus on safety and to a lesser degree on efficacy evaluation. In the case of 
the ERCF, only non-routine hospitalisations and related adverse events were 
meant to be recorded, however, health economists may have wanted to 
estimate overall hospitalisation rates for different groups of patients. On the 
other hand, different centres may be more or less likely to hospitalise patients 
for the treatment of pulmonary exacerbations, and thus exacerbations per se 
may be a more useful outcome measure.
However, pulmonary exacerbations were difficult to determine from the data. 
Fields from several files had to be cross-referenced and assumptions made
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about realistic time gaps between distinct episodes. The indiscriminate use of 
any one field alone (e.g. antibiotic use) would have misrepresented the 
number of events. It is common to have to use complex algorithms to retrieve 
data on episodes of care or illness from large databases (Schulman et al. 
2001). The strength of disease registries is their focus on a single condition, 
so they ought to enable more precise measurements of key outcome variables 
than are possible in generic databases. However, for some health outcomes of 
interest there may not be a clear and unambiguous clinical definition within 
the medical community (CF exacerbations are a case in point).
The timing of outcome events is important for longitudinal analyses; without 
timing data, it may be difficult even to distinguish between different 
episodes. The identified errors in lung function test dates seemed to have 
been largely due to clerical mistakes, as usually only one item of the day- 
month-year combination had to be corrected (the year of a date seemed 
particularly error-prone in dates near the turn of calendar years). 
Computerised data verification may highlight gaps of one year or more 
between reporting and test dates for checking.
Some degree of inaccuracy of data in pharmacoepidemiology may be 
acceptable so long as it  is random. Given the low level of inaccuracies found, 
it  was difficult to assess this issue with a sufficient degree of confidence. 
However, centre variations were an important factor here.
Much of the data cleaning process reported here was based on crosschecks of 
different variables and essentially a series of basic techniques and meticulous 
reporting. Such crosschecks allow a greater degree of confidence in the data 
quality resulting after the cleaning process. In some cases, dual reporting 
(i.e. the same variable reported in two files) introduced another possibility for 
crosschecking. For longitudinal records in particular, the time sequence of
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readings creates yet another opportunity to aid decisions on the likelihood of 
individual readings.
Some of the variations in recording and clinical practice between centres 
elicited here were suspected during data cleaning. Other differences may 
have gone undetected without the rigorous DQR and questioning process. The 
examples presented here present potentially significant problems for 
effectiveness and particularly cost-effectiveness analyses, as variations relate 
to (recording of) resource use such as clinic visits, and extent or practice of 
treatment, but also intended effects, as well as exacerbations.
4.3.5.1 Limitations of the DQR
There are two major problems of data quality in clinical databases: (1) where 
incorrect entry or lack of entry of available information occurred, or (2) the 
original source does not reflect the true condition of the patient (Sorensen et 
al. 1996). The focus of the data cleaning and DQR was only on the first of 
these. Even there, a multitude of causes could have resulted in the observed 
disagreements between ERCF and original data. Because of data protection 
regulations, I did not have access to original data and therefore did not have 
detailed insight into the nature of the data sources used by the DQR 
reviewers. This limited the exploration of causes for any errors detected and 
of possible improvements of the data source.
The sample was not a representative random sample of records from all 
centres, but partly focussed on records which had raised questions during data 
cleaning. Hence, the proportion of reports with disagreements may over­
estimate the true rate of disagreement in our dataset. However, there is no 
clear relationship between whether records have been found to contain 
possible discrepancies or missing data before the verification, and their
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likelihood of showing disagreements in the verification, probably because only 
certain types of errors could be identified a priori.
There was no further checking of the validity of the verification itself and it  is 
theoretically possible that some disagreements were missed. In some centres, 
staff that had been responsible for the original data entry were involved as 
verification reviewers. In theory, they might have preferred not to highlight 
discrepancies or errors, but there was no reason to suspect that that was the 
case.
The selection of variables for the sample verification was limited by the local 
data sources available for cross-referencing. Thus, it  would have been futile 
to attempt a verification of the variable “exacerbation”  as such. The ease of 
checking varied between local record systems. Future needs for data 
verification could already be envisaged and planned for at the onset of data 
collection for clinical databases.
The DQR was much hampered by data protection legislation, particularly its 
lack of clarity; the required proceedings may have limited the effectiveness 
and certainly the efficiency of the DQR.
Following this detailed examination of data quality within the ERCF, the next 
two sections describe the sample selected for analysis and explore whether 
this could be seen as representative of any meaningful target population to 
which any results might be generalisable.
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4.4 Study sample selection
There were 1,217 patients reported on in the ERCF sample; 24 patients were 
double entered, having initially been registered in a paediatric centre and 
then again when transferred to an adult centre without the records being 
linked. Four non-CF patients and five records with missing key demographic 
information were excluded. For the Case Study analysis, 44 patients with 
transplants had to be excluded, resulting in a sample of 1,140 patients (Figure 
4.2). After excluding under-five-year-olds, the final sample size was 999.
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Figure 4.2: Selection of study sample
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4.5 Representativeness
4.5.1 Introduction
Registries and studies based on their data are often considered to represent 
the clinical realities better than randomised controlled trials (Rittenhouse & 
O'Brien 1996). In addition, a broader spectrum of the potential patient 
population can be represented in a registry, whereas RCTs (and thus their 
findings) are limited to patients carefully selected according to narrowly 
defined inclusion and exclusion criteria. However, representativeness of a 
registry cannot be assumed, and neither can generalisability of a registry- 
based study (Lewis 2001).
The US General Accounting Office (GAO 1992) identified two major categories 
of work assessing the generalisability of existing studies. The first assesses the 
intention in the patient selection process to recruit a representative patient 
sample, whereas the second focuses on the results of the patient selection 
process, i.e. whether a representative sample has been achieved, judged by 
empirical comparisons with patient pools seen in medical practice.
This section records an attempt to determine the generalisability of the Case 
Study by eliciting the representativeness of the patient sample. This requires 
that the sample and target population are similar in relevant characteristics. 
As target populations I used both the UK CF population, and the European 
ERCF population, and the two following sections present comparisons of the 
dataset with those populations respectively. For the UK population there 
were relatively few comparisons possible as published data were limited.
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4.5.2 UK prevalence data
The prevalence of CF in the UK in the year 2000 has been estimated to be 
7,750 cases, an average annual rise of about 2.2% based on an estimated 6,500 
cases in 1992 (Dodge et al. 1997). The “ North of England” dataset from the 
seven participating centres contains contacts with between 754 and 932 
patients a year during its six years of data collection (see Table 4.9). This 
means that between 11% and 13% of the UK patients were in contact with the 
Northern centres in any one year.
Table 4.9 also illustrates that in 1994, the year of setting up the registry, the 
majority of patients were already recruited, but substantial numbers were 
added in the following years. After 1996, one centre no longer contributed 
data, and by 1999 further recruitment and reporting began to cease, which is 
reflected in declining numbers of patients reported on.
Table 4.9: Number of patients reported on during each calendar year
Year Number of patients reported on (n=1184)
1994 754
1995 910
1996 932
1997 846
1998 864
1999 808
The UK Cystic Fibrosis Survey (UKCFS) claims to hold data on all people 
resident in the UK with CF born since 1968 and before that year, if  they were 
still alive in 1977 (Dodge et al. 1997). Table 4.10 shows the number of cases 
reported in the UKCFS (Dodge et al. 1997) by their year of birth compared 
with the patients from the North of England dataset born during the same 
years (n=975). The per cent of UK cases registered in that dataset varied 
between 7% and 18% after 1969, with a rising trend towards later years. This 
may be because more patients from earlier birth years have already died
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before 1994 when the ERCF began enrolling patients. This comparison 
confirms that the North of England dataset contained data on about 12% of all 
known CF patients in the UK. However, complete coverage of any particular 
geographic area is very unlikely, even for centres with complete registration, 
as centres do not draw patients only from clearly demarcated regions, and not 
all shared care patients are registered.
Knowing that our dataset covered a reasonable proportion of the national 
population does not by itself guarantee generalisability of any findings. No 
further comparisons of the UK population were possible; it  is known for 
example that some genotypes are associated with more severe forms of the 
disease, and that genotypes vary geographically, probably also within this 
country. Similarly, the population coverage by specialist centres as well as 
treatment practices w ill vary - neither of which is sufficiently well described 
nationally.
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Table 4.10: Year of birth for North of England and UK CF patients and per 
cent of UK cases registered in North of England dataset (975 
patients born 1968 to 1994)
Year of Number of Cases reported in UKCFS North of England
birth patients in North 
of England dataset
(Dodge et al. 1997)* patients as % UKCFS 
cases
1968 16 367 4%
1969 17 356 5%
1970 38 388 10%
1971 42 407 10%
1972 23 326 7%
1973 32 309 10%
1974 35 316 11%
1975 31 291 11%
1976 31 299 10%
1977 32 278 12%
1978 54 292 18%
1979 51 302 17%
1980 52 302 17%
1981 44 302 15%
1982 38 356 11%
1983 35 301 12%
1984 22 310 7%
1985 46 311 15%
1986 36 276 13%
1987 38 294 13%
1988 48 326 15%
1989 42 290 14%
1990 30 295 10%
1991 41 259 16%
1992 37 239 15%
1993 33 202 16%
1994 31 205 15%
TOTAL 975 8199 12%
*UKCFS=UK Cystic Fibrosis Survey
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4.5.3 Comparison of the North of England with published ERCF 
data
This section compares the sample with ERCF data previously published and 
thus attempts to determine the representativeness of this European 
population. However, the coverage of the European CF population by the 
ERCF is in question; hence, the target population itself is a somewhat artificial 
creation. Comparisons were possible for several available variables: age, lung 
function baseline, treatment practices, dornase alfa use, and microbial 
colonisation.
4.5.3.1 Enrolment data: age and lung function
Koch et al. (1997) published enrolment details of patients enrolled on the 
ERCF between January 1994 and December 1995. Of the patients from the 
seven “ North of England" centres participating in the current study, 79% (931 
patients) were enrolled during that period. A comparison of this subset with 
the enrolment data published by Koch and colleagues is presented below.
Table 4.11 compares age and lung function data on enrolment from the two 
sources. Table 4.12 compares data from the North of England sample (n=1184) 
and enrolment data from the ERCF for the period 1994 to 1995 (Koch et at. 
1997) broken down by FEVi (%predicted) and age group. Comparisons between 
the ERCF population and the North of England sample are hampered firstly 
because of small numbers in the subgroups. Also, Koch et at. seemed to have 
excluded some 7% of registered patients because of missing data. It was 
unclear for example, whether missing lung function values on enrolment were 
a cause for exclusion; whereas no such missing data were indicated in any age 
groups, the age group under 6 years, where a significant number of missing 
values would be expected, still comprised 24% of their population. If missing 
data were excluded from our sample in these age groups, the proportions of 
the two samples would drift further apart to demonstrate even more starkly
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the older age of the current study sample. However, it  is unknown how many 
children’s and adult centres respectively contributed to the ERCF at the 
period in question.
Table 4.11: Age and lung function at enrolment, 931 study patients 
enrolled 1994-1995, compared with ERCF data
North of England sample ERCF (n=6,858)
(95% confidence interval) (Koch et al. 1997)
Age (years) n=931
Mean 14.7 (14.1 -15.3) 13.6
Median 14.0 12.0
FVC (% predicted) n=723
Mean 75.0 (73.3 -76.6) 78.0
Median 76.7 80.3
FEVi (% predicted) n=723
Mean 64.2 (62.3 - 66.0) 65.5
Median 65.4 66.5
Table 4.12: Breakdown of age and lung function at enrolment, 931 study 
patients enrolled 1994-1995, compared with ERCF data
North of England sample ERCF
(Koch et at. 1997)
Age (years)
<6
6-12
13-17
18 and over
Total
FEVi (% of Patient % Patient %
predicted) number number
200 21.5 1,662 24.2
<40 17 1.8 127 1.9
40-70 52 5.6 504 7.3
71-100 95 10.2 913 13.3
>100 33 3.5 275 4.0
Missing 23 2.5
<40 10 1.1 219 3.2
40-70 52 5.6 461 6.7
71-100 75 8.1 464 6.8
>100 13 1.4 80 1.1
Missing 14 1.5
<40 130 14.0 741 10.8
40-70 145 15.6 841 12.3
71-100 64 6.9 494 7.2
>100 5 0.5 77 1.1
Missing 3 0.3
931 100.0 6,858 100.0
Use of Databases in Drug Effectiveness Studies 165
Dornase Alfa Case Study: Further Methodological Issues
Table 4.11 and Table 4.12 raise the possibility that, at least in the first two 
years of the ERCF's existence, the North of England subset contained a slightly 
higher proportion of older patients than the ERCF as a whole. This may 
explain differences between the two sources in clinical variables such as lung 
function or also colonisation rates.
Table 4.13 and Table 4.14 present the mean and median FEVi and FVC % of 
predicted at enrolment. By comparison, the ERCF in 1998 reported mean 
values for FEVi of 90.5%, 78.9% and 67.3%, and 53.7% for the same age groups 
(<6 years, 6-12 years, 13-17 years, 18+ years respectively); the corresponding 
values for FVC were: 97.2%, 86.6%, 79.9%, and 71.4% respectively (Hodson et 
al. 1998a). However, these seem to be data based on multiple observations 
per individual, i.e. not only enrolment data.
Table 4.13: FEVi on enrolment report by age at enrolment, 878 patients 
with enrolment FEVi available (North of England)
Age (years) Number of Mean FEVi 
 patients (% of predicted)
<6 36 79
6-12 229 78
13-17 185 72
18 and over 428 51
Total 878 64
Table 4.14: FVC on enrolment report by age at enrolment, 877 patients 
with enrolment FVC available (North of England)
Age (years) Number of 
patients
Mean FVC 
(% of predicted)
<6 36 78
6-12 229 83
13-17 185 84
18 and over 427 66
Total 877 75
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It appears that the North of England sample may have included somewhat 
more severely affected young children and adults, but adolescents showed 
better values than were reported in the European comparison data. The North 
of England data also compared less favourably with data from the US from 
1990 (FitzSimmons 1994) which reported mean FEVi and FVC % of predicted of 
68.9% and 80.9% respectively (mean and median age: 14.5 and 12.5 years 
respectively), compared to 64% and 75% in the North of England sample. 
However, at least some of that difference may be accounted for by the use of 
different prediction formulae (FitzSimmons used a modification of the 
Knudson formulae).
These findings not only demonstrate age differences between the sample and 
ERCF population, but also strongly suggest that there were differences in 
severity of each group, which could mean that the population of young 
children registered on the ERCF is comparatively well. However, given what 
we knew about the completeness of registration within our children’s centres, 
this raises the question of whether the ERCF itself was representative of the 
actual European CF population. It is important to note that analysts of the 
ERCF population might not be aware of this problem or would not know the 
answer to the question, unless they truly know the completeness of 
registration from different centres (as we did from ours).
4.5.S.2 Enrolment data: treatment practices
There was also an opportunity to compare some treatment practices between 
the sample and the ERCF population. All centres reported using oral antibiotic 
prophylaxis routinely. Between 94% and 97% of patients reported on in each 
year had indications of continuous antibiotic prophylaxis recorded. Earlier 
reports on the ERCF in 1998 (Hodson et al. 1998a) indicate that 65.8% of 
patients were receiving continuous antibiotic prophylaxis; apart from centre 
(or indeed international) differences in routine clinical practice, the 
difference may also be due to a different definition being applied in the 1998
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study (e.g. continuous prophylaxis indicated throughout the observation 
period). Nevertheless, this represents a significant difference in a key 
prophylactic intervention which could mean that both progression and 
outcomes of the disease might be inherently different between sub­
populations of the ERCF.
Much of the comparison of treatment practices reported in the North of 
England sample and in the ERCF used data presented by Koch et al, (1997) 
(Table 4.15 to Table 4.20). Both sources indicate a rise in the use of oral 
bronchodilators with age and severity of pulmonary disease. In addition, 
inhaled bronchodilators saw an increased usage in patients with more severe 
pulmonary disease, but not age. In nearly all subgroups, the use of 
bronchodilators exceeded the number of patients recorded to be suffering 
from asthma-like symptoms. Overall, in the current study sample 36.2% of 
patients were reported to suffer bronchial hyper-reactivity or asthma-like 
symptoms on enrolment, in some subgroups 60% or more. The overall use of 
inhaled bronchodilators was reported to be 60%. By comparison Koch et al, 
reported a similar condition in up to 27% in any subgroup, whereas the 
indicated use of inhaled bronchodilators was in most age groups more similar 
to the rates observed by the current study, but about two or three times 
higher than the number of patients diagnosed in the ERCF (Koch et al. 1997) 
population.
Table 4.15 illustrates a point already made by Koch et al, (1997): their data 
indicated that in the UK inhaled corticosteroids are used far more (by 36% of 
patients on enrolment) than for example in France (10%) or Germany (12%). 
The authors put this down to the traditionally different approach to the 
treatment of asthma. The equivalent figure in the current sample is 34%. In 
both sources, the number of patients reported as being treated with oral 
steroids exceeds the number of patients reported to suffer from allergic 
bronchopulmonary aspergillosis (ABPA).
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Table 4.15: Inhaled corticosteroid treatment reported on enrolment, by 
age and lung function, 931 study patients enrolled 1994-1995, 
compared with ERCF data
North of England sample ERCF
 ____________________________________ (Koch et al. 1997)___
Age (years) FEVi (% of 
predicted)
Patient number % %
<6 58 29 17
6-12 <40 6 35 24
40-70 27 52 26
71-100 38 40 21
>100 7 21 26
13-17 <40 7 70 28
40-70 21 40 34
71-100 28 37 26
>100 6 46 21
18 and over <40 43 33 41
40-70 47 32 31
71-100 17 27 22
>100 0 0 17
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Table 4.16: Inhaled bronchodilator treatment reported on enrolment, by 
age and lung function, 931 study patients enrolled 1994-1995, 
compared with ERCF data
North of England sample ERCF 
___________________________________________________  (Koch et al. 1997)
Age (years) FEVi (% of 
predicted)
Patient number % %
<6 82 41 36
6-12 <40 11 65 63
40-70 32 62 57
71-100 46 48 47
>100 13 39 48
13-17 <40 10 100 74
40-70 39 75 63
71-100 49 65 53
>100 7 54 45
18 and over <40 102 78 80
40-70 106 73 68
71-100 41 64 52
>100 1 20 46
Table 4.17: Oral bronchodilator treatment reported on enrolment, by age 
and lung function, 931 study patients enrolled 1994-1995, 
compared with ERCF data
North of England sample ERCF
(Koch et at, 1997)
Age (years) FEVi (% of 
predicted)
Patient number % %
<6 2 1 3
6-12 <40 0 0 5
40-70 2 4 7
71-100 1 1 4
>100 1 3 5
13-17 <40 1 10 13
40-70 2 4 7
71-100 5 7 6
>100 1 8 5
18 and over <40 34 26 19
40-70 34 23 15
71-100 9 14 12
>100 1 20 10
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Table 4.18: Asthma-like symptoms reported on enrolment, by age and lung 
function, 931 study patients enrolled 1994-1995, compared 
with ERCF data
North of England sample ERCF
(Koch et al. '
Age (years) FEV1 (% of Patient number % %
predicted)
<6 47 24 14
6-12 <40 5 29 25
40-70 17 33 22
71-100 18 19 17
>100 4 12 11
13-17 <40 6 60 27
40-70 12 23 21
71-100 23 31 14
>100 3 23 10
18 and over <40 75 58 24
40-70 90 62 21
71-100 25 39 15
>100 1 20 13
The use of pancreatic enzymes seems broadly similar in both sources and is 
comparable with other published reports of the prevalence of pancreatic 
insufficiency in CF patients. Of the 1,140 patients, 1,085 (96%) have any use 
of pancreatic enzyme recorded. This figure is slightly higher than the 92% of 
screened children found to suffer pancreatic insufficiency at 1 year of age 
(Bronstein et al (1992) quoted in Littlewood and Wolfe (2000)). These authors 
also observed lower proportions of pancreatic enzyme users in higher age 
groups and more severe patients. Similarly, but broken down by age at 
enrolment, a clear trend is visible towards patients who are enrolled later in 
life (and conceivably of a less severe phenotype) being less likely to use 
pancreatic enzymes.
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Table 4.19: Pancreatic enzyme treatment reported on enrolment, by age 
and lung function, 931 study patients enrolled 1994-1995, 
compared with ERCF data
North of England sample ERCF 
___________________________ (Koch et al. 1997)
Age (years) FEVi (% of 
predicted)
Patient number % %
<6 189 95 93
6-12 <40 16 94 97
40-70 50 96 95
71-100 90 95 94
>100 33 100 94
13-17 <40 10 100 94
40-70 50 96 94
71-100 71 95 93
>100 12 92 86
18 and over <40 113 87 90
40-70 124 86 87
71-100 52 81 84
>100 4 80 78
4.5.3.3 Dornase alfa use
In Koch's et al. (1997) data from 1994 and 1995 the rates of dornase alfa 
treatment reported on enrolment varied between European countries from 
16% in the UK, 25% in Germany, to 49% in France, giving an overall rate of 25%. 
The equivalent figure for the North of England dataset was 14%. Table 4.20 
seems to indicate that the North of England dataset contained more users 
amongst children but fewer adults on dornase alfa compared to the overall UK 
figures.
This is an important finding as it  demonstrates considerable differences in 
treatment decisions (which are likely to be affected at least as much if  not 
more by economic than clinical factors). This adds further complexity to any 
analysis of the likely effect of dornase alfa based on this database.
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Table 4.20: Dornase alfa treatment reported on enrolment, by age and 
lung function, 931 study patients enrolled 1994-1995, 
compared with ERCF data
North of England sample ERCF (Koch et al. 1997)
UK subset Total ERCF 
of ERCF
Age (years) FEV1 (% of 
predicted)
Patient
number
% % %
<6 5 3 2 5
6-12 <40 8 47 40 50
40-70 14 27 21 38
71-100 10 11 6 17
>100 2 6 5 13
13-17 <40 7 70 54 57
40-70 21 40 34 44
71-100 5 7 9 21
>100 1 8 5 9
18 and over <40 33 25 45 53
40-70 13 9 21 34
71-100 4 6 7 17
>100 1 20 0 5
4.5.3.4 Microbiological colonisation (period prevalence)
Comparative data on microbiological colonisation of ERCF registered patients 
existed in the form of an abstract of a conference presentation in 2000 
(Mastella et al. 2000). The authors selected 12,066 patients registered 
between January 1994 and August 1999 who had at least two valid cultures. It 
was unclear what was meant by “valid cultures”  and also where exactly the 
included patients were from, but it  seemed reasonable to assume that a 
substantial proportion of them were UK patients, since the UK was one of the 
largest contributors of data to the ERCF. Their data are presented in Table 
4.21. The same table contains data from the North of England subset of 1,018 
patients who had at least two culture tests recorded during the entire 
observation period (up to December 1999). No adjustments for different 
observation periods have been made; hence, in theory one may expect to see 
a slightly higher prevalence in the North of England sample.
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The data seem to indicate a continuously higher prevalence of Pseudomonas 
aeruginosa across all age groups in the North of England centres, which was 
also higher than the overall prevalence of 83% in adolescents and adults 
reported by Penketh et al (1987).
For other micro-organisms (Table 4.22) the data also varied between the two 
sources (again, for the North of England sample only patients with at least two 
culture dates were included). Whereas for children and adolescents the 
reported prevalence of 6. cepacia was very similar to the ERCF report, the 
prevalence in adults was 2.5 times higher in the North of England sample. 
This reflects the epidemic of 8. cepacia infection in some adult centres in the 
early 1990s. Reported colonisation with H. influenzae was generally 
somewhat lower in the North of England sample, apart from that amongst 
adults, and reported colonisation with S. aureus was considerably lower, 
especially in children. Overall colonisation with the H. influenzae and S. 
aureus has previously been reported to be 68% and 60% respectively (Penketh 
et al. 1987). Colonisation with Candida shows higher rates in children and 
lower rates in adults of the North of England sample, and a generally more 
even distribution across age groups than that observed in the European data.
Table 4.21: Patients with Pseudomonas aeruginosa colonisation reported 
during the observation period 1994-1999 by age group, 1,081 
patients with more than one culture date recorded, compared 
with ERCF data
North of England sample ERCF data (Mastella et al. 2000)
Age (years) N Patients
affected
% affected 
of all 
patients
N Patients
affected
% affected 
of all 
patients
<6 236 108 45.8 1894 720 38.0
6<13 358 234 65.4 3754 2109 56.2
13<18 286 238 83.2 2192 2066 70.9
18 and over 486 457 94.0 4336 3600 83.0
Notes
Individual patients may appear in more than one cell.
All differences are significant at the 5% level (Chi square test).
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Table 4.22: Patients with any reported colonisation by different bacteria 
during the observation period 1994-1999 by age group, 1,081 
patients with more than one culture date recorded, compared 
with ERCF data (Mastella et al. 2000)
Staph, aureus B. cepacia H. influenzae Candida
NE ERCF NE ERCF NE ERCF NE ERCF
Age (years) % % % % % % % %
<6 18.2 43.7 1.3 1.5 35.2 45.6 36.4 19.8
6<13 36.9 60.0 3.6 3.9 30,4 40.7 31.0 29.9
13<18 34.3 57.4 7.3 7.2 22.7 25.2 24.5 32.2
18 and over 42.2 54.5 24.9 10.2 27.0 23.0 27.0 40.1
Notes:
NE=North of England sample; ERCF data from Mastella et al. (2000)
Individual patients may appear in more than one age and bacterial group.
Only bold data pairs are not significantly different at the 5% level.
Same “N” base group per age group as in Table 4.21.
4.5.4 Concluding remarks
There was a small amount of published data on the UK CF population, which 
would have been the more interesting target population to choose for 
determining representativeness. However, very little  detailed UK data had 
been published from the national CF surveys.
Therefore, much of the comparison relied on ERCF data. Whereas this still 
highlighted interesting parallels and differences, this approach was somewhat 
unsatisfactory, because any un-representativeness in the North England 
sample could have easily been repeated Europe-wide and would have been 
difficult to detect in that way. For example, the ERCF was supplied with data 
from CF centres, and patients not cared for in such centres are excluded - in 
all countries. Also, it  is known that the UK was one of the largest contributors 
to the ERCF and it  is therefore unlikely that the ERCF was representative of 
the European CF population. In addition, reporting errors could be similar
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across the ERCF as the same data collection mechanisms and instruments were 
used.
My familiarity with the actual situation in our regional participating centres 
was key to interpreting some of the findings (e.g. the high 8. Cepacia 
prevalence), but more importantly to raising questions about the 
completeness and representativeness of the ERCF itself (e.g. of younger age 
groups). Without such familiarity with the source and background of the data, 
analysts of the ERCF might find it  difficult to interpret their findings. This 
issue highlights that determining representativeness and data verification are 
closely related activities in practice and are vital in the preparatory stages of 
ESDs. Without confidence in the data source, any differences between that 
and a possible target population cannot be interpreted, and generalisability 
w ill remain an elusive concept - even though it  is held up as a strength of 
ESDs,
A range of published survey results offered further sources of comparisons. 
The usefulness of such comparisons is limited, if their own representativeness 
of any target population is unknown. Nevertheless, areas of uncertainty may 
be highlighted. As epidemics and outbreaks make it  difficult to compare 
microbiological data across geographic regions, such data are less useful in 
determining representativeness. A similar argument may apply to genotype 
information, which shows natural geographic variations. This makes the 
interpretation of any found variations difficult, as it  remains unclear how 
much of the variation is due to true geographic difference, and how much to 
sampling error.2
2 For example, in 81% of the sample (n=1,140), at least one DF508 mutation was reported. 
This is higher than the figure quoted by Rosenstein (2000) (66%) for the Caucasian population. 
In addition, 6% have at least one G551D mutation recorded, and 1.6% show a R117H mutation. 
Again, the prevalence of these mutations has been indicated to be several times lower in 
other populations (1.6% and 0.3% respectively) (Rosenstein 2000).
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4.6 Analysis
The detailed analysis of the dataset was undertaken by an analyst. I am 
therefore only able to present the analysis provided and critique it  vis-à-vis my 
knowledge of the data and relevant literature (see next chapter). This small 
section describes the approach of the analyst and in particular his relevant 
concerns.
The “ allocation” to dornase alfa, including pre-and post-registration status, 
was used to divide the study population into five groups for comparison. It 
should be remembered that little  is known of why some patients do, and 
others do not, respond to dornase alfa. Any categorisation without
randomisation may therefore be confounded by these unknown factors.
Five groups were produced from the application of two concepts:
(A) Continuity of use
(B) Use at time of enrolment
The resulting groups are presented in Table 4.23. As this study was based on 
historical data, the five groups with different allocation of treatment had to 
be taken as given, and interpretation based on a review of data quality, and 
the recorded characteristics of the patients and changes in variables and 
confounders over time.
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Table 4.23: Groups analysed by dornase alfa use
Group Use of dornase alfa Total
Continuous Some None patients
Starting
before
enrolment
Starting on 
or after 
enrolment
Starting Starting on 
before or after 
enrolment enrolment
Group ID 
number 1 2 3 4 5
After
excluding 
transplants 
Further 
exclusion of 
under-5-year 
olds
106
106
195
195
41
41
107
105
691
552
1140
999
The principal outcome variables were death, exacerbation, lung function 
change, and anthropometric measures. Data at enrolment were reviewed for 
ethnic group, sex, age, age at diagnosis, diabetic status (and age at diagnosis), 
FEVi and FVC, height, weight and body mass index (BMI).
In the investigation of lung function and anthropometric data, reports were 
amalgamated if  they fell into the same calendar quarter. The advantages of 
this approach were that arbitrary selection was avoided and all available data 
used. The disadvantage is that marked short-term changes would be averaged 
out. Given the length of the study period, this was considered a practical 
approach.
A particular problem in measuring lung-function decline - even in non-CF 
populations - is to identify if it  is a true ageing effect. The period of 
observation (although far longer than most published CF studies on dornase 
alfa) allowed only limited comparison with general lung-function data. 
Testing for the significance of differences is complex as the data have been 
standardised, and it  was unclear whether the quantity or quality of the data 
would allow the use of specialised tests. The current limited objective was to 
study annualised FEVi and FVC change rates, compiled from comparing the
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averages for readings in the first and last quarters of observation, and dividing 
for the period of observation. Calculations were made for both the Dundee 
and Knudson formulae. A subsidiary analysis was made of the group with no 
known use of dornase alfa prior to registration (Group 2).
Data display was intended to show the main effects apparent in the sample 
and to facilitate comparison with the literature. The analyst decided that the 
testing of hypotheses in the study sample would present difficulties for the 
following reasons:
1. Without random allocation to groups, there can be no assurance that 
unrecorded factors “ cancel out” . For example, little  information was 
available on why, at the time of enrolment, some patients were on 
dornase alfa, and others were not. Therefore, any test between groups 
for a particular factor may be undermined by confounding influences.
2. Lung function and anthropometric measures are conventionally 
standardised (percentage predicted lung function, height centile). It is 
not well appreciated that such procedures often invalidate the use of 
statistical procedures (e.g. t-tests) which assume particular 
distributions, because the original measurement unit has been 
discarded. Although other families of tests exist, these may lack power 
and require much larger numbers of patients.
3. Where repeated observations are made over time on the same 
individuals, the measurements are not independent, may not be at 
regular intervals or for the same overall time, and irregularities of 
timing or missing data may not be random (e.g. particularly ill patients 
may have more readings, or neglect routine appointments). All these 
features make analysis difficult.
4. Technical issues exist on separating out the influence of age, cohort, 
and period. Recent advances in treatment of CF (notably nutrition and 
antibiotics) have considerably increased life expectancy, and patients
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will have had a wide variety of treatments in childhood. In this study, 
data were reviewed both by cross-sectional age groups (e.g. on 
enrolment) and by following a cohort in time.
The following chapter summarises the findings. It must be appreciated - as 
indicated by the analyst's approach - that the analysis is limited to descriptive 
information to facilitate comparisons with the literature, and does not enable 
any conclusions about the effect of dornase alfa treatment.
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5.1 Results
The following quote summarises well the complexities of research on CF:
"Th/s [CF] patient population has proved challenging to clinical 
investigators fo r several reasons, including (1) a large intrasubject and 
intersubject variab ility in commonly used outcome measures (e.g. 
pulmonary function testing), (2) the progressive nature o f the illness, 
resulting in strong period effects, (3) wide variation in illness severity, 
(4) intercenter variab ility in treatment regimens, (5) confounding 
effects o f multiorgan dysfunction on pulmonary disease, (6) the 
occurrence o f periodic exacerbations o f pulmonary symptoms, and (7) 
the lim ited availability o f research tools fo r measuring progression o f 
disease in younger patients w ith m ild pulmonary involvement. ”
(Ramsey & Boat 1994 p. 178)
Due to the reasons described in the previous section, and not least the small 
sample size, the analysis is limited to descriptive approaches. This section of 
the report presents results in three blocks:
(1) The movement of patients into and out of the cohort (subsection 
5.1.1)
(2) Baseline data examining the main variables, their relationships,
and their distribution amongst the comparison groups
(subsection 5.1.2), and
(3) Presentation of longitudinal observations on sample outcomes
data (death, and lung function change) (subsections 5.1.3 and
5.1.4).
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5.1.1 Enrolment, follow-up, and discontinuations
In this section, the patterns of enrolment, follow-up, and discontinuations of 
the entire sample of 1,184 patients are examined.
5.1.1.1 Enrolment
The ERCF intended that participating centres would enrol all their patients 
onto the database. However, one children's centre had missed an estimated 
10 patients, and one adult centre reported that it  stopped enrolling patients 
for the ERCF after a certain number had been reached (about half to one third 
of the actual patient population of that centre). A further children's centre 
only contributed data for the first two years after which its participation in 
the ERCF ceased. Whereas for most of this centre’s patients the follow-up 
period was thus relatively short, some of them have been followed up in one 
of the adult centres.
Most patients were enrolled into the ERCF during 1994, the year it was 
initiated. In fact, enrolment slumped during 1996-8; Centre 2 had stopped 
recruiting patients to the ERCF, and Centre 7 was not enrolling any new 
patients until 1999 (Table 5.1). Only Centre 6 - and possibly Centre 1 - exhibit 
a steady influx of patients over the years following 1994.
Table 5.1 : Number of patients enrolled in each centre per calendar year
Centre 1994 1995 1996 1997 1998 1999 Total
1 115 13 7 6 6 13 160
2* 113 18 6 137
3 100 42 10 17 22 8 199
4 84 59 5 8 1 24 181
5 52 15 11 10 2 90
6 165 13 13 15 14 12 232
7 122 20 13 29 184
Total 751 180 65 56 45 86 1183
* This centre stopped participating in the ERCF during 1996.
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5.1.1.2 Deaths, discontinuations, and transfers
Ninety-nine patients (8.4%) included in the sample were reported to have died 
during the observation period (up to 1999). The mean and median ages at 
death reported were 23.9 (SD: 7.1) and 23.4 years respectively. Of all deaths, 
83% were caused by cardio-respiratory failure (3% unknown).
Sixteen patients were reported to have moved away, and another two were 
reported as lost to follow-up; one patient was reported to have requested to 
leave the database and another one was discontinued for undefined 
“ administrative” reasons.
During the observation period, 159 patients (13%) were transferred, two of 
them twice. Most transfers occurred between adult and children's centres 
within the same conurbation.
5.1.1.3 Follow-up
Table 4.9 above presented the number of patients reported on during each 
year. Overall, the regularity of reports varied considerably between individual 
patients; a sizable number of patients were only reported on once a year, 
some less often. This could have implications for the analysis, particularly if 
the reason for non-reporting is not known.
Sixty-two per cent of patients in the sample have been followed-up for over 3 
years. The median period of observation was 1,480 days (inter quartile range 
(IQR): 1,017), and the maximum was 2,100 days (5.8 years).
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5.1.2 Baseline data
Table 5.2 gives baseline data by dornase alfa group, for sex, ethnicity, age at 
enrolment, age at diagnosis, diabetes status, and age at first report. There 
were relatively few intermittent dornase users who started treatment prior to 
enrolment (group 3), but every group had a reasonable representation of 
males and females.
The group with no record of dornase alfa was markedly younger at enrolment 
than the others. There were higher rates of diabetes in the groups using 
dornase alfa, compared to never-users.
Table 5.2: Baseline data: Sex, race, age at enrolment, age at diagnosis,
genotype, and diabetes status
Use of dornase alfa Total
Continuous Some None
Sex Starting Starting on Starting Starting on
before or after before or after
enrolment enrolment enrolment enrolment
Group number 1 2 3 4 5
Sex m 56 80 21 58 327 542
f 50 115 20 47 225 457
all 106 195 41 105 552 999
Non-Caucasians 3 2 - - 13 18
Mean age at m 17.0 18.1 17.7 21.1 13.6 15.6
enrolment f 16.6 16.9 17.4 18.0 14.2 15.7
(years) all 16.8 17.4 17.5 19.7 13.9 15.7
Mean age at 1.6 2.2 1.0 3.1 2.8 2.54
diagnosis (years)
Diabetic - n 23 33 18 20 53 147
% 22% 17% 44% 19% 8% 13%
Table 5.3 gives baseline data for % predicted FEVi, FVC, and percentile height, 
weight, and body mass index standardised to the Child Growth Foundation 
1990 references. For % predicted FEVi and FVC lung function, the “ no
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recorded use” group had substantially better values. Amongst dornase alfa 
users, those having started use before enrolment appeared to have slightly 
lower values, but this was less clear for females. For FVC, female values may 
have been rather higher than males.
Compared with the Child Growth Foundation references, the whole sample 
(n=999) was about the 33rd percentile for height and weight, and the 39th 
percentile for BMI, with little  sex difference. Those with a record of 
continuous use of dornase alfa were 9 height percentiles, 18 weight 
percentiles, and 20 BMI percentiles lower than those in the group with no 
record of dornase alfa use.
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Table 5.3: Baseline data: FEVi, FVC at enrolment (% predicted by
Knudson formulae), height, weight, and BMI (standardised to 
Child Growth Foundation references), by sex and dornase alfa 
use group
Use of dornase alfa Total
Continuous Some None
Sex Starting Starting Starting Starting
before on or before on or
enrolment after enrolment after
enrolment enrolment
Group number 1 2 3 4 5
FEVi - n 80 174 39 102 434 829
m 51.7 54.7 46.7 56.2 77.8 67.7
f 48.5 59.7 58.0 56.8 78.1 66.5
all 50.0 57.7 52.5 56.5 77.9 67.1
FVC - n 80 174 39 102 432 827
m 67.1 67.3 57.3 68.0 82.7 75.9
f 62.7 73.2 72.3 73.3 86.4 78.1
all 64.8 70.8 65.0 70.4 84.2 76.9
Height m 27.9 30.8 25.8 32.2 34.8 32.9
percentile f 23.9 32.7 30.3 33.3 34.8 32.7
all 26.0 31.9 28.0 32.7 34.8 32.8
Weight m 21.3 23.2 24.1 24.4 37.6 31.9
percentile f 18.1 29.5 25.3 31.2 38.7 32.8
all 19.7 26.9 24.7 27.4 38.0 32.3
BMI m 26.6 27.0 33.3 27.0 45.9 38.7
Percentile f 24.6 33.7 31.0 36.4 45.8 38.8
all 25.7 31.0 32.2 31.2 45.8 38.7
This baseline overview already demonstrates stark baseline differences 
between dornase alfa treatment groups. A more detailed examination of lung 
function and anthropometric variables follows.
5.1.2.1 Lung function
Table 5.4 presents % predicted FEVi by sex, age, diabetes status, and also 
deaths and exacerbation rates. There was no statistically significant 
difference for the distribution of “ % predicted FEVV’ by sex. Unsurprisingly, 
deaths were associated with low values. Annualised “exacerbation” rates are 
more difficult to interpret - the statistically significant difference (p<0.001)
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between dichotomised high and low rates appeared to relate to males and not 
to females.
The association of FEVi bands with age was statistically significant at p<0.001, 
indicating the progressive nature of the disease. The association of low % 
predicted FEVi with diabetes (p<0.001) was common to both males and 
females.
Table 5.5 presents the same % predicted FEVi groups by dornase alfa use 
status, sex, and initial 5-year age bands. There were similar male and female 
patterns in the relation of dornase alfa usage class with % predicted FEVi 
classes. The highest proportion of <40% values were in the two “continuous 
use" groups, but about 10% of those with no recorded use had these low values 
(there may, of course, be medical or personal decisions for not using dornase 
alfa).
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Table 5.4: Categorized “ %predicted” FEVi lung function data (Dundee
formulae) on enrolment by sex, in itia l age, diabetes, death, 
and exacerbation rates (n=834 with in itia l lung function 
categorisation)
Sex Deaths Dichotomised
exacerbation rates
(>= 1 yr observation)
n = 732
%pred. Male Female Survivor Death Low High
FEVi
m <40 71 28 26 56
40<70 135 10 51 71
>70 203 5 110 67
all 409 43 187 194
f <40 53 23 27 39
40<70 127 15 66 63
>70 159 5 82 74
all 339 43 175 176
all <40 99 76 124 51 53 95
40<70 145 142 262 25 117 134
>70 208 164 362 10 192 141
all 452 382 748 86 362 370
Statistical P=0.32 all p<O.OO1 all p<0.001
significance - m, f: p<0.001 m: p<0.001 , f: p=0.26
Chi-squared test
Age Diabetes
%pred. <18 18+ No Yes
FEV1
m <40 20 79 70 29
40<70 67 78 130 15
>70 160 48 189 19
all 247 205 389 63
f <40 18 58 49 27
40<70 69 73 112 30
>70 134 30 144 20
all 221 161 305 77
all <40 38 137 119 56
4O<70 136 151 242 45
>70 294 78 333 39
all 468 366 694 140
Statistical all p<0.001 all p<0.001
significance - m, f: p<0.001 m,
oooC
L
4-Z
Chi-squared test
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Table 5.5: Categorized “%predicted" FEVi lung function data (Dundee
formulae) on enrolment by sex, dornase alfa user group, and 
age (<18/18+) (n=834 with initial lung function categorisation)
%pred. Use of dornase alfa
FEV1 Continuous Some None
Starting Starting on Starting Starting on All
before or after before or after
enrolment enrolment enrolment enrolment
1 2 3 4 5
m <40 22 21 9 19 28 99
40<70 19 29 4 21 72 145
>70 13 18 6 17 154 208
all 54 68 19 57 254 452
f <40 18 27 3 13 15 76
40<70 22 39 11 20 50 142
>70 6 33 6 13 106 164
all 46 99 20 46 171 382
all <40 40 48 12 32 43 175
40<70 41 68 15 41 122 287
>70 19 51 12 30 260 372
all 100 167 39 103 425 834
%pred. ___________Initial five-year age group (years)
FEV1 5<10 10<15 15<20 20<25 25<30 30<35 35+ Total
m <40 4 6 19 31 14 16 9 99
40<70 24 18 38 40 13 9 3 145
>70 78 42 55 24 5 3 1 208
all 106 66 112 95 32 28 13 452
f <40 4 9 13 21 16 8 5 76
40<70 22 28 37 26 20 5 4 142
>70 44 53 45 12 8 2 164
all 70 90 95 59 44 15 9 382
all <40 8 15 32 52 30 24 14 175
40<70 46 46 75 66 33 14 7 287
>70 122 95 100 36 13 5 1 372
all 176 156 207 154 76 43 22 834
5.1.2.2 Anthropometric data
Table 5.6 summarises height, weight and BMI percentiles standardised to Child 
Growth Foundation references by sex and 5-year age group. It should be 
noticed that some of the figures were based on very small numbers. This 
cross-sectional analysis indicates that in males there was no marked change 
over age in percentile for height but a steady decrease for weight, with,
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naturally, decreasing BMI percentile. The female data differed - there 
appears to be no clear trend, and maybe a “ dip” in the 10-15-year age group.
Table 5.6: Percentile of height, weight, and BMI data on enrolment, by
sex and age (standardised to Child Growth Foundation 1990 
references)
Age (years) Height Weight BMI n
Males
5 <10 37.6 43.9 53.0 179 - 181
10 < 15 34.1 36.2 40.9 67 - 70
15 < 20 27.9 25.2 34.7 117 - 118
20 < 25 28.3 22.7 28.4 96
25 < 30 39.9 25.3 21.5 32
30 < 35 26.5 15.1 19.3 26 - 27
35 + 35.5 24.8 23.0 13
Total males 32.9 31.9 38.7 531 - 537
Females
5 <10 31.1 36.9 47.3 126 - 127
10 < 15 25.4 26.0 35.0 89 - 91
15 < 20 33.0 31.5 40.4 102
20 < 25 36.8 31.4 31.5 58 - 59
25 < 30 41.4 37.7 33.3 44
30 < 35 38.8 39.3 36.0 16
35 + 43.8 29.6 21.9 11
Total females 32.7 32.8 38.8 446 - 450
Table 5.7 summarises anthropometric data for diabetes, which is a potential 
confounder for some analyses. There were no differences between the sexes. 
The analysis by diabetes status showed much poorer percentiles for diabetic 
patients, but there is probably also an age effect at play here: those identified 
as diabetic on enrolment were young adults seven years older than the non­
diabetic patients.
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Table 5.7: Baseline data: Height, weight, BMI percentiles (standardised to
Child Growth Foundation references), by diabetic status
Diabetes record Height Weight BMI n
Males No 33.7 33.7 40.8 465-472
Yes 26.8 19.4 23.4 65
Females No 33.5 34.0 40.3 367-371
Yes 29.4 26.8 31.8 79
All No 33.6 33.8 40.6 832-843
Yes 28.2 23.4 28.0 144
In summary, the baseline data present an interesting picture of not entirely 
surprising associations between factors such as diabetes with poorer lung 
function on enrolment. Predictably also, dornase alfa is used more in patients 
with poorer lung function, bacterial colonisation with particularly 
Pseudomonas, and those with more severe genotypes (see Appendix A for 
more baseline data presentation). Thus, dornase alfa users were not 
comparable to non-users at baseline. Lung function data by age also pointed 
at the progressive nature of the disease.
The next sections of this chapter give an illustrative overview of the outcome 
variables death, and change in lung function in the different dornase alfa use 
groups. Further information relating to the outcomes of exacerbation 
frequency, and anthropometric changes is contained in Appendix A.
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5.1.3 Outcome variable: Death
Numbers of deaths in the different comparison groups were small. Table 5.8 
presents an analysis of death by sex, age, and dornase alfa use. The rate of 
death increased with age and is higher in females. The oldest group at entry 
had small numbers and would be highly selected by survivalship from a time of 
less advanced care. The no-use group had the lowest rate of death. This is 
hardly surprising given the strong relationship between dornase alfa use and 
poor lung function, diabetes, and not least age. Also, the analyst observed 
that dornase alfa was often initiated during episodes of exacerbation.
Table 5.8: Death by sex, initial age group, and dornase alfa use (n=999)
Age (years) Total
0 <6 6 <11 11 <16 16 <21 21 <26 26 <31 31 <36 36+
Male Alive 88 106 80 103 67 32 16 9 501
Deaths 0 1 1 16 11 3 7 1 40
All 88 107 81 119 78 35 23 10 541
Female Alive 64 79 86 82 52 30 11 9 413
Deaths 1 4 8 14 7 7 2 1 44
All 65 83 94 96 59 37 13 10 457
Total Alive 152 185 166 185 119 62 27 18 914
Deaths 1 5 9 30 18 10 9 2 84
All 153 190 175 215 137 72 36 20 998
% deaths 1% 3% 5% 14% 13% 14% 25% 10% 8%
Note: Age at enrolment unknown for 1 patient.
Use of dornase alfa All
Continuous Some None
Starting Starting on Starting Starting
before or after before on or after
enrolment enrolment enrolment enrolment
Group number 1 2 3 4 5
Males Alive 86 167 32 89 540 914
and Deaths 20 28 9 16 12 85
females All 106 195 41 105 552 999
%
Deaths 19% 14% 22% 15% 2% 9%
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5.1.4 Outcome variable: FEVi lung function change
5.1.4.1 Lung function change in the five/six-year cohort: annual 
data and estimates of mean annual change
This section presents data for the cohort of patients enrolled in 1994 or 1995, 
who had been under observation for five or six years. Comparisons of FEVi 
lung function over time are presented for males and females by broad age 
group (<18 / 18+ years), and diabetes status (Table 5.9), and by dornase alfa 
usage group (Table 5.10). There is a clearer downward trend for women than 
men, particularly in the <18 age group, and non-diabetes group (Table 5.9).
Table 5.9: Six-year cohort - FEVi “% predicted” (Knudson formulae) by
sex, observation year, initial age (< 18/18+), and diabetes 
status (n=571)
Age___________ Diabetes
<18 18+ No Yes
n - Sex m 167 131 256 42
f 166 107 218 55
all 333 238 474 97
Males n - observations
Year 1 266 78.58 57.88 70.33 57.62
Year 2 286 79.83 60.11 72.05 57.84
Year 3 287 79.57 57.89 70.49 54.30
Year 4 293 79.22 58.09 69.48 53.82
Year 5 288 79.66 57.55 68.69 51.51
Year 6 209 81.25 56.86 67.21 50.97
All yrs 1629 79.56 58.05 69.81 54.54
Females n -observations
Year 1 248 76.83 60.01 72.51 58.45
Year 2 264 75.71 59.83 71.51 58.28
Year 3 268 73.31 56.16 67.68 53.76
Year 4 262 71.36 54.67 65.01 52.06
Year 5 267 69.74 55.80 64.07 51.87
Year 6 182 66.90 53.40 60.84 50.28
All yrs 1491 72.99 56.50 67.21 54.29
Males fit Females n - observations
Year 1 514 77.69 58.84 71.33 58.10
Year 2 550 77.73 59.99 71.80 58.09
Year 3 555 76.44 57.08 69.18 53.99
Year 4 555 75.40 56.52 67.46 52.81
Year 5 555 74.72 56.72 66.54 51.71
Year 6 391 74.23 55.30 64.43 50.55
All yrs 3120 76.28 57.34 68.62 54.40
194 Use of Databases in Drug Effectiveness Studies
Dornase Alfa Case Study: Findings
Table 5.10 allows comparison of FEVi lung function by year across the five- 
dornase alfa use groups. Group 1 and 3 had relatively small numbers, but no 
gross imbalance by sex. The results are difficult to interpret. Over years 1 to 
5 there was a general decrease in lung function, but higher for females than 
males (eight against three percentage points). The continuous user groups 1 
and 2 showed this sex difference clearly. The differences between groups 1 
and 2 might be due to selection or survival effects. Group 5 with no recorded 
dornase alfa use showed the same sex difference although lower losses over 
time.
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Table 5.10: Six-year cohort - FEVi “% predicted” (Knudson formulae) by 
sex, observation year, and dornase alfa groups (n=571)
Use of dornase alfa All n
Continuous Some None
Starting Starting Starting Starting on
before on or after before or after
enrolment enrolment enrolment enrolment
Group 1 2 3 4 5
number
Sex m 17 57 14 49 161 298
f 22 81 13 37 120 273
all 39 138 27 86 281 571
Males
Year 1 60 58 53 59 78 68 266
Year 2 58 58 57 60 80 70 286
Year 3 56 55 57 58 78 68 287
Year 4 56 52 62 56 78 67 293
Year 5 53 52 60 54 77 66 288
Year 6 57 51 59 57 74 65 209
All years 57 54 58 57 78 68 1629
Females
Year 1 58 65 57 62 79 70 248
Year 2 55 62 52 59 81 69 264
Year 3 51 57 49 57 77 65 268
Year 4 50 52 48 54 76 62 262
Year 5 49 51 47 53 75 62 267
Year 6 45 50 45 47 72 59 182
All years 52 57 50 56 77 65 1491
Males and females
Year 1 59 62 55 60 79 69 514
Year 2 56 61 54 60 81 70 550
Year 3 53 56 53 57 78 67 555
Year 4 52 52 56 55 77 65 555
Year 5 51 52 54 54 76 64 555
Year 6 50 51 52 52 73 62 391
All years 54 56 54 57 77 66 3120
Table 5.11 summarises for the cohort with 5 to 6 years of observation 
annualised FEVi change by age (<18 / 18+), diabetes status, dornase alfa 
group, and five-year age group at enrolment. The data comparison across 
dornase alfa use groups is difficult to interpret; women showed greater rates 
of decline than men. The decline in lung function was greater in younger age 
groups. The analysis by five-year age group at enrolment has reasonable 
group numbers only below age 25. There was no evidence of marked cohort
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effects, but if the older groups represent less severe cases, the loss rates were 
rather greater than might be expected. Note that the male group aged 25<30 
showed a gain of 1.6% per year, but with only 20 measurements this might be 
a random effect.
Table 5.11: Six-year cohort - annualised change “% predicted” FEVi by 
sex, age (< 18/18+), and diabetes status, use of dornase alfa, 
and initial age group (n= 473)
Age Diabetes
<18 18+ No Yes
Sex m -.72 -1.10 -.71 -2.10
f -3.10 -1.38 -2.42 -2.27
all -1.95 -1.22 -1.50 -2.19
n m 125 121 211 35
f 133 94 182 45
all 258 215 393 80
Use of dornase alfa
Continuous Some None All
n Starting Starting Starting Starting on
before on or after before or after
enrolment enrolment enrolment enrolment
1 5i 3 4 5
m 246 -.82 -1.45 1.88 -1.49 -.82 -.91
f 111 -2.30 -3.19 -2.74 -2.42 -1.79 -2.39
all 473 -1.61 -2.52 -.24 -1.90 -1.24 -1.62
Age group (years)
n 5<10 10<15 15<20 20<25 25<30 30<35 35+
m 246 -.76 -.38 -1.97 -1.13 1.63 -1.45 -.88 -.91
f 227 -3.70 -2.83 -2.77 -1.62 -1.12 -.68 -.03 -2.39
all 473 -2.07 -1.81 -2.35 -1.32 .02 -1.18 -.43 -1.62
5.1.4.2 “Before and after” dornase alfa initiation in one group
Patients in Group 2 were enrolled with no recorded use of dornase alfa, but 
later commenced continuous use. A comparison pre- and post- initiation of 
dornase alfa was made to see if  there were interpretable results.
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Records for the entire group (n=195) were examined for the existence of FEVi 
lung function measures (based on Knudson formulae) for the quarter of 
original enrolment, the quarter prior to dornase alfa initiation, and a later 
period of observation. Only 101 sets of records were available to compute 
“ before and after” rates; the numbers would be even lower if  a minimum 
period of observation of one year was imposed.
Table 5.12: Group 2 - lung function as “% predicted” FEVi (Knudson 
formulae) longitudinal comparison pre- and post dornase alfa 
initiation
Rate computed on individual basis as percentage point change over time and summarized
Division of observation period relative to 
dornase alfa initiation
Pre-initiation Post-initiation
Male 
N= 44
Observed 1.69 years 2.29 years
Annual rate + 0.6 -2.1
Female 
N= 57
Observed 1.54 years 2.62 years
Annual rate - 1.3 - 4.0
All Observed 1.60 years 2.48 years
Annual rate -0.5 - 3.2
Background data:
Age 49 under 18, 52 18+ years
Deaths 14 deaths, 87 survivors
Genotype 92 with one or more DF508, 9 without
Diabetes_____ Children (<18) 5 of 49, adults (18+) 12 of 52
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5.2 Discussion of results
The Dornase Alfa Case Study set out to analyse the experience of homogenous 
groups of dornase alfa users in terms of a number of outcome variables (death, 
respiratory exacerbation, lung function decline, and anthropometric changes). 
The results presented are descriptive and exploratory and intended to show 
differences between the groups, but also allow readers to compare the data 
with that from other samples. In this sample, dornase alfa users were clearly 
not comparable to non-users at baseline in terms of colonisation with 
Pseudomonas or 8. Cepacia, initial lung function, anthropometric measures, 
diabetes, or severity indicated by genotype. Non-users were also younger at 
baseline. The sample also showed already familiar epidemiological patterns, 
with female patients being comparatively more severely affected.
Death was shown to be associated with age, except for the highest age group, 
which would be highly selected in terms of survivalship. Dornase alfa use 
groups showed considerably higher death rates than non-users. However, 
little  can be said concerning the impact of dornase alfa on survival, as 
numbers of deaths in the sample were too small for meaningful comparisons 
between the dornase alfa use groups (Table 5.8), and the analysis does not 
permit any conclusions regarding the impact of dornase alfa due to the 
considerable baseline differences between treated and non-treated patients.
For less than 40% of deceased patients, lung function measurements from the 
last quarter of observation were available. For 26 males and 29 females, the 
FEVi at death was 29% and 33.5% respectively, i.e. close to the 30% level used 
in the literature to indicate a 50% chance of death in the next two years 
(Kerem et al. 1992). However, these are very small numbers, and there was 
wide scatter. For 43 patients for whom a rate of FEVi lung function decline
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could be calculated, the rates for both males and females indicated much 
faster decline than in the patient population generally (-3.69% and -5.77% for 
males and females respectively).
The generally observed decrease in FEVi over time is higher for females than 
males (Table 5.10). Again, the differences between the non-user group 
(Group 5), and Groups 1 and 2 cannot be interpreted as Group 5 had much 
higher lung function, and this would affect selection for dornase alfa use.
The analysis by dornase alfa use pattern was equally difficult to interpret 
(Table 5.11). The patients with “ no recorded dornase alfa use” lost FEVi more 
slowly than patients who started use after enrolment and have used it  
continuously, but how the users would have fared without it, or the non-users 
with it, is unknown; and lung function at commencement was different. As 
usual, female rates of decrease in lung function are higher. Group 2 (n=195) 
was examined in detail. Although the records indicated general observation of 
the UK licensing requirement for at least 40% predicted FVC before 
commencement, only 101 sets of records were available to compute “ before 
and after” rates. By inspection, the loss of lung function was faster after 
initiation onto dornase alfa, for both males and females. However, the 
detailed statistics showed marked variation, and there were no controls for 
the group. The data analyst noticed, in reviewing all data for the 101 
patients, that there were a number of cases where dornase alfa appeared to 
have been initiated after large fluctuations in FEVi measurements, and it  is 
possible, therefore, that dornase alfa was selectively offered in an acute 
situation and continued thereafter. This shows that treatment decisions which 
are unrecorded in the database and therefore unable to be accounted for, can 
have potential significant impact on the results of an ESD and their 
interpretation.
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Overall, the data presented here did not allow conclusions regarding the 
effectiveness of dornase alfa, but also showed no indication that treatment 
improved disease progression. The comparatively poor “ outcomes” in the 
dornase use groups were not surprising given the differences at baseline.
Johnson et a i  (1999) undertook an observational study to estimate the effect 
of dornase alfa by using data from the North American ESCF. Patients aged 6 
years or more with >=40% of predicted FEVi who had been enrolled for at least 
18 months were eligible for the analysis. A baseline spirometry from at least 6 
months post-enrolment had to be available, as well as a test approximately 12 
months after (treated patients were required to have started dornase alfa at 
least 6 months after enrolment). The primary outcome was change in FEVi (% 
predicted) from baseline. The multiple regression analysis retained 18 
variables in the final model, after having considered 49. Those retained 
included the number of exacerbations prior to baseline spirometry, age, 
weight-for-age percentile, baseline FEVi, wheeze, cough, sex, centre 
affiliation and type of practice, several micro-organisms detected at 
respiratory culture, and the use of inhaled corticosteroids, supplemental 
oxygen, and bronchodilators. From my experience, several of these variables 
would have been highly unreliable in the ERCF, which raises questions about 
their potential reliability in the US dataset. There was no obvious attempt in 
the Johnson paper to account for data quality in a similarly rigorous manner to 
what I had attempted to do in the Dornase Alfa Case study.
The 283 patients treated for an average of 329 days (SD 45) showed an 
adjusted benefit of dornase treatment of 4.3 (SE: 0.9) points of predicted FEVi 
over 2,382 untreated patients. Treated and untreated patients started with a 
mean FEVi of 76.1% (SD: 19.1) and 87.5% (SD: 19.4) predicted respectively at 
baseline. After twelve months, treated and untreated patients showed 80.0% 
(SD: 21.0) and 85.9% (SD: 20.2) predicted FEVi. An intention to treat analysis 
included patients starting the treatment but not continuing for a year or
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changing the regimen. The adjusted benefit of domase alfa was an estimated 
difference in mean change from baseline of 3.2 (SE: 0.7) in favour of the 
dornase group.
There are several differences between this and the Dornase Alfa Case Study. 
Firstly, patients in the Johnson study had markedly better baseline FEVi (Table 
5.13), and were younger than those in the Case Study. It must be 
remembered that the Case Study Group 2, which is the best comparison group, 
would have included a wide range of treatment durations.
Table 5.13: Differences between patients included by Johnson et al.
(1999) and Dornase Alfa Case Study patients (Group 2) on 
enrolment
Johnson et al 1999 Dornase Alfa Case Study
Continuous
treatment
No treatment Group 2 No treatment
Mean FEVi %pred. at 
enrolment
76.1% 87.5% 57.7% 77.8%
Mean age (years) 14.1 13.9 17.4 13.9
N 283 2382 195 552
In the current study all treated groups lost FEVi over the 6-year observation 
period, and the untreated group lost FEVi more slowly than treated patients of 
group 2 (-1.24% and -2.52% respectively). It is possible that Johnson captured 
an initial positive response in the treatment group; this would tally with the 
observations of a 2-year RCT where treated patients had returned to their 
baseline FEVi after two years, despite significant improvements after one year 
(Quan et al, 2001). It is thus possible that the initial improvement is not 
maintained over several years, and that more severely affected patients 
respond less favourably to treatment (which has been observed elsewhere by 
Hodson et al. 2003). UK centres may be comparatively less likely to use 
dornase alfa (according to the ERCF, this is certainly the case compared to 
other European countries) and hence reserve treatment for a more severely
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affected group of patients. Therefore, any analysis of a UK dataset might 
might not be comparable to other populations.
The use of multivariate analytical approaches appears tempting. However, 
the analyst refrained from further analysis of the database. Johnson et al. 
(1999) also bemoan the low R2 value in their study, despite having included 
nearly 50 variables (which in itself may be considered questionable). Thus the 
extent to which further confounding may have influenced their results is in 
question. Significantly, they have also stopped short of using death as an 
outcome.
Poor data quality and completeness of other key variables, in particular 
exacerbations, further deter from multivariate analytical approaches. 
Significantly, no explicit rationale was available for initiation of treatment for 
patients commenced on dornase alfa, and there was good indication that the 
decisions to offer dornase alfa differed between centres. Recording practices 
in different centres invariably impacted on the data. Lung function values 
varied little  between individual years, but did vary between centres (e.g. one 
centre reported that relatively “ good” values were selected and recorded for 
each observation period between visits; this centre did show higher values 
compared to others).
It is interesting that Johnson et at. (1999) did not comment on data quality; 
they stated that “ patients were eligible fo r entry into the analysis data set 
based prim arily on availability o f data”  (p.735). The numbers of patients 
excluded were not reported, and neither was any comparison between 
included and excluded patients. Thus, the generalisability of the study is 
difficult to judge, regardless of how complete the database itself might have 
been in terms of capturing the North American CF population. Their sample 
may also be subject to further selection bias, as patients had to survive for the 
observation period to be included.
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It is also interesting to observe that a later published analysis of the ERCF 
entitled “ Dornase alfa in the treatment of cystic fibrosis: a report from the 
Epidemiologic Registry of Cystic Fibrosis”  (Hodson et al. 2003) stopped short of 
multi-variate analysis, although the authors had access to the entire European 
database including 13,684 patients. Nevertheless, they only presented a 
descriptive un controlled comparison of treated and un treated patients over 
two years, examining change in FEVi, and numbers of exacerbations (despite 
similar baseline differences to the ones reported here). Despite the baseline 
differences, the study reported a larger reduction in exacerbation rates in 
treated compared to non-treated patients (mean -0.19 and 0.06 respectively), 
as well as a slower reduction in lung function (2.5% and -1.1% change from 
baseline after one year, and 0.3% and -2.3% change from baseline after two 
years). Interestingly, no subsequent multi-variate analysis has ever been 
published, and my enquiries about this remained un-answered.
Hodson et al. (2003) as well as Johnson et al. (1999) differ in their conclusions 
(certainly in terms of lung function) from the results of the Dornase Alfa Case 
Study. A methodological study by Rothman and Wentworth (2003) described 
below provides valuable insights into the possible variations in results from 
multi variate analyses in CF due to residual confounding, which might have 
affected the Johnson paper. Data quality aspects may indeed play a role in 
both papers, which we can only appreciate based on our detailed explorations 
prior to analysis. The UK has a low rate of dornase alfa use compared to other 
European countries, which may mean that patients receiving the drug here are 
more severely affected by the disease than the average European dornase 
users. Indeed, Hodson et al. (2003) report a mean FEVi %predicted of 60.2 for 
the treated group, whereas all dornase use groups in the Case Study started at 
lower mean baseline levels (between 50 and 57.7). There is some indication 
in the literature that less severely affected patients respond better to dornase 
alfa treatment.
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The second outcome variable used by Hodson et al. (2003) is exacerbation 
frequency. Given the definitional problems with this variable identified in the 
Dornase Alfa Case Study, and the variable completeness in reporting between 
centres, as well as the fact that dornase alfa seems at least in some centres to 
be introduced in response to exacerbations, a reduction in exacerbations in 
the year following initiation seems perhaps less surprising.
The renowned statisticians Rothman and Wentworth (2003) skilfully illustrated 
the precarious nature of multivariate approaches in cystic fibrosis. The 
authors used US Cystic Fibrosis Foundation registry data in a retrospective 
cohort study of the risk of death of patients using or not using tobramycin. 
They found the crude risk of death to be 3.5 times higher in the treated group 
compared to the non-treated group. Controlling for age, lung function, height 
and infection with P. aeruginosa reduced the risk ratio to 1.2. The authors 
found it  difficult to remove the strong confounding by indication. However, an 
analysis of patients who would have met the inclusion criteria of an RCT of 
tobramycin resulted in a risk ratio of 1.05 (or 1.06, depending on the duration 
of use). This vast change in risk ratio is taken as a strong indication that 
residual confounding could easily be masking a positive result in favour of 
tobramycin. It is worth remembering at this point, that the Case Study DQR 
identified 10% of deaths as missing from the registry!
The authors point out that sensitivity and specificity of confounder measures 
have a significant impact on residual confounding. Based on previous work by 
Savitz and Baron (quoted in Rothman and Wentworth, 2003) they assume that 
75% of the confounding in the observed data might be controlled and calculate 
that the completely controlled risk ratio could theoretically be 0.46. This is 
close to the 0.43 (on protocol analysis) reported in the RCT. This study 
provides a convincing illustration that the interpretation of data greatly 
depends on assumptions and residual biases. It also is a stark reminder of how
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vulnerable and difficult to interpret a multi-variate analysis of the Dornase 
Alfa Case Study would have been, given the existing concerns about the data 
quality of key confounders, such as exacerbations.
The Case Study analysis has paid little  attention to the duration of dornase 
alfa use, and the pragmatic groupings hide a considerable variation of use 
patterns, as Table 5.14 demonstrates. Two thirds of dornase alfa users had 
started on or after enrolment (Groups 2 and 4), but a majority of Group 4 
(intermittent users) used dornase alfa for less than one year. All other studies 
discussed here have only selected patients treated continuously over the study 
period. A selection of patients continuously treated over a significant length 
of time, with sufficient data available from the pre-initiation period, would 
have generated a small sample, too small for meaningful multi variate 
analysis.
Table 5.14: Cumulative duration of treatment of patients on dornase alfa 
(n=447) by use group
Total sum of days Use of dornase alfa Total
on treatment
Continuous Some
Starting before Starting on or Starting before Starting on or 
enrolment after enrolment enrolment after enrolment
0 - 365 8 8% 31 16% 14 34% 63 60% 116 21%
366 - 730 20 19% 43 22% 6 15% 10 10% 79 14%
731 - 1095 18 17% 37 19% 7 17% 12 11% 74 13%
1096 - 1460 9 9% 36 19% 5 12% 11 11% 61 11%
1461 - 1825 39 37% 36 19% 8 20% 7 7% 90 16%
1826+ 12 11% 2 1% 1 2% 15 3%
Unknown 10 5% 2 2% 12 2%
Total 106 100% 195 100% 41 100% 105 100% 447 100%
This demonstrates that the study design for any ultimate ESD analysis should 
be foreseen and accounted for in the design of the database, as post-hoc
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categorisations of comparison groups are fraught with difficulty, and poor 
definitions of key outcome variables cannot be remedied later.
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5.3 Concluding remarks
The analysis of the Dornase Alfa Case Study confirmed some known 
epidemiological patterns in this sample of CF patients from the North of 
England: there was a slight predominance of males, which increased with 
higher age groups due to known survival advantages. Differences in genotype 
severity between conurbations were also observed. Diabetic patients tended 
to have lower lung function at baseline, and higher dornase alfa use rates. 
Not all observations were easily explained, and some may have arisen due to 
poor data quality.
The analysis also showed that there were variations in decisions to initiate 
dornase alfa treatment, which are neither clear nor recorded on the database. 
This means that an analyst of an ESD is largely unable to account for such 
variations albeit that they would have significant implications on group 
allocation and interpreting any findings. Similarly, there were differences in 
practice and recording between centres, resulting in systematic differences on 
certain variables.
As in other observational studies, the analysis showed a range of important 
baseline differences between patients treated and not treated with dornase 
alfa. Generally speaking, dornase alfa users were older, and less well. 
Treated patients had lower lung function values at baseline, and were at 
lower percentiles for height and weight, more likely to show microbiological 
colonisation, and more likely to be diabetic. Only a small number of the 
available variables have been used; however, it  is already clear from the 
above that key information relevant for the analysis has not been collected in 
the database (e.g. reason for treatment decision, shared care, and 
compliance).
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The analysis shows higher numbers of deaths, and a faster lung function 
decline and anthropometric deterioration in treated groups compared to non­
treated patients. However, direct comparisons are difficult to interpret, as 
the large baseline differences would need to be accounted for. The groupings 
of dornase alfa users hide considerable differences in duration of treatment, 
which further impede interpretation.
A careful multi-variate analysis of a larger population, such as the entire UK 
ERCF population, might be of interest. However, given the likely residual 
confounding and poor quality of outcome variables (except possibly lung- 
function values), the results would remain very difficult to interpret. Hence, 
we abandoned further analysis attempts.
The experience of preparing and undertaking the Dornase Alfa Case Study thus 
had revealed a whole host of methodological concerns about the quality of 
data and their use in analysis. I was therefore interested to review whether 
other researchers having undertaken similar ESDs of drug treatments 
acknowledged similar problems, and how they might have addressed them. 
The next chapter describes my review of published ESDs in which I explore this 
question.
Use of Databases in Drug Effectiveness Studies 209
Comprehensive Review of ESDs of Drug Therapies
6 Comprehensive Review of ESDs 
Therapies
Drug
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6.1 Introduction
The earlier literature review highlighted both the increasing popularity of as 
well as reservations about the use of databases in effectiveness research. 
Several systematic reviews of different aspects of comparisons of randomised 
and non-randomised studies have contributed to the methodological 
knowledge about study designs. The need for more methodological research 
has been highlighted, including a need for more direct evidence about the 
comparability of findings from different study designs (MacLehose et al. 2000). 
However, no systematic effort to assess ESDs and their contribution to 
effectiveness research has yet been undertaken.
ESDs follow non-randomised designs and much of the methodological evidence 
on those designs can be expected to be relevant to ESDs. However, the nature 
of the data sources used in ESDs may give rise to specific strengths and 
weaknesses. This review therefore aimed to identify ESDs, and to provide an 
overview of specific study features relating to their internal and external 
validity.
This work followed on from the Dornase Alfa Case Study which was essentially 
unable to answer the question of long-term effectiveness of dornase alfa. I 
hoped that a review of similar ESDs would confirm some of the methodological 
lessons highlighted in the Dornase Alfa Case Study, identify additional lessons 
beneficial to future research, and allow me to generalise and thus better 
describe some of the issues.
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6.2 Aim
Explore in existing ESDs features relevant to their internal and external 
validity.
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6.3 Objectives
1. Identify and retrieve published effectiveness evaluations of individual 
drug therapies using routinely available data or databases;
2. Describe ESDs by data sources and their use, and other features 
relevant to internal validity (including control of bias and confounding 
through study design and analysis, data quality, and results), and 
external validity (including sample selection and participation);
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6.4 Methods
6.4.1 Search strategy
A gold standard systematic literature search not only examines several 
bibliographic databases, but also grey literature, and includes hand searching 
of journals. Whereas a systematic identification of all ESDs would have been 
desirable, it  was clear from the outset that this was an unrealistic 
expectation, given the comparatively poor indexing of observational studies in 
bibliographical databases (MacLehose et a i  2000). These difficulties are 
compounded when databases are included as a search criterion. The intention 
thus was to follow the principles of a systematic literature search within 
existing resource constraints, and describe the methods used in sufficient 
detail to permit the reader to judge their limitations (see section 6.6). The 
exploratory nature of this work justifies the restrictions applied to the search 
methods. Due to these limitiations in identifying potential studies for 
inclusion, this review is described as "comprehensive” rather than 
“ systematic” .
Hence, the search strategy included two main groups of methodological terms: 
those relating to the data source, as well as those indicating effectiveness 
studies. The choice of free-text terms used was informed by the terminology 
used in previously identified relevant texts and articles (by having undertaken 
pilot searches). The search strategy (Table 6.1) was performed on Medline 
(1966-2002) on 24 October 2002. This review was limited to studies on drug 
therapies in humans.
Only journals included in the Abridged Index Medicus were searched (as 
indicated by the term "Core Clinical Journals” - see Table 6.1). This Index
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comprises 120 high-quality core clinical English language journals (National 
Library of Medicine 2001). This restriction had been applied previously in a 
key publication on comparing randomised and non-randomised studies (Benson 
& Hartz 2000). A limitation of the search to these sources is deliberate, given 
the intention to select studies for later comparisons with randomised 
controlled trials and the inevitably low positive predictive value of the search 
strategy. Again, given the exploratory nature of this work, learning from 
potentially high-quality examples of ESDs was of more interest than a 
comprehensive retrieval of all existing published and unpublished ESDs. A 
restriction to English-language articles was necessary because of my own 
resource constraints.
Table 6.1 : Main search strategy for effectiveness studies using secondary
data
Search Hits
#1 Search "CHEMICALS AND DRUGS CATEGORY" [MESH] AND (EFFECTIVENESS 
OR EFFICACY OR OUTCOME OR EFFECT OR EFFECTS) AND (DATABASE OR 
DATABASES OR DATABASES OR DATABASE OR REGISTER OR REGISTRY OR 
REGISTERS OR REGISTRIES OR DATASET OR COHORT OR "CLAIMS DATA" OR 
"SECONDARY ANALYSIS") Limits: English, Human, Core clinical journals
4452
#2 Search #1 Field: All Fields, Limits: English, Randomised Controlled Trial, 
Human, Core clinical journals
498
#3 Search #1 Field: All Fields, Limits: English, Meta-Analysis, Human, Core 
clinical journals
198
#4 Search #1 NOT (#2 OR #3) Field: All Fields, Limits: English, Human, Core 
clinical journals
3760
The NHS Information Centre operates a directory of clinical databases in the 
UK (DoCDAT), and it  was hoped that effectiveness studies which had used 
those databases could be identified. All names of the 44 registered clinical 
databases were searched for on Medline, but no additional study reference 
was identified which met the inclusion criteria. A later personal 
communication (September 2003) with one of the DoCDAT researchers 
confirmed this finding.
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Several earlier searches had been undertaken before the main search strategy 
(in particular, an earlier search used the subject heading "DRUG THERAPY" 
instead of the more appropriate "CHEMICALS AND DRUGS CATEGORY"); 
additional references identified from those preliminary searches as well as 
references already known to the researcher have been included in the review. 
The fact that the main strategy had missed some of these studies is an 
indication of its limited sensitivity.
6.4.2 Inclusion and exclusion criteria for ESDs
I scanned titles and abstracts of the 3,760 identified studies and applied the 
criteria listed below. The criteria show the intention to identify studies with 
similar features as the Dornase Alfa Case Study described in Chapter 3 to 5.
Inclusion criteria:
1. Study uses patient-level data which has been routinely collected as part 
of an electronic patient record system, a registry or database
2. Study evaluates effectiveness of a particular drug intervention
3. Study includes a comparison group, i.e. either comparison between 
different intervention groups or intervention and control groups
4. Study is published in English.
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Exclusion criteria:
1. Data were collected for the exclusive purpose of addressing the 
objectives of the reported study or another single research hypothesis
2. Reviews of patient records (paper records), if they are not part of an 
existing electronic patient database
3. Studies including any additional data collection from e.g. paper 
records, except for validation of the routinely available electronic data
4. Uncertainty regarding the inclusion criteria
If the abstract of a paper is unclear as to whether the data stem 
from a database, and the total sample size is <500, the paper is 
excluded.
5. Safety studies (adverse events as the only outcomes)
6. Studies evaluating groups of drugs (e.g. anti-hypertensives) or 
combination therapies (e.g. "chemotherapy” ) without presenting 
results for individual drugs
7. Dosing studies, i.e. comparisons of groups using different doses of the 
same drug
8. Studies comparing use of the same drug in different contexts
6.4.3 Data extraction
I extracted key information from included studies using a form devised in
Microsoft Excel. The information items extracted are presented in Table 6.2.
Table 6.2: Information extracted from published ESDs
General information about the study
Author
Publication year
Full reference
Affiliation and contact details of first author
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Inclusion criteria of search
Comparison group
Patient-level data
Routinely collected data only used
Efficacy / effectiveness of particular drug evaluated
Trial data used / included?
Information on the data source used
Name of database 
Purpose of database 
Patient numbers in database
Stated main aim of the study
Study design
Cohort / case-control 
Retrospective / prospective 
Historic or concurrent controls 
Length of follow-up 
Study funding
Source of comparison group
Ethics and data protection
Research ethics committee approval or equivalent 
Degree of data anonymisation 
Patient consent
Authors’ involvement with database / registry
Internal validity
Patients "naïve” to treatment?
Primary and other outcomes assessed 
Definition of variables 
Measurement of variables 
Blinding of patients and assessors 
Validation and quality checks reported 
Patient numbers extracted for study 
Patient numbers analysed 
Loss to follow-up 
Data processing
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External validity
Countries participating
Number of centres involved
Source of population
Period of data collection
Inclusion and exclusion criteria of study
Method of sample selection
Indication of representativeness of national population 
Analysis
Power calculation 
Analysis methods used 
Sensitivity analyses
Differences between groups at baseline and their control 
Identification of confounders and their control 
Missing data
Main results
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6.5 Results
A total of 42 identified studies met the inclusion criteria (Table 6.3). The 
main search strategy (3,760 hits) identified 32 of the 42 studies (76%). Of the 
remaining ten studies, four were known to me, and six were found in an 
earlier search using the term “ drug therapy”  (2,621 hits; only three studies 
were identified by both searches). Twenty-nine (69%) of the included studies 
were published in 1998 or later, and none prior to 1989.
220 Use of Databases in Drug Effectiveness Studies
Comprehensive Review of ESDs of Drug Therapies
Table 6.3: Search results: ESDs of drug therapies
First author Year of 
publication
Assessed drug treatment(s) and condition
Bowman 2000 Antibiotics after treatment failure in paediatric infection
Benvegnu L. 1998 Interferon for virus-related cirrhosis
Berman S. 1997 Antibiotics in paediatric otitis-media
Butterworth J. 1998 Sufentanil, fentanyl; vecuronium, pancuronium in anaesthesia
Chew D. 2001 Clopidogrel in acute myocardial infarction (AMI)
Choi H. 2002 Methotrexate in rheumatoid arthritis (RA)
Eggleston A.* 1996 Cisapride, ranitidine, omeprazole in gastro-oesophageal reflux disease 
(GORD)
Fedson D. 1993 Influenza vaccination
Gable C. 1990 Pneumococcal vaccination
Garcia L .3) 1999 Acid-suppressants in secondary prevention of upper gastro intestinal
Ghani A.2)
bleeding (UGIB)
2001 PI- and NNRTI-containing regimens in HIV
Giralt S. 2000 Interferon alfa in bone marrow transplant (BMT)
Goldstein R. 1996 Aspirin in coronary disease
Graham N. 1991 Zidovudine and (pneumocystis carinii prophylaxis (PCP) in AIDS
Heudebert G.2) 1993 Niacin, séquestrants, lovastatin in hypercholesterolemia
Huang X.2) 1999 Ciprofloxacin, nitrofurantoin, and trimethoprim/sulfamethoxazole 
(TMP/SMZ) for urinary tract infection (UTI) in females
IBMTR** 1989 Methotrexate in BMT for acute lymphatic leukaemia (ALL)
Johnson C. 1999 Dornase alfa in cystic fibrosis (CF)
Krumholz H. 1995 Aspirin in AMI
Krumholz H. 1998 iv heparin in AMI
Krumholz H. 2001 Aspirin (and angiotensin-converting enzyme inhibitors (ACE-I)) in AMI
Kuhn L. 2000 Zidovudine perinatally for HIV infected children
Lawrenson R.3) 2001 Trimethoprim, amoxicillin, cefalexin, co-trimoxazole, nitrofurantoin, 
cefradine, norfloxacin, ampicillin, ciprofloxacin, cefadroxil, in UTI
Lundgren J 1994 Zidovudine in AIDS
McDougall R.3) 1994 Prednisone in RA
Moore R. 1991 Zidovudine in AIDS
Nichol K. 1994 Influenza vaccination in elderly
Nichol K. 1999a Influenza vaccination in elderly with chronic lung disease
Nichol K. 1999b Pneumococcal vaccination in elderly with chronic lung disease
Nordin J. 2001 Influenza vaccination in elderly
Peterson L. 2) 1999 Alteplase (rt-PA) post coronary artery bypass graft (CABG)
Pethica B.1) 1998 Budesonide and beclomethasone in asthma
Price D.2) 1998 Salmeterol in asthma
Rabinowitz J. 2001 Olanzapine or risperidone for schizophrenia
Rahme E. 2002 Naproxen to prevent AMI
Sebaldt R.3) 1999 Etidronate in corticosteroid-induced bone loss
Sernyak M. 2001 Clozapine on inpatient resource utilisation
Solomon D. 2002 NSAIDs in AMI prevention
Tiefenbrunn A.1) 1998 Alteplase in AMI
van Staa T. 1998 Cyclical etidronate in prevention of non-vertebral fractures
Weintraub J. 2001 Dental sealants
Ziegelstein R. n 2001 iv magnesium in AMI
•Paper identified published abstract of previous work which met inclusion criteria.
** International Bone Marrow Transplant Register
Identified in: 1)main and previous search; ^previous search only; 3)known to researcher (all 
others identified in meain search only).
Use of Databases in Drug Effectiveness Studies 221
Comprehensive Review of ESDs of Drug Therapies
6.5.1 Overview of conditions and interventions assessed
The majority (18) of the identified studies investigated treatments or 
preventative interventions (e.g. of myocardial infarction or recurrence of 
upper gastrointestinal bleeding) in chronic diseases or conditions such as 
rheumatoid arthritis, asthma, schizophrenia, cystic fibrosis, gastro- 
oesophageal reflux disease, or corticosteroid-induced bone loss (see Figure 
6.1). A further five studies evaluated HIV/AIDS treatment. The majority of 
interventions were treatments, but a considerable number were of a 
preventative nature.
Figure 6.1: Conditions and interventions represented in identified studies
Prevention and treatment of chronic conditions 
(other than HIV/AlOS)
Vaccinations
HIV/AIDS
Myocardial infarction (acute treatments only) 
Antibiotics for infections 
Bone marrow transplant-related treatments
Other
18
£J6
J 5
J 4
Number of studies
6.5.2 Data sources used by ESDs
The databases used in each study, as well as their purposes and size are listed 
in Table B.1 in the Appendix.
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Purpose of the databases
The original intentions of the databases - as far as they are stated in the study 
reports - included the following:
• Evaluation / description of disease process
• Description of process (including costs) and outcomes of care
• Instigation of improvements in care
• Claims data, prescription or comprehensive patient record system
• Market research
• Medical and health research (including drug safety studies)
• Evaluation of predictive potential of diagnostic tests
Fourteen studies (33%) used claims databases, of which three studies used 
more than one database, and two databases (GroupHealth, Inc., Medicaid) 
were being used by three different studies. Twenty-two studies (52%) used 
disease-specific data sources. Two of these databases were used three times 
(NRMI-2, CCP), and one twice (IBMTR). In total, 38 different data sources 
were used (sources of demographic statistics such as the National Death Index 
were not counted; different sets of Medicaid data were counted as one data 
source).
Numbers of patients in database and study
The numbers of patients in each main source database and subsequent 
numbers of patients sampled for the 42 studies are reported in Table B.1. 
Figure 6.2 provides an overview. A remarkably large proportion of studies do 
not describe the size of their source database (18; 43%).
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Figure 6.2: Size of database(s) used by ESDs
Number of patients in source database
Not reported
> 1 million
50,000 -  1 million
1 0 ,0 0 0 -5 0 ,0 0 0
1,0 00 -  10,000
<1000
Number of studies
(Further details in Table B.1 )
The number of patients included in the actual study analysis varied from a 
mere 37 (Price 1998, using a primary care database) to over 170,000 
(Ziegelstein 2001 ) (see Table B.1). Of the four largest ESDs with known 
patient numbers (over 40,000 patients), two used the Second National Registry 
of Myocardial Infarction (NRMI-2) (Peterson, Ziegelstein), one used the General 
Practice Research Database (GPRD) (Lawrenson), and one used computerised 
prescription records of a pharmacy benefits management company (PCS 
HealthSystems Inc.) (Bowman).
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Figure 6.3: ESDs (n=39) ranked by reported number of included patients
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Location of databases
USA institutions contributed to databases used in at least 28 of the studies (for 
“ international” studies, US participation was not automatically assumed), in 
25 of these the USA were the sole contributor.
In terms of authorship, the affiliation of the first author was a USA institution 
in 29 studies (69%), UK-based in four studies (10%), and Canadian in three 
studies (7%). Of one study each, the first author was based in Belgium, 
Denmark, Italy, Israel, New Zealand, or Spain.
Use of Databases in Drug Effectiveness Studies 225
Comprehensive Review of ESDs of Drug Therapies
6.5.3 Study design
Thirty-eight studies (90%) were retrospective cohort studies, three were case- 
control studies with concurrent controls, and one study used both designs.
Sample selection and selection criteria
All but three studies based their sample selection on a set of selection criteria 
(Eggleston used a random sample, Goldstein and Ziegelstein used all patients 
in the database; the IBMTR study was not clear about whether data from all 
patients were analysed). Five studies selected under 2% of the database 
population for their study sample, seven between 2-20%, five between 20-50%; 
and five between 50-99%; only two studies were able to include the entire 
database population (details in Table B.1).
Inclusion and exclusion criteria of studies were often similar to those found in 
RCTs (contraindications, previous use of interventional drug, exclusion of 
conditions causing same or similar symptoms). However, frequent additional 
exclusions had to be defined because of poor or missing data or key variables 
of interest.
Centres
Twenty-five studies (60%) did not report the number of centres contributing to 
the data source. Five studies were single-centre studies, and for a further 
twelve studies, the number of centres varied between 15 and over 1,500. A 
large number of contributing centres, however, does not guarantee 
representativeness (the NRMI-2 for example is biased towards larger, academic 
centres). Only a minority of studies considered potential centre differences 
(e.g. in treatment) in the analysis.
Comparison groups
All studies selected their comparison groups from the same data source as the 
intervention group. Whereas 25 of the cohort-designs clearly used concurrent
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controls, in the other 14 studies this was less clear. Many used data on 
patients recruited over several years, which meant that controls could 
potentially represent a different cohort. Only three studies adjusted for 
differences in calendar periods.
Representativeness
In only a handful of studies was it  possible to conclude that the sample was 
representative of the national population with the condition in question (e.g. 
if the data source was a comprehensive national database, or 
representativeness had been previously examined and reported). Most studies 
did not comment on their likely representativeness of a particular target 
population, not even if  the sample size and number of centres were very 
large. This is regrettable as it  leaves the reader to assume generalisability 
without there being a clear case made for it.
Only very few studies gave any indication of the characteristics of excluded 
patients. For example, Fedson reported that they accounted for about half of 
influenza vaccinations dispensed in the region and assumed that most of the 
remainder was used for institutionalised patients which were excluded from 
their study. Similarly, McDougall reported characteristics of database patients 
excluded from the analysis. However, their database stemmed from the 
region’s sole rheumatoid arthritis (RA) referral centre, which was estimated to 
see about half of all resident RA patients. This may have meant that non­
registered patients were treated in primary care and might have been more 
mildly affected.
Definition of variables
The interventional variable (pharmaceutical intervention) was relatively easy 
to define clearly. Some studies reported treatment codes used to extract 
relevant records from a database. Most but not all studies required their 
patients to be newly introduced (“ naïve” ) to the interventional drug or free 
from its use for a significant period before the observational period. In many
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cases, however, this was not relevant (e.g. influenza vaccination, or acute 
interventions after myocardial infarction).
In terms of outcome variables, twenty-five studies (59%) defined their primary 
outcomes through clinical information (including hospitalisation episodes); five 
studies (12%) defined primary outcomes based on drug treatment data (e.g. 
occurrence of another treatment episode within a given time is rated as a 
failure of the original treatment). The remaining twelve studies (29%) used 
mortality or survival as primary outcome. Table B.2 lists effectiveness 
outcomes used in each BSD. The definitional detail varied; some studies used 
International Classification of Diseases (ICD) coding or required records of 
clinical examinations (which may have been more or less subjective).
Other variables considered in analyses were mostly only listed, rather than 
defined. Few studies recorded ICD codes used.
Measurement and quality of variables
The quality of measurements of interventions and outcomes varied also. 
Single-centre databases (e.g. McDougall) may have examined patients on 
regular follow-up visits and may even have reported the measurement 
instruments used, including regular calibration. In the case of multi-centre 
databases, the use of standardised forms for data collection was often 
mentioned. In claims databases, prescription records had to be extracted 
depending on their coding.
Surprisingly, the studies' authors rarely explicitly raised issues of data quality. 
Only one study reported the undertaking of consistency or range checks of 
data. Krumholz reported reliability testing for the interventional variable in 
all three studies.
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Only seven studies (17%) reported having undertaken data validation against 
other data sources; four further studies have used data sources previously 
validated.
In most studies, the basis for treatment allocation (i.e. the clinicians’ 
decision, treatment protocols, patient preferences) was completely unknown. 
Only one study (Choi) explicitly took account in the analysis of factors 
underlying the main clinician’s decisions.
Patients and staff were understandably never blinded in the observational 
databases used, and neither were the assessors of outcomes of interest.
Most studies used variables reported in a single database. Very few studies 
linked data from their main data source with data from another source, e.g. 
for outcome measures. For example the National Death Index (USA) was used 
to confirm mortality outcomes (Moore, Choi), or specific hospitalisation 
databases were used to identify such outcomes (e.g. Rabinowitz).
Length of follow-up
The reviewed ESDs demonstrate little  to no experience with follow-up periods 
which are substantially longer than in likely RCTs. Length of follow-up varied 
widely. The longest mean follow-up was reported by McDougall (mean 18.1 
years); Weintraub followed patients for up to 8 years. Eighteen studies (43%) 
reported a mean, median, or overall follow-up period of two years or more. 
Four reported only acute treatment outcomes. Similarly, the studies 
evaluating influenza or pneumococcal vaccination or antibiotic treatment used 
comparatively short follow-up periods, typically covering some 4 months.
Some studies presented outcomes at particular follow-up intervals, with 
numbers of patients decreasing as the length of follow-up increased (e.g. 
outcomes presented for 1, 2, 3 or more years of individual follow-up);
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similarly, in studies using survival analyses, a mean or median time of follow- 
up may have been reported; other studies presented outcomes at only a fixed 
time point (e.g. 1 -year survival).
Differential follow-up between patient groups is a potential source of bias. In 
most studies, this was clearly not a problem, but in some ten studies, it  was 
unclear whether there was such a differential. One study (Sebaldt) lost a 
substantial number of control patients over three years (22 of 37 patients), 
whereas the main outcome measure was available for all patients in the 
treatment group.
Study management and funding
The findings suggest that industry involvement in ESDs of drug therapies may 
be less significant than in drug RCTs. Seventeen studies (40%) had at least 
been partly funded by industry sources; a further three studies (7%) used the 
National Registry of Myocardial Infarction 2, which is industry-funded, but the 
authors were only identified by academic affiliations. Seventeen studies (40%) 
involved public funding, and seven (17%) reported financial support from 
charities or foundations. For six studies (14%), there was no identifiable 
funding source, with all authors reporting only academic or health sector 
affiliations.
6.5.4 Analysis methods used
A main criticism of ESDs is the possible confounding by indication. A variety of 
analytic and design control methods were represented in the reviewed studies: 
stratification, matching, restriction, and multivariate analysis. The majority 
of studies used more or less elaborate multivariate analyses to control for 
predictors and confounders (mostly logistic or proportional hazards regression 
models). Only one study used the propensity score method.
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Most of those not using any control procedures were only reporting descriptive 
data or had a decision tree analysis as their main focus (Heudebert), or 
appeared to deem identified baseline differences of insufficient importance to 
control statistically (e.g. Huang). The control of baseline differences of 
course depends on the availability and quality of suitable variables, and thus 
the number of variables considered varied considerably between studies.
Ten studies did not explicitly report or assess differences between comparison 
groups at baseline; however, seven of them still used analysis methods which 
adjust for potential confounders. This implies a detection of baseline 
differences.
A third of studies took the dose or duration of the investigational treatment 
into account; for several others, this would not have been appropriate (e.g. 
vaccinations or one-off acute interventions).
Thirty-seven studies (88%) did not report any power calculation, from one 
study it  could be inferred that such a calculation was done, and four studies 
explicitly reported having performed one.
6.5.5 Reported results
In 35 (83%) of the studies the results clearly favoured one or more of the 
investigational drugs over others or non-intervention control groups. These 
are indicated in Table 6.4 as “ successful” drugs. As can also be seen on the 
same table, manufacturing pharmaceutical companies sponsored a minority of 
those studies. Twenty-nine studies (69%) did not report any study-specific 
involvement or funding by pharmaceutical industry, albeit that several 
researchers declared other financial support from such sources.
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6.5.6 Ethics and data protection
Ten studies (24%) clearly had been approved by a research ethics 
committee or equivalent (studies using the General Practice Research 
Database (GPRD) were automatically included in this number, because they 
were known to have needed approval by a specific ethics committee). The 
remaining studies reported no ethics committee approvals.
Published reports did not clarify whether anonymous data (i.e. where no 
decoding key existed anywhere) had been used, but in most studies this 
was would hardly have been possible, given their longitudinal design. 
Moreover, authors of several studies included clinicians of the centres 
where databases or registries were compiled, and it  must be assumed that 
at least some authors were able to identify included patients.
Most studies did not comment on data protection, anonymity, or 
confidentiality, or any attempts to protect them.
Only one study explicitly reported to have sought patient consent, another 
study sought consent for patients registered on the database, and a third 
study reported to have been exempt from the requirement of consent by a 
“ university human subjects committee” .
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6.6 Discussion
Notwithstanding issues of possible publication bias, the identified 42 ESDs 
are relatively recent (1989 onwards) and could be seen to indicate an 
increase in publications of this nature. The increasing computerisation of 
databases and clinical systems must be expected to speed this up further. 
Both clinical databases and claims databases were equally represented as 
data sources for ESDs. A small number of databases were used for several 
published ESDs (e.g. GPRD, NRMI-2, Medicaid data). There is a strong USA- 
predominance in the running of, contributing to, and analysing of identified 
databases.
It is interesting to note the findings of a review of the potential use of 
routine databases in UK health technology assessments, which was 
published after this work was completed (Raftery et al. 2005). The review 
(which was not limited to drug effectiveness studies) also found very few 
published effectiveness studies having used UK-based routine databases. It 
furthermore noted that drug treatments so far were the bulk of treatments 
amenable to health technology assessment using UK routine databases.
ESDs vary considerably in their size (from 37 to over 170,000 patients). Of 
the 32 ESDs with known patient numbers, 22 (69%) included more than 
1,000 patients, and only 10 (31%) over 10,000 patients. This was to a large 
extent a reflection of the size of the databases used. It shows that ESDs 
are not as a rule much larger than RCTs. In addition, plenty of smaller ESDs 
seem to be published in high quality journals.
The majority of studies were retrospective cohort studies and were 
concerned with preventive or treatment interventions for chronic 
conditions, which by their nature make long-term evaluations desirable. 
The follow-up periods ranged from several days (following acute
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interventions) to an exceptional and not unproblematic 18 years in a single­
centre study. However, there was next to no valuable experience with 
truly long follow-up periods and how these might be usefully managed in an 
analysis to take account of changes over time, such as involved in cohort 
and period effects.
The external validity of ESDs was rarely discussed or demonstrated by their 
authors. It may suffer because of poor availability and completeness of 
data needed for meaningful analysis, which necessitates pragmatic 
exclusion criteria. However, current ESDs could exploit their strengths 
more by explicitly addressing questions of external validity and 
generalisability.
The level of detail of any description of data collection and processing 
procedures varied between studies. Authors seemed to focus on potential 
sources of error and thus may mention the use of trained data abstractors 
or standard data report forms, or even a description of measurement 
processes and instruments. However, further discussions of data quality 
were sparse, and only a minority of studies used data which had been 
assessed for its validity or reliability. This is a serious concern, considering 
that our Dornase Alfa Case Study identified a plethora of data quality 
issues, although we dealt with a database which was routinely subjected to 
data checking processes!
Potential sources of bias were less frequently addressed. This may be 
because studies drew all patients from the same source database, and thus 
data definitions and measurements would have been assumed to be 
uniform for all patients. However, other sources of bias would have 
remained, e.g. where outcome assessors were aware of the study 
objectives, or due to differential detection or loss to follow-up.
Adjusting for confounders, particularly confounding by indication, was a 
prime concern of analysts in reviewed ESDs, and most presented an
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assessment of baseline characteristics of the analysed patient groups. The 
adjustment for predictors and confounders was primarily undertaken by 
statistical methods and less frequently by study design features such as 
matching. However, the success of these adjustments was very rarely 
assessed or reported. Treatment allocation decisions or centre differences 
in practice were very rarely considered. Again, the Dornase Alfa Case 
Study showed that centre differences would have been an absolutely vital 
consideration in any multi variate analysis due to differences in 
interpretation of definitions, clinical practice, and reporting practice.
There is an indication that industry funding may be less prevalent in drug 
ESDs compared to RCTs; also manufacturing pharmaceutical companies 
sponsored a minority of the 35 studies favouring a particular drug. It is of 
course possible that non-company studies favour non-RCT methods for 
financial reasons. However, post-marketing surveillance databases are 
frequently industry-funded and represent a significant potential resource 
for ESDs in future. This and the vulnerability of ESDs to selection and other 
biases should underline the importance of more rigorous and objective 
quality control of published ESDs.
6.6.1 Methods and limitations
The positive predictive value of the main search strategy was only 0.85% 
(=number of records identified by the search which met the criteria divided 
by all records identified by the search). Systematic searching for ESDs is at 
least as difficult as for observational studies, not least because there is a 
lack of relevant search terms in bibliographic databases. It is thus almost 
inevitable that relevant studies w ill have been missed.
Nevertheless, it  was surprising that the separate search for studies using 
databases registered in the Directory of Clinical Databases (DoCDAT) 
retrieved not one study. This gives rise to the hypothesis that few such
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studies have so far been conducted on UK clinical databases (a notion later 
confirmed by Raftery et al. 2005).
The restriction of the search to Abridged Index Medicus journals - although 
defensible - may mean that the identified studies were not representative 
of other ESDs published elsewhere, or indeed unpublished studies. ESDs 
may find it  more difficu lt to achieve publication in a top-ranking journal. 
Any review should consider the potential for publication bias, as studies 
with significant results are more likely to be published and more likely to 
be published faster than those without significant results (Sterne et al. 
2001). Particularly in the area of drug effectiveness research, the 
commercial interests of commissioning pharmaceutical companies 
contribute substantially to the decision on whether to publish any results at 
all (Sterne et al. 2001). Whereas there are statistical and graphical 
methods to explore the likelihood of publication bias for systematic 
reviews, this review was limited to reporting on issues which might be 
considered relevant, such as study size, significance of the results, and 
funding organisation.
In 35 (83%) of the studies the results favoured one or more of the 
investigational therapies over others or non-intervention control groups. 
This high proportion may indicate that a degree of publication bias was 
indeed at play and that ESDs with non-significant results were less likely to 
be published. This would not be surprising, as the same is true for RCTs 
(Sterne et al. 2001). However, selective reporting of outcome measures 
may still give rise to additional reporting bias. Large databases permit a 
wealth of analytical approaches, and it  is impossible for readers of ESD 
reports to estimate that bias, unless they know the capabilities and 
parameters of the data source.
Systematic reviews usually involve a team of researchers, and many steps 
in the review process are double-checked or undertaken by two researchers 
independently to improve the validity of the process and outcomes. This
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review was undertaken by only myself and may thus be more prone to 
error.
It was realised from the outset that this review could not be systematic, 
and existing resource constraints dictated pragmatic choices. For example, 
the exclusion of papers whose abstract was unclear as to whether the data 
stemmed from a database, and whose total sample size was <500 
(exclusion criterion 4), constituted a pragmatic step which was a practical 
necessity given the number of observational studies which did not clearly 
identify the nature or sources of their data. Not infrequently, even the full 
paper did not permit a clear decision as to whether all or any data were 
collected specifically for the published study, or whether all data had been 
collected prior to the conception of the study.
The review was limited to drug interventions, and studies based on reviews 
of paper records were excluded. These restrictions, which have been 
applied to parallel the parameters of the Dornase Alfa Case Study, mean 
that the findings may not be applicable to studies of other interventions 
(e.g. surgical) or using other methods.
6.6.2 Concluding remarks
This review has described some of the key features of existing published 
drug ESDs. The findings do not encourage confidence in the quality of such 
studies and indicate in any case that their reporting is generally poor and 
usually does not equip the reader to assess their quality or 
representativeness fully. Many reports did not concern themselves with 
some of the key lessons I had identified in the Dornase Alfa Case Study 
(data access, selection of variables and patients, data management and 
quality, or data protection). Disappointingly, these studies added very 
little  in terms of innovative solutions.
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The work confirmed - and to some extent also quantified - some of the 
criticisms and strengths of database effectiveness studies referred to in the 
methodological literature. ESDs share many potential biases with other 
study designs, including RCTs (e.g. attrition bias, detection bias). The 
main concern, confounding by indication, is commonly controlled through 
statistical adjustment and sensitivity analyses. However, there may be 
doubt over the extent to which selection bias has been controlled. 
Furthermore, authors le ft much relevant methodological detail unreported. 
Therefore study evaluations, including an assessment of their 
generalisability, remain difficult, and potential strengths of ESDs, such as 
greater external validity, are often not fully exploited. If existing 
recommended reporting formats were followed (Huston 6t Naylor 1996, van 
Elm 2007), this would go some way towards increasing the value of such 
publications.
A carefully conducted and reported ESD should be able to make a valuable 
contribution to the body of effectiveness evidence around a particular 
treatment. The next chapter assesses the comparability of ESDs with RCTs 
on a sample of four case studies, and the contribution ESDs have made to 
the relevant body of knowledge.
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7 Comparisons of ESDs with RCTs
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7.1 Introduction
A small number of the ESDs identified in the review in Chapter 6 were 
subjected to case study comparisons with randomised controlled trials 
which had addressed a comparable research question. The intention was to 
contribute to the number of case studies of comparisons of randomised and 
non-randomised studies and particularly see whether there are ESD-specific 
lessons.
Britton et al. (1998) have suggested previously that the outcomes of RCTs 
and non-randomised studies would best approximate each other when the 
same selection criteria were used and differences in prognostic factors 
were adjusted for in non-randomised studies. The case studies aimed to 
explore this notion for ESDs.
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7.2 Aim
Assess whether ESDs and RCTs show comparable results when 
selection criteria are the same and baseline differences in ESDs 
have been adjusted for.
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7.3 Objectives
1. Assess study quality;
2. Assess comparability of ESDs and available RCTs;
3. Compare effect sizes of ESDs and comparable RCTs;
4. Explore reasons for any difference in findings and direction of 
differences;
5. Explore the contribution of ESDs to a relevant body of effectiveness 
evidence.
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7.4 Methods
7.4.1 Selection of case studies
ESDs from the review described in the previous chapter were selected for 
case study comparison if  the efficacy of the assessed drug treatment had 
also been the subject of a published Cochrane Collaboration review. 
Tapping into this ready resource avoided the need to undertake a fu ll 
systematic review of the trials literature for each case study, as Cochrane 
reviews involve comprehensive systematic searches of international tria l 
databases, as well as grey literature and in many cases hand searching. 
Four such comparison case studies were identified.
7.4.2 Assessment of study quality
The main purpose of quality assessment of studies is to guide the 
interpretation of the results, particularly when comparing findings between 
studies of different types, and to lim it bias (Cochrane Collaboration 2001). 
Study features to be assessed according to the Cochrane Collaboration are 
internal and external validity, and certain design characteristics that affect 
interpretation of results.
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Randomised controlled trials:
For the quality assessment of RCTs, an existing instrument was selected 
(Jadad et at. 1996). This is one of the most widely used and validated 
instruments available. It is also quick to use (the authors suggest no more 
than 10 minutes). By means of three questions, the instrument assesses 
whether a study was described as randomised, double blind, and whether 
withdrawals and dropouts were described. Scores are adjusted depending 
on the appropriateness of any described methods of randomisation or 
blinding.
ESDs:
There were few rigorously developed and validated instruments to assess 
the quality of observational studies. Such instruments included: Downs & 
Black (1997) (adapted by MacLehose et at. (2000), who suggested a further 
review of the instrument), Zaza et at. (2000), and the Newcastle Ottawa 
Assessment Scales (Wells et at. 2003). Others, such as the York Centre for 
Reviews and Dissemination (CRD 2001), and Cochrane Effective Practice 
and Organisation of Care Review Group (EPOC 1998) have suggested items 
to be included in quality assessments of observational or non-randomised 
studies.3 Appendix C includes an overview table of the items assessed by 
different instruments and checklists. Existing instruments and
methodological literature on ESDs (Huston & Naylor 1996; Motheral 6t 
Fairman 1997) suggested the following elements for quality assessments of 
ESDs:
□ Internal validity
□ External validity
□ Data processing
□ Statistical analysis
□ Reporting of the study
3 Since this work was undertaken, the CONSORT group has developed guidance on 
reporting observational studies (von Elm et at. 2007), and Deeks et at. (2003) have 
reviewed quality assessment tools for non-randomised studies. They considered only six of 
194 identified tools as suitable for systematic reviews.
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As far as possible, questions from existing validated instruments were used 
for quality assessment. In addition, questions on issues specific to ESDs 
using secondary data were formulated. Some of these issues have been 
raised in the literature (Huston 6t Naylor 1996; Motheral & Fair man 1997), 
others have arisen during the work reported here.4 The Schedule was 
revised after having been piloted on two non-selected ESDs. No overall 
scoring was intended.
7.4.3 Data extraction
A data extraction sheet was developed, based on the types of information 
suggested for extraction in published guides to systematic reviews (EPOC 
1998; CRD 2001) (see Table 7.1 for an overview of items extracted). The 
form was piloted on four ESDs not included in the case studies and revised 
following the pilot. For each of the four comparison case studies, the data 
extraction sheet needed to be adapted to take account of the specific 
disease areas and relevant patient and treatment characteristics. In 
particular, the collection of results had to be case study specific; only 
results on outcomes reported in the ESDs were collected (see Appendix C 
for a generic version of the form which highlights changes made following 
piloting). The same form was used for RCTs and ESDs, with a small number 
of questions being relevant to only one study type (e.g. planned duration of 
follow-up for RCTs).
4 see Appendix C for the Quality Assessment Schedule for ESDs [together with an indication 
of the source of each question], and the Guide to completing the Schedule.
248 Use of Databases in Drug Effectiveness Studies
Comparisons of ESDs with RCTs
Table 7.1: Information extracted from ESDs and RCTs included in the
comparison case studies
General information about the study
Author
Publication year 
Full reference
Affiliation and contact details of first author 
Countries participating 
Number of centres involved
Stated aim of the study
Patient characteristics and setting
Source population and study setting
Data collection period
Inclusion and exclusion criteria
Treatment and control conditions for each group
Sample baseline characteristics
Duration of follow-up
Intervention
Dose and duration of drug treatment 
Continuity of treatment (including compliance)
Outcome measures
Primary and secondary outcomes 
Assessment method 
Assessment timing
Analysis
Type of analysis
Numbers of patients enrolled and included in analysis 
Number of patients dropped out and reasons 
Main analysis methods 
Variables controlled in analysis
Results
Use of concomitant treatments in each group
Within and between group differences reported at different time points
7.4.4 Comparison of RCTs with ESDs
Treatment characteristics, selection criteria, outcomes measured, and 
analysis methods used in the included studies were reviewed and 
compared.
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The comparability of RCTs and ESDs (beyond intervention, participants, and 
outcome assessments) was considered in terms of selection criteria used 
and adjustments for baseline differences in ESDs.
To compare results between studies of different types, pooled odds ratios 
and confidence intervals were used. Calculations were undertaken using 
the statistical software StatsDirect (Version 2.4.1).
The exploration of observed differences focused on the following issues 
relevant to internal and external study validity:
• Inclusion / exclusion criteria used in ESDs and RCTs
• Participation of patients and centres
• Adjustment for baseline differences in ESDs
• Follow-up
Finally, an attempt was made to assess the contribution of the ESD to the 
relevant body of effectiveness evidence mainly by reviewing the study's 
stated objectives and reported findings in comparison with other evidence.
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7.5 Results
7.5.1 Case studies selected
The ESDs and related Cochrane reviews selected for the four case studies 
are listed in Table 7.2. Two case studies related to treatments for chronic 
conditions (rheumatoid arthritis, and osteoporosis), one to interventions 
after acute myocardial infarction (AMI), and the fourth dealt with drug 
therapies for gastro-oesophageal reflux disease (GORD).
The identified Cochrane reviews were considered to be sufficiently recent 
and close to the time of publication of the relevant ESDs. In most cases, 
the last substantive update of the relevant Cochrane review post-dated the 
ESD by up to 5 years. The timely relationship between the publication of 
the ESDs and the relevant comparison trials varied. In two case studies, 
the ESD post-dated most or all relevant comparison trials (case studies 1 
and 2). In case study 4, the situation was reversed: all tria l publications 
post-dated the ESD, apart from one trial published in the same year. In 
case study 3, three of six RCTs post-dated the ESD by one year (which 
almost certainly means that the trial itself would have at least coincided 
with if  not predated the ESD).
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Table 7.2: List of case studies: ESDs and corresponding Cochrane
reviews
ESD COCHRANE REVIEW
(The Cochrane Library, Issue 4, 
2002)
Case study 1 Sebaldt et ai. (1999):
36 month intermittent cyclical 
etidronate treatment in patients 
with established corticosteroid 
induced osteoporosis
van Staa et at. (1998):
Use of cyclical etidronate and 
prevention of non-vertebral 
fractures
Homik et a /.(1998):
Bisphosphonates for steroid 
induced osteoporosis
Case study 2 Tiefenbrunn et at. (1998):
Clinical experience with primary 
percutaneous transluminal coronary 
angioplasty compared with alteplase 
(recombinant tissue-type 
plasminogen activator) in patients 
with acute myocardial infarction
Cucherat et a /.(1999):
Primary angioplasty versus 
intravenous thrombolysis for acute 
myocardial infarction
Case study 3 McDougall et al. (1994):
Outcome in patients with 
rheumatoid arthritis receiving 
prednisone compared to matched 
controls
Criswell et a /.(1998):
Moderate-term, low-dose 
corticosteroids for rheumatoid 
arthritis
Case study 4 Eggleston et ai. (1996):
Outcome research in gastro- 
oesophageal reflux disease: 
retrospective analysis of prescription 
data (Mediplus® UK) on cisapride, 
ranitidine and omeprazole
van Pinxteren et a /.(2001): 
Short-term treatment with proton 
pump inhibitors, H2-receptor 
antagonists and prokinetics for 
gastro-oesophageal reflux disease­
like symptoms and endoscopy 
negative reflux disease.
7.5.2 Methodological quality
a) ESDs:
The results of the quality assessment of the ESDs are presented in Appendix 
C. The four observational studies assessed (McDougall et al. 1994; 
Tiefenbrunn et al. 1998; van Staa et al. 1998; Sebaldt et al. 1999) offered 
no reassurance on the validity or reliability of their intervention variables 
(Eggleston's (1996) study was only available in abstract form and could 
therefore not be subjected to detailed quality assessment.). In van Staa's
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(1998) study it  is conceivable that routine data cross-checking in practices 
contributing to the data source might have covered the variable of interest 
(etidronate prescriptions). The main outcome measure in this study was 
clearly validated in a previous study, not so in the other three assessed 
studies.
Only in one study (McDougall et al. 1994) was it  clear that patients have 
not been exposed to the intervention prior to the treatment period in 
question, even though this may be assumed in most other studies.
All four assessed studies presented baseline comparisons between the 
observed groups. All studies used only variables measured in the source 
database for the analysis.
In most studies, the representativeness of the sample and even of the 
source database from which it  was drawn was not addressed.
b) RCTs:
Table 7.3 presents the quality rating of RCTs, showing a wide spread of 
quality scores in three case studies, and more consistent quality scores in 
case study 2.
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Table 7.3: Quality of RCTs in case studies
Case study reference No. STUDY JADADSCORE
(Jadad et al. 1996)
Case study 1 : (Pitt et al. 1998) 4
Etidronate for established (Worth et al. 1994) 2
bone loss (Skingle 6t Crisp 1994) 1
Case study 2: (GUSTO lib 1997) 3
Alteplase versus PTC A for (Grines et al. 1993) 3
Ml (Ribichini et al. 1998) 3
(Garcia et al. 1999) 1
Case study 3: (Kirwan 1995) 5
Prednisolone for (Stenberg et al. 1992) 4
rheumatoid arthritis (van G estel et al. 1995) 4
(Harris et al. 1983) 3
(van Schaardenburg et al. 1995) 3
(Million et al. 1984) 1
Case study 4: (Hatlebakk et al. 1999) 4
Cimetidine, cisapride, (Venables et al. 1997) 4
ranitidine for GORD (Bate et al. 1996) 3(Carlsson et al. 1998) 3
(Galmiche et al. 1997) 3
(Richter et al. 2000) 3
(Bate et al. 1997) 2
(Hallerback et al. 1998) 1
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7.5.3 CASE STUDY 1: Etidronate for established bone loss
For this case study, there were two ESDs, both having assessed outcomes 
following treatment of osteoporosis patients with etidronate (van Staa et 
al. 1998; Sebaldt et al. 1999).
The Cochrane review by Homik et al. (1998) included 13 randomised and 
quasi-randomised trials, ten of which assessed etidronate as an 
intervention. Of these ten studies, six assessed etidronate as primary 
prevention and were thus excluded from the case study. Of the four 
remaining trials, one was a controlled clinical tria l (Struys et al. 1995) and 
thus also excluded. Thus three RCTs were included in the case study 
comparison (S king le & Crisp 1994; Worth et al. 1994; Pitt et al. 1998).
Table 7.4: Criteria fo r inclusion of studies in Cochrane review by
Homik e t a l. (1998)
Types of studies
All controlled clinical trials were selected for further assessment.
Types of participants
Studies where participants were men and/or women over the age of 18, with underlying 
inflammatory disorders, initiating treatment or currently being treated with systemic 
corticosteroids (primary or secondary prevention), and who had not received 
bisphosphonates in the six months prior to the start of the study. Only those trials 
where the mean corticosteroid dose was 7.5 mg/day or higher were used.
Types of intervention
Controlled clinical trials that included any of the first or second-generation 
bisphosphonates, alone or in combination with calcium and/or vitamin D, with the 
control group taking placebo, alone or in combination with calcium and/or vitamin D 
were included.
Types of outcome measures
Primary outcome: percent change in bone mineral density (BMD) at one year at the 
lumbar spine or femoral neck. ______________________________
Treatment characteristics
The duration of treatment in the included studies ranged from technically 
just 3 months (the minimum in van Staa’s BSD) to three years (Sebaldt)
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(Table 7.5). Only in Worth’s paper was it clear that compliance had been 
assessed during the trial.
All studies except van Staa et al. (1998) included calcium administration 
for the control group. That study, however, reported that around a quarter 
of patients in both groups have had calcium prescribed in the year prior to 
baseline. Worth et al. (1994) included vitamin D for the treatment group, 
but not the control group, whereas Pitt et al. (1998) administered vitamin 
D to both groups in their study.
Table 7.5: Treatments investigated by studies in case study 1
Study Intervention (daily dose) Control conditions Compliance
assessed
Duration of 
treatment
SEBALDT 1999 Etidronate 400 mg for 14 
days, followed by 76 days 
calcium carbonate (SOOrng)
Calcium carbonate 
(500-1000 mg)
Not reported 3 years 
(12 cycles)
VAN STAA 1998 At least one prescription for 
cyclical etidronate (14 days 
etidronate followed by 76 
days calcium)
Matched controls 
without etidronate 
prescription
No Min. 1 cycle, 
(mean 1.3 
years follow- 
up)
PITT 1998 Etidronate 400 mg for 14 
days; followed by 97 mg 
elemental Ca + 400 units 
vitamin D for 76 days
Placebo for 14 days; 
97 mg elemental 
calcium + 400 units 
vitamin D for 76 days
Unclear 2 years 
(8 cycles)
SKINGLE 1994 Etidronate 400 mg + calcium 
lOOOmg daily for 14 days 
followed by 13 weeks of 
calcium 1000 mg
1 g calcium Unclear 2 years
WORTH 1994 Vitamin D 1000 units, 
etidronate 7.5 mg/kg, 
calcium 1000 mg
1 g calcium Yes 6 months
Sample selection
None of the trials reported from which country patients were recruited or 
how many centres participated. For both ESDs, this information was 
available. These two studies, however, differed considerably; Sebaldt’s 
paper was based on an analysis of 61 patients from one specialist centre, 
whereas van Staa’s analysis of the GPRD included nearly 16,000 patients. 
Female patients dominated all samples (see Table 7.9).
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Table 7.6: Characteristics of included studies in case study 1
Study Countries Number of Number of Number of Setting
participating centres patients
screened
patients
included
SEBALDT 1999 Canada 1 Not reported 61 Specialist care
VAN STAA 1998 UK 550 Not reported 15,954 Primary care
PITT 1998 Not reported Not reported 136 49 Not reported
SKINGLE 1994 Not reported Not reported Not reported 55 Not reported
WORTH 1994 Not reported Not reported Not reported 40 Not reported
Only part of van Staa’s patients were taking corticosteroids in the year 
prior to study entry. All other studies included only patients on 
corticosteroids for significant periods of time (Table 7.7). In addition, Pitt 
specified a certain degree of bone loss as entry criterion.
Table 7.7: Diagnoses and previous corticosteroid treatment of patients
in case study 1
Study Corticosteroid treatment Diagnosis
SEBALDT 1999 Mean >10 years prior to study Corticosteroid-induced osteoporosis
VAN STAA 1998 26% of treatment group and 14% 
of control group on 
corticosteroids during year prior 
to study
Authors state that in the UK the 
indication for etidronate is established 
vertebral osteoporosis
PITT 1998 Mean >8 years prior to study Asthma, polymyalgia rheumatica, 
systemic lupus erythematosus etc.
SKINGLE 1994 Minimum 5 mg prednisolone 
equivalent daily (entry criterion)
Polymyalgia rheumatica, temporal 
arteritis, chronic obstructive airways 
disease
WORTH 1994 Mean ca. 7 years prior to study Asthma
Use of Databases in Drug Effectiveness Studies 257
Comparisons of ESDs with RCTs
Table 7.8: Inclusion and exclusion criteria (case study 1)
Study Inclusion criteria Exclusion criteria
SEBALDT 1999 Ambulatory, corticosteroids for 
236 months; had lumbar spine 
bone mineral density 
measurement at baseline, at 
12, 24, and 36 months 
VAN STAA 1998 None specified
PITT 1998 Corticosteroids equivalent to 5- 
20mg prednisolone daily for >6 
months; age: >30 years 
Lumbar spine z-score <1
SKINGLE 1994
WORTH 1994
>5mg equivalent oral 
prednisolone
Clinically stable asthmatics 
without hypoxemia; >5mg 
prednisone or equivalent for >9 
months; “adult”
Medication other than etidronate known 
to affect bone metabolism within 6 
months of study entry; diseases known to 
affect bone metabolism
None specified
Pre menopausal women unless sterilised 
or post-hysterectomy;
Generalised bone disease, including 
rheumatoid arthritis; inflammatory bowel 
disease; previous treatment with bone 
active agents in the therapeutic range 
Medication interfering with bone 
metabolism
Disorders of bone and mineral 
metabolism other than osteoporosis, 
disorders of liver or renal function; drugs 
other than corticosteroids affecting bone 
metabolism; osteoporosis treatment prior 
to study
The reported baseline differences between groups in each RCT were 
minimal. The groups in van Staa’s study were comparable on basic 
demographic data, but available medical history of e.g. prevalence of back 
pain, osteoporosis, use of hormone replacement therapy or corticosteroids, 
as well as fractures in the year before baseline differed considerably. 
Sebaldt reported longer use of corticosteroids in the etidronate group (11.1 
compared to 3.8 years) and significantly lower BMD on all three bone sites 
measured (lumbar, femoral neck, and trochanter).
Table 7.9: Baseline characteristics of patient groups (case study 1)
Study Number of patients Mean lumbar spine % Female Mean age
_(number completed) BMD (g/cm2)___________________________________
TG CG TG CG TG CG TG CG
SEBALDT 1999 24 (24*) 37 (37*) 0.89 1.10 83 59 60 55
VAN STAA 1998 7977*** 7977 n.rep. n.rep. 91 91 72 73
PITT 1998 26 (21**) 23 (16**) 0.74 0.76 62 61 59 59
SKINGLE 1994 n.rep.(9)
n.rep.
(12) n.rep. n.rep. 80 (n.s. difference) (n.s. difference)
WORTH 1994 20 (14) 20(19) 0.72 0.76 79 53 55 58
BMD = bone mineral density, TG=treatment group, CG=control group, n.rep.=not reported, 
n.s.=not significant;
patients with lumbar BMD data at end of 3 years (femoral neck data available for only 
23 and 21 patients of TG and CG respectively, trochanter data for 23 and 15 patients 
respectively);
** patients with lumbar BMD data at end of 2 years;
*** 1828 patients were treated for 2 or more years.
258 Use of Databases in Drug Effectiveness Studies
Comparisons of ESDs with RCTs
Outcomes, analysis methods, and results
Given van Staa’s use of the GPRD as a data source, the choice of fractures 
as outcome measures is understandable, as BMD measurements would be 
far less likely to be recorded. All other studies used BMD outcomes, with 
some having used fractures or other markers of bone metabolism (Table 
7.10).
Sebaldt and Worth reported regular calibration of the measurement 
instrument, and Pitt performed operator precision testing by repeat 
measurements on volunteers. The publication by Skingle & Crisp was a 
letter to The Lancet and thus lacked detail.
The definition of fractures varied significantly. Worth used x-ray 
radiographical measurements of vertebral height, whereby a decrease by 
15% or more from a previous measurement was considered a new fracture. 
Van Staa used International Classification of Diseases codes, and Sebaldt 
relied on documentation or radiological determination. Van Staa stated a 
priori that the number of patients incurring fractures was the outcome 
chosen; Worth reported the number of atraumatic fractures, and Sebaldt 
reported both the number of patients and number of fractures.
Van Staa determined incidence rates (number of patients with fractures 
divided by patient-years of follow-up). Adjusted relative rates were 
estimated by Poisson regression model which included selected 
confounders. Cumulative survival curves, and Cox proportional hazards 
models were fitted. The presence of a linear trend over time was 
estimated for each cohort using Poisson regression; the trend difference 
was similarly estimated, including confounders, and - if  significant - the 
baseline fracture history.
Sebaldt used repeated measures analysis of variance (ANOVA) and analysis 
of covariance (ANCOVA) to test differences in outcomes within and
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between groups. A slope test examined covariate effect. The Wilcoxon 
rank sum test was used to test differences in corticosteriod doses between 
groups.
A main difference between the two ESDs was thus the approach to sample 
selection. Whereas Sebaldt selected a small sample of patients based on 
available follow-up of at least three years for the main outcomes, van Staa 
selected a sample by treatment allocation and based the analysis on 
person-time of follow-up.
Only Pitt adjusted the between-group comparison of outcomes for 
differences in mean daily corticosteroid use during the study, using 
ANCOVA. Skingle used t-tests to analyse changes in mean BMD from 
baseline and for comparing both groups. Worth used the Mann-Whitney U- 
test for their analysis.
Table 7.10: Outcome measures used by studies in case study 1
Study Outcome measures
SEBALDT 1999
VAN STAA 1998
PITT 1998
SKINGLE 1994
WORTH 1994
BMD lumbar spine (% change in g/cm );
BMD femoral neck (% change in g /cm 2);
BMD trochanter (% change in g /cm 2);
Hip fractures;
Vertebral fractures.
Number of patients experiencing:
Fracture of hip;
Fracture of wrist;
Vertebral fracture;
All non-vertebral fractures.
BMD lumbar spine (% change in g /cm 2);
BMD femoral neck (% change in g /cm 2);
BMD trochanter (% change in g /cm 2);
Serum and urine markers of bone metabolism. 
BMD lumbar spine (% change in g /cm 2);
BMD femoral neck (% change in g /cm 2).
BMD lumbar spine (% change in g /cm 2); 
Fracture incidence of lumbar spine._________
BMD = bone mineral density
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Table 7.11 presents the comparison of results for those outcomes measured 
in both ESDs and RCTs. No pooled estimates could be calculated, because 
standard deviations were only available for one RCT.
Table 7.11 : Results of studies in case study 1
Outcomes Study Results
BMD lumbar SEBALDT 1999
Treatm ent group 
5.2 (SD 9.8)
Control group 
-1.4 (SD 9.1)
Between-group
difference
n.s.
Years
follow -up
3
spine* PITT 1998 5.1 (SE 1.0) 1 (SE 1.5) 4.5 (SE 1.65)% 
P=0.007
2
SKINGLE 1994 4.8 -0.7 P<0.05 2
WORTH 1994 5 -4.3 P<0.01 1/2
BMD
femoral
neck*
SEBALDT 1999 
PITT 1998
0.5 (SD 11.4) 
2.5 (SE 1.3)
-2.6 (SD 7.3) 
3.6 (SE 1.7)
n.s.
n.s.
3
2
SKINGLE 1994 No statistically significant changes observed after 1 
and 2 years in either group; both decrease of 1% at 1 
year in both groups, and increase of 3% at 2 years in 
treatment group^
576 (SD 14.6) Ô.Ô (SD 6.3}....................n.s.
No differences observed 
5 fractures in 3 
patients (8%)
BMD
trochanter*
Vertebral
fractures
SEBALDT 1999 
PITT 1998 
SEBALDT Ï 999
VAN STAA 1998
WORTH 1994
Not tested1 fracture in 1 
patient (4%)
RR: 1.26, Cl: 0.95-1.67; risk in etidronate group 
decreased significantly over time.
0 6 fractures in 4 n.s.
patients (21%)
2 patients 0 patients Not tested
RR: 0.66, Cl: 0.51-0.85, in favour of etidronate
1/2
3Hip
fractures
SEBALDT 1999 
VAN STAA 1998
mean percentage change from baseline
Discussion
Comparability
Both ESDs used statistical adjustments for baseline differences and 
confounders in their analyses. Van Staa did not specify any exclusion 
criteria, and it  is likely that their sample contained patients which would 
have been excluded in other studies. A further issue possibly affecting 
comparability of ESDs with RCTs was the lack of blinding in the single­
centre study by Sebaldt; however, a calibrated instrument was used to 
measure BMD.
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Comparison of effect estimates
For BMD percentage changes of the lumbar spine from baseline, Sebaldt 
observed significant differences between both groups for up to 2 years in 
favour of etidronate (percentage difference 6.0% (SD 17.4), p=0.011), but 
not after 3 years (percentage difference 3.9% (SD 21.1), p=0.167). By 
comparison, the three RCTs all reported significant differences between 
the groups at their endpoints (after Vi or 2 years). Differences between 
groups of trochanter or femoral neck BMD percentage change were not 
significant at any time point in SebaldVs study, and no RCT found any 
significant between-group differences. The control group achieved 
remarkably positive results in some instances (e.g. in P itt’s study).
Thus, the BSD and RCTs corresponded well in terms of their overall 
findings. The possibility that different parts of the skeleton may be 
affected differently by corticosteroids has been raised previously (Schaadt 
1984 referred to by Pitt). P itt’s study (which incidentally achieved a 
stagnation of bone loss compared to other control groups) was the only 
study which included vitamin D for the control group.
The largest benefits of etidronate have been observed by Worth, whose 
study lasted 6 months. Pitt has also suggested that the benefit of 
etidronate might plateau after that time. On the other hand, Worth was 
the only study having used continuous rather than cyclical treatment, and 
having adjusted the dose for body weight. It is worth noting here that 
continuous therapy with etidronate is now considered harmful.
The data on fractures is d ifficult to interpret. As mentioned above, the 
determination of fractures varied considerably. Unlike other studies, van 
Staa followed etidronate takers (and their matched controls) until 6 months 
after their last prescription. Fractures were sought in medical records, 
based on ICD-9 categories. Van Staa observed a significant reduction in 
fracture risks on all observed sites, but a larger reduction for non-vertebral 
(RR: 0.80, Cl: 0.70-0.92) compared to vertebral fractures. The authors
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themselves recorded several possible limitations of their ESD, including 
detection bias, whereby doctors may have been more likely to recognise 
fractures in treated than untreated patients. In addition, only a limited 
number of possible confounders were available in the database and could 
thus be controlled for.
Inclusion / exclusion criteria
Van Staa’s study did not specify any inclusion or exclusion criteria but 
included all patients prescribed at least one course of etidronate 
treatment. For control subjects, the authors selected patients from the 
same practice, diagnosed with osteoporosis but not treated with 
etidronate. Arguably, this was thus the least restrictive patient sample. 
No exclusion criteria were specified, but a range of variables which might 
have been chosen as exclusion criteria were considered as potential 
confounders (e.g. hormone replacement therapy). By contrast, the second 
ESD (Sebaldt) made inclusion primarily dependent on availability of follow- 
up data for long-term corticosteroid users.
All studies except van Staa sought to exclude patients previously treated 
with drugs affecting bone metabolism or for osteoporosis. However, van 
Staa might have had the opportunity to identify the first course of 
treatment of their patients, as long as this was already recorded on the 
GPRD. Problems may arise, where patients have previously tried the drug 
or commenced regular treatment before their practice began to report 
data to the GPRD, although this seems unlikely (GPRD started from 
1991/2).
Participation of patients and centres
Given the inclusiveness of the study by van Staa and the representativeness 
of their data source (the GPRD) of the UK population, it  might be argued 
that the generalisability of their study to all etidronate takers in the UK is 
exceptionally high. The indication for etidronate in the UK is established 
vertebral osteoporosis.
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By contrast, Sebaldt included only patients from their own specialist 
tertiary care centre, whose data were registered at a national clinical 
database for osteoporosis. For the RCTs, neither the recruitment source 
nor the setting were known, and there was no possibility to judge their 
representativeness of any source population.
There was considerable variation in the reported diagnoses of patients. 
Whereas Worth restricted their sample to asthmatics treated with 
corticosteroids, the other studies were not restrictive on the indication for 
corticosteroid use.
Adjustment for baseline differences in ESDs
Both ESDs observed considerable baseline differences between their study 
groups. Sebaldt reported that they had started patients who were 
prescribed corticosteroids on etidronate, either because of their low BMD 
at initial evaluation or because of accelerated bone loss on follow-up. 
Thus, the difference in BMD at study baseline was to be expected. No 
difference in age or corticosteroid use was observed. Van Staa chose to 
match the study groups for age, sex, and possibly medical practice and 
selected a range of potential confounders for statistical adjustment, 
including corticosteroid use, and vertebral fracture history which differed 
between the groups at baseline (both higher in the etidronate group).
The nature of the dataset used by Sebaldt was far more disease-specific 
than the GPRD used by van Staa. Sebaldt and colleagues had relatively 
more control over the dataset, given that they must have known the small 
number of patients whose data were analysed. However, they reported 
adjusting for duration of corticosteroid use, but did not list other factors 
adjusted for in the analysis. It is likely that they would have had the 
majority of known variables available.
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Follow-up
As mentioned above, the ESDs handled the issue of follow-up in different 
ways. However, whereas Sebaldt had complete data for lumbar spine BMD, 
data for other sites were severely depleted at the end of the three-year 
follow-up period (from 37 to 15 patients (-60%) in the control group). Van 
Staa’s paper, on the other hand, unfortunately limited the reporting of the 
numbers followed up and the changes in relative risks over time.
Skingle & Crisp also reported that only 38% of patients were assessed after 
2 years, with withdrawals at least partly caused by a drop in corticosteroid 
dose below the required level. Pitt had data from 81% of the treatment 
group and 70% of the control group available for analysis after 2 years 
(fewer for femoral neck BMD). Worth withdrew three patients for poor 
compliance and three further patients because of side effects from the 
treatment group of 20 patients (i.e. 30%). Only one patient was withdrawn 
from the control group.
Contribution to effectiveness evidence
Sebaldt explicitly aimed to “ determine the effect”  of etidronate in 
corticosteroid induced osteoporosis. Sebaldt's stated motivation was to 
provide long-term evidence (beyond 2 years), as an initial observed 
increase in BMD might only be temporary. Van Staa intended to 
“ document” fracture rates for etidronate takers and osteoporosis patients 
not taking bisphosphonates in primary care.
Both study authors provided several justifications, some defending an 
observational study design (e.g. by referring to a possible lack of 
generalisability of tria l evidence), others stressing the need for evidence on 
the direct effects of treatment on fracture risk, particularly non-vertebral 
fractures, which had rarely been considered.
The ESDs have thus clearly sought to reach beyond existing evidence by 
pursuing long-term evaluations, or assessing outcomes hitherto not
Use of Databases in Drug Effectiveness Studies 265
Comparisons of ESDs with RCTs
evaluated. In addition, van Staa’s large-scale primary care based 
evaluation was able to assess fracture risk, which RCTs had not been able 
to address sufficiently.
Little can be said about the comparability of results, as insufficient data 
were available, and selection criteria, and measured outcomes varied 
between studies and study types. However, both types of studies favoured 
etidronate over control treatment and thus concurred in their conclusion. 
There is no indication of an overestimate of effect in the observational 
studies.
Concluding comments
One of the most interesting observations in this case study is actually the 
comparison between the two ESDs. They vary in their declared purpose (to 
demonstrate effectiveness vs. describing fracture rates), as much as their 
size and nature: a one-site analysis of a subject-specific database, where 
authors quite possibly were involved in the clinical care as well as outcome 
measurements, compared to an analysis of a vast primary care database 
without even applying explicit exclusion criteria.
These examples also highlight potential biases and strengths of both 
studies. On the one hand, a small single-centre study suffered from a lack 
of assessor blinding, as well as the potentially suspicious lack of 
adjustments of the analysis beyond a single factor (duration of 
corticosteroid use), and considerable loss to follow-up on a number of 
outcome variables. A single-subject database should have presented the 
opportunity to plan subject selection, data collection, and variable 
definition carefully to best support the testing of a specific hypothesis. 
The large G PRO-based study by comparison w ill have had the advantage of 
size, but w ill have had little  control over errors, whether systematic or 
random, and w ill have faced potentially more pitfalls than our Dornase Alfa 
Case Study.
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Almost paradoxically, the potential strengths (long follow-up and use of an 
outcome measure not normally amenable to RCTs - i.e. fractures) might 
have constituted some of the main potential biases in these ESDs. Future 
methodological developments to improve the quality of ESDs w ill have to 
concern themselves with such issues specifically.
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7.5.4 CASE STUDY 2: Alteplase versus PTCA for AMI
The ESD for this case study (Tiefenbrunn et al. 1998) used the NRMI-2 
database to compare primary PTCA with thrombolysis using alteplase for 
AMI. The outcomes assessed were in-hospital mortality, stroke, and 
subsequent events and procedures.
The Cochrane review on primary angioplasty versus intravenous 
thrombolysis for acute myocardial infarction by Cucherat et al. (1999) 
included ten randomised trials; four of them tested alteplase and are thus 
included in this case study (Grines et al. 1993; GUSTO lib 1997; Ribichini et 
al. 1998; Garcia et al. 1999).
Table 7.12: Criteria fo r inclusion of studies in Cochrane review by 
Cucherat e t al. (1999)
Types of studies
All randomised studies comparing primary PTCA with thrombolysis were eligible if they 
reported clinical outcomes within the in-hospital stay, regardless of language. Double 
blinding is unrealistic in this situation, the use of a placebo of angioplasty being unethical.
Types of participants
Patients with suspected acute myocardial infarction.
Types of intervention
Experimental treatment: Primary balloon angioplasty without stenting 
Control treatment: Intravenous fibrinolytic therapy with alteplase
Types of outcome measures
In-hospital endpoints:
- death from all causes
- reinfarction
- recurrent ischaemia
- stroke: any stroke, haemorrhagic or non haemorrhagic
- severe bleeding (needing at least transfusion)
- combined endpoint (death and reinfarction or death, reinfarction and stroke)
- long-term mortality (six months or 1 year)._______________________________
Treatment characteristics
AU studies included heparin (or herudin) for both treatment arms - PTCA 
and thrombolysis with alteplase. In the ESD, 95% of patients or more
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received heparin in both comparison groups. The Gusto MB trial only 
randomised the first 89% of patients to either heparin or herudin.
Table 7.13: Treatment investigated by studies in case study 2
Study Intervention Control conditions
TIEFENBRUNN 1998 PTC A (iv. heparin in 95% of Alteplase (iv. heparin in 97% of
patients) patients)
GARCIA 1999 Primary PTC A by catheter-balloon Alteplase starting with 15mg iv
(with 10,000 I.U. heparin); stents bolus, then infusion of 0.75 mg/kg 
for suboptimal balloon PTC A over 30 min (max 50mg), and 0.5
results or flow-limiting dissections mg/kg over 60 min (max 35 mg).
Simultaneous heparin 5,000 I.U. 
bolus, followed by cont. perfusion 
GUSTO MB 1997 * PTC A Accelerated rt-PA: 15mg bolus,
infusion 0.75mg/kg for 30min, 0.5 
mg/kg for 60min (max 100 mg) 
GRINES 1993 5,000-10,000 units heparin -PTCA t-PA (Activase) 100mg (or
- followed by 3-5 days iv. heparin 1.26mg/kg if <65kg body weight)
RIBICHINI 1998 10,000 units heparin iv;
prophylactic bolus of iv lidocain 
(1 mg/kg); PTC A; heparin infusion 
for 48 hrs, ticlopidine 500mg/day 
for 1 month
for 3 hrs - followed by 3-5 days iv. 
heparin
rt-PA according to GUSTO protocol
First 1012 patients also randomised to heparin or herudin iv.
Sample selection
Gusto MB was the largest of the RCTs involving 1,138 patients of 57 centres. 
Grines' similarly was another multi-centre trial by the Primary Angioplasty 
in Myocardial Infarction Study Group (PAMI), but involved only 395 patients. 
The remaining two trials were smaller single-centre trials. By comparison, 
Tiefenbrunn’s BSD was based on the NRMI-2, an observational post­
marketing study sponsored by Genentech, Inc.. In 50 states of the USA, 
over 170,000 patients admitted to hospitals because of AMI were enrolled 
between June 1994 and October 1995. Of these 28,757 were included in 
the BSD.
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Table 7.14: Characteristics of included studies in case study 2
Study Countries participating Number of 
centres
Number of
patients
screened
Number of
patients
included
TIEFENBRUNN 1998 USA Not reported 38787 treated 
with either 
PTCA or rt-PA
28757
GARCIA 1999 Spain 1 Not reported 220
GUSTO IIB 1997 USA, Spain, Belgium, 
Italy, Germany, Sweden, 
Switzerland, Australia, 
Canada
57 Not reported 1138
GRINES 1993 USA, France 12 Not reported 395
RIBICHINI 1998 Italy 1 Not reported 110
All trials had set inclusion criteria relating to AMI diagnostic criteria. 
Ribichini in particular aimed to exclude small posterior AMIs. This study 
also excluded those aged 80 years or older and selected only patients 
presenting within 6 hours of symptom onset. The other trials, if  at all, 
specified a 12-hour period for this, as did Tiefenbrunn. None apart from 
Ribichini excluded elderly patients. Tiefenbrunn also restricted their 
sample to patients with sufficient follow-up data available, in order not to 
miss any outcomes of interest. Only patients who had not been transferred 
and were eligible for thrombolysis were selected.
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Table 7.15: Inclusion and exclusion criteria (case study 2)
Study Inclusion criteria Exclusion criteria
treated within 12 hours from onset of AMI transferred from other 
symptoms; minimum of 48 hours in- institution, contraindication to 
hospital follow-up (or death) thrombolysis
Age: >18 years; females of childbearing age;
suspected AMI, if chest pain 30 min - 5 Contraindications to 
hours, and no response to nitrates, and ST thrombolysis, left bundle 
elevation >0.2mV in >2 contiguous branch block
precordial leads.
<12 hrs of symptom onset (chest pain for Warfarin use, active bleeding, 
>20min, of ST elevation of >0.2mV in >2 history of stroke,
contiguous leads or left bundle branch contraindication to heparin,
block) renal insufficiency, systolic
blood pressure >200mg Hg, 
diastolic >110mg Hg, 
childbearing potential, serum 
creatinine >2.0 mg/dl.
<12 hours of onset of chest pain, ST Inability to provide informed
elevation >1mm in >2 contiguous ECG consent, dementia, complete
leads left bundle branch block,
cardiogenic shock, higher- 
than-normal risk of bleeding 
Age: <80 years; Formal contraindications to
<6 hrs of symptom onset (chest pain for > thrombolysis or heparin,
30min, ST elevation >0.1 mV on >2 inferior cardiogenic shock, or blood 
leads, and concomitant ST depression in pressure <80mgHg, anticipated 
>3 precordial leads, totalling >3mm) impossibility of percutaneous
femoral vascular access.
In terms of baseline characteristics, the ESD included more severely ill 
patients (expressed as percentage of patients belonging to Killip class IV) in 
the PTC A group than were found in the trials; however, not many trials 
reported that data. The ESD also included considerably more female 
patients and the largest proportions of patients with previous AMI and 
diabetes.
There were some imbalances also between groups included in particularly 
the smallest RCT (Ribichini); e.g. more patients with previous AMI were 
included in the PTC A group.
TIEFENBRUNN
1998
GARCIA 1999 
GUSTO MB 1997
GRIMES 1993 
RIBICHINI 1998
Use of Databases in Drug Effectiveness Studies 271
Comparisons of ESDs with RCTs
Table 7.16: Baseline characteristics of patient groups (case study 2)
Study % with previous AMI % diabetic % hypertensive
PTCA Alteplase PTCA Alteplase PTCA Alteplase
TIEFENBRUNN 1998 18.8 18.0 17.1 18.4 41.7 42.4
GARCIA 1999 n.rep. n.rep. 12 17 32 39
GUSTO MB 1997 12.9** 14.8** 17.5** 13.4** 39.8** 38.0**
GRINES 1993 15 14 13 12 47 39
RIBICHINI 1998 18.2 10.9 16.3 10.9 40 45.5
% in Killip class IV % female Mean age
PTCA Alteplase PTCA Alteplase PTCA Alteplase
TIEFENBRUNN 1998 4.2 1.3 27.5 29.2 60.5 61.1
GARCIA 1999 2 4 16 20 63* 60*
GUSTO MB 1997 0.9** 0.3** 24.6 21.5 63.5* 61.9*
GRINES 1993 n.rep. n.rep. 26 28 60 60
RIBICHINI 1998 n.rep. n.rep. 18 15 63.4 60.2
* median age; ** data not available for some patients; n.rep. = not reported
Outcomes, analysis methods, and results
Two of the smaller trials included a particularly large array of clinical 
outcomes, and one of them also outcomes after 1 -year follow-up. Also, 
Gusto MB involved a follow-up period of 30 days, and Garcia assessed all 
outcomes also on 6-month follow-up. Tiefenbrunn included fewer outcome 
measures, and a minimum 48-hour hospital stay for follow-up.
Tiefenbrunn tested differences between the two treatment groups with 
chi-square or t-test depending on the nature of the variables; the effect of 
treatment on mortality was assessed after adjustment for potential 
confounders in a multiple logistic regression analysis. Garcia used the same 
method for adjustment.
In addition to standard chi-square and t-tests, Ribichini used Kaplan-Meier 
curves to analyse event-free survival (only the first occurrence of multiple 
events was considered). Gusto-IIB used survival analyses to study the 
primary endpoint. Logistic regression modelling was used to assess 
interactions. In addition, pre-specified subgroup analyses were performed 
in relation to primary and secondary endpoints. Grines undertook an 
intention-to-treat as well as a post hoc analysis.
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Table 7.17: Outcome measures used by studies in case study 2
Study Outcomes
TIEFENBRUNN 1998 Mortality in hospital 
Stroke
Subsequent events 
Subsequent procedures 
GARCIA 1999 Mortality
Nonfatal re infarction (defined)
Post-infarction ischaemia (defined)
Need for revascularisation procedure after initial treatment (defined) 
All were also assessed on 6-month follow-up 
GUSTO IIB 1997 Composite outcome of death, nonfatal reinfarction, and nonfatal
disabling stroke within 30 days 
Mortality from all causes at 30 days
Mortality from all causes and nonfatal reinfarction at 30 days 
Composite end point consisting of death, reinfarction, disabling 
stroke, and congestive heart failure (CHF)at 30 days 
Recurrent medically refractory ischaemia 
Major bleeding 
GRIMES 1993 Death
Reinfarction (defined)
Stroke
Bleeding
Pulmonary oedema
Intubation
Hypotension
Arrhythmias
Pericarditis
Vascular surgical repair 
Dialysis
RIBICHINI 1998 IN-HOSPITAL:
Death
Reinfarction
Recurrence of angina at rest
Need for new target vessel revascularisation
Nonfatal stroke
Vascular or haemorrhagic complications needing blood transfusions
Severe ventricular arrhythmia
CHF
Angiographic results
Peak creatine kinase and time to peak
Length of initial hospital stay.
AT 1 YEAR FOLLOW-UP:
Death
Reinfarction 
Recurrence of angina 
New target vessel
revascularisation and 
non-target vessel revascularisation 
CHF with admission 
All new admissions
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Table 7.18 compares the comparable outcome measures of included 
studies. For in-hospital mortality, Garcia’s study is the only study which 
individually reports a significantly lower mortality in the PTC A group 
compared to the thrombolysis group. However, the pooled OR of the RCTs 
is 0.31 (Cl: 0.13-0.69), compared to an OR of 0.96 (Cl: 0.83-1.12) of the 
BSD.
New revascularisations are defined differently in each study, and hence 
difficult to compare; the outcome tends to favour the PTC A group, but less 
clearly so in the BSD.
Table 7.18: Results of studies in case study 2
Outcomes Study Results
PTC A: 
Cases (%)
Alteplase: 
Cases(%)
Between-group
difference
In-hospital mortality TIEFENBRUNN 1998# 
GARCIA 1999
211 (5.2%) 
3 (2.8%)
1334 (5.4%) 
12 (10.8%)
n.s.
p=0.02
GRINES 1993 
RIBICHINI 1998
5 (2.6%) 
1 (1.8%)
13 (6.5%) 
3 (5.5%)
p=0.06
p=O.6
30-day mortality GUSTO 1997 32 (5.7%) 40 (7.0%) p=0.37
In-hospital stroke TIEFENBRUNN 1998 
GARCIA 1999 
GRINES 1993 
RIBICHINI 1998
173 (0.7%) 
0 
0 
0
65 (1.6%) 
3 (2.7%) 
7 (3.5%) 
0
p<0.0001
p=O.OB
n.s.
n.s.
Stroke within 30 days GUSTO 1997 6 (1.1%) 11 (1.9%) Not reported
Reinfarction TIEFENBRUNN 1998# 101 (2.5%) 716 (2.9%) n.s.
GRINES 1993 
GARCIA 1999 
RIBICHINI 1998
5 (2.6%) 
4 (3.7%) 
1 (1.8%)
13 (6.5%) 
6 (5.5%) 
5 (9.1%)
p=0.06
n.s.
p=0.2
Reinfarction within 
30 days
GUSTO 1997 25 (4.4%) 37 (6.5%) p=0.13
New
revascularisation 
procedure in hospital
TIEFENBRUNN 1998*# 
GARCIA 1999** 
GRINES 1993*** 
GUSTO 1997+ 
RIBICHINI 1998*** 
RIBICHINI 1998++
993 (24.5%) 
24 (22.0%) 
26 (13.3%) 
42 (7.5%)
2 (3.6%)
2 (3.6%)
7263 (29.4%) 
53 (47.7%) 
126 (63%) 
47 (8.3%) 
14 (25%)
16 (29.1%)
Not reported
p<0.001
p<0.001
Not reported
p=0.01
p=0.0003
# includes only patients not in shock
* includes: elective and rescue PTC A, elective and immediate CABG.
** includes: PTC A to left anterior descending coronary artery, or CABG
* includes: unscheduled catheterisation only
+ includes: CABG only
++ includes: target vessel revascularisation
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Figure 7.1: L'Abbe plot of in-hospital m ortality (%) (Case study 2)
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Note: Size of points is proportional to study population.
Figure 7.2: Odds ratio meta-analysis plot of RCTs of in-hospital 
mortality, favouring PTCA
Odds ratio meta-analysis plot [fixed effects]
GARCIA 1999 0.233 (0.041, 0.906)
GRINES 1993 0.379(0.104, 1.162)
RIBICHINI 1998 0.321 (0.006, 4 184)
combined [fixed] 0.310(0.144, 0.667)
0.001 0.01 0.1 0 2 0.5 2 51
odds ratio (95% confidence interval)
Note: ORs and CIs based on Mantel-Haenszel estimates.
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Discussion
Comparability
Tiefenbrunn used statistical adjustments of confounding for the analysis of 
mortality outcome. Patients in shock were only included in the stroke 
outcome analysis. The exclusion of patients not remaining in hospital for 
at least 48 hours or having been transferred from other centres raised the 
possibility of selection bias. Also, whereas the authors demonstrated that 
transfers away fared no differently in terms of mortality outcomes, this 
was not assessed for patients transferred from  elsewhere.
Comparison of effect estimates
Only one RCT (Garcia) showed a significant benefit of PTC A in terms of in- 
hospital mortality, but the pooled OR of three RCTs favoured PTC A. 
Adjusted ORs presented by Tiefenbrunn and Garcia did not alter their 
respective conclusions.
The difference observed by Garcia seemed to be largely due to a greater 
number of deaths in the alteplase group than fewer deaths in the PTCA 
group, by comparison to the other studies. The causes of death were 
mainly cardiogenic shock and free-wall rupture (5 patients each). The 
baseline differences of this study on a number of variables seemed to 
favour the PTCA group. Garcia did include 31 (14%) of patients randomised 
for another similar trial.
Garcia also achieved exceptionally short times from onset of symptoms to 
treatment: median time from onset of symptoms to first balloon inflation 
was 197 minutes (25th-75th percentile: 150-250 minutes). Most other 
studies allowed up to 12 hours from symptom onset to presentation, and 
Garcia noted that their fast interventions resulted in the selection of 
relatively well patients.
Tiefenbrunn had excluded patients in shock from the main analysis. For 
patients in shock, mortality is significantly higher in the alteplase
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compared to PTCA group (52.3% vs. 32.4% respectively: p<0.0001 ). This 
puts a different light on the comparability of the mortality results, as it  is 
likely that two RCTs did not exclude patients in shock (including Garcia).
Also, Tiefenbrunn considered that incomplete follow-up of patients may 
have been a problem which affected both groups differently, as 
thrombolysis patients tended to be transferred earlier. All patients had a 
follow-up of a minimum of 48 hours (or until death), which was considered 
to be sufficient to capture the majority of deaths.
In-hospital strokes were rare in all studies and therefore difficult to 
compare. Interestingly, this was the only significant outcome in favour of 
PTCA reported by Tiefenbrunn in their main analysis, and the only outcome 
reported without excluding patients in shock. The authors suggested that 
the difference might have been due to having included more older 
patients.
Tiefenbrunn selected only those patients who actually underwent PTCA or 
thrombolysis with alteplase. Grines and Ribichini claimed to have 
performed intention-to-treat analyses and would thus have had to include 
patients not having received the allocated treatment (2% in Grines’ PTCA 
group only). However, also in Gusto MB only 82% of those allocated to PTCA 
underwent angioplasty. It is unclear whether they have been included in 
the PTCA group for analysis purposes.
Reinfarction rates did not differ significantly between the treatment groups 
of any study. Arguably, this was a rather less interesting in-hospital 
outcome, as patients could readily be subjected to further 
revascularisation procedures should these have been required in order to 
prevent reinfarction. Revascularisations were not reported uniformly, but 
the available data from most studies suggested that PTCA groups required 
significantly fewer such procedures. Again, there was a possibility that
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Tiefenbrunn's study had suffered from differential loss to follow-up 
between the groups.
Inclusion / exclusion criteria
Tiefenbrunn noted that the mortality of patients presenting in cardiogenic 
shock was high in both groups, but significantly higher in the alteplase 
group. Two RCTs had excluded those patients. Whereas all exclusion 
criteria were logical, there was little  consistency across studies. Garcia 
mentioned also that eligible patients were excluded due to physician's 
preference.
Tiefenbrunn had to apply pragmatic exclusion criteria (48-hour follow-up) 
to protect against differentially missing follow-up data. Similarly, patients 
transferred from other institutions were excluded.
Participation of patients and centres
The exclusion of non-thrombolysis eligible patients had significant 
implications for the generalisability of reported success rates from the 
presented studies, including the BSD. Garcia acknowledged that the profile 
of their sample was unrepresentative of their usual patient population. 
Whereas the PTCA group experienced an in-hospital mortality of 2.8%, the 
authors quoted a comparison figure from their clinical practice of 16.4% for 
patients with AMI treated with primary PTCA within 6 hours of symptom 
onset (and a 16% prevalence of shock at admission). They also reported 
that 67 patients were not randomised but referred directly to PTCA either 
because of exclusion criteria, patient's refusal, or physician's preference. 
The latter seems to imply that physicians favoured PTCA, and were willing 
to consider thrombolysis on equal terms with PTCA for only a selected 
group of patients.
In the evaluation of skill-based procedures such as PTCA, single-centre 
studies were rather limited in their ability to generalise their findings. The 
positive outcomes for PTCA in Garcia’s study may not be repeatable in
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centres with less experienced staff. The rate of success in performing 
PTC As was similar across the RCTs (93% and more), but such rates cannot 
be generalised.
Tiefenbrunn briefly presented a comparison of their sample with those 
patients excluded because of having been transferred within 48 hours. The 
comparison showed some more favourable prognostic variables in the 
transferred patients; these patients were younger, more likely to be male 
or in lower Killip classes, and having experienced lower incidence of 
previous stroke. However, their mortality risk was similar. A preceding 
write-up of the NRMI reported that 14.4% of all US hospitals were 
represented in the registry, but these were more likely to have coronary 
care and invasive cardiac facilities than non-registry hospitals (Rogers et al. 
1994).
Adjustment for baseline differences in the ESP
Tiefenbrunn used a multiple logistic regression model to adjust for 
potential confounders. Variables independently predictive of mortality risk 
were Killip class 2 or 3, age >=75 years, previous stroke, female gender, 
treatment interval >4 hours from symptom onset and anterior infarct 
location. It would appear that no such adjustment has taken place for the 
analysis of the other outcomes which were only reported as percentages 
with the level of the significance of the difference.
Follow-up
Loss to follow-up in trials was not a problem for the short-term outcomes in 
question. The potential for differential loss to follow-up in the BSD has 
been commented on above.
Contribution to effectiveness evidence
Tiefenbrunn phrased the study objective in terms of a comparison of 
outcomes following (or “ experience” with) PTCA or thrombolysis with 
alteplase. However, the study was not limited to describing outcomes
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following both treatments, but fully tested their equality. It is regrettable 
that the authors did not adhere to their original intention but rather 
pursued this comparative focus, which necessitated patient exclusions. 
They might have served the evidence base better if  they had described the 
characteristics of patients “ naturally”  selected by clinicians in different 
centres for each treatment, and patients’ experience (e.g. time to 
treatment, co-treatment used) and outcomes as they progressed through 
the treatment phases. Given the number of patients observed, this 
approach would have provided a rich source of naturalistic data on 
treatment and outcome, which could both generate clinical considerations 
and new hypotheses, as well as inform economic evaluations.
The literature review presented in the ESD pointed at conflicting small tria l 
evidence, and the lack of evidence produced under non-trial conditions. 
Thus, a two-pronged extension to the tria l evidence was aimed for: an 
analysis of a large number of cases, and conditions free from trial 
constraints. Whereas both have been achieved, neither has been fully 
exploited. The generalisability to a wider population of AMI patients is 
somewhat compromised by the fact that the NRMI-2 centres are largely 
specialist centres, and both interventions assessed are highly dependent on 
timing as well as technical skill.
Concluding comments
This case study is particularly interesting because of the divergent results 
between RCTs and ESDs. It has to be said that using conflicting small trial 
evidence as a justification for the Tiefenbrunn’s study is somewhat 
unsatisfactory, as already two systematic reviews had been published at 
the time (Michels and Yusuf 1995, Weaver et at. 1997), both favouring 
primary angioplasty. However, the debate about the relative merits of the 
two alternative revascularisation methods continued for some time after 
that and was probably resolved in the UK in favour of PTC A at the time of 
the publication of the relevant HTA systematic review (Hartwell et at. 
2005).
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There are several possible reasons for the divergent findings of the ESD, 
and some can be glimpsed from Gusto’s presentations of survival curves 
and sub-group analyses. These clearly show the survival advantage of PTC A 
starting after approximately one week (depending on outcome). 
Tiefenbrunn’s short follow-up period could have missed much of that 
benefit. Similarly, there is an indication that higher-risk patients do better 
after PTC A; Tiefenbrunn excluded patients who were in shock (which some 
RCTs did too), but also those transferred from other centres. Given that 
the database draws on specialist units, it  is possible that this would have 
excluded more severely affected patients, but also those with relatively 
late presentation (again, patients presenting relatively late have now been 
shown to benefit more from PTCA).
This case study thus demonstrated that selection criteria which may have 
been chosen for practical and unprejudiced reasons might distort the 
conclusions. It may also be worth noting that the authors of the ESD have 
consulting agreements with the company which manufactures rt-PA and 
funds the database (Genentech Inc.).
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7.5.5 CASE STUDY 3: Prednisone for rheumatoid arthritis
This case study included the ESD with the longest follow-up period 
(McDougall et al. 1994). The authors termed it  a case-control study, but 
they included only patients with rheumatoid arthritis (RA) and compared 
outcomes (disease activity, mortality, and adverse events) between 
patients treated with prednisone and those not receiving that treatment. 
By conventional definition, studies allocating groups on the basis of the 
exposure, which is followed by an outcome of interest, are cohort studies 
(Hennekens & Buring 1987).
A Cochrane review of “ moderate-term, low-dose corticosteroids for 
rheumatoid arthritis”  included seven RCTs (Criswell et al. 1998). One very 
early trial used cortisone acetate (Empire Rheumatism Council 1955) and 
was therefore excluded. Million et al. (1984) and Kirwan et al. (1995) used 
prednisolone; all other trials used prednisone (Harris et al. 1983; Stenberg 
et al. 1992; van G estel et al. 1995; van Schaardenburg et al. 1995). 
Stenberg et al. (1992) used a complicated cross-over design, including two 
induction periods followed by patient-controlled medication with 
prednisone during two treatment periods.
Table 7.19: Criteria for inclusion of studies in Cochrane review by 
Criswell et al. (1998)
Types of studies
Only randomised controlled or cross over trials of 3 months or longer were included. 
Types of participants
Patients with a diagnosis of active rheumatoid arthritis (RA).
Types of intervention
Studies that used prednisone (or a comparable corticosteroid preparation) at a mean 
dose of less than or equal to 15 mg per day; studies that utilised either placebo controls 
or active controls (i.e. comparative studies).
Types of outcome measures
At least one of the following outcome measures in a quantitative fashion: joint 
tenderness joint swelling, grip strength, or erythrocyte sedimentation rate.
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Treatment characteristics
McDougall’ s study was based on the analysis of a clinical database started 
in 1966 in the Rheumatic Disease Unit in Saskatoon (Saskatchewan, 
Canada). All RA patients having been prescribed prednisone at some point, 
but not before study enrolment, were considered for the intervention 
group, regardless of treatment duration or dose. Control group patients 
came from the same source and were matched for age, sex, disease 
duration, and physician global assessment. Standard examinations and 
physician’s global assessments (which are not further defined) on 
enrolment and during annual visits of patients were recorded, as were the 
results of semi-annually mailed Stanford Health Assessment Questionnaires.
Million used prednisolone as required for the treatment group (max. 20 
mg), whereas the comparison group was allocated to bed rest and splints 
for inflamed joints, without steroids during active disease phases. 
Similarly, Sten berg permitted variable but patient-controlled doses of 
prednisone. Two RCTs (Harris, Kirwan) used low-dose prednisone; two 
further RCTs (van Gestel, van Schaardenburg) used higher doses which were 
then tapered off. Van Schaardenburg’s RCT permitted additional 
chloroquine (the control treatment) if  prednisone was considered 
ineffective.
The study duration of RCTs varied from 3 months to 10 years. Compliance 
testing was only reported in one study (Stenberg).
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Table 7.20: Treatments investigated by studies in case study 3
Study Intervention (daily dose) Control conditions Compliance
assessed
Duration of 
treatment
McDOUGALL 1994 Prednisone at some time Matched controls 
during follow-up (mean S.Owithout corticosteroid
mg)
Prednisone 5 mg 
Prednisone 7.5mg 
Prednisolone as required 
Patient controlled 
prednisone medication 
(objective: average 2.5 
mg)
Prednisone lOmg for 12 
weeks; gradually tapered 
off thereafter 
VAN SCHAARDENBURG Prednisone 15mg for 1
month, then tapered down after loading during 
to effective dose; if first two months. If 
ineffective after 3 months, ineffective for 3 
or discontinued - months or discontinued
chloroquine added - change onto gold
_______________________ therapy
HARRIS 1983 
KIRWAN 1995 
MILLION 1984* 
STENBERG 1992
VAN GESTEL 1995
treatment
Placebo
Placebo
Rest and splints 
Placebo
Placebo
Not reported
Not reported 
Not reported 
Not reported 
Yes
Mean 
6.9 years
23 weeks 
2 years 
10 years 
90 days
Not reported 18 weeks
1995
Chloroquine 100mg/dayNot reported 2 years
Patients whose disease could not be controlled after min. 6 months were treated with 
combination of both therapies.
Sample selection
Most RCTs were small (under 100 patients in total), except for the two UK 
trials (Kirwan, Million). The ESD is almost twice as large as the largest RCT 
in patient number terms; however, it  is worth considering that the number 
of patient years of observation is more than six times as large (256 years 
for Kirwan, compared to 1684 for McDougall).
It was unclear in most studies, whether patients were recruited from 
tertiary or other centres (except for McDougall and Harris based in 
specialist centres).
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Table 7.21: Characteristics of included studies in case study 3
Study Countries
participating
Number of 
centres
Number of
patients
screened
Number of
patients
included
Setting/
Recruitment
source
McDOUGALL 1994 Canada 1 1191 on
database
244 University
rheumatism
centre
HARRIS 1983 Pennsylvania Not reported Not reported 41 Arthritis centre
KIRWAN 1995 UK 13 162 “invited” 128 Recruitment at 
hospitals
MILLION 1984 UK Not reported Not reported 103 Rheumatic 
disease centre
STENBERG 1992 USA Not reported Not reported 22 Not reported
VAN GESTEL 1995 The
Netherlands
1 55 40 Recruitment at 
outpatients
VAN SCHAARDENBURG The 
1995 Netherlands
2 Not reported 56 Recruitment at 
hospital and 
clinic
All studies took care in defining the diagnosis of rheumatoid arthritis for 
patient selection. The disease had to be active for recruitment into the 
RCTs, except for Million where treatment was administered as required 
whenever the disease did become active. All studies enrolled adult 
patients, and van Schaardenburg limited recruitment to patients of 60 
years or older.
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Table 7.22: Inclusion and exclusion criteria (case study 3)
Study Inclusion criteria Exclusion criteria
McDOUGALL 1994 Definite or classic RA Prednisone before initial study enrolment;
incomplete data, comorbidity requiring 
prednisone
Age: 18-75 years; Active peptic ulcer, renal or hepatic
At least 3 of 5 indices positive disease, rectal bleeding, diabetes,
for activity of disease (defined) symptomatic idiopathic osteoporosis,
cataracts, cardiovascular disease, cytotoxic 
treatment or levamisole, intra-articular 
glucocorticoid injections <6 weeks prior to 
study
Age: 18-69 years; None stated
RA for <2 years and currently 
active (defined)
Definite or classical RA for 2-24 None stated 
months
Age: >18 years; Glucocorticoid use within 6 weeks
RA according to American preceding the study, change in any slow-
Council of Rheumatologists acting or investigational antirheumatic drug
(ACR) criteria, able to give within past 6 months, pregnancy, range of
consent and understand other conditions
instructions for use of 
prednisone, active disease 
(defined)
VAN GESTEL 1995 Definite or classical RA, when Diseases or medication that might affect
treatment of gold was bone mass; women <3 yr post menopausal
considered; or with irregular cycles.
>3 of 5 defined disease criteria 
VAN Definite or classic RA according Use of disease-modifying anti-rheumatic
SCHAARDENBURG to ACR criteria at age >60, drugs or prednisone during preceding 3
1995 active disease (defined), months, use of thiazide diuretics,
unresponsive to 3 months of inadequately controlled hypertension,
NSAIDs peptic ulcer, hepatic, or renal disease,
diabetes, ophthalmologic contraindications 
to chloroquine, osteoporosis, diseases 
precluding evaluation of therapeutic 
effects.
Baseline characteristics (see Table 7.23) varied considerably in terms of 
disease history, with McDougall reporting on the sample with the longest 
disease history (around 14 years), followed by S ten berg (9.6 years). 
Females dominated all samples, and van Schaardenburg's sample seemed 
particularly poorly balanced in terms of gender. Mean ages were in excess 
of 48 years throughout.
HARRIS 1983
KiRWAN 1995
MILLION 1984 
STENBERG 1992
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Table 7.23: Baseline characteristics of patient groups (case study 3)
Study Mean duration of % female Mean age (years)
______________________ illness (years)____________________________________________
Treatment Control Treatment Control Treatment Control
group group group group group group
McDOUGALL1994 14.1 13.8 70 70 55.9 56.0
HARRIS 1983 7.1 6.9 72 63 54.9 53.9
KIRWAN 1995 1.3 1.3 62 66 48.2 50.3
MILLION 1984* {2-24 month) 78 83 48.0 47.7
STENBERG 1992* 9.6 61 60.9
VAN GESTEL 1995 1.8 2.5 70 70 57** 56**
VAN SCHAARDENBURG 
1995 0.9 0.8 71 43 69 70
*Baseline data excludes deaths and dropouts 
""Median age
Outcomes, analysis methods, and results
The variety of outcomes assessed in the different studies was staggering 
and ranged from generic health questionnaires, generic and symptom- 
specific assessments of disease progression, such as jo in t swelling, pain, 
grip strength, inflammatory markers, and subjective assessments, to bone 
mineral density, and mortality. A vast array of scoring systems and 
instruments were used (see Table 7.24). Clearly, a direct quantitative 
comparison of results was impossible given the diverse outcome measures.
Table 7.24: Outcome measures used by studies in case study 3 
Outcomes
McDOUGALL 1994 Physician Global Assessment (scores: 0 to 100)
Mortality
Lansbury index (summarises indices of rheumatic activity) 
Functional class
Stanford Health Assessment Questionnaire 
Side effects:
Fractures 
Cataracts 
Osteonecrosis 
HARRIS 1983 DISEASE ACTIVITY:
Pain
Joint swelling 
Tenderness
(combination of joints evaluated)
Global sense of well-being 
Duration of morning stiffness 
Grip strength
Time taken to walk 15.2 meters 
Erythrocyte sedimentation rate (ESR)
QUALITATIVE T E S T S : _________________________
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KIRWAN 1995
MILLION 1984
STENBERG 1992
Outcomes
Subjective assessment 
Functional class 
Functional capacity 
Radiographic examinations of hands for soft tissue swelling, joint 
space narrowing, progression of erosion and osteoporosis, 
and lumbar spine for fractures and osteoporosis 
Ophthalmological changes 
Progression of damage (Radiographs of hand)
Development of erosions on hands without erosions at baseline 
(Erosive or nonerosive, and joint destruction of each finger or 
wrist joint scored by Larson method (0-5) - scores from 0 -140  
for sum of joint scores)
Disability (Health Assessment Questionnaire)
Joint inflammation (Articular index weighted for joint size)
Pain over prev. 24 hours (visual analogue scale)
Acute-phase responses (ESR, C-reactive protein, or plasma 
viscosity, depending on centre)
Duration of morning stiffness 
Number of inflamed joints 
Degree of pain 
Synovial thickening 
Range of motion 
Subluxation
Instability and ankylosis 
Grip strength 
Functional capacity 
ESR
Blood pressure 
ARA criteria 
Rheumatoid factor 
White-cell count
Radiographs of hands, wrists, metatarsophalangeal joints, knees, 
hips
Tender joint count 
Swollen joint count 
Duration of morning stiffness 
Time until fatigue 
ESR
Haemoglobin
Daily total pain score (diary)
Number of painful joints (diary)
Extent of morning stiffness (diary)
Global assessment (diary)
Medication used (diary)_________________________________
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Outcomes
VAN GESTEL 1995 Disease activity score (A composed index containing Ritchie
articular index, number of swollen joints, ESR and visual 
analogue scale (VAS)-self-assessed general health) 
Patient-assessment of pain (visual analogue scale)
Morning stiffness (in minutes)
Haemoglobin 
Thrombocytes 
Mean grip strength
Functional capacity (Dutch equivalent of Stanford Health 
Assessment Questionnaire (HAQ) (from 0 to 3))
Joint erosions (independently by two observers)
Joint space narrowing (modified Sharp method - reference given) 
VAN Patient assessment of disease in comparison with baseline (4-
SCHAARDENBURG point scale)
1995 Dutch Health Assessment Questionnaire
Number of swollen joints 
Modified Ritchie Articular Index (max 69)
ESR
Radiographs (Scoring of joint erosions and space narrowing)
BMI
Degree of osteophytosis in lumbar spine 
Physical activity 
Bone mineral density
_____________  Biochemical parameters____________________________________
In terms of analytical approaches, McDougall used standard tests to 
compare outcomes between matched groups: t-test, chi-square test for 
paired data, Fisher's exact method for comparison of proportions, and 
Mantel-Haenszel method for mortality rates comparisons. Thus matching 
seems to have been the only method for adjusting for baseline differences.
Standard statistical tests were used in the RCTs (chi-square or Fisher's 
exact test, t-tests, and Wilcoxon rank sum test), and in the case of 
S ten berg's cross-over study, analysis of variance for repeated measures. 
Skewed distributions were log-transformed. In addition, Kirwan took 
account of different methods used in different centres to measure 
response, by standardising values. Van Schaardenburg used analysis of 
variance for repeated measures to be able to use available data on patients 
not completing the study.
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Table 7.25 attempts to give a comparative overview of outcomes between 
the studies. No pooling of results was possible, due to the diversity of 
outcome measures used in different studies.
Table 7.25: Results of studies in case study 3
Outcomes Study Results
Treatment Control group Between-group Years
group difference* follow-up
Mortality MCDOUGALL 1994 (52) 42% (67) 54% P<0.05 10
VAN SCHAARDENBURG 0 4 (14%) 2
1995
Stanford Health MCDOUGALL1994 Mean 1.6 Mean 1.3 n.s. 10
Assessment
Questionnaire
Health Assessment VAN SCHAARDENBURG Improvement Improvement n.s. 2
Questionnaire 1995 (p<0.01) (p<0.01)
General health VAN GESTEL 1995 at 12 weeks (before tapering off) 0.23
significantly better in treatment group (+)Global sense of well­ HARRIS 1983 Mean: 32.6 Mean: 7.8 P<0.01 (+) 0.46being (percentage of
baseline)
Functional class MCDOUGALL 1994 No significant difference between groups
until year 10 (p<0.01) (-)
(Score 1 -5) MILLION 1984 2.6 3.2 n.s. 10
(Score 1 -4) HARRIS 1983 Not clearly reported, but difference at 24 0.46
weeks seems n.s.
Lansbury Index MCDOUGALL 1994 75.6 57.4 p<0.01 (-) 10
Larsen Score (measures KIRWAN 1995 0.02±0.43 0.30±0.52 p=0.004 (+) 2
joint destruction)
Number of inflamed MILLION 1984 N.s. difference between groups 10
joints
Disease Activity Score VAN GESTEL 1995 at 12 weeks (before tapering off) 0.23
significantly better in treatment group (+)
Radiographic scores: VAN SCHAARDENBURG Significant Significant n.s. 2
Joint space narrowing, 1995 progression progression
erosion score, and
number of affected
joints
Fractures MCDOUGALL 1994 31 patients 19 patients p<0.05 (■) 10
VAN SCHAARDENBURG 3 patients 1 patient 2
1995 (11%) (4%)
* (+)= significant in favour of treatment, (-)= significant in favour of control intervention
Discussion
Comparability
The comparability between the BSD and RCTs in this case study is clearly 
not satisfactory. It was difficult to judge whether the samples in the ESD 
and trials were similar. Firstly, the trials used different exclusion criteria,
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and it  is possible that patients who would have been excluded from trials 
were included in the ESD. Patients with contraindications to prednisone 
may in theory have been over-represented in the control group. Moreover, 
the ESD excluded a large number of patients who had been treated with 
prednisone before enrolment, which may have given rise to selection bias. 
Even baseline data were difficu lt to compare, as some trials excluded 
deaths and dropouts from baseline data presentation. McDougall used a 
matched study design, but did not account for other differences in the 
analysis, in particular a differential use of disease modifying drugs between 
the treatment and control groups.
Globally speaking McDougall’s results suggested that there might be no 
long-term benefit from the use of prednisone in RA, as for example 
indicated in the significantly poorer results on physician's global 
assessment after 10 years. McDougall followed patients from 1966, and 
most of the RCTs have been published in the mid-1990s. There was no 
directly comparable RCT in terms of length of follow-up. Million argued 
that their tria l tested two alternative long-term regimens for synovitis, not 
prednisone, and many of their patients either dropped out or moved on to 
a jo in t regimen. The 2-year trials (Kirwan, van Schaardenburg) were 
continuous trials and thus hardly comparable. The same applied to the 
remaining shorter-term trials.
Comparison of effect estimates
The incompatibilities in outcome measures across studies made any 
attempted comparisons difficu lt and synthesis impossible. The multitude 
of measures raises the possibility for selective reporting and thus reporting 
bias, which is d ifficu lt to assess. Similarly, trialists may have been 
tempted to perform multiple testing and thus could in theory achieve and 
report spuriously significant results. It would seem surprising if a clinical 
database like the one used by McDougall was not also recording grip 
strength for example. However, this was not reported.
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The between-group difference in mortality observed by McDougall after 10 
years was statistically significant, but the authors put this down to a 
difference in recruitment period between the groups. Mortality results 
could also be gleaned from van Schaardenburg’s trial, albeit that this was 
not reported as an outcome measure. Four control-group patients died of 
causes unrelated to the control treatment (chloroquine). During Million's 
10-year study, 17% (9/53) and 16% (8/50) in the treatment and control 
groups respectively died.
The comparatively low rates are noteworthy (McDougall: 42% and 54% in 
treatment and control group respectively). A simple explanation for the 
difference could be the age of patients, but this was impossible to 
determine, since Million only reported baseline data for patients 
completing the study. The difference in duration of illness prior to study 
enrolment (2-24 months in Million's study, and around 14 years in 
McDougall's) may indicate that the studies had indeed recruited patients 
from essentially different age groups. But it  is also possible that 
McDougall's sample contained more patients who were diagnosed earlier in 
life and that the difference in mortality was real.
As for more disease-specific indicators, McDougall observed a statistically 
significantly poorer Lansbury Index in the treatment group compared to the 
control group after 10 years (but not 5 years). Shorter RCTs indicated more 
positive results for the treatment group. For example, van Gestel’s 
treatment group fared better in terms of Disease Activity Score, but also 
Ritchie Articular Index, than the control group after 12 weeks' treatment; 
however, the difference disappeared after the treatment was tapered off. 
The most favourable result for prednisolone in terms of jo in t destruction 
came from Kirwan’s two-year study of continuous low-dose therapy. The 
number of inflamed joints rated in Million's study did not differ between 
groups after 10 years, regardless of whether patients were considered who 
followed the original regimen or patients who had moved onto a jo in t
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regimen. However, deaths and dropouts were not considered in the 
analysis. Results by van Schaardenburg were similar.
Global assessments of health and well-being showed no advantage of 
prednisone over control group outcomes in the BSD or a 2-year study by van 
Schaardenburg. However, this latter study was limited to elderly patients, 
whose co-morbidity may account for a considerable background level of 
poor health. Again, shorter trials by van Gestel and Harris showed more 
positive results for prednisone; this was similar to the findings by 
Stenberg’s cross over study of 90-day treatment periods. Patient-rated 
global assessment was significantly better during prednisone periods 
compared to placebo periods. However, this tria l also used a washout 
period, whereby 3 (14%) patients not responsive to a 14-day prednisone 
course were excluded from the trial. Also, a large placebo effect was 
observed, despite significant between-group differences.
During post-treatment follow-up periods, these positive results changed 
considerably in both van Gestel’ s and Harris’ studies. In the latter, the 
treatment group showed an improvement from baseline by +32.6% (5%CI: 
±16.5) after 24 weeks’ treatment, and a deterioration of -23.6% (5%CI: 
±20.2) from baseline only 8 weeks later. This rebound phenomenon may 
explain some of the lack of benefit seen in the 10-year studies which would 
have involved episodic rather than continuous treatment.
Inclusion /  exclusion criteria
Exclusion criteria in the RCTs - as far as stated - centred around the use of 
glucocorticoids within specified periods prior to study entry and conditions 
in which prednisolone would only be used with caution (e.g. renal 
impairment). Thus, neither of those criteria should have restricted the 
eligibility of patients considerably more than the BSD did. In fact, the 
latter had to exclude patients with incomplete data (4% of the study 
cohort). Perhaps the most restrictive exclusion criterion was used by van
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Gestel, who excluded all conditions and medications affecting bone mass, 
without having specified these further.
Inclusion criteria were relatively homogeneous between studies, except for 
van Schaardenburg's sampling of patients of 60 or more years of age.
Participation of patients and centres
McDougall presented a comparison between the patients included in their 
study and those excluded but registered on the source database. Despite a 
good match between the groups in terms of age, sex, age at RA onset, and 
some disease markers, there were several differences observed, e.g. 
matched subjects had significantly longer follow-up periods. They were 
also more likely to be treated with disease-modifying drugs. It is possible 
that the included and treated patients were referred earlier to the centre 
and thus more likely to have been started on prednisone after enrolment to 
the database (starting treatment before enrolment was one of the 
exclusion criteria).
McDougall, however, represented 50% of their region’s RA patients, despite 
being a single-centre study. Theirs was the only referral centre in the 
region, which raises the question of whether the remaining not-referred 
patients were systematically different from those included in the database. 
McDougall did not further comment on this. Neither did the RCTs allow any 
assessment of generalisability of their findings.
Adjustment for baseline differences in ESDs
In McDougall’s study, the baseline characteristics were remarkably similar 
between the two groups, including disease markers not matched for, such 
as functional class, Lansbury index, or erythrocyte sedimentation rate. 
However, the only presented significant difference - a greater likelihood in 
the treatment group of receiving disease-modifying drugs - was not 
adjusted for in the analysis.
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Follow-up
Of the 122 matched pairs of patients included in the ESD, only 77 and 70 
patients were followed-up for 10 years in the treatment and control group 
respectively. However, for some outcomes, data availability was even 
more restricted, e.g. Physician Global Assessment was only available for 55 
and 39 patients respectively. This further limits the generalisability of the 
case study, unless missingness can be shown to have been random.
In the other 10-year study (Million) 15% of patients died and a further 19% 
were lost to follow-up. None of them seemed to have been included in the 
analysis. Of an original 53 and 50 patients in the prednisone and rest/splint 
group respectively, 37 and 29 completed 10 years of treatment. Only 24 
(65%) and 22 (76%) of these stayed on the original programme, with the 
remaining patients having moved to combined treatment.
The loss to follow-up in most of the shorter RCTs was small. However, in 
van Schaardenburg’s study, 43% (12/28) and 39% (11/28) of patients moved 
from prednisone and chloroquine single-treatment respectively to various 
combined treatment options.
Contribution to effectiveness evidence
Similarly to the ESDs in case study 1, McDougall’s objective was clearly 
centred around assessing long-term outcomes, and the 10-year follow-up 
easily exceeded the duration of available trials, apart from the rather 
unusual tria l by Million. The confidence in the findings must, however, be 
limited for several reasons: firstly, this was a single-centre study based in 
an academic rheumatic disease unit, with thus limited generalisability. 
The long observation period of nearly two decades may also be detrimental 
to both generalisability and internal validity as management and 
assessment practices change. The control of possible confounding by 
indication was only managed by a matched design, and thus differences in 
supplementary treatments were not accounted for.
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The case of prednisolone for RA may be similar to that of dornase alfa for 
cystic fibrosis (except for the more detrimental side effect profile of the 
former): despite encouraging short-term evidence for the treatment, no 
RCTs have assessed the long-term benefits. The BSD assessed relatively 
older and much longer-suffering patients than the RCTs, and observed them 
during normal clinical practice, regardless of duration or continuity of 
treatment. The authors caution against embracing long-term therapy, but 
have not clearly presented the outcomes for patients on continuous long­
term therapy (some 43% of patients used prednisolone for more than 5 
years), compared to maybe those with interm ittent treatment. This seems 
a lost opportunity, and it  is d ifficu lt to see what clear conclusions clinicians 
may be able to draw from the presentation of this study.
Concluding comments
Clearly this case study was not a success in terms of comparability of 
outcomes. However, some general lessons may be drawn from it. The 
generalisability of a single-centre BSD is by necessity severely limited, and 
it  may contribute little  to the effectiveness evidence base (apart from a 
one-centre case study). The example further highlights possible limitations 
of very long follow-up periods of ESDs: the patient cohort may change over 
time and this may impact on outcomes; similarly assessors w ill change and 
hence their potential consistency may suffer; lastly, treatment decisions 
(and hence patient selection for treatment) may change, e.g. due to new 
alternatives, and therefore may render the results ultimately irrelevant in 
a new context.
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7.5.6 CASE STUDY 4: Omeprazole, cisapride, ranitidine for 
gastro-oesophageal reflux disease (GORD)
The ESD by Eggleston et al. (1996) used the Mediplus® UK database, a 
commercially owned database used for marketing research. A random 
sample of patients on the study drugs was screened for patients with a first 
diagnosis of gastro-oesophageal reflux disease (GORD) (n=279). The study 
has only been published in abstract form. Further data were requested 
from the authors directly, but were said to no longer be available.
Of 17 trials included in a Cochrane review by van Pinxteren et al. (2001), 
eight could be included in the case study (see Table 7.27). The remaining 
nine trials used drugs or outcome measures not comparable with those in 
Eggleston et al. (1996).
Table 7.26: Criteria fo r inclusion of studies in Cochrane review by van 
Pinxteren e t al. (2001 )
Types of studies
Randomised controlled trials with a single- or double-blind design, in which one of the 
intervention types was contrasted with placebo or another intervention type.
Types of participants
Adults, both gender
Predominant heartburn (a retrosternal burning sensation), diagnosed as GORD or reflux­
like dyspepsia
Types of intervention
Short-term treatment (one to twelve weeks) with proton pump inhibitors (esopremazole, 
lansoprazole, omeprazole, pantoprazole and rabeprazole), HZ-receptor antagonists 
(cimetidine, famotidine, nizatidine and ranitidine) or prokinetics (cisapride, 
domperidone and metoclopramide).
Types of outcome measures
Primary: heartburn remission (defined as no more than one day per week with mild 
heartburn)
Secondary: (partial) symptom relief; quality of life
Treatment characteristics
Seven of the eight RCTs included in case study 4 assessed omeprazole, two 
each included ranitidine, and cisapride, and one cimetidine. Apart from
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Hallerback (1998), the double-blind period of all other RCTs lasted for at 
least 4 weeks. The ESD by Eggleston (1996) - which was only available in 
abstract form - did not describe the duration of treatment, nor the doses 
used; rather, outcome assessments were made dependent on the duration 
of the initial treatment with one of the study drugs.
Table 7.27: Treatments investigated by studies in case study 4
Study Interventions tested (daily dose)* Compliance
assessed
Duration of 
treatment 
(double-blind 
phase in RCTs)
EGGLESTON 1996 CIS, RAN, OME (doses unspecified) No Not reported
BATE 1996 OME (20mg) - Placebo Unclear 
(patients are 
excluded due 
to non- 
compliance)
4 weeks
BATE 1997 OME (20mg) - CIM (1600mg) Not reported 4 weeks
CARLSSON 1998 OME (20mg) - OME (lOmg) - Placebo 
(only endoscopy-negative patients 
randomised to placebo)
Not reported 4 weeks
GALMICHE 1997 OME (20mg) - OME (10mg) - 
CIS (40mg)
Yes 4 weeks;
(+ 4 weeks for 
those still 
experiencing 
symptoms)
HALLERBACK 1998 RAN (300mg) - Placebo Yes 2 weeks
HATLEBAKK 1999 OME (20mg) - CIS (20mg) - Placebo Not reported 8 weeks
RICHTER 2000 OME (20mg) OME (10mg) - Placebo Yes 4 weeks
VENABLES 1997 OME (20mg) - OME (10mg) - 
RAN (300mg)
Yes 4 weeks
* CIM=Cimetidine, CIS=Cisapride, OME=Omeprazole, RAN=Ranitidine
Sample selection
Only two RCTs reported the number of patients screened before 
randomisation; the majority recruited patients in primary care. The 
sample size varied from 209 to 994, with the ESD being one of the smaller 
studies.
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Table 7.28: Characteristics of included studies in case study 4
Study Countries
participating
Number of 
centres
Number of 
patients screened 
for inclusion
Number of
patients
included
EGGLESTON 1996 UK Not reported unknown 279
BATE 1996 UK/ Ireland 23 unknown 209
BATE 1997 UK 19 unknown 221
CARLSSON 1998 Australia, Holland, 
Norway, UK
36 unknown 538
GALMICHE 1997 France multicentre
study
unknown 424
HALLERBÀCK
1998
Sweden, Finland, 
Norway
21 441 427
HATLEBAKK 1999 Norway 65 573 483
RICHTER 2000 USA 36 unknown 359
VENABLES 1997 UK 106 unknown 994
Whereas Eggleston (1996) restricted their study to patients with the f irs t  
diagnosis of GORD, many of the RCTs specifically selected patients with a 
history of complaints lasting at least one or three months. Only a minority 
of studies used endoscopy to verify a diagnosis or exclude oesophagitis. 
Thus, some RCTs included patients with endoscopic abnormalities, whereas 
others excluded them.
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Table 7.29: Inclusion and exclusion criteria (case study 4)
Study Inclusion criteria Exclusion criteria
EGGLESTON 1996 Patients with a first diagnosis of
GORD occurring after 1.1.1993 and 
treated with any of the study drugs.
BATE 1996 18-80 years; heartburn as
predominant symptom; 
endoscopically verified normal 
oesophageal mucosa or erythema 
with no erosions.
BATE 1997 18-80 years; heartburn as
Recurrent diagnosis of GORD, H2- 
refractory GORD, referral prior to first 
treatment
Ulcer, duodenitis, angina, ischaemic 
heart disease, biliary disease, 
pancreatitis, inflammatory bowel 
disease (IBD), Barrett’s oesophagus, 
active gastro-intestinal (Gl) bleeding, 
varices, stricture, motility disorder, 
surgery, significant illness, omeprazole 
or H2 antagonists, anti-reflux drugs, 
warfarin, phenytoin.
CARLSSON 1998
Ulcer, erosive gastritis, duodenitis, 
predominant symptom in month prior angina, ischaemic heart disease, biliary 
to entry; heartburn on <2 or 7 days tract disease, oesoph. motility
before medication; normal oesoph. disorder, varices, stricture, surgery, H2
mucosa or oesophagitis without frank antagonists, lactose intolerance, 
ulcer. anticipated poor compliance.
18-80 years; history of upper gastro- Oesophageal ulcer or stricture,
intestinal symptoms for >3months; Barrett’s oesophagus, peptic ulcer
disease, history of oesophago-gastric 
surgery or Gl bleed
GALMICHE 1997
episodes of upper Gl symptoms 
occurring *2 days during the past 7 
days.
>18 years; heartburn as predominant Erosive oesophagitis with significant 
symptom >3 months; erosions, ulcer, stricture, Barrett’s
Normal or erythematous oesophagus oesophagus, complications of GORD, 
or non-circumferential erosive surgery, H2 antagonist or acid pump 
oesophagitis; heartburn on >2 days inhibitor use 
during last week of 2-week alginic 
acid run-in.
>18 years; presenting with reflux like Oesoph. stricture, Barrett’s 
symptoms (at least 2 of following: oesophagus, ulcer, varices
retrosternal burning pain, epigastric 
pain, fluid acid regurgitation.
HATLEBAKK 1999 18-80 years; heartburn as Severe oesophagitis, Barrett’s
predominant symptom for >3 months oesophagus, ulcer, gallstone, surgery, 
and a3 days in past week during 14 prokinetic or antisecretory drugs,
HALLERBÀCK
1998
days run-in.
RICHTER 2000
VENABLES 1997
alcohol misuse, concomitant disease, 
need for interpreter 
Conditions interfering with assessment 
of heartburn, ulcers, Gl bleeding, 
Zollinger-Ellison syndrome, 
pancreatitis, malabsorption, IBD, 
severe illness, PPI, H2-antagonists, 
anticipated need for range of 
medications, including NSAIDs 
>18 years; heartburn as predominant History of ulcer, oesoph. stricture, Gl 
symptom for >3 months; patients who surgery, severe illness, anticipated 
remained symptomatic after 2 weeks poor compliance 
run-in.
>18 years; history of heartburn >12 
months as predominant symptom of 
GERD and current episodes of 
moderate to severe heartburn on >4 
of 7 days prior to endoscopy.
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In most studies, the duration of symptoms suffered by the majority of 
patients prior to recruitment was over one year, for four studies the 
duration is not clearly reported (Table 7.30).
Table 7.30: Duration of symptoms at baseline (case study 4)
Study Duration of symptoms at baseline
EGGLESTON 1996 Unknown
BATE 1996 Unknown
BATE 1997 Mean circa 10 months
CARLSSON 1998 Majority >1 year
GALMICHE 1997 Majority >1 year
HALLERBÀCK 1998 Majority >1 year
HATLEBAKK 1999 Unknown, but inclusion criteria require minimum 3 months
RICHTER 2000 Seemingly majority >1 year
VENABLES 1997 Majority >1 year
Outcomes, analysis methods, and results
Table 7.31 presents the outcome measures used by the studies included in 
case study 4. The rather crude outcomes used in the ESD were based on 
medication use alone; they did not directly match any of the outcome 
measures presented in RCTs. Also these were not homogeneous, as some 
measured freedom from (one or more) symptoms, and others the 
proportion of patients suffering a defined maximum of symptoms on study 
completion (e.g. <=1 day with mild symptoms within one week).
Given the brief abstract publication, Eggleston reported only percentages 
of outcome occurrences in each group of patients. Neither p-values or 
confidence intervals, nor statistical control of potential confounders were 
available from the publication.
For efficacy outcomes, the RCTs had on the whole used simple analysis 
methods and statistical testing for comparisons of outcomes between the 
different treatment and control groups. In addition, some had used 
longitudinal analysis methods for particular outcomes, or regression 
analysis methods to identify factors associated with particular outcomes.
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Table 7.32 presents the results of outcome measures related to those used 
in the ESD by Eggleston et al. (1996). For a quantitative comparison, the 
odds ratio (OR) for Eggleston’s results was assumed as 1.0, based on their 
statement: “ in each group -half of the pts received medication for 1mo” 
(data were requested from the authors but not made available). This was 
compared to a pooled OR of 4.94 (Cl: 3.43-7.16). Figure 7.3 shows the 
results of cisapride vs. omeprazole in a L’Abbé plot.
Table 7.31: Outcome measures used by studies in case study 4
Study Outcome measures
EGGLESTON 1996 
BATE 1996
BATE 1997 
CARLSSON 1998
GALMICHE 1997
HALLERBÀCK 1998 
HATLEBAKK 1999
RICHTER 2000
VENABLES 1997
success rates = reflux medication prescribed for <=3 months;
failure rates = switch of prescriptions in first 3 months or subsequent
reflux prescriptions for >3 months;
relapse rates in 6 months in successfully treated patients
Proportion of patients without heartburn, regurgitation and other
symptoms
Proportion of patients without symptoms
Odynophagia
Psychological well-being
Proportion of patients free of heartburn
Proportion of patients in remission of heartburn
Complete relief of upper gastro intestinal symptoms
Sufficient control of symptoms
6-month relapse rate
Quality of life
Effective resolution (<1 day with mild episodes of heartburn during 
last 7 days)
Complete absence of heartburn in past 7 days 
Quality of life
Complete symptom relief (=all reflux symptoms ceased)
Improved (=fewer symptoms)
Responders (=satisfied with improvement)
Adequate control of heartburn (<1 day with no more than mild 
heartburn in 7 days before 4-week visit)
Antacid consumption
Severity and number of days with heartburn in 7 days before each 
visit
Severity of other (specified) symptoms 
Adverse events
Complete resolution of heartburn 
Proportion of patients with no heartburn on each day 
No heartburn for 7 days prior to evaluation 
Severity of other (specified) symptoms
Relief of heartburn after 4 weeks treatment (<1 day of mild symptoms 
in last 7 days)
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Table 7.32: Results of studies in case study 4
Study Outcome measures Results
EGGLESTON 1996 “Success rates”
(medication for <3 months)
OME: 75%; CIS: 70%; RAN: 79%
"In each group, about half of the patients received medication for <1 month."
BATE 1996 Symptom-free after 4 weeks OME20: 43%; Placebo: 14%
BATE 1997 Patients in remission of heartburn at 
4 weeks
Patients reporting no heartburn in 
past 7 days after 4 weeks
OME20: 66%; CIM1600: 31% 
OME20: 56%; CIM1600: 24%
CARLSSON 1998 “complete relief” after 4 weeks
“sufficient control of upper gastro­
intestinal symptoms” after 4 weeks
OME20: 41 (CI:34-48)%; OME10: 35 (Cl: 29-42)%; 
Placebo: 19%
(only endoscopy-negative patients randomised 
to placebo group!)
OME20: 73 (Cl: 67-79)%; OME10: 62 (Cl: 55- 
68)%; Placebo: 35%
(only endoscopy-negative patients randomised 
to placebo group!)
GALMICHE 1997 Complete absence of heartburn in 
past 7 days at 4 weeks
OME20: 55%; OME10: 42%; CIS40: 29%
<1day with mild heartburn in past 7 
days
OME20: 65 (Cl: 57-73)%; OME10: 56 (Cl: 48- 
64)%; CIS40: 41 (Cl: 32-49)%
HALLERBÀCK 1998 Complete symptom relief after 2 
weeks
RAN300: 41%; Placebo: 32% (no significant 
difference)
HATLEBAKK 1999 Adequate control of heartburn at 4 
weeks
OME20: 71 (Cl: 64-78)%; CIS20: 22 (Cl: 15-29)%; 
Placebo: 18 (Cl: 12-24)%
RICHTER 2000 
VENABLES 1997
Complete resolution of heartburn for OME20: 48%; OME10: 27%; placebo: 5% 
a whole week at week 4
<1 day of mild symptoms of OME20: 61%; OME10: 49%; RAN300: 40% 
heartburn in week 4
EGGLESTON 1996 Relapse rates at 6 months OME: 37%; CIS: 23%; RAN: 52%.
CARLSSON 1998 6-months relapse rate 83% of 268 OME patients entering follow-up 
phase
CIM=Cimetidine, CIS=Cisapride, OME=Omeprazole, RAN=Ranitidine
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Figure 7.3: Percent of patients w ith adequate control of heartburn 
after 4 weeks of omeprazole or cisapride
60
Egglestoi
Galmichi40
30
Hatlebakkl
20 40
Omeprazole
80
Outcome measures presented:
Hatlebakk <=1 day in past 7 with mild symptoms
Galmiche No heart burn in last week
Eggleston_____Medication for <=1 months__________
Notes: Numbers in Eggleston had to be estimated (see text).
Size of points is proportional to size of study population.
Figure 7.4: Odds ratio meta-analysis plot of RCTs of 4-week outcome 
for omeprazole vs. cisapride, favouring omeprazole
HATLEBAKK
GALMICHE
combined [fixed]
Odds ratio meta-analysis plot [fixed effects]
8 56(5.03, 14 61)
2.70(1.58, 4.62)
4.83 (3.40, 6.85)
1 ------------------------ 1-------------------- 1---------------------------
2 5 10
odds ratio (95% confidence interval)
100
Note: ORs and CIs here are based on Mantel-Haenszel estimates.
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Discussion
Comparability
The outcomes assessed in the ESD were not easily comparable with those 
from the available RCTs, mainly because Eggleston used a 3-month cut-off 
for defining treatment success, and moreover defined this by a lack of 
further treatment. The selection criteria of this ESD were also more 
restrictive than those used in trials, as only new cases of GORD were 
included. The samples could not be compared because baseline data were 
not available in Eggleston’s abstract. Eggleston also reported no statistical 
adjustment for any possible baseline differences.
Comparison of effect estimates
Relative outcomes could only be compared between omeprazole and 
cisapride groups. From Figure 7.3 above it  can already be gleaned that the 
effect size between those drugs was much larger (in favour of omeprazole) 
in the RCTs (Galmiche, Hatlebakk) than the ESD. As for absolute success 
rates, one might have assumed that Eggleston’ s outcome of “ about half”  of 
the patients in each group having received medication for <1 month means 
that -50% of each group were completely free of symptoms after 1 month. 
If so, this compared reasonably well with the success rates achieved by 
omeprazole in the RCTs, particularly omeprazole 20mg. The dose of 
omeprazole used in the RCTs was either 10 or 20mg, however, a dose of 
10mg is recommended only for ulcer relapse prevention (British National 
Formulary 2003), and it  is therefore conceivable that patients included in 
Eggleston’s study have used higher doses at least for their initial 
treatment. However, for cisapride and ranitidine the relevant RCTs quoted 
considerably lower success rates than 50% (Galmiche: CIS (40mg): 29%, 
Hallerback: RAN (300mg): 41% (after 2 weeks), Hatlebakk: CIS (20mg): 22%, 
Venables: RAN (300mg): 40%).
Given that the Mediplus database recorded prescriptions rather than actual 
medication use, it  would have been reasonable to expect a greater rate of 
drop-out than might be observed in a closely monitored RCT. If so, the
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outcome measure “ discontinuation of prescriptions”  would have over­
estimated the drug effectiveness. It was interesting, however, that the 
absolute effectiveness estimates varied less between the study types than 
the relative success of omeprazole and cisapride. One possible explanation 
would be a differential dropout between the two drugs in the ESD (i.e. 
cisapride being more likely to be discontinued before symptoms are 
controlled).
The validity of the measurement of the intervention is also threatened by 
the practice of prescribing and using medications. It is possible that 
patients spread a month's medication supply over a longer period by using 
it  less frequently than prescribed. The renewal of the prescription would 
not appear on the system for longer than expected. Thus when it  does, it  
might mistakenly be considered as a new prescription and counted into the 
relapse rate.
Indeed the difference in relapse rates for omeprazole between Eggleston 
(37%) and Carlsson (83%) was remarkable. Both studies followed up 
successfully treated patients for 6 months. Obviously, Carlsson and 
colleagues followed patients actively by phoning them, and this could 
explain some if  not most of the differential. A possible explanation is that 
Mediplus might have missed patients whose symptoms have reoccurred, 
e.g. if  symptomatic patients did not seek further medication within 6 
months. A further possibility would be that the patients were essentially 
different in both studies. Whereas Eggleston included only patients with a 
first diagnosis, most of Carlsson's patients had suffered symptoms for more 
than one year. Eggleston did not, however, report duration of symptoms.
Inclusion / exclusion criteria
All studies seemed to have sought to recruit patients with uncomplicated 
GORD. Eggleston and colleagues limited their sample to patients with a 
first diagnosis of GORD (it is unclear how far back the authors were able to 
verify the GORD-free status of included patients). Particularly with first
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diagnoses, there is room for misdiagnosis, and affected patients may have 
stopped their GORD medication early and have been considered as 
successfully treated. It seems likely that the population sampled in RCTs 
was different, because it  included patients with repeat-diagnosis of GORD. 
Thus the inclusion criteria of the ESD seemed more selective, which may 
seem surprising, but was an attempt to avoid the need for taking account 
of this particular baseline difference.
Eggleston used a limited set of exclusion criteria compared to RCTs. It is 
conceivable that some of the possible misdiagnosis in the ESD might have 
been avoided by excluding differential diagnoses. The exclusion criteria 
used in the RCTs varied inasmuch as some RCTs have excluded most 
conditions which could have caused symptoms similar to heartburn, 
whereas others have not explicitly done so.
Participation of patients and centres
Table 7.28 gives an indication of the number of centres involved in the 
various studies, which range from 19 to 106. Only Eggleston and Galmiche 
did not report the number of centres involved. Apart from Eggleston, three 
RCTs recruited patients in primary care (Carlsson, Hatlebakk, Venables), 
and Bate 1996 used both primary care and hospitals as recruitment source. 
Bate 1997 was the only study having recruited only from hospitals. The 
remaining three studies (Galmiche, Hallerback, and Richter) did not report 
the source of recruitment.
It is interesting to note that - probably due to the random sampling of 
eligible patients - the number of patients included in the ESD was amongst 
the smallest of all comparison studies; this may have been because the 
study was essentially undertaken as the basis for a cost analysis and 
therefore only a random sample of eligible patients was included. 
Together with most RCTs, Eggleston did not report the number of patients 
screened for inclusion.
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Adjustment for baseline differences in ESP
The abstract by Eggleston did not report any adjustment for baseline 
differences, but a subsequent cost-effectiveness study by the same authors 
- which may have referred to this study - noted that the comparison groups 
were similar in terms of age, gender, and co-morbidity with other forms of 
gastrointestinal disease (Eggleston et al. 1998). It is of course not possible 
to say whether there were other confounders which related both to a 
physician's choice of first-line treatment as well as the outcome. Any 
perception of severity may have been a serious confounder, as omeprazole 
may have been chosen for more severe cases.
Follow-up
In this case study, the follow-up of patients was comparable between ESD 
and RCTs.
Contribution to effectiveness evidence
Eggleston and colleagues did not set a concrete study objective; rather 
they claimed to be undertaking an "hypothesis-generating exercise". They 
avoided any claim of providing either efficacy or effectiveness evidence, 
but concluded that “ there is t it t le  evidence to support a hypothesis o f 
differences in response rates...” . Thus, the extraction of any effectiveness 
evidence from the study may have been unjustified. Interestingly, all 
comparable trials post-dated the ESD (previous trials mostly included 
different drugs or placebo control groups).
In 1998, a meta-analysis of the same three drugs investigated by Eggleston 
for GORD was published (Iskedjian Et Einarson 1998); the study was funded 
by the Canadian branch of the same pharmaceutical company as Eggleston 
(which markets cisapride). The review concluded that omeprazole was the 
treatment of choice, but suggests that (an unusually high dose of) 80mg 
cisapride was most effective in mild cases. Four-week cure rates for 
cisapride were not analysed due to lack of raw data. The analysis has, 
however, neither assessed quality nor heterogeneity. A meta-analysis of
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treatments in more severe GORD concluded that proton pump inhibitors 
were more effective than H2-receptor antagonists and cisapride in terms of 
their overall healing proportion: 83.6% [Cl: 79.2-88.1], 51.9% [Cl: 46.9 - 
56.9] and 37.9% [no Cl reported] respectively (Chiba et a i  1997). 
However, comparisons were made between rather than within studies. The 
later Cochrane review (van Pinxteren et al. 2001) concluded that “ when 
patients are selected prim arily  based on symptoms (i.e. heartburn meeting 
certain crite ria) and diagnostic probability o f GORD is high, proton pump 
inhibitors are superior to both H2-receptor antagonists and prokinetics in 
achieving heartburn remission” . PPIs are now firm ly established as first- 
line treatment for GORD (National Institute for Clinical Excellence 2004). 
Thus, the hypothesis of equal response rates raised in the Eggleston study 
was not confirmed subsequently.
Eggleston and colleagues stressed the fact that their data were primary 
care based, rather than having assessed treatments in specialist centres 
which is usual for clinical trials. Indeed, the three RCTs undertaken in 
primary care were published after Eggleston’s study (Carlsson, Hatlebakk, 
Venables). However, GORD severity may be more likely to account for any 
difference in findings, than treatment setting. Galmiche's RCT suggested 
that the relative efficacy of omeprazole vs. cisapride was higher in the 
presence of oesophagitis.
Outcomes assessed by GORD trials vary, and the Cochrane review authors 
have criticised the lack of comparable and meaningful dichotomous 
outcomes, such as cure rates (van Pinxteren et al. 2001). This means that 
several studies have been excluded from both the Cochrane review as well 
as this case study on the basis of their outcome measures. Arguably, cure 
rates are meaningful, since if no total symptom relief is achieved, 
treatment switches or further investigations are initiated in practice. This 
is highly relevant in terms of determining the overall costs (to patients and 
the health service) of different treatment options.
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Eggleston's cost analysis of the three comparison drugs (Eggleston et al. 
1998) argued that on the basis of the 6-month cost being cheapest for 
cisapride, this should be the first-line treatment of GORD. However, this 
cost study did not mention patient outcomes and assumes equivalent 
effectiveness of the three drugs, based on the very ESD, despite having 
claimed there that this was merely a hypotheses-generating exercise. 
Referring to the ESD, the background section of the cost study concluded 
by saying “ given such therapeutic equivalence i t  is appropriate fo r  this 
analysis to concentrate on identifying the strategy tha t achieves this 
common outcome w ith the lowest consumption o f scarce health care 
resources.”  (Eggleston et al. 1998 p.14) However, the cost study and its 
conclusions (suggesting a step up approach of treatment) were in 
contradiction with several other publications and have been criticised by an 
evidence-based healthcare review (Bandolier 2002).
Concluding comments
In summary, the database study by Eggleston provided probably more 
confusion than enlightenment to the body of effectiveness evidence of 
GORD treatments. Whereas it  claimed to be hypothesis generating, the 
authors have based a cost analysis in its findings. In the absence of any 
consideration of possible confounding by indication or selection bias, 
presenting a primary care-based assessment (as opposed to specialist care) 
seems a comparatively minor contribution. A fu ll manuscript has never 
been published.
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7.6 Discussion
In the four case studies, it  was attempted to match ESDs with existing RCTs 
previously included in reviews by the Cochrane Collaboration. The 
comparison of results between ESDs and RCTs did not show any systematic 
difference in terms of effect estimation. This is perhaps unsurprising, 
given the findings of recent systematic reviews of randomised vs. non­
randomised study designs (Britton et al. 1998; Mac Le hose et al. 2000). 
There was no indication that ESDs over-estimated the effectiveness of an 
investigational drug, relative to the RCTs’ conclusions.
One may assume that ESDs outweigh some of their potential methodological 
shortcomings with a larger sample size and longer follow-up. In the four 
case studies, most ESDs were considerably larger than comparable RCTs. 
Particularly those ESDs based on the NRMI-2 and GPRD belong to the largest 
identified (Tiefenbrunn, van Staa). By contrast, Eggleston’s was a very 
small ESD, particularly given that the source database (Mediplus UK) would 
have permitted a much larger study.
Case study 1 illustrated the diverse nature of ESDs: whereas van Staa 
included nearly 16,000 patients from the GPRD, Sebaldt reported on a 3- 
year follow-up of a mere 61 patients in a single centre - still more patients 
than were included in comparable RCTs. Nevertheless, these two examples 
demonstrate the potential problems with these two extremes very well. 
On the one hand, a cottage industry of single-centre databases with little  
outside involvement or quality control and potentially poor broader 
representativeness probably adds little  to a body of effectiveness evidence. 
On the other hand, a large non-disease specific database such as the GPRD 
or Mediplus present inevitable limitations in data quality, definition and 
completeness.
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The definition of outcome variables is critical to an ESD. This, however, is 
inevitably very challenging for effectiveness studies of databases which 
were essentially designed to identify adverse drug reactions (such as the 
GPRD). However, this is not to say that subject-specific databases are 
necessarily any better equipped with good quality outcome variables (as 
the ERCF case has shown).
In terms of follow-up, both ESDs in case study 1 offered follow-up periods 
of up to around 3 years, which exceeded those of comparison RCTs (max. 2 
years). Case studies 4 and 2 involved suitably short follow-up periods in all 
included studies. However, in case study 2, the ESD had to restrict its 
sample selection based on the availability of a suitable follow-up period for 
each patient. Patients transferred within 48 hours of having received the 
intervention had to be excluded to avoid missing outcomes data. The 
authors were, however, able to offer a comparison between patients who 
were transferred early and those included in the study. The ESD in case 
study 3 differed from included RCTs not only in terms of a longer follow-up 
of the ESD, but also inasmuch as it  observed interm ittent use of the 
interventional drug over 10 years, rather than continuous use as was 
assessed in most RCTs. The only RCT of comparable duration to the ESD 
was rather different in the nature of its comparison treatments. Thus, 
ESDs did not offer outstandingly longer follow-up than comparison RCTs. 
However, it  may be argued that with ongoing data collection in longitudinal 
databases, the available follow-up periods w ill increase in future.
Another point on which ESDs are often defended is their likely inclusion of a 
broad range of patients not normally represented in RCTs. The ESDs 
included in the four case studies offered little  direct discussion of this 
point. Eggleston included so few patients of the large Mediplus UK 
database that it  is questionable that their sample was representative of 
primary care practice in the UK. Similarly, McDougall was based on data 
from only one tertiary centre, which may not have been comparable to 
other centres or primary care. By contrast, van Staa's study based on the
312 Use of Databases in Drug Effectiveness Studies
Comparisons of ESDs with RCTs
GPRD included all primary care patients prescribed the investigational drug 
of several dozen practices across the UK, which is arguably one of the most 
convincing sources of data from everyday clinical practice.
The database used by Tiefenbrunn also included data from some 14% of US 
hospitals, but despite efforts to represent normal clinical care (e.g. by 
excluding patients enrolled in the large GUSTO trial) the database was 
somewhat biased towards hospitals with coronary interventional facilities 
(Rogers et al. 1994). This probably mattered less for a study testing an 
interventional cardiological therapy, as non-interventional centres would 
automatically be excluded. The generalisability to a naturalistic setting is 
primarily determined by the source database, and as more and better 
quality routinely-collected data become available, for example through the 
UK NHS’ Connecting for Health information technology programme, ESDs 
could become more able to reflect treatment use and outcomes in 
everyday practice. Having to fall back on prescription use as an outcome 
measure w ill hopefully become a thing of the past.
The representativeness of the sample compared to a desired target 
population can be strengthened by broader inclusion criteria and assessed 
through reported baseline characteristics. Here one would expect ESDs to 
include more severely ill, maybe multi-morbid, older patients than RCTs. 
Indeed van Staa (case study 1) and Tiefenbrunn (case study 2) included 
more women than comparable RCTs, van Staa included older patients, and 
Tiefenbrunn more patients with previous AMI. McDougall (case study 3) 
included patients with far longer disease history (pre-study entry) than did 
comparison RCTs.
This chapter also explored issues regarding the potential contribution of 
ESPDs to a body of effectiveness evidence. Two questions may be asked: 
(1) is it  possible to control alternative explanations for the findings of an 
ESPD (in particular bias and confounding), and (2) can ESDs provide 
evidence for causality?
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The case studies identified typical sources of observation bias in ESDs, in 
particular detection bias, and attrition bias (caused by differential dropout 
rates between study groups). In addition, longitudinal databases may be 
subject to bias through the use of historic controls, cohort, age, and 
survivor effects. Detection bias is minimised in investigations of 
unanticipated or unambiguous outcomes (such as mortality). This is not 
always the case in ESDs. Attrition bias is also not always possible to 
account for in a retrospective database. These biases potentially lead to 
over-estimation of treatment effects, whereas non-differential under­
reporting may lead to under-estimation.
There are several statistical methods available for adjusting for 
confounding, and together with sensitivity analyses, these may reassure 
readers that sufficient control has been applied and results are robust, 
particularly if  valid and reliable measures of all known confounders were 
available.5 However, adjustment is no guarantee of fu ll control of all 
possible confounders. Thus, some threats to validity are impossible to 
control, even with perfect data quality.
Whereas the question of whether suffic ient control through adjustment is 
possible is beyond the scope of this thesis, the case studies support 
suggestions from the existing literature that congruence with RCT results is 
frequently the case. However, comparisons were complicated by 
differences in outcomes, selection criteria, and follow-up.
On the question of positive evidence for a causal relationship measured on 
the criteria of chronological relationship between cause and effect, the 
strength of a relationship, a dose-response relationship, consistency, and 
specificity (Elwood 1998), ESDs offer considerable potential, at least in
5 To the average reader, the quality of the adjustment may be secondary to it having 
taken place, as the sophistication of adjustment methods has surpassed the level of 
his/her understanding. A publication in a reputable journal may be seen as sufficient 
justification to take the results seriously.
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theory. The chronological relationship between drug intervention and 
outcomes is usually easily established, particularly where ESDs are also in a 
position to determine previous exposure to the investigational drug. If 
under-reporting (resulting in under-estimates of the true effect) is indeed 
the main validity problem, a highly significant effect can provide strong 
evidence. Comprehensive databases should be able to assess possible dose- 
response relationships as patients are receiving the investigational drug 
over varying periods and in varying doses. Finally, size of and variability in 
the sample may provide for the assessment of consistency and specificity of 
results. Thus, ESDs should aim to provide evidence for causality in practice 
by demonstrating how they meet these criteria.
7.6.1 Methods and limitations
The incompatibility of outcome measures limited the comparability in some 
case studies. For example, of 17 trials included in the Cochrane review by 
van Pinxteren et al. (2001), nine could not be included in case study 4, 
because they used outcome measures not comparable to those used in the 
ESD. Outcome measures used in trials were clinical parameters and 
measurements which the prescription database used by the ESD (Mediplus 
UK) would not have been able to collect.
Strictly speaking, no case study fulfilled all the criteria for comparability 
(outcome measures, population, intervention, selection criteria, 
adjustment for confounding in ESD), and comparability is at times difficult 
to judge due to limited data presentation.
The comparison RCTs were exclusively drawn from existing Cochrane 
reviews. Whereas this meant a timely close proximity with the ESDs, newer 
trials might have been missed. Similarly, trials excluded by the Cochrane 
reviewers could have been missed. This seems possible in theory in case 
study 3 (amongst the studies excluded by the Cochrane review are four 
further potential candidate RCTs [excluding continuations of earlier trials],
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but they are early trials of analgesic treatments and unlikely to include 
comparable outcomes).
There are limitations to the usefulness of such comparisons, since they test 
the validity of an ESD against the standard of an RCT. It might be argued 
that the validity (external, but also internal) of an ESD cannot be measured 
satisfactorily against an RCT, because the nature of the hypothesis should 
differ. Thus, one is looking for an indication that an ESD assesses a 
distinctly different hypothesis, e.g. one aimed at effectiveness rather than 
efficacy. A meaningful difference between both study designs (in terms of 
generalisability to a naturalistic situation and defined target population, 
and follow-up) thus should be expected.
For the assessment of the quality of ESDs, a checklist was used, which was 
based on instruments designed for the quality assessment of non­
randomised studies as well as suggestions from the literature. The 
checklist focused on internal and external validity, data processing, 
analysis, and reporting. This currently rather lengthy list offers a basis for 
the development of an assessment instrument suitable for ESDs. In both 
quality assessment and data extraction, it  would have improved the validity 
of this review, if  a second researcher had been available to double-check 
extracted data and rate the quality of the studies.
Lastly, only very limited numbers of outcomes were compared for a small 
number of case studies, and therefore the findings cannot be considered 
conclusive.
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7.7 Concluding remarks
The four comparison case studies offer no support to the claim that 
observational studies tend to over-estimate effectiveness. Their actual 
comparability was limited due to differences in outcome measures, or 
patient selection criteria, which may explain some of the differences in 
results. The included ESDs were not always clear about their hypothesis 
and thus their proper contribution to effectiveness evidence. In 
retrospect, none of the ESDs seem to have been seminal studies in building 
the relevant evidence base.
ESDs presented considerable scope for biases and may have been unable to 
control fully for confounding by indication. They were essentially plagued 
by the pre-existing nature of the databases used. This meant that they had 
no control over data collection or data quality, except through adapting 
their own study design to accommodate known limitations. However, 
complete adjustment for confounders may be an illusion, and as a 
minimum, the extent of uncontrolled confounding should be estimated.
There is an urgent need for stricter quality controls on the conduct and 
reporting of ESDs from all sources, particularly industry, as the potential 
for misuse and misinterpretation of data and analyses is currently far 
greater than necessary, given even the existing methodological knowledge. 
More methodological research is needed to improve the validity of ESDs, 
bearing in mind that RCTs may not always be the best test of validity. The 
goal has to be to improve confidence in ESD results particularly where no 
RCTs are possible.
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This chapter draws out the methodological findings from the Dornase Alfa 
Case Study and reviews presented in previous chapters, and highlights how 
they have contributed to the existing body of knowledge; the chapter falls 
into the following sections:
8.1 Databases for ESDs
8.2 Design and analysis issues for ESDs
8.3 Generalisability
8.4 Data protection
8.5 Next steps for ESDs
Much previous work has focussed on databases, rather than effectiveness 
studies based on the analysis of their data. This thesis clearly presents a 
further step in as much as it  explored the detailed methodological issues 
incurred in the use of databases for effectiveness evaluations of drug 
treatments.
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8.1 Databases for ESDs
The Review I have undertaken suggests a recent rise in actual publications 
of ESDs in high-quality peer-reviewed journals (those included in the 
Abridged Index Medicus). The first identified study was published in 1989, 
and nine of the included 42 studies were published in 2001 alone (the last 
complete year included in the search). This underlines the importance of 
methodological efforts to improve the quality of such studies. In this 
section, I focus on the role of databases in this endeavour. The main 
attention has to be on improving data quality and completeness, reducing 
opportunity for bias, and improving the control of confounding by 
indication.
The vast majority of studies identified in the Review were retrospective 
and used pre-existing databases. Some of these were disease-specific and 
may or may not have been collated with particular research hypotheses in 
mind. Other databases used were generic large data sources collated for 
different purposes such as claims management or primarily for the 
identification of adverse drug events (such as GPRD). Such generic data 
sources inevitably lack variables needed for a comprehensive analysis of a 
particular hypothesis; authors have at times resorted to the use of 
approximate measures (such as occurrences of prescriptions). This 
invariably results in potential biases. However, even disease-specific 
databases do not guarantee the availability of well-defined and high quality 
variables, as the Dornase Alfa Case Study demonstrated. This was despite 
the fact that this was essentially a post-marketing database for dornase 
alfa, and relevant specific research hypotheses would have been 
anticipated.
Therefore, the quality control of key variables is absolutely vital in 
databases. The ERCF collected a vast number of variables; only some were
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subject to routine quality control processes. For a small number of key 
variables, we were able to undertake a data validation against existing 
clinic information. Enthusiastic database initiators are understandably 
keen to include a large number of variables to test a range of foreseeable 
(or un- foreseeable) hypotheses later. However, for effectiveness 
hypotheses, and particularly where only a moderate effect size has to be 
expected, attention to data quality must be given priority over including a 
large number of variables.
The availability of variables in the source database is a key determinant of 
the success of an ESD. Where studies are forced to use proxy measures for 
exposure, such as prescription records, the exposure measurement loses 
precision. In some reviewed studies, even outcomes were assessed through 
prescriptions rather than clinical parameters, for example in Eggleston's 
study of GORD, and several others assessing antibiotics in acute infections 
(Bowman, Huang, Lawrenson). The validity of such outcome measures 
depends on how closely a new or alternative prescription represents 
“ treatment failure" (and no new prescription represents “ cure” ). This 
would depend on the inevitability of treatment (e.g. non-drug alternatives 
may be used but not recorded), the likelihood of patients to seek 
treatment, and to seek it  at the same source, and the required follow-up 
period (and danger of differential follow-up, e.g. due to side effects). 
Non-disease specific databases are unlikely to have recorded the indication 
and rigorous outcome variables for many treatments they may record. This 
severely limits their potential use in ESDs. Any databases should ensure 
that the link between diagnosis /  indication and treatment can be clearly 
established for subsequent analysis.
This implies that we should be concerned about the use of non-treatment 
specific databases in the evaluation of drug effectiveness, since their scope 
for sufficient attention to data quality w ill be severely limited - 
notwithstanding their possible lack of appropriate variables in the first 
place! This is, however, what is proposed by some in the HTA community
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(Rawlins 2008). This does not negate the value of such data sources for 
HTA, but their potential to generate effectiveness evidence for drug 
treatments may still be limited. Similarly, the NHS “ Connecting for 
Health" IT programme may be raising hopes one day to be able to use vast 
amounts of routinely collected data for outcomes research on a population 
basis. In the case of evaluating most drug treatments, particularly on what 
are often moderate or long-term effects, this hope may be considerably 
misplaced.
Having just emphasised the importance of data quality, it  was both 
surprising and disappointing that many reviewed reports did not describe 
data quality in any meaningful detail. Given the multitude of data quality 
problems identified in the ERCF (despite the detailed data quality 
assurance processes in place there), this is one of the most serious 
shortcomings of existing ESDs identified by the Review. Since this work was 
undertaken, more guidance on the conduct of databases has become 
available, notably through work by the Agency for Healthcare Research and 
Quality (Gliklich Et Dreyer 2007). However, guidance on reporting ESDs 
already existed and was clearly not heeded. Therefore, more effort needs 
to be invested in the short-term into ensuring that databases - and 
particularly those subjected to ESDs - conform to existing guidance, and 
can objectively demonstrate compliance. The DoCDat directory in the UK 
may present a resource for supporting such assessments. It currently 
assesses the quality of databases registered on DoCDat, but this assessment 
relies on interviews and does not seem to be verified.
The Review noted that some databases have already been used for several 
publications of drug ESDs, sometimes by the same or a similar group of 
authors. The setting up of an ESD involves much work in terms of 
negotiating access, validating and processing data, and exploring 
possibilities for analysis. Therefore, it  seems likely that once these 
preparatory stages have been passed through successfully, several studies 
are run on the same database by the same group of researchers. It remains
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unclear whether many databases are never used for effectiveness studies, 
or to what extent they may have been subject to failed attempts of 
undertaking such studies. None of the studies identified used any of the UK 
databases registered by DoCDat. Raftery et al. (2005) also identified a 
minority of studies having used UK databases for effectiveness research, 
usually evaluating non-drug treatments.
This raises the issue of access to databases for research / HTA. As the 
Dornase Alfa Case Study showed, there are many players who have interests 
to protect and who may influence the decision of whether to undertake an 
ESD or give permission for such a study: pharmaceutical companies, the 
organisation funding the database (which may be a pharmaceutical 
company), staff responsible for the database, and the clinics providing data 
which may give insights into variations in patient care. In the case of the 
ERCF, clinicians and researchers responsible for the database had a strong 
interest in protecting its credibility. This was compounded by the fact that 
further funding for the database was being sought on the basis of arguing 
for its use as a research tool. Many ESDs were published by researchers 
involved with the database and/or regularly involved in analysing it, 
suggesting that the use of databases may remain limited to a core group of 
individuals. Apart from wishing unfavourable outcomes not to become 
identifiable, clinicians may prefer data not to be made available to outside 
research teams, as they may wish to conduct research themselves. A 
current example is the bariatric surgery registry - a collaboration between 
professional organisations and a commercial company - which is unwilling 
to open the database to NHS researchers.
Whereas this did not apply in the ERCF, it  is possible that patients may also 
prefer certain hypotheses not to be addressed, as they may risk losing a 
favoured treatment option. This may be particularly relevant when cost- 
effectiveness evaluations are proposed, as in the case of lysomal storage 
disorders, where both patients and clinicians are currently actively 
undermining such a study. Database funders and operators should clarify a
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priori the access conditions and rights for outside researchers. This process 
needs to take account of consent from contributing clinicians and patients 
if  necessary (see later section on data protection).
It was not possible in the Review to assess the magnitude of any publication 
bias, albeit that such a bias is highly likely. A majority of studies presented 
significant findings, and whereas overall not many studies were directly 
funded by the pharmaceutical companies marketing the investigational 
drug, no study showing negative results for an investigational drug had 
received direct funding from the relevant company. Of course, the issue of 
publication bias is more complicated in the case of BSD: there may be a 
bias towards publishing significant results, which could be significant in 
either direction. However, if  the results do not concur with those of 
randomised trials, these studies are often criticised for confounding by 
indication, and this may present a barrier to publication. In the UK, the 
DoCDat directory of databases reports publications from registered 
databases but is not complete and does not record non-published analyses. 
If it  did, it  could theoretically assess publication bias at least of UK-based 
ESDs (if any were indeed undertaken on UK databases!).
The Dornase Alfa Case Study identified some very specific lessons for 
routine data audits, data cleaning and data verification processes. 
Comparisons with original records, such as in the DQR, are important in 
estimating the extent of possible errors. Databases should therefore plan 
such verification processes from the outset and should ensure that they are 
undertaken periodically. Similarly, routine data checks can be pre-planned 
and supported with appropriate variables for cross-referencing. Data 
audits need to include routine comparisons between centres to identify and 
subsequently assess any systematic differences between data from 
different centres.
However, researchers also need to understand the entire process of data 
collection before they can make assumptions about the appropriateness of
324 Use of Databases in Drug Effectiveness Studies
Discussion
the data for any research hypothesis. Moreover, particularly in m ulti­
centre databases or for less clearly defined variables, data collection 
processes may be subject to assumptions and interpretations by people 
from a range of different perspectives (clinicians, database managers, data 
entry clerks, and not least researchers). Examples of resulting differences 
are the choice of lung function results reported by different centres in the 
Dornase Alfa Case Study, as well as the rather loose interpretation of what 
constituted “ exacerbations” . Database operators should therefore give 
careful attention to standardisation of data definitions and assess their 
reliability prior to implementation. Also, the Dornase Alfa Case Study 
identified that the motivation of contributing centres to contributing high 
quality data could have been improved. Incentives could be made 
dependent on data quality, particularly where contributors receive 
payments.
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8.2 Design and analysis issues for ESDs
The Dornase Alfa Case Study and Reviews have identified a number of 
problems in the conduct and analysis of ESDs which have implications for 
their validity. The main challenge for ESDs is to avoid a range of possible 
biases (information bias, selection bias) and confounding; hence careful 
study design and analytical approaches are required to identify potential 
bias and control it. This section brings together the discussion of specific 
problems identified as part of the work on this thesis.
The primary criticism of ESDs concerns their susceptibility to bias due to a 
non-randomised treatment allocation. In many of the reviewed ESDs, as 
well as the Dornase Alfa Case Study, this led to a range of baseline 
differences between comparison groups (except of course for those 
variables used for matching by some studies). Most studies have used 
analysis methods aimed at adjusting for such differences as well as other 
known confounders. However, many reports were not detailed enough to 
permit any assessment of the adjustment process; the reporting of both 
adjusted and unadjusted results was rare, and variables used for 
adjustment were not always listed.
Only one study identified in the Review used the propensity score method, 
which is now becoming more widely used for such analyses. A propensity 
score is a conditional probability that a subject w ill be "treated" based on 
an observed group of covariates (Rosenbaum 6t Rubin 1983; Newgard et of. 
2004). However, a recent review suggests that propensity score methods 
so far have not shown themselves to yield substantially different estimates 
compared to conventional multivariate analysis methods (Stürmer et a/. 
2006). There are other methods available (Berger 2008) and the 
assessment of their respective strengths w ill require further work. In any
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case, researchers need to not only report but also assess the extent of any 
adjustment and residual confounding.
In many reviewed studies, as well as the Dornase Alfa Case Study, very 
little  was known about the rationale for the initial treatment allocation. In 
the Dornase Alfa Case Study, clinicians held that - besides licensing 
indications - financial considerations determined how many patients could 
be initiated on dornase alfa. Eventually, patients at most centres were 
commenced on treatment following a successful tria l period; non­
responders did not continue treatment beyond this period. Thus, the 
treatment choice could have been influenced by a variety of factors 
unknown to the analyst and/or been difficu lt to measure and thus control. 
Only one ESD explicitly reported having adjusted for variables which the 
clinician on the team routinely used for his treatment decisions (Choi). Not 
being able to control for such factors poses a serious risk of selection bias, 
which may be unmanageable in retrospective analyses. Database designers 
therefore need to endeavour to record such variables.
The measurement and recording of variables in a database are likely to be 
less rigorous than under tria l conditions. Some reviewed studies have 
reported regular calibration of their measurement instruments, but this 
may not be the norm, even less so across several centres. However, a 
beneficial feature of an ESD may be that blinding to the research 
hypothesis may be less necessary, where outcome assessors may not be 
aware of future effectiveness evaluations using their data. Nevertheless, it 
is likely - particularly in single-centre clinical databases - that clinicians 
have in mind particular research hypotheses which they want to address in 
the analysis of their database. Thus, observation bias is still a real 
possibility. In one study (McDougall), one clinician had scored the global 
assessment of all patients. He died before the study was conducted, but it  
is possible that he foresaw such use of his data. How likely such bias is w ill 
not only depend on the preference of the assessor, but also on the degree 
of subjectivity of the measurement process. In McDougall’ s case, several
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outcome measures chosen were subjective scoring instruments, for which 
no validity or reliability data were reported. Database designers and 
researchers therefore ought to consider testing the reliability of 
instruments in a given data collection context.
The definition of variables poses a variety of potential threats to validity 
and precision. Firstly, an exposure status to the treatment of interest 
needs to be assigned to each individual. The Dornase Alfa Case Study 
highlighted several possible pitfalls in this regard. Some centres did not 
record treatment trial periods on dornase alfa, which means that some 
patients had received the treatment at a point unknown to the analyst and 
would have been categorised as non-users. This indicates a lack of 
consistency in variable definition and data collection. Similarly, the 
categorisation into dornase alfa use groups is open to criticism. Short-term 
treatment and interruptions of treatment could have been handled in a 
number of ways. For example, an intention-to-treat analysis could have 
compared all non-users (recognising that there was room for 
misclassification of those also) with patients having ever tried or used 
dornase alfa. However, the distinction into continuous and intermittent 
use offered the theoretical possibility of detecting a dose-response 
relationship as well as generating a group better comparable to 
continuously treated trial patients. The lack of reliable data on treatment 
compliance observed in the Dornase Alfa Case Study (and indeed in 
reviewed ESDs) needs to be considered in this context also. Taken 
together, these findings illustrate the considerable complexity in defining 
the exposure variable alone. However, it can be argued that a smaller 
number of well-defined variables collected in a database is more useful 
than a large number of poorly defined and controlled variables.
The Dornase Alfa Case Study undertook very detailed data cleaning and 
verification processes. It is hard to over-estimate the importance of this 
work, and analysts need to allow sufficient time for a detailed assessment 
of the quality of variables they wish to use in the analysis. Where under­
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reporting seems likely (particularly of outcome variables or drug exposure 
variables), such as in the case of deaths and exacerbations in the Dornase 
Alfa Case Study, analysts at least need to assure themselves that the level 
of under-reporting is the same across all comparison groups.
Data may be missing for a variety of reasons, which represents another 
source of bias. The Dornase Alfa Case Study identified that different 
centres saw their patients at different intervals. Hence, mildly affected 
patients may not attend frequently enough to generate a minimum number 
of database reports necessary for analysis (this may have been the case in 
Johnson's study). Similarly, patients not continuously enrolled with a 
claims database cannot easily be included in studies (the CF patients for 
whom reporting continuity was lost on transfer between centres may have 
been excluded from certain analyses, if this had not been identified). This 
alone can give rise to selection bias, as transferred patients or less stable 
populations may systematically differ from others.
^classification is of course also possible for outcome variables. Outcome 
variables, however, pose additional threats to validity, if assessors are not 
blinded. ESDs do not comment on blinding, but in several reviewed 
studies, one may suspect that clinicians contributing to a database would 
have been aware of the later researched hypothesis. In addition, a 
doctor’s perception of a treatment may still distort his or her assessment of 
patients. Similarly, there may be detection bias at play, where doctors are 
aware of possible consequences of treatment or more aware of 
complications in patients under treatment and thus more likely to detect 
them there (e.g. fractures in patients treated with etidronate as in case 
study 1).
A degree of misclassification of intervention or outcomes is to be expected 
in databases, not least due to missing claims or under-reporting. 
Misclassification of outcomes seems most likely where their measurements 
are subjective, data linkage has to be relied on, or where assessors may be
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aware of the study hypothesis. Misclassification of patients to intervention 
or control groups seems most likely where claims are missed, or where 
medication might be sourced outside the observed system. Both would 
underestimate the effectiveness of the treatment. Given the many 
uncertainties in terms of variable definition and measurement, it is 
surprising that only few reviewed studies reported having undertaken any 
form of sensitivity analysis.
A possible source of error or even bias may stem from not being able to 
secure baseline measurements, e.g. where patients are recruited onto a 
database after having first tried or commenced the interventional drug. 
Even where sampling starts at the licensing date of the drug, patients may 
have participated in pre-marketing trials, particularly if they are suffering 
from a rare disease treated in specialist centres (such as CF). Several 
reviewed studies aimed to exclude patients who were not clearly free of 
the use of the drug for a significant time before the beginning of the 
observational period. Ideally, a database would determine previous use of 
drugs of interest. This method has not been reported in any studies, but 
would be helpful for excluding patients who started the drug early during 
their enrolment on a database.
Reviewed studies did not describe their choice of variables in detail. In 
some cases, it might be suspected that several outcome variables might 
have been available, but there was no rationale presented for choosing 
those to be analysed and ultimately included in the published report. This 
could hide serious biases, and it is difficult to see how such bias could be 
detected, unless authors clearly state all outcome variables available and 
the basis for selecting any for inclusion in the analysis. In the case of 
dornase alfa, the treatment outcome in terms of number of exacerbations 
may be of at least as much interest as lung function changes. Johnson et 
al. (1999) have not reported this outcome at all, although it would have 
been measured. However, if the ESCF is similar to the ERCF in its multiple
330 Use of Databases in Drug Effectiveness Studies
Discussion
recording of exacerbation events, then it is easy to see why Johnson and 
colleagues may have had to ignore that outcome.
The duration of available follow-up may make a database attractive for 
effectiveness research. The Dornase Alfa Case Study has highlighted a 
number of further issues relating to longitudinal analyses of chronic disease 
populations: the known difficulty in isolating the effect of aging on lung 
function decline from an effect of treatment, comparing patients who have 
had different experiences of treatment by virtue of their age cohort, as 
well as coping with differential survival of severely and less severely 
affected patients. As a database ages, representativeness and/or 
continuity of follow-up may be affected. Similar problems might have 
affected the longest ESD in the four comparison case studies (McDougall). 
Thus, the main advantages of ESDs cannot be taken for granted, but 
necessitate careful assessment, study design and analysis so as not to turn 
into major pitfalls.
The databases used in the identified studies are to a large extent 
longitudinal data sources, some of which are continuing to collect data and 
will thus provide increasingly long periods of follow-up. A long follow-up is 
sometimes seen as an advantage of ESDs. Nevertheless, only some seven 
studies (16%) included a follow-up of more than three years on average. In 
many cases a hypothesis does not require particularly long follow-up, e.g. 
in the evaluation of acute treatment or some preventive interventions, 
such as vaccinations.
Twenty-two of the reviewed studies addressed interventions for chronic 
diseases and conditions, including HIV/AIDS. It is these for which the 
possibility of a longer follow-up period is of interest. However, the 
Dornase Alfa Case Study highlighted the limitations of longitudinal analyses 
due to cohort and survival effects. Similarly, excessive duration of follow- 
up may introduce selection bias threatening external and internal validity. 
Small databases, however long their follow-up, may not support the
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complex design and analysis techniques required for control of confounding 
in effectiveness evaluations. There is thus currently limited experience 
with significantly longer follow-up analyses than would be realistic for 
RCTs.
Rawlins (2008) recently argued for historical controlled trials (essentially 
cohort studies which compare groups treated - or not treated - at different 
time periods), as well as prospective data collection on particular disease 
cohorts with a view to subjecting data to such study designs later on. He 
suggests that key Bradford-Hill criteria for causal association could be used 
to judge the suitability of such study designs (Hill 1965). It can indeed 
easily be argued that ESDs have considerable potential to meet these 
criteria and hence theoretically are able to assess treatment effectiveness 
in the absence of randomisation. However, this does not address the 
considerable data quality issues identified in the Dornase Alfa Case Study, 
as well as the potential cohort and period effects affecting effectiveness 
analyses in chronic disease patient populations (such as CF).
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8.3 Generalisability
Generalîsability is an often-quoted advantage of observational studies over 
RCTs and therefore warrants closer scrutiny here. The essence of 
generalisability is abstraction from the specific situation of the investigated 
sample to a general situation (Rothman fit Greenland 1998). 
Generalisability of an individual study has to be judged based on an 
understanding of the sampling process, as well as the research hypothesis 
in question (Hennekens & Buring 1987).
How much different types of hypotheses (of efficacy or effectiveness) can 
be at odds with each other is illustrated by this extract from an 
epidemiological text on intervention studies (Hennekens & Buring 1987, p. 
204):
“Consequently, any procedure that maximises compliance, thus 
increasing the chances of obtaining a valid result, will positively 
affect the ability to generalise that finding to other populations. ”
It is implied here that applying stringent controls on compliance can 
increase the internal validity of an intervention study. This is true for 
studies assessing efficacy, not, however, for effectiveness. Effectiveness 
relates to the outcomes observed in populations (or subgroups) - usually 
outside trial conditions. Here, (non-(compliance is not a factor to be 
influenced and controlled, but rather one to be observed and taken into 
account. Thus arguably the (internal) validity of a study assessing 
effectiveness - and thus also its generalisability - will increase if factors 
such as compliance are left un-influenced (but not un-measured) by the 
study design.
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Frequently, hypotheses are investigated on a defined sample of subjects 
taken from a target or reference population. The generalisability of the 
study of an efficacy-related hypothesis will benefit if the sample can be 
clearly distinguished as having the condition of interest (and preferably no 
other), and if the exposure to the intervention is rigorously controlled (i.e. 
patients are either receiving the drug or not). If so, it should be possible to 
infer from the results, whether the intervention has the potential to cause 
a certain outcome in patients with particular characteristics. In 
investigating an effectiveness- related hypothesis, the statistical 
representativeness of the study sample in relation to the target population 
might be argued to be more important. Here researchers aim for 
generalisability of their results to a typical patient population in real life 
(which probably exhibits a mixture of compliance patterns, co-morbidities 
etc.).
Very few reviewed studies discussed generalisability. The characteristics of 
excluded patients were hardly ever reported, and in many cases no 
indication of the representativeness of the source database or the sample 
in terms of any target population was given. The sample selection from the 
source database was usually achieved by applying a set of inclusion and 
exclusion criteria. An examination of these, together with the 
documentation of baseline characteristics, should permit limited 
judgements on the likely representativeness of the sample (GAO 1992; 
Rittenhouse & O’Brien 1996).
However, exclusion criteria used by the ESDs centred on issues of data 
validity, i.e. excluding possibilities for misclassification or erroneous 
judgments on key variables. This included typical criteria such as previous 
treatment with substances similar to the study drug, but also 
administrative criteria such as excluding patients with missing data on drug 
dose, or other missing data (albeit that few studies report such exclusions). 
Thus patients lost to follow-up or with incomplete or insufficient follow-up 
(e.g. due to leaving the database) were excluded a priori. If available
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duration of follow-up is used as an exclusion criterion, the resulting sample 
could easily vary systematically from patients with shorter follow-up. 
Similarly, some studies excluded transferred patients (e.g. Tiefenbrunn et 
al. 1998; Peterson et al. 1999; Krumholz et al. 1998, 2001), and may thus 
have jeopardised generalisability. The main point here is that incomplete 
reporting in all or any subgroups can seriously jeopardise the potential for 
an ESD to be representative and benefit from a database’s wide 
recruitment base (even if that itself is representative).
Whereas baseline differences between comparison groups were readily 
presented, authors rarely reported characteristics of excluded patients, 
such as in the study by Tiefenbrunn et al. (1998). However, this would 
have enabled at least some assessment of the representativeness of the 
sample. It is encouraging that disease severity or co-morbidities rarely 
featured as exclusion criteria. This may support the argument that ESDs 
have comparatively high external validity (GAO 1992; Rittenhouse & O'Brien 
1996).
Some, but not all ESDs, excluded patients with contraindications to the 
treatment. This has implications for the comparability of the no-treatment 
control group, as in studies without such exclusion criteria, one would 
expect to see a comparatively larger proportion of patients with 
contraindications in that group. Database designers should ensure that 
relevant variables for adjusting are available.
Very few studies allude to an intended target population (of which the 
sample may be representative), and sample characteristics are rarely 
compared with those of target populations or excluded patients. Whereas 
there was some indication that ESDs may have included older and more 
severely ill patients than RCTs (e.g. case study 2), Eggleston’s inclusion 
criteria (case study 4) are more restrictive than those in comparable RCTs, 
most probably because the authors sought to avoid baseline differences in 
severity and confounding by indication.
Use of Databases in Drug Effectiveness Studies 335
Discussion
In summary, it is disappointing to observe that claims for greater 
generalisabitity in ESDs were rarely substantiated in the Review. Even 
retrospective ESDs should be able to assess and report the extent to which 
their final sample is representative of a wider target patient population to 
which the authors wish to generalise their findings; as a minimum, authors 
need to comment on existing limitations for doing so, as was done in the 
Dornase Alfa Case Study.
336 Use of Databases in Drug Effectiveness Studies
Discussion
8.4 Data protection
Given the difficulties, the Dornase Alfa Case Study experienced due to data 
protection considerations, and the importance of this subject for similar 
epidemiological research, this section is dedicated to relevant issue for 
ESDs, and puts these into the context of current UK guidance and ongoing 
debate.
The identified published ESDs showed a remarkable lack of consideration of 
confidentiality and data protection issues. Hardly any paper mentioned 
whether data were anonymised, and only three reports considered patient 
consent in any form. This may point at a then still relatively relaxed 
approach to the use of patient data for research. Given the recent changes 
in regulations concerning the use of patient data for research (and 
international variations in these), it is impossible to judge, whether studies 
would have fulfilled any legal requirements applicable at the time.
During the Dornase Alfa Case Study, the NHS Trusts' decision-making on the 
data protection and confidentiality questions were hampered by 
uncertainties surrounding the interpretation and application of new laws 
and guidelines coming into force at the time. In the NHS, these 
developments coincided with the introduction of a new system of 
“Caldicott Guardians” in every Trust. These guardians and their local 
teams and advisors were only beginning to learn to exercise their new 
responsibilities. Similarly, the role of research ethics committees in data 
protection and confidentiality was rather unclear at the time. In addition, 
the concurrent negative publicity of medical research misconduct 
contributed not only to the development of new procedures and guidelines, 
but also to the insecurities felt within hospital Trusts, particularly 
children's hospitals (Jones 2000; Woodman 2000).
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Despite one Trust data protection officer initially deciding otherwise, 
others clearly interpreted the Data Protection Act 1998 as demanding 
explicit patient consent for an outside researcher accessing patients’ 
medical records. This was at a time when well-meaning clinicians might 
still have felt in control of decisions about their patients’ records and been 
inclined to grant a researcher or fellow health professional access to 
records for research based on trust. However, such disclosure would have 
constituted a clear breach of confidence (Romano-Critchley & Sommerville 
1999); at the time, this was much less clearly understood by clinicians.
Today, the implications of the Data Protection Act 1998 and Health and 
Social Care Act 20016 are very widely appreciated, and application 
processes for access to patient data are increasingly streamlined. Only 
recently (November 2008), a new Coordinating System for gaining NHS 
Permissions (CSP) has been introduced to the NHS in England. Starting with 
National Institute for Health Research Clinical Research Network “portfolio 
studies’’, this will streamline the process of applying for permissions for 
new research and reduce duplication across NHS organisations. Through a 
single entry point via the Integrated Research Application System (IRAS), 
researchers will be able to apply for permissions from all NHS sites through 
one point. The application covers information relevant to approvals from a 
range of bodies, including research ethics committees, local NHS research 
offices, and the Patient Information Advisory Group (PIAG) (now subsumed 
into the National Information Governance Board). Arguably, such a
Section 60 of the Health and Social Care Act 2001 permits processing of confidential 
patient information in specified circumstances where it is not currently practicable to 
satisfy the common law confidentiality obligations, e.g. seek consent.
The Act also allows for disclosure of information to specific bodies for specific purposes; 
these have to be approved by Parliament. The Health Service (Control of Patient 
Information) Regulations 2002 (Anonymous 2002) (for England and Wales only) were the 
first to be made under the Act. They support the operations of cancer registries in respect 
of medical purposes (including research) related to cancer, and the Public Health 
Laboratory Services (PHLS, now the Health Protection Agency) in respect of communicable 
diseases and other risks to public health (mainly in terms of control and monitoring them). 
Interestingly, research is not listed as one of the purposes for which confidential 
information may be processed by the PHLS.
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streamlined approval process could prevent some of the discrepancies in 
local decision-making which we experienced with the Dornase Alfa Case 
Study. One may hope that this process reduces the time- and resource­
intensive application and decision-making phases which reportedly have 
dogged epidemiological research for some time now (as illustrated by our 
own publication (Strobl et al. 2000) and others which followed, such as 
recently Metcalfe et al. (2008), who demonstrated that a PIAG application 
alone lost their team £560,000 of funded research time).
However, it is likely that the access to at least some disease databases and 
research databanks may have to be negotiated separately at least for some 
time. The process for applying for the use of the ERCF had not been 
devised prior to our application. But there is evidence that at least some 
database operators are already much clearer about their relevant access 
and governance processes, including information governance and 
intellectual property agreements (examples include the UK CF register at 
Dundee University, the MRC and Wellcome Trust report on access to 
collections of data and materials for health research (Lowrance 2006), as 
well as work under the NHS Connecting for Health Research Capability 
Programme (Care Record Development Board 2007)).
At a very early stage of the Dornase Alfa Case Study, an honorary contract 
was sought with one of the Trusts, in order to bring me as a researcher and 
health professional into the “NHS family” and thus within the sphere of 
influence of its disciplinary procedures. Again, this was not uncommon 
practice at the time. However, it would have been difficult to argue that I 
was involved in the care of patients whose records I would have accessed. 
Whereas audit is sometimes argued to be part of the healthcare process - 
and thus does not require consent - , the same cannot be said about
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research.7 Therefore, it was unclear, how a court of law might have looked 
upon an honorary contract in this context. The Department of Health now 
recommends the use of a “Research Passport” for researchers not 
employed by the NHS. This provides a mechanism for streamlining the pre­
engagement checks for such researchers and assuring NHS organisations 
that they have taken place, and thus is effectively akin to an honorary 
contract with one organisation which is recognised by others. It must be 
stressed that this does not permit researchers access to data (without 
consent) they would not otherwise have had.
The uncertainty of how anonymous data was to be defined impinged on the 
confusion as to whether consent was required for the use of the ERCF in 
the Dornase Alfa Case Study. The Data Protection Commissioner held that 
any coded data was personal data, regardless of the location of the 
decoding key. This is a very contentious issue with epidemiologists, as 
much of their research would simply be impossible to conduct on totally 
anonymous data, because updating longitudinal data or validating any data 
would be impossible.
Understandably, there was much protest and ample misunderstanding 
around this issue in the literature, where some guidance documents clearly 
saw coded data as legitimate material for research, without patient 
consent. This certainly seems to have been the view in the BMA's guidance 
(Romano-Critchley fit Sommerville 1999), albeit that it advised members to 
seek legal advice before using anonymised data. In many guidance 
documents it was not clear, whether the authors distinguished whether 
decoding keys still were still in existence or not.
7 This leads to the question of whether audit involving personal data but performed by 
persons not involved in the care of patients concerned (e.g. audit assistants employed by 
or contracted by the Trust) requires patient consent. Some Trusts may routinely enter 
honorary contracts with such audit personnel in an attempt to resolve this issue. It would 
seem that there is at least a theoretical temptation to brand a project “audit” rather than 
“research”, particularly where there is uncertainty about the distinction.
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Thus, the Data Protection Commissioner was at odds with at least some of 
them. In the eyes of the Information Commissioner, the anonymised ERCF 
data constituted personal data to the Trusts. The act of anonymisation is 
seen as an instance of processing (Information Commissioner 2001). The 
Commissioner's letter implied that the data also remained personal data to 
the researchers. However, his more recent guidance opens the possibility 
for a different interpretation (Information Commissioner 2001): the 
Commissioner implies that the data controller must hold or be likely to 
come into possession of information which could identify individuals. She 
states “whether or not data which have been stripped of all personal 
identifiers are personal data in the hands of a person to whom they are 
disclosed, will depend upon that person being in possession of, or likely to 
come into the possession of, other information (Information Commissioner 
2001, p.14). Some clarity seems to have emerged over time, and 
definitions appearing in more recent documents are increasingly congruent 
along the lines of the MRC definitions in Table 8.1. Thus, it can be argued 
that the data were not actually personal to myself, and current definitions 
of pseudonymised data would bear that out. Nevertheless, there is still 
room for interpretation as to where exactly the line lies between 
anonymised and pseudonymised data (Fistein 2008).
Similarly, it seemed impossible to extract a clear answer from guidance 
documents as to whether disclosure of anonymised data constituted a 
breach of confidentiality. However, if one accepted that anonymised data 
was personal data, then the disclosure of the data to the researcher as a 
third person would have had to conform to the Act. According to the Act, 
an individual's consent is needed for disclosure of their personal 
information. Helpfully, the House of Lords decided a case8 recently which 
addressed a number of issues with a direct bearing on what constitutes 
personal information. It gives comfort to the view that:
“. . . pseudonymous information may be disclosed like anonymous 
information so long as the key to the re-identification is only held by the
8 Common Services Agency v Scottish Information Commissioner -  9 July 2008
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discloser. This may be of considerable sisnificance to those in the health 
sector, who often need access to uniquely coded data for research 
purposes, but where the recipient of the information does not need access 
to the code. ”
Table 8.1 : MRC Data fit Tissues Tool Kit - Definitions of Anonymised Data9 
Anonymised data /  information
Anonymised data are data prepared from information from which the person to whom is 
relates cannot be identified. The term is used when referring to robustly pseudonymised /
linked data or unlinked anonymised data. ___________________________________________
Pseudonymised data, also referred to as linked anonymised
This is anonymous to the people who receive and hold it (e.g. a research team), but 
contains information or codes that would allow others (e.g. those responsible for the
individual's care) to identify an individual from it.________ _____________________________
Unlinked anonymised data, or truly anonymised data
This contains no information that could reasonably be used, by anyone, to identify the 
individual or study participant._______________________________
The earlier Department of Health document “Building the Information 
Core: Protecting and Using Confidential Patient Information” laid down the 
strategy for making the NHS compliant with legal and ethical requirements 
(Department of Health 2001a). The document considers that "consent [to 
processing] is not required where information has been effectively 
anonymised” (p.1). Anonymisation here includes pseudonymisation. 
However, patients still need to be informed.
The response letter from the Data Protection Commissioner’s office was 
not very clear on this point. The letter suggested that “pseudonymised” 
(i.e. coded) data could be processed in accordance with the Act, if a well- 
constructed security protocol prevented the breaking of the code by 
anyone outside the CF centres/NHS Trusts. Crucially, the letter suggested 
that informing patients of the likely uses of their data (including disclosure 
for research) and giving them an opportunity to object to such uses was 
sufficient to comply with the First Principle of the Act. Thus in the eyes of
The MRC Data 6t Tissues Tool Kit is now an authoritative source of guidance which has 
been developed in partnership with key NHS and research organisations, http://www.dt- 
toolkit.ac.uk/home.cfm
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the Commissioner the Act did not demand explicit written consent for the 
given project. It could also be implied that information about the possible 
use for research in general - and not necessarily a particular project - is 
sufficient information. However, as stated above, colleagues in one Trust 
interpreted this differently. The problems such differences in 
interpretation of the Act or related guidance could pose for data access for 
multi-centre research were drawn to the attention of the medical 
community (Strobl et al. 2000). Current practice is for data protection 
officers to approve a research protocol before its submission to a research 
ethics committee. Other data protection officers are expected to accept 
the decision of the first officer, but are legally required to make their own 
decision. Clearly, such decisions always require a degree of judgement, 
and it is likely that officers are risk-averse in their decisions, as they may 
not be trained nor encouraged to assess the risks involved in permitting 
access to coded records.
There is a current fierce debate on the issue of whether researchers should 
be able to access patient records without consent to identify potential 
research participants who could then be approached to consent to 
research. An earlier draft of the new NHS Constitution had included a 
sentence which would have ensured that this was possible. This sentence 
was removed in the final version (Department of Health 2009). 
Nevertheless, the presentation of the issue on the National Institute of 
Health Research (NIHR) website permits some reading between the lines 
which illustrates that this debate is still not resolved.10
Speaking at a summit in 2008, Mr A Johnson (then Health Secretary) said:
7 want every patient in the NHS to have the right to take part in approved medical 
research that is appropriate for them, if they choose t o . . . / ’
[the NIHR web text continues:] This means that in future, all patients in the NHS will have the 
right to expect that their health record will be used... to identify whether they are suitable to 
take part in approved research which is relevant to them. Appropriate patients will be notified 
of opportunities to join in, and will be free to choose whether they wish to do so, after a full 
explanation. Speaking at the Health Research Summit, Harpal Kumar, Chief Executive of 
Cancer Research UK, said:
"The Government's announcement today is extremely welcome given that it helps to 
place health research at the core of the NHS. It shows a commitment to provide more 
information about the health research taking place in this country, and to involve and 
recruit more patients in clinical trials. ... "
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From some guidance documents it might be inferred that consent to the 
use of data for research may be implied where patients are informed that 
their data could be used for this purpose and do not object. A similar 
position was presented in the letter from the Data Protection 
Commissioner’s Office. However, routine mechanisms to merely inform 
patients in advance about the potential use of their personal data for 
further research (for example, through notices in waiting rooms) may not 
be seen as constituting sufficient consent (personal communication with a 
data protection officer). It was also somewhat unclear, whether patients 
who do not register their refusal can be said to have consented. 
Essentially, I depended on the Trusts’ interpretation of whether their 
(routine) patient information processes about possible uses of patient data 
were sufficient to comply with the Act. However, the nature of consent 
required is still not entirely clear today (Fistein 2008).
In 2003, the Department published its code of practice for NHS staff in 
England and Wales on the issue of confidentiality (Department of Health 
2003). Explicit/express consent is defined as “dear and voluntary 
indication of preference or choice, usually given orally or in writing and 
freely given in circumstances where the available options and the 
consequences have been made clear.” (p.5) Such consent is needed for 
disclosure of identifiable data for research, unless public interest justifies 
the disclosure, or where the Health & Social Care Act 2001 Section 60 
supports disclosure temporarily. It is made clear that patients’ agreement 
with their use of data for research cannot be assumed, as this is not part of 
the healthcare process.
The Commissioner's recent documents (Information Commissioner 2001; 
Information Commissioner 2002) provide some better clarification on the 
nature of consent required than was available at the time the Dornase Alfa 
Case Study project evolved. The Commissioner considers that consent does 
not necessarily have to be in writing. However, a non-response to
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communication or information cannot be considered consent. Explicit 
consent should be absolutely clear in terms of specific details of 
processing, including purposes and nature of processing and any specific 
aspects relevant to the individual. Thus to inform patients at ERCF 
registration specifically about the possibility of later disclosure of the 
anonymised ERCF data for particular types of research, and giving patients 
an opportunity to object to this (as well as documenting their response) 
could be argued to be sufficient to satisfy the requirements of the Act in 
relation to the Dornase Alfa Case Study. Whereas written consent is not 
required, it would seem prudent to seek such documentation of a patient's 
agreement.
The debate as to whether consent to the use of medical records in research 
should be required at all continues today with committed proponents on 
both sides of the argument, those favouring consent on the basis of 
patients' right to know and understand the use of their data (Clayton 
2008), and those defending the feasibility of epidemiological research, 
including leaders of large research funding charities (see Cooper 2009). 
Each side claims support from patient and public views, but repeated calls 
for wider public debate have largely remained hollow, as the debate 
remains limited to research and legal-ethical fora and relevant NHS bodies.
Finally, the status of medical research itself within the Data Protection Act 
remains painfully uncertain, as Fistein (2008) explains in a working paper 
on the issue of consent for the NHS Connecting for Health Research 
Capability Programme. Fistein points out that the Act permits the use of 
health data for research as long as a "Schedule 2" condition is met. One of 
these conditions refers to processing necessary "in the public interest". 
Fistein argues that this point in particular (as well as other Schedule 2 
conditions) needs urgent clarification in relation to research.
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The problems are thus far from resolved, resulting in an ongoing situation 
which is well summarised in the still topical words of the Academy of 
Medical Sciences from 2006:
“The legal framework around the use of personal data in research is a 
complicated patchwork involving UK legislation, case decisions and 
European directives, augmented by various guidance documents. There are 
many areas of imprecision, and the courts have not tested the legislation 
as it applies to medical research. ... The resulting variable legal 
interpretations have been a source of great difficulty, delay and 
disillusionment for researchers. ” (Academy of Medical Sciences, 2006, p. 3)
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8.5 Next steps for ESDs
Notwithstanding the slow progress in addressing data protection issues in 
ESDs and databases, and the un-exploited potential of greater 
generalisability of ESDs, the main remaining concerns centre on the 
internal validity of such studies. Earlier sections in this chapter have 
identified a considerable number of potential sources of bias and 
misclassification which were identified or might have been suspected in 
some of the studies included in the Review. Whereas prospective cohort 
studies have at their disposal methods for better ensuring validity and 
accuracy of the data, the mostly retrospective ESDs included in the Review 
were limited by the data they had available. Serious methodological 
criticisms have in the past been levied against disease registries (Lewis 
2001), and researchers using them for ESD have limited options for 
retrospectively correcting any shortfalls. They can only carefully assess 
them - and the DQR has shown the practical problems in even doing that -, 
and adapt the study design accordingly, risking a loss of validity of the 
study. Any use of pre-existing data in ESDs therefore must be approached 
with extreme caution and should probably remain limited - if used at all - 
to assessments of large treatment effects, provided study validity is clearly 
established.
So what about prospective data collection? An ESD of prospectively 
collected data is methodologically a prospective cohort study (i.e. the 
outcome develops after study initiation), the qualities of which are 
described in any epidemiological textbook; such studies tend to be awarded 
a relatively higher position in hierarchies of research evidence. The crucial 
point, however, is that some defenders of database studies seem to argue 
for setting up databases designed without specific (effectiveness) 
hypotheses in mind (Rawlins 2008). This means that ESDs of such 
prospective databases may not benefit from bespoke data definition and
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collection designed to control specific biases, which may well negate any 
benefits of prospective data collection. The methodological limitations of 
cohort studies compared to RCTs are not going to be addressed by such an 
approach; rather one set of limitations would be exchanged for another.
The goal for effectiveness research surely has to be to capitalise on the 
vastly increased amount of data potentially available thanks to information 
technological advances, without compromising validity. The Dornase Alfa 
Case Study is an excellent example for testing the requirements; it should 
have been as close as anything to a hypothesis-testing design (admittedly, 
and perhaps surprisingly, the stated aims did not imply that). 
Nevertheless, the methodological issues were considerable, and 
improvements suggested based on the work here need to be heeded in the 
design of hypothesis-specific databases.
This underlines the need for a more controlled approach to setting up 
databases where data collection methods and procedures as well as 
variable definitions are rigorously developed, piloted and their reliability 
and validity assessed before implementation. This might most meaningfully 
be achieved by focussing on a very small number of new databases. These 
could be set up to allow comparison with concurrent RCTs to enable more 
learning on the validity of ESDs. This experience should then inform the 
design of prospective ESDs in areas where RCTs are no longer possible (e.g. 
where equipoise is lost). This may affect many drugs in the post-marketing 
phase, and post-marketing surveillance databases and their use may be an 
appropriate focus for such methodological research.
Rawlins (2008) seems to favour setting up databases to create potential 
research resources for the future, but not necessarily with any specific 
hypothesis in mind (he strengthens his arguments by referring repeatedly to 
the use of databases in identifying adverse outcomes, rather than 
beneficial outcomes). He represents a wider current enthusiasm for 
collecting data in various clinical areas, often for rare conditions or
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interventions, in the hope of being able to undertake future research - not 
infrequently on effectiveness and outcomes. This enthusiasm seems to 
span the HTA community, industry, as well as clinical communities. The 
ERCF is a stark reminder that even meticulously planned databases can 
encounter a whole host of unforeseen problems in the analysis and 
interpretation of subsequent effectiveness evaluations. It seems therefore 
unlikely that databases set up with no specific research focus and 
extremely tight controls of data quality and completeness in place could 
ever become reliable and worthwhile future resources for effectiveness 
research.
The lack of any systematic approach to assessing and discussing such 
potential sources of bias in study reports, however, remains a major 
concern, particularly since the Review was limited to high-quality journals. 
In the interest of safeguarding and promoting the quality of such reports, 
more systematic and rigorous approaches need to be applied to peer review 
processes. The British Medical Journal has recently suggested that authors 
should make raw data available to peer reviewers; in a similar way, peer 
reviewers of ESDs should routinely be furnished with all necessary evidence 
to judge the quality of the source database, its appropriate use, and the 
interpretation of findings by the ESD authors. The recently published 
guidance documents represent useful tools for this (Huston and Naylor 
1996; Motheral and Fairman 1997; Gliklich 6t Dreyer 2007; van Elm et al. 
2007; Berger et al. 2008).
Once study quality of ESDs has been established, the interpretation of their 
evidence in relation to a body of evidence requires further consideration 
also. The comparison case studies have highlighted that direct comparison 
with RCTs may be problematic for several reasons, and the results of ESDs 
may be misinterpreted or misused. It may be argued that a direct 
comparison is inappropriate as both study designs may (and arguably 
should) address different hypotheses. The literature on synthesis methods 
suggests systematic approaches to assessing rigorously the contribution of
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ESDs to any evidence base (GAO 1992; Labin 2007). The potential of these 
methods specifically in drug effectiveness evaluations warrants further 
development.
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Use of Databases in Drug Effectiveness Studies 351
Conclusion
9.1 Summary of Findings
I had set out to describe and explore the methodological challenges of ESDs 
by undertaking a drug effectiveness case study using an existing database 
(the Dornase Alfa Case Study), comprehensively reviewing comparable 
published studies, and by comparing the findings of ESDs with RCTs of the 
same research question. The path has not been a smooth one! The 
Dornase Alfa Case Study highlighted considerable problems with 
undertaking effectiveness studies on pre-existing databases, particularly 
around data quality and completeness, but also regulatory issues on access 
to health data for research. In turn, the review of published ESDs was 
limited by the poor bibliographic indexing and reporting practices of such 
studies, and the four comparison case studies were limited by their diverse 
nature. Nevertheless, the thesis' resulting contribution to knowledge is 
considerable and centres on a number of achievements arising from the 
Dornase Alfa Case Study, Review, and comparison case studies with RCTs. 
These are summarised in turn:
Firstly, the Dornase Alfa Case Study - despite not having fulfilled its original 
aim of evaluating long-term effectiveness of the drug - has identified 
important methodological lessons through the detailed approach taken. 
These have been published in high-ranking peer-reviewed journals (Strobl 
et al. 2000; Strobl et al. 2003):
The data quality and DQR processes included the first direct validation of 
the ERCF database and demonstrated that some key outcome variables 
were poorly defined (e.g. exacerbations) and incompletely reported (e.g. 
exacerbations, deaths). Also other variables lacked clear definitions and 
comprehensive reporting. The work demonstrated that despite extensive 
routine data verification processes built into the ERCF operation, relatively 
trivial data checks as part of data cleaning here identified further errors in
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the key variables. The ERCF had also ignored important softer information 
and centre differences in clinical and reporting practice; these would not 
have been available to analysts who did not know the situation in the 
centres in sufficient detail. There was a lack of control of patient transfer 
processes, resulting in discontinuity of records. I identified possible 
sources of bias arising from the data collection processes (e.g. information 
bias resulting from different frequencies of follow-up visits and reports). 
These findings represent lessons for databases in general. Nevertheless, 
the recent seminal work on disease registries by the Agency for Healthcare 
Research and Quality (Gliklich fit Dreyer 2007) presents the corresponding 
US sister database of the ERCF, the ESCF, as one of its case examples. 
Thus even highly regarded and intensively resourced registries may show 
considerable flaws when carefully examined.
The Dornase Alfa Case Study also gave rise to a detailed examination of the 
uncertain legal and guidance framework relating to confidentiality and data 
protection applicable to research using health records. At the time, there 
was little clarity and plenty of conflicting guidance and advice. I explored 
the existing law and guidance in an attempt to answer the relevant 
questions of consent and access to (coded) patient data for the Dornase 
Alfa Case Study, and ultimately published these vital concerns for the 
epidemiological research community in a paper in the British Medical 
Journal. This is still a much-debated area of law and ethics today.
The Dornase Alfa Case Study identified that generalisability - an oft-quoted 
potential strength of observational studies - is difficult to assess and even 
more difficult to achieve in databases. This is because they depend 
entirely on the registration of individual cases, usually through clinical 
centres which may not be representative of the relevant target patient 
population of interest. The extent of patient recruitment to the ERCF 
varied between participating centres, and clinicians considered that 
shared-care patients (who receive only part of their care from a specialist 
centre) should have been distinguished from the main cohort. Database
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operators (and analysts) may thus remain in the dark about the extent of 
completeness of the registration of all patients from each centre, as well 
as the representativeness of the sample vis-à-vis the target population of 
all CF patients.
Lastly, the Dornase Alfa Case Study provides descriptive data for 
comparison with other published data on CF populations, and it uses 
existing recent observational studies on the effectiveness of dornase alfa to 
discuss the merits and pitfalls of multi-variate analyses in what remains a 
challenging patient population for epidemiological research.
Secondly, the findings of the comprehensive review of ESDs of drug 
therapies presented here represent a further major achievement. Much 
has been written on databases and also their use in HTA (Lewsey et al. 
2000; Williams et at. 2003; Raftery et al. 2005; Gliklich and Dreyer 2007), 
and on how database studies should be reported (Motheral and Fan man 
1997; von Elm et at. 2007), but so far no systematic review of studies 
having used databases for (drug) effectiveness research has been reported.
The Review identified that increasing numbers of ESDs are being published. 
It is likely that a significant publication bias is at play here, as by far the 
majority of identified studies reported a significant effectiveness outcome. 
Most studies were retrospective, and perhaps surprisingly few reported 
direct or indirect industry funding. This suggests that this relatively in­
expensive research design is more broadly accessible to other clinical and 
research communities. Nevertheless, there is scope for significant industry 
involvement (and control), particularly through post-marketing surveillance 
databases; this could limit - and at worst distort - the use of such resources 
for genuine HTA.
Issues of consent and data protection appeared to concern a worryingly 
small minority of authors; this was probably a sign of the time and may be 
explained by data protection regulations having come into force only
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relatively recently. An equally surprisingly small number of studies made 
any attempt to demonstrate their representativeness of a target population 
or their greater generalisability compared to randomised trials. This is 
disappointing, given the theoretical potential of ESDs in this area.
Many authors did not report any assessments of data quality, which raises 
doubts as to whether rigorous data quality assessments such as the ones 
applied in the Dornase Alfa Case Study are the rule in published studies. 
The definition of exposure variables (drug treatment) was often sufficiently 
clear, but the outcome variables of some studies relied on proxy measures 
(e.g. prescribing). Very few studies were able to refer to data validation 
against external information sources. Most studies attempted to adjust for 
confounding in the analysis, however, the methods used were simple, and 
the success of any statistical adjustment was rarely reported. In summary, 
the overview of published ESDs provided by the Review does not give any 
cause for confidence in the current use of this study design.
Thirdly, the four case study comparisons of ESDs with available RCTs having 
addressed the same effectiveness question, add to the knowledge available 
from other reviews which did not explicitly focus on ESDs (e.g. Britton et 
al. 1998; Benson and Hartz 2000; loannidis et al. 2001; Kunz and Oxman 
1998; MacLehose et al. 2000). There was no detectable systematic pattern 
of differences in results between study types. However, the true 
comparability of ESDs and RCTs (in terms of patient selection, or outcome 
variables) could be questioned, and this may explain some discrepancies in 
results. Nevertheless, this may also apply to some of the previously 
published reviews.
In two case study comparisons (1 and 3), the results appeared to concur, 
but the comparison could not be quantified, and in one case may be 
entirely spurious due to variations in outcome measures (case study 3). In 
the remaining two case studies (2 and 4) the ESDs claimed equivalence of 
effectiveness of two comparator treatments, whereas the RCTs favoured
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one particular treatment. Both ESDs had some industry involvement, and 
in one case (case study 4) the findings were later mis-represented in a cost- 
effectiveness analysis in favour of a drug which is nowadays clearly not the 
drug of first choice (but manufactured by the drug company leading on the 
ESD). In the second case (case study 2) the difference in results may be 
partly explained by patient selection and insufficient follow-up in the ESD - 
decisions which might have been made without prejudice.
In terms of frequently cited benefits of ESDs vis-à-vis RCTs, ESDs were 
often larger than comparator RCTs, but not as a rule; similarly their follow- 
up was not always significantly longer than RCTs', and in case study 2 most 
likely too short. Equally disappointing is the lack of emphasis of ESDs on 
demonstrating their generalisability, rather than just claiming it and using 
it as a justification for the chosen research design. Exclusion criteria of 
ESDs often mimic those of RCTs, but pragmatic ones often have to be 
added, particularly due to poor data quality or missing data; this itself can 
introduce selection bias and jeopardise generalisability.
Thus, the four case study comparisons have highlighted some strengths of 
ESDs vis-à-vis RCTs (e.g. the ability to measure outcomes over a long time 
frame and large populations), but probably more pitfalls. In addition, the 
poor reporting and seemingly lack of quality control of this design in peer 
review processes, as well as the likely control of many large databases by 
industry pose considerable potential for biased use.
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9.2 Conclusions
There is considerable interest in ESDs in the HTA community, as 
demonstrated by a recent paper by Rawlins (2008), the Chair of the UK’s 
National Institute for Health and Clinical Excellence, in which he underlines 
the virtues of observational research. There also appears to be a degree of 
consensus in the recent literature on the complementary values of 
randomised and observational study designs and the fact that neither are 
immune to bias or provide perfect information (Rawlins 2008; Sorensen et 
al. 2006). Albeit that at times such discussions - although acknowledging 
the value of both designs - are largely limited to pointing out the 
weaknesses of one study design, and arguing for the other on the basis of 
emphasising its strengths.
The rising importance of ESDs is further underlined by the increase over 
time in the numbers of published ESDs identified by the Review, and the 
recent publications of relevant guidance on disease registries as well as 
observational research (Gliklich & Dreyer 2007; von Elm et al. 2007). 
Information technological advances in healthcare have vastly increased the 
potential for routine health data collection and the theoretical potential 
for ESDs.
Clinical communities as well as health technology assessors often show 
considerable enthusiasm for database projects to capitalise on the 
increasing computerisation of clinical systems. However, little 
consideration seems to be given to the later uses of such databases. 
Rawlins (2008) argued in favour of observational studies, largely based on 
their known strengths in investigating adverse effects of treatments. It 
would be entirely inappropriate to conclude that such designs are equally 
well suited to investigating beneficial effects of treatments (i.e. 
effectiveness). There are after all many examples of observational study
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findings having misled the clinical community (and thus harmed patients) 
until robust trial and systematic review evidence emerged (MacMahon and 
Collins 2001). Rawlins is right in arguing for the need for judgment in 
interpreting evidence, but the first question in judging an evidence base is 
still: is the evidence reliable? Current ESD publications do not permit a 
confident positive response to that question.
The overwhelming conclusion of the thesis is that despite the current 
enthusiasm for databases and disease registries, and the implicit hope that 
they could successfully be used for future ESDs, published ESDs are poorly 
reported, and the methodological challenges are poorly appreciated and 
addressed. Despite theoretical awareness of methodological solutions, 
existing examples leave much to be desired. Through meticulous detailed 
and critical analysis, this thesis provides first-hand evidence of actual 
analytical and practical problems associated with the retrospective use of 
databases and highlights severe limitations.
The ERCF might have been seen as one of the most promising disease 
databases for an ESD, given that its primary focus was on one drug 
treatment, it involved control patients, and above all, it operated intensive 
routine data quality assurance processes. Nevertheless, the Dornase Alfa 
Case Study essentially was unable to undertake a reliable effectiveness 
analysis on the available sample, and no credible effectiveness analysis has 
ever been achieved and published from the complete ERCF dataset either.
The findings from the presented Review of other published drug ESDs did 
little to improve confidence in the current quality of such studies. 
Together with the Dornase Alfa Case Study, the Review demonstrated that 
a variety of identified data quality problems, as well as confounding by 
indication, are very difficult to address within a retrospective study design 
and thus result in further study limitations (e.g. additional exclusion 
criteria having to be applied, which may limit generalisability). In 
addition, there is a strong indication that publication bias is at play here.
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and the poor quality controls seemingly applied by peer reviewers do little 
to limit potential bias arising from commercial interests.
Glicklich & Dreyer (2007) provide detailed guidance on the development 
and use of registries, and example databases or ESDs quoted by them are 
presented for illustrative purposes, but not critically reviewed. The Review 
presented here demonstrates that the application of existing 
methodological knowledge is still limited in this area. The contribution of 
existing published ESDs to an evidence base has to be severely questioned 
not merely on the basis of methodological weaknesses, but simply on the 
basis of poor reporting which does not allow any comprehensive appraisal 
of the validity and generalisability of many such studies.
The findings of this thesis draw attention to a considerable number of 
potential and actual shortfalls of published ESDs, which are largely 
retrospective, and their value in effectiveness research hence has to be 
questionned. It is clear that observational studies cannot replace RCTs, 
particularly where effects are moderate or small (MacMahon and Collins
2001), and neither do RCTs make observational studies redundant. 
Nevertheless, ESDs have undeniable strengths, such as potentially better 
generalisability, larger sample sizes, and longer follow-up periods under 
naturalistic conditions, but these are currently not being exploited. Also, 
at least theoretically, ESDs should be able to fulfil key Bradford-Hill criteria 
of causality11 (Hill 1965) and have the potential to contribute much to an 
effectiveness evidence base; and there will always be scenarios where RCTs 
are simply not possible. However, most existing drug ESDs are not of 
sufficient quality to be relied upon as sole sources of effectiveness 
evidence. Thus the current question is not necessarily whether ESDs could 
or should be used where RCTs are not possible, but how we can improve 
their quality and validity so they add value to effectiveness evidence.
11 Strength and association, consistency, specificity, temporality, dose-response, biological 
plausibility, biological coherence, experimental evidence, analogy.
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The answer to the question of whether ESDs are worthwhile pursuing is 
therefore: yes, if data quality and better control of biases are achievable. 
There are essentially two main ways forward. Firstly, the rigorous 
implementation of existing guidance as well as recommendations arising 
from this thesis. Together they constitute a considerable body of 
knowledge, which has probably rarely if ever been put into practice in 
existing databases; certainly the reviewed ESDs (albeit that they pre dated 
some key guidance) do not demonstrate the application of much of this 
knowledge. The use of databases set up prospectively with a single 
planned hypothesis for an ESD is a more promising approach than the 
retrospective analysis of databases collected for different purposes.
In addition, internal and external quality control efforts need to be 
strengthened considerably. The latter should include external peer review 
and assessment not just of ESDs, but of databases themselves, regardless of 
ownership. Peer-reviews of ESDs submitted for publication need to apply 
more rigorously the available methodological evidence; a tool for study 
quality assessment would be helpful for this, and should be developed.
Secondly, more methodological research should support the quality 
improvement of ESDs. Research needs to address the role and implications 
of patient and clinician preference, and means for adjustment in data 
analysis. Such research will probably need to use comparisons between 
study designs in order to validate new approaches in ESDs. Methodological 
work could initially be limited to relatively uncomplicated settings (e.g. 
short-term treatment) to enable more focussed attention on particular 
features of ESDs at any one time (e.g. generalisability, control of 
confounding by indication).
Better quality ESDs would also enable further development and a more 
confident use of some promising approaches to evidence generation, 
particularly the randomised database study (Sacristan et al. 1998; Mosis 
2006), and cross design synthesis (GAO 2002). The use of both has hitherto
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been regrettably limited, and arguably they would themselves benefit from 
higher quality databases and ESDs being available.
Finally, the contribution of existing published ESDs to an evidence base has 
to be questioned not merely on the basis of methodological weaknesses, 
but also simply on the basis of poor reporting which does not allow any 
comprehensive appraisal of the validity and generalisability of many such 
studies. The review found that publication bias of ESDs is likely to be 
considerable, and that commercial interests may exploit the current lack of 
rigour and of widely accepted quality standards of ESD publications. To 
address these has to be one of the most urgent priorities in the short-term.
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9.3 Recommendations
Whether ESDs are used within or outside methodological research, they 
ought to heed existing guidance as well as the recommendations arising 
from the work presented here. Recently the US Agency for Healthcare 
Research and Quality has published a seminal piece of guidance on the 
establishment and use of registries for evaluating patient outcomes
(Gliklich Et Dreyer 2007). Whereas this publication addresses many points 
identified in this thesis, most of the recommendations listed below are 
additional to those in the publication.
9.3.1 Recommendations for databases supporting ESDs
1. The thesis found that key variables were often poorly defined or
absent and thus not usable for ESD analysis. In order to support
ESDs, databases need to provide variables which permit an
unambiguous description of baseline characteristics including co- 
morbidities and possible confounders, treatment decisions, exposure 
to treatment, and key outcomes.
a. In particular, the rationale for why patients are commenced 
on treatment needs to be recorded; this will also lead to the 
identification of potential confounding variables to be 
controlled in the analysis.
b. Prior use of drugs of interest (including prior to enrolment on 
the database) needs to be recorded for each patient so that 
treatment naYvity can be determined.
c. In order to characterise the exposure to the treatment of 
interest, databases need to include reliable assessments of 
compliance with treatment.
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d. Variable definitions, as well as data collection processes, 
need to be robustly defined and piloted with participating 
clinicians /  centres.
2. Far more attention than hitherto needs to be paid to data quality 
and completeness. It is unlikely that databases which collect dozens 
of variables can realistically dedicate sufficient efforts to ensuring 
the quality of all of them.
a. A prudently selected small number of variables should be 
collected. This needs to be informed by the anticipated 
analysis. Collecting any data possible “for a rainy day”, i.e. 
unclear research hypotheses, is likely to risk significant data 
quality problems.
b. Routine validation against external sources of information 
(e.g. original records or other information sources) has to 
ensure the data quality of at least key variables, including 
exposure and outcome variables.
c. Cross-checking of variables against each other (e.g. age and 
height) and also checks of consistency over time (e.g. of body 
weight or height) need to be part of the data quality routine.
d. Information on treatment timing and duration enables better 
categorisation of exposure to the treatment of interest, 
particularly over a longer follow-up period. Timing errors 
(particularly where the year is wrong, e.g. where a course of 
antibiotics is recorded to have lasted for one year AND two 
weeks, when normal practice is a 2-week course) should 
therefore be routinely assessed.
e. Imbalances in reporting and likely under-reporting (e.g. from 
different centres or on particular variables) need to be 
identified and investigated routinely.
f. The Dornase Alfa Case Study identified differences in 
interpretations of variable definitions between centres. 
Contributing clinicians and centres need to be bound to 
consistent unambiguous variable definitions and reporting
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practices; incentives for participation should be linked to data 
quality and consistency in reporting, rather than numbers of 
patients registered.
g. Sharing the intended investigative hypothesis with 
participating clinicians and centres will improve their 
cooperation, but will also be a source of assessment bias. 
Outcome assessors should therefore be blinded if at all 
possible, unless outcomes are unambiguous (e.g. death).
h. The Dornase Alfa Case Study identified a loss of continuity of 
records for patients transferred between participating 
centres. Clear processes for transfers of patients between 
centres need to be established to avoid discontinuity of 
records.
i. Database operators need to remain close to clinicians to 
understand softer issues relevant to the analysis, as well as 
changing practice over time.
3. Database operators need to consider how their database can 
demonstrate and verify the representativeness of the registered 
patient population against the source population.
4. Databases need to ensure they collect data in a way that is conform 
with current data protection legislation. This means that consent of 
patients for inclusion on the database but also for subsequent 
studies based on the database should be sought before patients are 
registered.
5. Database operators (and funders) need to define conditions and 
processes for access to and use of the data they hold. Given the 
possibility of industry sponsors limiting the use of database resources 
for bona fide research, patients should be made aware of any 
proposed access restrictions for such research prior to giving their 
consent.
6. Clear rules should be specified by regulatory authorities for the 
setting up and operating of post-marketing surveillance databases
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and their use (and access to their data) to ensure they are available 
for research.
9.3.2 Recommendations for the conduct and reporting of 
ESDs
These recommendations have arisen from the work on this thesis and 
complement those identified in previous and subsequent guidance (Berger 
et al. 2008; Huston and Naylor 1996; Motheral and Fairman 1997; van Elm 
et al. 2007). An over-arching recommendation therefore is to amalgamate 
these into a widely-publicised consensus document. Much of the criticisms 
this thesis levelled against published ESDs might have been avoidable if 
researchers had followed such guidance in conducting and reporting ESDs.
1. Database analysts need to demonstrate clearly why an ESD should be 
undertaken rather than an RCT, including how the ESD hypothesis is 
different from one which a potential randomised study could 
address. If an RCT is impossible or unnecessary, the reasons need to 
be reported.
2. Database analysts need to ensure themselves of the quality of the 
database (see above recommendations). It is unlikely that non­
condition-specific databases such as Mediplus or claims databases, 
and maybe GPRD to a lesser extent, will be able to meet these 
recommendations. They will remain problematic for much 
effectiveness research, particularly of drug treatments, as the 
indication for treatment is often not recorded, outcome measures 
might need to rely on proxy measures, and determination of 
exposure will be subject to errors and potentially bias.
3. Many published studies do not address the strengths of ESDs or only 
pay lip service to them; ESDs need to capitalise on their strengths; 
part of this is the demonstration of true greater representativeness 
and external validity.
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a. The implications of and reasons for inclusion and exclusion 
criteria (both of the database as well as the ESD) need to be 
considered and reported.
b. Studies need to report the number of patients screened for 
inclusion into the study, and to assess and report the 
characteristics of excluded patients compared to included 
patients.
c. Comparisons of the sample with potential target populations 
should be undertaken and reported to permit judgments of 
likely representativeness.
4. Analysts need to familiarise themselves with recording and clinical 
practices within contributing centres to be able to identify and 
interpret systematic differences in the data. Data cleaning needs to 
focus on centre differences in reporting frequency, systematic 
differences in values of variables, and variations in outcomes.
5. The Dornase Alfa Case Study found that centre differences played a 
considerable but hidden role, but were rarely considered by 
published ESDs. Such centre differences need to be taken account of 
in any analysis.
6. ESDs need to consider the use of newer analytical methods better 
suited to controlling confounding by indication (see Berger et al. 
2008). Unadjusted and adjusted results should be reported, and the 
likely extent of residual confounding explored.
7. Treatment decisions need to be taken into account in the analysis.
8. A sensitivity analysis should explore the likely impact of potential 
errors in the data.
9. The potential for under-reporting of variables needs to be assessed 
carefully and reported, and in particular, any possible non- 
randomness of under-reporting.
10. ESDs should explicitly address each potential source of bias, 
particularly selection bias, information bias, measurement bias, 
differential misclassification.
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11. ESD reports need to record the possible variables and how the choice 
was made for using particular ones, and how these were defined.
12. Similarly, the quality assessments of individual variables should be 
reported.
13. ESD analysts need to consider the implications of lengthy follow-up 
in terms of changes in clinical practice.
14. Intention to treat analyses should be undertaken as a preference.
15. On the question of positive evidence for a causal relationship 
measured on the chronological relationship between cause and 
effect, the strength of a relationship, a dose-response relationship, 
consistency, and specificity (Elwood 1998), ESDs offer considerable 
potential. ESD reports should examine how they meet such criteria 
for causality.
9.3.3 Recommendations for further long-term effectiveness 
evaluations of dornase alfa
The ERCF was discontinued several years ago, and it is unlikely that the 
bulk of its data can be sufficiently well verified and improved to enable 
rigorous analysis of the long-term effects of dornase alfa. The most 
promising way forward to address any such hypothesis is for the existing UK 
CF database and other international database teams to join in a bespoke 
and pre-planned ESD, taking account of the lessons from the ERCF and of 
this thesis.
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9.4 Suggestions for further research
• Whereas much has been written about the potential and potential
pitfalls of observational studies as well as registries, the specific
case of ESDs has barely been considered in the methodological
literature. The increasing popularity of such studies needs to be 
accompanied by carefully planned research into their ability to make 
a valid contribution to an emerging effectiveness evidence base for 
treatments in routine use. This research should focus on the issues 
raised in this thesis and by others, and their actual impact on study 
validity. Post-marketing surveillance databases could provide a 
useful focus for this research.
• Methodological research on prospective ESDs should first focus on 
areas where comparisons between different designs are possible.
• Given the increasing use of ESDs, an instrument to assess the quality 
of such studies needs to be developed with some urgency. In 
addition to assessing dimensions relevant to observational studies, 
such an instrument needs to address the nature of the data source(s) 
and their use by a particular study, as well as focus on the potential 
biases of ESDs.
• Despite much rhetoric, the complementary strengths of study 
designs have not been fully exploited for effectiveness research. 
Cross design synthesis deserves further methodological attention.
• The publication bias of ESDs is worth examining, particularly in the 
area of drug research, where pharmaceutical companies may 
influence the decision to publish.
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Literature review: CF and the effectiveness of 
dornase alfa
This section presents the background to the objectives of the dornase alfa 
study. An overview of the epidemiology of CF with a focus on prognostic 
factors relevant to this study forms the introduction to a more detailed 
review of the existing literature on dornase alfa, focussing on different 
methods used in estimating its efficacy and effectiveness.
Epidemiology of CF
Incidence, prevalence and survival o f CF in the UK
Cystic fibrosis is an inherited disease, affecting an estimated one in 2,500 
newborn babies in the UK (Dodge et al. 1997), but there are considerable 
national variations in reported incidence. The median life expectancy has 
increased significantly over the past decades due to comprehensive 
symptomatic treatment regimens. For a child born with CF today, the 
median life expectancy has been estimated to be around 40 years (Elborn 
et at. 1991). A recent estimate of the size of the UK's entire CF 
population in the year 2000 was 7,750, compared to 6,500 in 1992 (Dodge 
et a i  1997). This increase was experienced only in the adult population, 
with the child population having stabilised at some 4,500 children owing 
to now very low mortality rates in children. A more recent paper 
estimating the survival of adults with CF in the UK born between 1947 and 
1967 points out that whilst the survival into later adulthood is rising, the 
mortality in those age groups does not appear to be improving (Lewis et 
al. 1999).
Factors associated with poor prognosis of CF are chiefly poor lung function 
and nutritional status, pancreatic in-sufficiency, but also a respiratory
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colonisation with Burkholderia cepacia, and according to some studies 
also Pseudomonas aerusinosa (Walters 2000). There is also a broad 
consensus that patients treated by specialist centres enjoy better clinical 
outcomes. CF patients suffer a high prevalence of diabetes mellitus, 
especially in later life, and the presence of diabetes has also been 
associated with a considerably lower median survival (Koch et al. 1999). 
In most countries, the life expectancy of female patients is shorter than 
that of male patients, although it is not clear whether this is a gender- 
specific issue per se. Patients born in the UK in more recent years seem 
to show an equilibrium of age-specific mortality rates between gender 
(Lewis 2000).
Genotype
CF is caused by abnormal function of the chloride channel CFTR. 
Numerous mutations of the gene encoding this CFTR have so far been 
identified (to date more than 800). A growing body of research is 
dedicated to the exploration of the relationship between genotype and 
phenotype in CF. The most common mutation in Caucasian populations 
seems to be DF508, which is reported to occur in 68% of CF alleles 
(Rosenstein 2000). A recent summary on this topic concludes that it is 
clear that defects in each copy of the relevant gene cause the CF 
phenotype, and that even among patients with the classic form of CF, 
variability can be observed. A second conclusion was that genotype 
correlates more closely with certain phenotypic features and that 
decreasing levels of CFTR function are associated with progressive 
involvement of more organ systems (Cutting 2000). Although some 
genotypes are associated with milder or less mild phenotype, prognosis 
cannot be determined by genotype analysis alone (Walters 2000).
Diagnosis
An initial diagnosis of CF is based on the presence of typical clinical 
symptoms characteristic of the CF phenotype (e.g. chronic respiratory 
disease, malabsorption and intestinal obstructive disorders, including
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meconium ileus, pancreatic insufficiency). The presence of these 
symptoms is then evaluated against family history or a positive neonatal 
screening test, and the evidence of genetic abnormality from elevated 
sweat chloride concentrations, or the identification of CF mutations. In a 
cross-sectional study of a US CF registry, 15.7% of patients had meconium 
ileus at birth recorded; at the time of diagnosis, respiratory symptoms 
were present in 44.6% of patients, failure to thrive or malnutrition in 
35.6%, and steatorrhoea and malabsorption in 21.1% of patients 
(FitzSimmons 1994).
The US registry study found that in 1990 70% of patients were diagnosed 
during the first year of their lives, 80% by the age of four years, and 90% 
by the age of twelve years (FitzSimmons 1994). However, diagnosis in 
later life is always a possibility; this has been associated with milder 
clinical symptoms and their progression as well as a lower prevalence of 
P. aeruginosa infections (Gan et al. 1995). A Dutch study of 143 patients 
comparing those diagnosed before and after the age of 16 years found no 
patients homozygous for DF508 in the latter group (Gan et al. 1995).
One might assume that screening is associated with better prognosis, 
because treatment can commence earlier, but clinical advantages have 
proved difficult to demonstrate. A study based on data from the 
Epidemiologic Registry of Cystic Fibrosis (ERCF) compared patients who 
were diagnosed by neonatal screening (1,684 of 13,684 patients) with the 
rest of the registered population (Navarro et al. 1999). Whereas 
nutritional status of the under-13-year-olds was better in the group 
diagnosed by screening, an advantage in respiratory status of this group 
was only observed in the youngest patients under 6 years of age (Navarro 
et al. 1999).
Respiratory disease and lung function
The main manifestation of CF is respiratory disease. The altered 
secretions of the respiratory tract lead to viscous mucus, which is
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susceptible to infections with a variety of microorganisms. Persistent 
infections lead to chronic inflammation.
Forced Expiratory Flow in one second (FEVi) is one of the most frequently 
used monitoring indicators and outcome measures in CF, together with 
Forced Vital Capacity (FVC). Both FEVi and FVC are usefully expressed in 
a standardised form as per cent of the value predicted for the age, sex, 
and height of a patient ("% of predicted”). FEVi is generally regarded as 
the most significant predictor of mortality amongst CF patients. A cohort 
study undertaken in the late 1970s and 1980s in Canada signalled that 
patients with an FEVi of less than 30% of predicted had a two-year 
mortality rate of over 50% (Kerem et al. 1992).
Once airways obstruction has sufficiently progressed, the lung function of 
CF patients deteriorates progressively; according to various cohort 
studies, this decline is approximately 3-5% of predicted FEVi per annum 
(Walters 2000). In terms of therapeutic effectiveness, any achieved 
delay, slow-down, or suspension of this decline is beneficial compared to 
continued decline. One of the main sources of data on annual lung- 
function decline to be expected in CF is a 4-year randomised trial of 
ibuprofen in CF. The placebo group showed an annual rate of decline in 
FEVi of -3.60±0.55% (mean slopetSE). However, the study only included 
patients with a baseline value of >60% of predicted FEVi and also excluded 
patients colonised with B. cepacia and other medical conditions relevant 
to the investigational drug (Konstan et al. 1995).
Braggion and colleagues (1997) retrospectively reviewed the decline in 
FEVi of a cohort of 57 selected patients between the ages of seven and 
twelve years. They too report an annual decline of -3.6+2.9% predicted 
FEVi (Braggion et al. 1997). Another Italian study followed 48 children 
aged 6-15 years for an average of 5.8±0.6 years and estimated a mean 
annual decline of -2.1 (range: -5 to 1.4) (Lucidi et al. 1997).
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Some variation in the rates of decline has been put down to factors such 
as age or baseline FEVi value. Data from 366 patients on a Canadian 
database, who had at least one pulmonary function test recorded before 
they were 10 years of age, showed great variations in decline between 
subgroups of patients. The authors remark that average rates of decline 
were significantly (negatively) related to survival age. Women and 
patients with pancreatic insufficiency showed a steeper decline (Corey et 
al. 1997). A study of 5,313 ERCF patients with an observation period of >2 
years identified an association of above average FEVi decline with 
diabetes, colonisation with 6. cepacia, and severe malnutrition (Mastella 
et al. 1999).
The North-American sister database of the ERCF, the Epidemiological 
Survey of CF (ESCF) (Morgan et al. 1999) provided data for a longitudinal 
assessment whereby rapid and non-dediners in predicted FEVi values 
were defined amongst 6-12-year-old patients observed over 18 months, 
based on the upper and lower thirds of annual change in FEVi. A body 
weight of <10th percentile, P. aeruginosa colonisation, and daily sputum 
production were independently associated with an increased risk of a 
rapid decline of FEVi (Stokes et al. 1997).
A cross-sectional analysis of ERCF data on patients aged 6 years and older 
indicates that an FEVi value of >10% less than predicted was associated 
with lower weight for age percentiles, pulmonary symptoms as well as 
colonisation with P. aeruginosa and 6. cepacia (Navarro et al. 2001). 
Unsurprisingly, treatment-related variables such as the use of oral 
corticosteroids, non-steroidal anti-inflammatory drugs, dornase alfa, or 
oxygen were associated with lower FEVi values.
There is evidence that not only premature mortality but also lung function 
decline is reducing in the CF population; the Adult CF Unit in Manchester 
reported significant differences in the rate of lung function decline in 
their patients aged over 26 years, when comparing data from within one
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decade (the periods 1985-6, 1989-90, and 1993-4); the latter periods 
showed the slowest decline (Abbott et al. 1995).
Anthropometries
Besides lung function, poor nutritional status is one of the main predictive 
factors in CF disease. In a cross-sectional study of some 3,000 patients 
from the majority of the UK's large CF specialist centres (i.e. nearly half 
of the CF population) during 1994/5, Morison et al. (1997) have shown 
that height and weight in the first 10 years of life is now at approximately 
0.5 standard deviations (SD) below the population mean, despite poorer 
SD scores during the first year of life (possibly due to late detection of 
mild cases as well as some catch-up growth in the following years). It is 
also not clear what part low birth weight might play, if any. The weight 
of adults is still deviating considerably from the norm, particularly in 
men, which could be due to fewer severely affected women surviving to 
older age groups.
A US study of over 13,000 patients in 1993 indicated that mean and 
median height- and weight-for-age of CF children were at the 20th and 
30th percentiles based on the National Center for Health Statistics/Centers 
for Disease Control growth reference. Twenty per cent of the children 
were below the 5th percentile (Lai et al. 1998). A study based on ERCF 
data indicates that adolescents with CF maintain a constant disadvantage 
of about one standard deviation from the normal growth curve (Navarro et 
al. 2000). The youngest age group (<6 years) and adults of 18 years or 
older seem to show a slight catch-up growth; in 6-12-year-olds the 
opposite was observed. However, it is argued that given the present 
treatment possibilities, nutritional state and growth in most CF patients 
should be normal (Rosenstein 2000).
Microbiological colonisa tion
Recurrent and chronic infections of the viscous sputum are amongst the 
main complications of CF. The organism most frequently found in sputum
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cultures, particularly in the UK, is Pseudomonas aeruginosa, which tends 
to be more prevalent in older age groups. Similarly, Burkholderia cepacia 
is more likely to be found in older patients, albeit that its prevalence is 
much lower. For both organisms prevalence varies between countries and 
centres. B.cepacia is often seen as a factor associated with worse 
prognosis (Walters 2000). According to a matched case-control study 
involving 125 patients, 8. cepacia infection per se is not necessarily 
associated with poor pulmonary status, but is associated with poor long­
term survival (Frangolias et al. 1999). Similarly, data from the ERCF 
indicates that colonisation with 6. cepacia was associated with shortened 
survival (Koch et al. 1999) and lower average change per year in weight- 
for-age Z-score (Navarro et al. 2000).
Exacerbation
Pulmonary exacerbations of CF are generally indicated by a raised 
temperature, cough, increased sputum production, weight loss, decreased 
lung function or similar symptoms indicating an inflammatory response to 
an infection. A one-year retrospective review of 299 adult patients in 3 
CF centres in the UK estimated the annual rate of exacerbation episodes 
as 3.54 per patient; this varied between centres, presumably also partly 
due to differences in defining diagnostic criteria for exacerbations (Bilton 
et al. 1998).
Diabetes
Diabetes is particularly common in CF and rising with age. Of 114 CF 
patients aged 30-59 years and registered with the French registry of CF 
(male/female: 1.6), 12% had insulin-dependent diabetes mellitus (Badet 
et al. 2001). Similarly, the prevalence of diabetes mellitus in the Danish 
CF population has been reported to be 14.7%, (Lang et al. 1994) and the 
mean age at diagnosis 21 years (Lang et al. 1995). The presence of 
diabetes has been strongly linked to poorer lung function across all age 
groups as well as poor nutritional status (Koch et al. 2000).
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Efficacy and effectiveness of dornase alfa
The following sections review the evidence on dornase alfa depending on 
the type of study design used (i.e. randomised and non-randomised 
studies). For this review, the bibliographic databases Medline and Embase 
were searched for “(DORNASE ALFA OR DORNASE OR 
DEOXYRIBONUCLEASE OR PULMOZYME) AND CYSTIC FIBROSIS". 
Original reports of studies evaluating the drug were included in the 
review. In addition, abstracts of the European CF Conferences since the 
licensing of dornase alfa (1994) have been searched.
Evidence from randomised triais
A recent Cochrane review addressed the question of whether dornase alfa 
was associated with reduced mortality and morbidity compared to 
placebo (Kearney & Wallis 2003). The authors conclude that the available 
studies were of insufficient duration to assess the impact on mortality or 
whether the identified beneficial effect on lung function is sustained in 
the long-term. Hence, there was no evidence that dornase alfa affects 
the natural history of lung disease in CF patients in the long-term or that 
long-term use improves life expectancy. All seven trials included in the 
Cochrane review are represented here, together with more recently 
published studies as well as some studies excluded by the Cochrane 
review (studies not included there were: (Hubbard et al. 1992; Robinson 
et al. 2000; Nasr et al. 2001; Quan et al. 2001).
Aitken and colleagues (1992) reported an early non-randomised trial to 
assess the safety of dornase alfa on 12 healthy subjects and 14 CF patients 
with an FVC of >40% predicted and no recent exacerbations. After a 2- 
week treatment period and later re-challenge with a single dose the 
authors concluded that dornase alfa appeared safe in both normal and CF 
subjects. Another early and similarly small study (Hubbard et al. 1992) 
confirms these safety results.
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Of four further short trials (Ramsey et al. 1993; Ranasinha et al. 1993; 
Laube et al. 1996; Wilmott et al. 1996), three (Ramsey et al. 1993; 
Ranasinha et al. 1993; Laube et al. 1996) showed significant 
improvements in lung function over placebo (see Table A.1). The phase II 
study by Ranasinha and colleagues (1993) was followed by a 6-month 
open-label extension of 59 patients. This showed a further improvement 
during the first month and than stabilised at a mean increase of 6.2% FEVi 
(Cl: 4.6-7.8%) and 7.2% FVC (Cl: 5.1-10.2%) from baseline (Shah et al. 
1995b). Two weeks after the therapy was discontinued, FEVi and FVC fell 
5.7% and 5.9% below the baseline respectively. A further 18-month open- 
label extension involving 52 patients was initiated using 2.5mg dornase 
alfa once daily (rather than twice daily as before). During these 18 
months, FEVi and FVC increased again by a mean 8% and 1.2% respectively 
from the new baseline (Shah et al. 1995c). This improvement was 
accompanied by a gradual weight gain also. A recent 7-day RCT, with 
ciliary and cough clearance as its main outcome of interest, observed a 
significant increase from baseline, but the difference between the 
improvement of the placebo and treatment group was only significant for 
FVC, but not FEVi as outcome measure (Robinson et al. 2000).
There are so far only two RCTs of severely affected patients (FVC <40%), 
for whom the drug is currently not licensed. The first showed an 
improvement in FEVi in the dornase alfa group of 9.4% from baseline, 
compared with 2.1% in the placebo group (p<0.001) after three months 
(McCoy et al. 1996). The randomised phase of the second study was only 
2 weeks and did not show a significant difference between the two groups 
in mean percentage change from baseline in per cent of predicted FEVi or 
FVC (FEVi: 1.4% [SEM 2.1] in the dornase alfa group, and 4.2% [SEM 2.2] in 
the placebo group; FVC: 8.8% [SEM 3.6] in the dornase alfa group, and 
13.7% [SEM 3.8] in the placebo group) (Shah et al. 1995a). Sixty-four 
patients entered a 6-month open-label extension of this trial, but only 38 
completed the study; the overall mean improvement was 9% of predicted
Use of Databases in Drug Effectiveness Studies 397
Appendix A
FEVi and 18% of predicted FVC. The efficacy of dornase alfa in severe 
patients is thus still under question (Newman et at. 2001).
Most studies have included patients from age five or more upwards. Nasr 
and colleagues (2001 ) performed a placebo-controlled randomised trial of 
dornase alfa over 100 days on 12 children under 5 years of age. The 
outcome measures used were high-resolution computer tomography 
(HRCT) of the chest and chest x-ray (CXR), since spirometry measures are 
not reliable in small children. Two scorers rated the scans and x-rays and 
average scores between them were used for the analysis. The HRCT but 
not the CXR scores showed a significant improvement in the mean change 
from baseline between the placebo and treatment groups.
Until recently, the most important RCT was a multi-centre 6-month 
phase-III trial, involving 968 patients (Fuchs et at. 1994). Main outcome 
variables were the occurrence of exacerbations of respiratory symptoms 
requiring parenteral antibiotics, and pulmonary function. The age- 
adjusted risk of a defined exacerbation requiring parenteral antibiotic 
treatment was reduced by 28% (relative risk, 0.72; 95%CI: 0.52 - 0.98; 
p=0.04) in patients receiving 2.5mg dornase alfa once daily and 37% 
(relative risk 0.63; 95%CI: 0.46 - 0.87; p<0.01) in those receiving the same 
dose twice daily, compared to a placebo group (for all exacerbations - 
including those not meeting the study's criteria - see Table A.1). Over 
the duration of the study, FEVi improved on average by 5.8% (SD: 0.7) and 
5.6% (SD: 0.7) in the group treated with 2.5mg dornase alfa once and 
twice daily respectively (p<0.01 compared with placebo). Compared with 
the placebo group, those receiving 2.5mg dornase alfa once daily spent 
1.3 fewer days in hospital (p=O.O6), those receiving the dose twice daily, 
1.0 fewer days (p=O.5). The first treatment group spent 2.7 fewer days 
receiving parenteral antibiotics (p=0.05), the second 2.2 fewer days 
(p=0.13), compared with the placebo group.
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In December 2001, results of a 2-year RCT funded by Genentech, Inc, and 
Hofmann-La Roche, Ltd. were published (Quan et al. 2001). Patients 
were of a mean age of 8.4 years and had mean FEVi of 95% of predicted at 
baseline (FVC: 102%). After an initial improvement following initiation of 
dornase alfa treatment, mean FEVi values of the treatment group 
returned to baseline after 96 weeks. The advantage over the control 
group was a mean 3.2% predicted FEVi (SD: 1.2; p=0.006), however, at 
one year follow up, this was not significantly different. The risk of 
respiratory tract exacerbations was reduced by 34%, which was not 
statistically significant (95%CI: 0.44-1.00; p=0.48).
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Appendix A
Evidence from non-randomised studies with control groups
An overview of non-randomised studies with control groups is presented in 
Table A.2. The possibly longest available follow-up period is documented in a 
matched case-controlled study lasting four years (Shah et al. 2001). Over a 4- 
year period, the difference in the rate of decline of the treatment and control 
groups did not reach statistical significance. However, if data from the 2 
years preceding dornase alfa treatment are included, the difference in the 
rate of decline is significant (decrease of the slope from -1.68 to -0.57 in 
treatment group, vs. increase from -0.76 to -2.19 in control group; p=0.002). 
Of the non-randomised controlled studies, this seems to be the only one 
having demonstrated a significantly improved exacerbation rate in the 
treatment group. There was a significant difference in the number of 
infective episodes experienced during the 4-year period (median 3.13 [IQR: 
1.25-4.25] in the control group, vs. 1.25 [0.6-3.0] in the treatment group 
(p=0.035)). The median numbers of days of intravenous antibiotic treatment 
differed to a similar extent.
Johnson et al. (1999a) have analysed ESC F data to assess the effectiveness of 
dornase alfa using a multiple regression analysis to account for 49 potentially 
biasing factors. The follow-up period was only one year, and the study does 
not report any analysis of deceased patients' records or give any information 
on survival. The estimated benefit over the control group from using dornase 
alfa was 4.3% of predicted FEVi (3.2% on the intention-to-treat analysis which 
included patients who have been on dornase alfa only for part of the 
observational period). The crude mean values of FEVi for treated patients 
improved by 3.9% of predicted FEVi (95%CI: 2.14 - 5.67) compared with a 
decline of 1.6% (95%CI: 1.01 - 2.19) in the untreated cohort. This study also 
shed some light on the differences in populations on and off dornase alfa. 
Those treated had lower pulmonary function, more bacterial colonisation, and 
more exacerbations at baseline.
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A conference abstract presented in 1999 (Hodson et al. 1999) reported an 
analysis of ERCF data: FEVi values of 431 patients who had received dornase 
alfa for 2 years were compared with the values for 2,125 patients who had not 
received the drug. Patients on dornase alfa for a shorter time were excluded 
from the study. Overall mean change in FEVi was -0.7% in the treated group, 
compared with -2.2% in the patients not treated, less encouraging than the 
findings of the North-American study of ESCF data (Johnson et al. 1999a) 
which used half the follow-up period. On the ERCF study, a comparison of 
untreated patients with patients who had one year without treatment 
followed by one year of treatment showed significantly fewer exacerbations in 
the treated group; males, patients between 6 and 12 years of age, and those 
without bacterial colonisation showed better responses. No lung function data 
are reported for this before-after comparison.
In 2003 - after the completion of the Dornase Alfa Case Study - Hodson and 
colleagues published another study of dornase alfa based on ERCF data 
(Hodson et al. 2003), comparing patients after 2 years of treatment with an 
untreated comparison group. The analysis was a simple comparison of the two 
groups without statistical control of known baseline differences in age and 
lung function. Treated patients had improved lung function after 1 year (by 
2.5%), but not after 2 years (0.3%), compared to deterioration of -1.1 and 2.3% 
predicted after 1 and 2 years in the untreated group. The frequency of 
exacerbations had improved by -0.25 (Cl: -0.12 to -0.39) in the treatment 
compared to the untreated group (comparison between year 1 and 2).
A retrospective study using data on lung function from the two years prior and 
two years post initiation of dornase alfa treatment found a mild significantly 
improved decline with treatment compared to the period without treatment 
(difference in slopes -2.08, Cl: -1.13 - -3.03, p<0.0001) (Milla 1998). The 
author explained that the level of pulmonary function in his patient group has
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been considerably better than that of previously investigated patients, and 
that the subjects belonged to one single practice where an intensive 
treatment regimen already focused heavily on mucus clearance.
A French study on 55 patients aged 3 to 27 years reported no change in FEVi 
during a year of follow-up (from 52.1% [SD: 23.5] to 53.5% [SD: 19.5]), whereas 
there was significant deterioration during the preceding year in which patients 
were treated with the standard aerosolised sodium 2 mercapto ethane 
sulfonate and oral ambroxol (57.1% [SD: 15.8] to 52.1% [SD: 23.5]; p<0.05) 
(Bertolo-Houriez et al. 1997).
A small German open-label study of dornase alfa observed 12 patients with 
mild to moderate lung disease (FVC: 45-107% of predicted) for 18 months, 
including a 3-month treatment pause after 12 months. The overall positive 
response after the first 12 months was remarkable and also continued to rise 
throughout the year, reaching a mean difference from baseline of 21.8% (Cl: - 
25.5 to 76.1) in FEVi (Heuckmann et al, 1999). After the 3-month treatment 
interruption, the difference from baseline had fallen to 8.4% (Cl: -27.5 - 
33.9), but rose to 23.4% (Cl: -13.7 - 52.6) after a further 3 months treatment. 
FVC results mirrored those observed on FEVi, albeit at lower levels. Whereas 
all 12 patients improved in the first year, the response shown during that 
period interestingly was repeatable only in 5 of 12 patients (difference <5%) 
during the second treatment period (Heuckmann et al. 1999).
Follow-up studies without controi groups
There is one large multi-national study of 974 patients on dornase alfa 
(baseline FVC before initiation: 40-70% of predicted; age 5 years or over) 
(Harms et al. 1998a) which reported a mean improvement from baseline of 
10.5% in FEVi and 7.2% in FVC after 12 weeks, a result which compares very 
well with the evidence available from many trials.
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Small “open label” studies without control groups are frequently reported, 
particularly at conferences. Most of these studies include few patients, lack 
comparison groups, and are of short duration (typically less than 4 weeks). 
However, some of these studies have followed patients for a longer period and 
are mentioned here. It has to be said that in many cases, the reports are only 
available in abstract form and therefore allow only a very limited critical 
appraisal. Publication bias may be significant.
Amarales and colleagues (1998) report a 12-month follow-up of 18 patients 
aged 8-24 who experienced a mean improvement of +6.7% in FVC (p<0.037), 
and +8.4% FEVi (p<0.025). However, typically the response varied greatly, and 
on both those outcome measures 4 patients deteriorated. A study following 63 
Czech patients over one year also reported a statistically significant 
improvement over the baseline values of FEVi (p<0.05) (Bartosovâ et a i  1999). 
A retrospective review of data on 65 children during their first year of dornase 
alfa therapy reported a median increase of 11.1% (Cl: 0-18.8) in FEVi and 5.6% 
(Cl: 0-17) in FVC after 9 months with substantial variability of responses 
between patients (Davies et al. 1997).
A retrospective review was undertaken on 71 patients using dornase alfa in 
Leeds, some of whom could be followed for up to 6 years. Overall the per 
cent of predicted FEVi values of all patients declined through every year (0.7% 
from baseline after one year, 6.3% after 2 years and then by approximately 3% 
per year to 5 years) (Ratnalingam et al. 2001). A sub-analysis comparing 
responders (those with at least 5% increase in FEVi or FEF25-75 after 1 month) 
to non-responders found improved FEVi values in the responders for the first 
two years, compared with a fall in values in non-responders.
Significant differences from baseline in FEVi or FVC after one year in mild to 
moderate disease have been found by several authors (Nousia-Arvanitakis et 
at. 1997; Nowakowska et al. 1997). Other studies found a similar response
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after two (Wizla-Derambure et ai. 1998; Ratnalingam et al. 2001; Santos et aL 
2001) or three (Sands et ai. 2000) years. In two of these studies (Ratnalingam 
et ai. 2001; Santos et ai. 2001), the improvement was not significant after 
three or more years.
Comparisons with hypertonic saline
A recent open cross over trial of 12 weeks duration examined whether daily 
administration of dornase alfa was equally effective as alternate-day 
treatment, or treatment with hypertonic saline in 48 children (Suri et ai. 
2001). The increase in FEVi over 12 weeks was comparable for the two 
dornase alfa treatment groups: 16% (SO 25%) and 14% (SO 22%) for daily and 
alternate-day dornase respectively, the difference being not statistically 
significant (2%; 95%CI: -4 to 9%; p=0.01). However, FEVi increased only by a 
mean 3% (SO 21%) following treatment with hypertonic saline. Daily dornase 
treatment resulted in an 8% (Cl: 2 to 14) greater increase in FEVi than did 
saline (p=0.01). Most patients (83%) had been dornase alfa users before the 
trial, and the response varied considerably between individual patients. 
Previous short-term and pilot studies had shown larger increases of FEVi with 
hypertonic saline: 15% increase after 2 weeks in a study by Eng (1996), and 8% 
after a 3-week pilot study, which used a larger volume of saline (Ballmann 6 
Hardt 2002). Suri and colleagues (2001) suggest that the initial good response 
to hypertonic saline may not be sustained over time.
Cost-effectiveness of dornase alfa
The study of Fuchs et al. (1994) has been used to assess the effects of dornase 
alfa on the cost of treating respiratory tract infections (RTIs). Over 24 weeks, 
the treatment of RTIs for patients receiving dornase alfa was estimated to be 
$814-1,682 less, but this did not take into account the cost of dornase alfa 
itself. The economic evaluations based on Fuchs’ data concluded that the
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cost of the drug was only offset to about 15-35% by reductions in pulmonary 
exacerbations and hospitalisations (Oster et al. 1995; Menzin et a i  1996).
In a similar study - also based on Fuchs’ data - Schulenburg and co-workers 
(1995) estimated the cost-effective ness of dornase alfa in a German context 
and with a health insurance perspective. Again, the drug costs were omitted 
from the analysis. The study reported a difference in net direct total costs of 
1,970 German Marks after 6 months treatment (roughly £6,000). Treatment 
costs are approximately twice that high.
A Canadian Health Technology Assessment of dornase alfa also dealt with its 
clinical and economic impacts (Perras & Otten 1996). Based on a record 
review of a very small number of patients over a period of 12 and 15.9 
months, the authors tentatively note that the drug may become more cost- 
effective over time, but such a conclusion was premature given the lack of 
information on long-term effectiveness of dornase alfa. The outcome of 
interest was rate of hospitalisation. Costs included those associated with 
hospitalisation, antibiotic use, and, of course, dornase alfa use.
The most recent report by the Wessex Institute on the topic has modelled the 
possible long-term benefits of dornase alfa, for want of evidence of long-term 
effectiveness (Christopher et al. 1999). An attempt has been made to 
estimate costs per life year gained. The authors model FEVi decline based on 
findings from Fuchs et al. (1994) and studies on the prediction of lung function 
decline (Kerem et al. 1992; Konstan et al. 1995). Their resulting cost- 
effectiveness calculations conclude that if all patients were treated 
throughout their lifetime after their FEVi fell below a typical level (a duration 
of treatment of 30 years was assumed), two additional life years might be 
gained at a discounted cost of £52,550 each (range between £25,000 and 
£57,000, depending on sensitivity analysis); if therapy was restricted to 
patients with an FEVi of 70% of predicted or less who responded to treatment,
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seven life years might be gained at a cost of £16,110 each (range: £18,000 - 
£36,600) (it was assumed that 30% of patients tried on dornase alfa had a 
mean improvement of 20% in FEVi; a duration of treatment of 37 years was 
assumed).
McIntyre (1999) (of Roche Products Ltd) reports the results of her model as 
giving two extra years of life at a cost per life year gained between £34,854 
and £45,234. Her assumptions differ inasmuch as she does not allow for the 
selection of responders for treatment but rather assumes everyone to be 
treated below 70% of predicted FEVi, and she takes account of the costs offset 
by dornase alfa (Oster et al. 1995).
Johnson et a i  (1999b) have estimated the cost of treatment for Alberta 
(Canada) patients with CF under conventional (not randomised) conditions 
using individual-level data, and determined the impact of dornase alfa therapy 
- amongst other factors - on cost of care, using multivariate linear regression 
analyses. Patient and resource use data from the ESCF and cost data from US 
sources were used. Known predictors of morbidity and mortality in CF tended 
to determine use and cost of care, and severity of disease was an important 
determinant of cost, independent of dornase alfa. However, having received 
dornase alfa significantly contributed to higher costs. It accounted for 44% of 
estimated overall care costs of the 303 patients included in the sample.
A trial by Suri and colleagues suggests that alternate day dornase alfa use is 
equally effective as daily administration (Suri et a i  2001). The mean 
incremental cost of using daily rather than alternate treatment was £513 (Cl: 
£-546 to £1,510) over a 12-week period; daily dornase alfa use rather than 
hypertonic saline incurred a mean incremental cost increase of £1,409 (Cl: 
£440 to £2,318). It was mentioned earlier that there was no difference 
between daily and alternate-day dornase alfa use over the trial period (2% 
difference in mean increase of FEVi (Cl: -4 - 9, p=0.55).
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Further observations regarding the use and effectiveness of 
dornase alfa
There are several issues raised by efficacy and effectiveness evaluations of 
different types; these issues, which mainly relate to treatment response and 
its observed variations, are discussed here in turn.
Varying response
One of the most elusive questions regarding dornase alfa use concerns the 
significant proportion of patients who do not experience a favourable response 
to the therapy. Significant variations in the quality of the response has been 
observed and emphasised by many authors.
A Spanish study examined medical records of 199 patients (mean age 14.5 
years, mean FEVi 54.1%, mean FVC 65.5%) using dornase alfa with a minimum 
follow-up period of 1 year (Cobos et al. 2000). The authors drew particular 
attention to the large inter-individual variability in response to treatment, 
with benefits being doubtful in some 50% of patients included in their study, 
whose FEVi had fallen over a 2-year period. Over the same period, 34% had 
improved 10% or more over their baseline values. Overall, a mean change in 
FEVi of 3.3% (Cl: -1.1 to 7.6) and 5.1% (Cl: -0.7 to 10.9) was reported after one 
and two years respectively. The medium-term response was correlated with 
the early response shown during the first 3 months. Similarly, Blau et al. 
(1997) reported that only 30-50% of patients with an FVC between 40-70% 
predicted had experienced significant improvements in their pulmonary 
function after 3 months. After 6 months, 11% of patients had experienced a 
fall in FVC of more than 20% from the baseline. Overall, both FVC and FEVi 
had improved at the 1-month assessment, but fallen again thereafter.
In the retrospective study by Mi Ha (1998), who compared individual lung 
function changes from the 2-year period before and 2-year period after
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initiation of dornase alfa treatment, over 60% of the 190 patients showed no 
change in their FEVi trends, nearly 30% experienced a decline and less than 
10% experienced an improvement. Milla stresses the importance of assessing 
the benefit of treatment on an individual basis, also allowing for adverse 
responses.
No study seems to have found a way to predict response to therapy from any 
baseline values, including pulmonary function. Response after 6, 9 and 12 
months correlated well with the response found after 3 months in a 
retrospective study of 65 children using dornase alfa (Davies et al. 1997), a 
finding similar to that of another study (Davies et al. 1997; Wizla-Derambure 
et al. 1998). Most centres therefore operate initiation protocols, monitoring 
the response in each eligible patient.
However, there is also an indication that the same individual may show a 
different response at different times. A very small German study on 12 
patients reported that only in 5 patients could the response observed during 
one year of treatment be repeated (difference <5%) after a 3-month treatment 
interruption and further 3 months treatment (Heuckmann et al. 1999). 
Finally, it has been suggested that poor inhalation technique could be 
responsible for a poor response and that a more intelligent aerosol delivery 
system which can compensate for poor technique may benefit patients who 
previously have not shown an adequate response (<10% increase in FEVi during 
a period of 2 weeks) to dornase alfa treatment (Scott et al. 2001).
Severity at baseline
There are indications that patients with poorer lung function at baseline show 
less improvement following treatment with dornase alfa than patients with 
mild or moderate disease (Cimino et al. 1997). However, a small Spanish 
study saw less improvement after 21 months in the subgroup with >70% 
predicted FVC at baseline compared with a group who had baseline values
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between 40 and 70% (Dapena et al. 1997). A French study reports similar 
findings after a 2-year follow-up (Deneuville et ai. 1997), and another small 1- 
month open-label study also observed that initial lung function was 
significantly less in responders (13 patients who showed a 10% or greater 
increase in FEVi from baseline out of a total sample of 20 patients) than non­
responders (Henry et at. 1998). Observations from the ERCF signal that young 
patients and those with mild disease may benefit most from dornase alfa 
treatment (Hodson et ai. 1999).
Deterioration after treatment
Some authors have reported significant decreases in lung function several days 
after treatment, despite initial significant improvements (Shah et al. 1995b; 
Amelina et ai. 1999). In the early short RCTs, significantly improved 
spirometry values after 10 days had deteriorated back to baseline values one 
month after cessation of therapy (Ramsey et al. 1993; Ranasinha et al. 1993).
Fumy a and colleagues (2001 ) observed patients during a 3-month treatment 
period followed by a 3-month period on placebo. The significant gain in lung 
function during the first three months was followed by a return to baseline 
values at the end of the placebo period. The small German open-label study 
with a 3-month treatment interruption after 12 months (Heuckmann et ai. 
1999) similarly observed a deterioration during the treatment interval. Such 
findings seem to point at the need for continuous treatment.
Maintenance of improvement
Some studies report in more detail on the course of lung function changes 
during treatment. In several cases, an initial improvement has been followed 
by a subsequent deterioration. De Vuyst and colleagues (2000) report an 18- 
month follow-up of 33 patients with moderate disease. An increase in FVC of 
8.5% at 6 weeks was followed by a decrease during which baseline values were 
reached at about 24 weeks, after which FVC remained stable. Similarly, FEVi
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increased by 14.4% in 6 weeks and reached baseline values at the 60th week, 
remaining stable thereafter. A small 6-month study of 20 patients with mild 
to moderate CF reported that overall, both FVC and FEVi had improved at the 
1-month assessment, but fallen again thereafter (FVC at baseline: 60.7+2.5% 
predicted, at 3 months 70.4±2.8%, and at 6 months 63.3+4.2%) (Blau et al.
1997). Hence, such reports suggest that the extent of an initial favourable 
response may be reduced during ongoing therapy. However, other studies 
have reported continuous rises of the relevant lung function parameters over 
12 months (Heuckmann et al. 1999).
Side effects
The largest trial (Fuchs et al. 1994) reports that the administration of dornase 
alfa was associated with voice alterations (mainly hoarseness), pharyngitis and 
laryngitis, but no anaphylaxis. These types of side effects have been reported 
in many other studies. In an open-label study of similar size (974 patients), 
the most common treatment-related adverse events, voice alterations and 
pharyngitis, were each experienced by around 16% of the sample (Harms et al. 
1998a).
Compliance
The administration of dornase alfa via a nebuliser requires a significant time 
commitment from patients. Whereas this may be convenient in hospital, it 
may be less so as part of a busy lifestyle at home or work. A Czech study 
based on anonymous questionnaires found that 52.3% (45 patients) of 
responding CF patients reported that they omitted their inhalations 
occasionally; a further 8.1% (seven patients) forgot more often (Bartosovâ et 
al. 2000). A small study in Manchester assessed “compliance” by comparing 
the expected cost of dornase alfa treatment for 10 children and 13 adults with 
the actual recorded cost of encashed GP prescriptions for the drug (Talbot et 
al. 1998). Of course, encashed prescriptions do not equate directly to 
compliance, but they can be assumed to come closer to the truth than mere
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prescription records themselves. Of the adult and child patients, 59% and 78% 
of the expected cost respectively were actually incurred. Suri and colleagues 
(2001) had observed 84% compliance in a 3-month trial of dornase alfa 
involving 48 children.
A study by Ollendorf et al. (2000) used healthcare claims over 30 months of 
dornase alfa treatment to estimate costs of care associated with different 
levels of use of dornase alfa. Interestingly, the median number of therapy 
days over the period was only 355. The 12 patients below median use showed 
a median of 180 days, the other half of the patients used it for a median of 
494 days, still well below 100%-use. This small study points at the possibility 
that low use may be associated with higher costs of respiratory care, whereas 
prolonged use may reduce such costs; an annual saving of $2,500 was 
contrasted with an increase in the low-use group of $17,000, compared to 
costs calculated on the basis of a 6-month period preceding the initiation of 
dornase alfa.
Treatment practices
Early data from the ERCF (1994 and 1995) indicates that 25% of the then 6,858 
registered patients were receiving dornase alfa on enrolment, with only 16% in 
the UK (3,433 UK patients were then registered) (Koch et al. 1997). However, 
the intensity of and indications for use seem to still vary considerably. 
Whereas some see the main reason for prescribing dornase alfa to be for 
immediate symptom benefit (Geddes & Shah 1999), others may envisage a 
more or less continuous daily use at least in some patients.
Given the varied response as well as the cost of treatment, many centres have 
developed treatment initiation protocols, at times in co-operation with their 
respective purchasing authorities. Bradley and colleagues (2001) surveyed 49 
CF centres in the UK and Ireland. Of the 42 responding centres, 22 had a 
standard written protocol for the commencement of dornase alfa. Indications
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most commonly used for the initiation of treatment are: age >5 years, thick 
purulent sputum, difficulty expectorating sputum, deteriorating lung function, 
and recurrent infections. Outcome measures to assess the treatment's 
effectiveness include respiratory function, sputum production, pulse oximetry, 
and subjective awareness over an agreed trial period. The duration of 
individual trial periods on dornase alfa varies between centres from 2 weeks to 
3 months (Geddes £t Shah 1999). There are indications from some studies, 
that long-term response may be predicted on the basis of response shown 
after 3 months (Davies et al. 1997; Wizla-Derambure et al. 1998).
Some authors advocate formal “n-of-1 trials”, incorporating randomisation, 
double-blinding and placebo control periods, to determine the individual 
response of any patient eligible for treatment (Innes 1998). Clinicians from 
Leeds for example reported their use of a 2-week trial period (longer for 
severe patients), after which the efficacy of dornase alfa is assessed by a 
minimum 10%-increase in FEVi or FVC from baseline and by subjective 
impression (Conway 1997). The adult centre at Liverpool uses an 
improvement in FEVi of >10% as the criterion for response (Ledson et al.
1998).
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Summary
❖ There are indications that benefits of dornase alfa in CF in terms of a 
reduced lung function decline and a reduced risk of respiratory 
exacerbations may continue over the long term. Randomised controlled 
trial evidence of the efficacy of dornase alfa is now available for a 
follow-up period of 2 years. In the longest (two-year) RCT, the 
treatment group exhibited a significantly reduced lung function decline 
vis-à-vis the control group. However, after one year, this difference 
was not significant (Quan et al. 2001).
❖ Longer-term RCTs do not exist and are very unlikely to be possible in 
future. Observational studies of more than two years follow-up are 
rare; they are so far of relatively small scale and frequently without 
comparison groups. The authors of a relatively recent four-year case- 
control study recommended further long-term studies involving larger 
cohorts (Shah et al. 2001).
❖ Considerable variations in the nature and extent of response between 
and probably also within individuals as well as practice variations 
between different CF centres add to the difficulties in evaluating the 
effectiveness of dornase alfa.
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Data Entry Forms Used by the ERCF
418 Use of Databases in Drug Effectiveness Studies
Physician:
m l
- 'Ai/
c— C E L n _Patient*;
DEMOGRAPHICS
^  8  z , , .  Da,e°»b,rth; m m r r
DD MM -----
lace/Ethnidty ( check all that apply): 
□  Caucasian Q  African 
D  Other IsoedhA:
CF d i a g n o s i s
ear of CF diagnosis: |~i | 9 | | |
W  M^ nutrtttorV-absorption
LJ Pulmonary Infection
Screening 
Family history
□  Ves »  "yes, check mutations;
Chromosome 
#1 #2□ □
c l i n i c a l  s t a t u s
i â a i i æ
Enrollment at «me of: Q  CKnta vb# «
U  New patient z H
I— 1— ,— , /• R.*
Height C C D  cm
□  No 
AF508
” aigm 1 1 1
n < .w 2 ? ,e VOlume a*Pectorated: ^
Sputum colour Q c e *  n  ^  ^  , I
Oxygen satUr a « o n : Q ^ Q % Dfloom ak Q  
pco9: r - r - i  u S r2
m e d i c a l  h is t o r y
Other (specify): 
^her (specify):
Jnknown:
□ □
□  D
□ □
r o u t i n e  t h e r a p i e s
D M ^ B tp e c to ra n .
Nutrition:
S  suPPlementsTuho
Mrway clearance 
echnique/CPT 
Regular exercise
Ironchodilator (oral) n  W—i
r n s mîulin U  Other (specify):
al h y p o g l y c a e m i c ----------------------- -
(other than «acartwtfon. of
Pulmonary:
□  Bronchial hyperreactivity
HaemopiYffig;
Q  Scant (streaking)
□  Submassive (<i cup in 24h)
LJ Massive (^i cup in 24h)
Uver/Gastrolntestlnal:
-
U  Gall bladder disease 
U  Portal hypertension
□  Elevated LFTs (bilirubin, enzymes)
□  Nasal polyposis 
Sinusitis (symptomatic)
Other:
□  Congestive heart failure 
LJ Other (specify):
/
   \ Gcayy.___________
I ^ s T y t r ^ ” ^  a v «  □
I Organ transplant
1
•v ‘ : R
_
v u H o ^ m m m
_ D 0  M M
Epidemiologic Registry of Cystic Fibrosis
FORM 2 - CLINIC VISIT
Centre #: Patient #:
Physician: [
CLINICAL STATUS
Purpose of visit (check one):
□  ^outine D  Exacerbation
Height cm Weight
□  Research study
QZDD*(If patient <18 years)
Cough frequency since last visit ( c h e c k  o n e ) : 
□ None □  Occasionally Q  Daily
Sputum productivity since last visit ( c h e c k  o n e /
□  None □  Occasionally [ ]  Daily
It daily, estim ate volum e expectorated
□ a S f e . e  □minimal 
Sputum colour
a lot
□ gireenCD Clear CD Yellow
Physical findings [c h e c k  a H  th a t  a p p ly ) :
□  C ^ u o n »  □  Wheezing □  Oubbmg D  Hyperinflation
Oxygen saturation:(3  | | | % d m * * , *  O ù »  0 % ,
I---1---- 1 001 dCne
pC° 2 : I I I mm Hg (Ton)
MEDICAL CONDITIONS *  check if none
Pulmonary:
□  Bronchial hyperreactivity
CJ Allergic bronchopulmonary aspergillosis
LJ Mycobacterial disease (treated)
CD Pneumothorax 
Hagmoptysis;
CD Scant (streaking)
□  Submassive (<i cup in 24h)
CD Massive fei cup in 24h) 
Uver/Gastrolntestlnal:
CD Distal intestinal obstruction syndrome 
LD G astro-oesophageal reflux 
CD Gall bladder disease 
U  Portai hypertension 
CD Elevated LFTs (bilirubin, enzymes)
EHT:
Q  Nasal polyposis 
CD Sinusitis (symptomatic)
Other:
U  Congestive heart failure
b j ° r9an transplant (specify):__________________
D  Other ( s p e c if y ) : __________________________________________________
DORNASE ALFA THERAPY
Indicate status of domase alfa therapy since last visit 
U  Not prescribed
□  Prescription continued
□  p S S d  behveeTvisfts ->  Date. I I I f T " )  Q
] [ I□  Prescription discontinued ->  Bate: Reason for d d
discontinuation:
□[
MM
Current domase alfa regimen:
Dose: I— I J . I I mg 0 ampoule domase alfa = 2.5 m
Number of doses per day: j
If one dose per day: □  a.m. Q  p.m.
Usage: Q  Daily Q  Other(spec»yy): -
Domase alfa in relation r-, nrimo „
to physiotherapy (PT): □  before PT °  af1
Type of nebulizer/compressor /  —:•   f  
Indicate the number of prescribed 
doses missed in the last 7 d?vs:
ROUTINE THERAPIES ch.eçk if r
-SSESEkSB.
CD Regular exercise
□  Bronchodllator (oral)
□  Bronchodllator (inhaled)
□  Contraceptive (oral/implant)
LD Corticosteroid (oral)
bEFE^ 8□  Insulin U  Other (specify):
_D_Oral hypogiycaemic
□  NSAID 
Nutrition:
□  Oral supplements 
CD Tube feeding
□  Parenteral
□  Oxygen
□  Assisted ventilation
Coordinator____
I Ï^o/GenentechAssociate:
Date:
Date:
SEW
ADDITIONAL FORMS
Hasa spirometry or full PFT been performed since last visit?
CD NoS > Z0nlPJ ete Form 3’ Section A 
Hasnatipnt how S! resu,ts since last visit) 
j—i a resP'ratory culture obtained since last visit?
H M®s y Complete Form 3, Section B
hJt L .. , . (most recent culture or obtained at current x
respiratory ^ % 2 t ?  ^  antjblotlcs for
□  NoS ^ Complete Form 3, Section C
ce"counl and serum '9G
R No”   ^ Complete Form
(most recent values or obtained at current v
no^ roulfne hospteSn sfnœTasfvisrtT °r ^  3 
□  No8 ~~~^ComP,3*e Form 4 ____
Epidemiologic Registry of Cystic Fibrosis
FORM 3 - PULMONARY FUNCTION TESTS, MICROBIOLOGY, ANTIBIOTICS, WBC. IgG
Visit Date:
DP
mm
MM YY----
Centre #: Patient #:
Physician:
A. PULMONARY FUNCTION TESTS (A ctua l)
Date of Test
DD MM YY
Height
(cm) 
(lf<18yeerfl
FVC
(I)
FEV,
(I)
FEF25-75% 
(l/sec)
RV
(I)
chock if no
TLC
(0
m n . D m DJ D . n . i
D. 0.1 D. D . n i
B. MICROBIOLOGY check if nc
Sampling Date Type of Culture
Organisms Present
Codes* Other
(circle all that apply)DD | MM | YY
i i ii n r a □  Sputum □  Throat D  BAL
0 1  2 3 4 5 6 7 8 9  10 11 12— > specify:
•N ote: 0. None/Normal flora
1. P. aeruginosa (non-mucold)
2. P. aeruginosa (mucoid)
3. P. aeruglnoaa (multlpty resistant)
4. P. cepacia
5. Other Pseudomonas
6. Staph, aureus
7. H. Influenzae
C. ANTIBIOTICS
8. Xanthomonas
9. Candida
10. Aspergillus
12. Other(specify on above line)
check if no
Complete section If patient Is currently (Including prescription of this clinic visit) receiving or he* been prescribed since last visit: 
i.v.. Inhaled, or oral antibiotics for respiratory conditions. . ,
CODING INSTRUCTIONS
Indication: 1 « Prophylaxis, continuous use
2 = Prophylaxis, Intermittent use
3 = Exacerbation of RT1
Route: 1 *  I.v. In hospital 3 *  Inhaled
2 « I.v. at home 4 ■ Oral
Antibiotic Name
(Generic Name)
Indication 
Code
Route
Code
Start Date
Check It start dale unknown
4,xZ DD MM YY
Stop Date
Cheek It continuing
4y
V DD MM YY
D
D ][
D
□
□ □
□ D
0 D
D D ]□:
D. WHITE BLO OD CELL COUNT AND SERUM IgG
Date of Test
DD MM YY
WBC
(109/l)
Date of Test
DD MM YY
IgG
(9/1)
mma . n .0
Coordinator: Date:
Roche/ 
Genentech 
Associate: _ Date:
CLINICAL STATUS
Purpose of visit (check one):
( J  Routine Q  Exacerbation
Height [  I I cm Weight [
D  Research study
Sreen
(If patient <18  years)
Cough frequency since last visit (check one):
□  None Q  Occasionally Q  Daily
Sputum productivity since last visit (check one):
D None □  Occasionally Q  Dally
If daily, estimate volume expectorated-
de :
0 —  o , » .  0 l
Physical findings ( check all that apply)- 
□  CnpWhn. □  Wheezhg D  D  HypaHnWon
Oxygen samraHon:|^~ j J [% □ Hoomair
pC° 2 : I I I mm Hg (Ton)
MEDICAL CONDITIONS ■  check if none
Pulmonary:
□  Bronchial hyperreactivity
Q  Allergic bronchopulmonary aspergillosis 
U  Mycobacterial disease (treated)
□  Pneumothorax 
Haemoptysis:
□  Scant (streaking)
□  Submassive (<i cup in 24h)
□  Massive fel cup in 24h)
Uver/Gaatrolntestlnal:
□  Distal intestinal obstruction syndrome 
U  G astro-oesophageal reflux
JJ Gall bladder disease 
D  Portal hypertension
□  Elevated LFTs (bilirubin, enzymes)
ENT:
S  Nasal polyposis 
jU  Sinusitis (symptomatic)
Other:
U  Congestive heart failure 
U  Organ transplant (specify):
Q Other (specify): ________
DORNASEALFA THERAPY
Indicate status of domase alfa therapy since last visit- 
U  Not prescribed
□  Prescription continued
□  Prescribed at this visit _ r _ ____
□  Prescribed between visits -> dSK: [  I 1 | Q
□  Prescription discontinued -> dSS: f l  11 F l  f~  
Reason for o d mIvi —>
discontinuation:___ _________
Current domase alfa regimen:
Dose; 1 I I . I I mg 0 ampoule domase alia = 2.5 m 
Number of doses per day:
If one dose per day: □  a.m. ' □p.m.
Usage: DoaUy □  Olf«(sp«sM ;_ _________
Domase alfa in relation <—. „
to physiotherapy (PT): D  SforeSpT D  OomaseaD
TvnA nf nûKi___ _____
*ys:
ROUTINE THERAPIES
p s s s s s s .U  Airway clearance n  n _________I—I At□
technique/CRT
□  Regular exercise
□  Bronchodllator (oral)
□  Bronchodllator (inhaled)
□  Contraceptive (oraMmpiant) 
U  Corticosteroid (oral)
^Oralhypoglycaemic
□  Mucolytic/Expectora
□  NSAID 
Nutrition:
□  Oral supplements
□  Tube feeding 
D  Parenteral
□  Oxygen
□  Assisted ventilation
ADDITIONAL fo r m s
C^oordinator
y^ oehe/Genentech
Date:
te: Date:
—  ...
Has a spirometry or full PFT been performed since last visit?
□  n?  %11!pJ e,e F?’ Sectlon
H^patrent had a re s p lra lo r^% |^ e % Z )1 %  last visit? 
n  n ?  ^ Complete Form 3, Section B
sscSS—
□  N? >  Complete Form 3, Section C
Z S Z Z Z ? ce"coun' and— w
f l  NrT >  Complete Form 3, Section O
(most recent values or obtained at current v
no^ roulfne hS ^S tion  sfn^TasTvis!^  ^  ^  ^  3 
U  Yes -— ^Complete Form 4------------------
Epidemiologic Registry of Cystic Fibrosis
FORM 4 -H O SPITALISATION / SERIOUS ADVERSE EVENT
Bale of Report: | _[ || | || [ | Cent™*:
hysiclan: WOBfltSBtfaBffll
SERIOUS ADVERSE EVENT INCLUDING NON-ROUTINE HOSPITALISATION
ost significant event/illness or reason 
r hospitalisation: Onset 
of event: DO
Event resolved? D v e s  D no reÜ5ut!on: L l 11 I IL  L
escribe event (Including relevant medical history, tests, and laboratory data). DO MM
itcomes attributed to serious adverse event (check all that apply): 
3  Hospitalisation
■   m m : '
)ate of 
dmission: DO MM YY
K e :  r a c n n z ]DO MM YY
3  Prolonged hospitalisation
3  Life-threatening
3  Required intervention 
(to prevent permanent 
impairment or damage)
3  Permanent disability 
3  Other (specify):  ______
I I Death — > Date: [  
(complete Form 5) 00 MM YY
Cause(s) of death:
D  Cardio-respiratory failure
I I Other (specify):_______
□  Other (specify):_______
I i Other (specify):_______ _
•use of event
ieck all that apply):
]  Complications of CF
1 Domase alfa*
J (See note below)
]  Other medication
(specify):_________
]  Other
(specify):_________
]  Unknown
Was patient receiving dornase alfa therapy 
at time of event? i— i i— i
I—I Yes L J lI No
If yes, is event related to domase alfa*? I I Yes I 1 No Chan9e In dornase alfa therapi1---------1 I--1 (if aDDlicable nharlt nnn\‘
If yes, please complete:
Domase alfa initiation date: | j 11 | 11 | |
  DO MM YY
Dose: 1 1 I . [% ] mg <1 ampoule domase alfa = 2.5 mg)
Number of doses per day: |
(if appli l , check one):
□  No change 
D  Reduced dose
□  Increased dose
□  Interruptedn ___ ..
To physician: If you consider this event related to dornase alfa therapy,
sigh form below and Immediately FAX to Quintiles +49-6102-206 2 9 6
Physician’s signature: ----------  FAX date: —- ---------
irdinator: n t^P-
--------------------------------- UD MM VY
Roche/Genentech
Associate: n ^ „.aphone Number: /  /Country Area Extension
Epidemiologic Registry of Cystic Fibrosis
NON-SERIOUS ADVERSE DRUG REACTION REPORT F
Date of Report: Centre #: Patient #: _
Physician:
• :> V ^  ; DEMOGRAPHY V • r -  - %
Sex: □  Male
1 1 Female
Date of birth: Height Weight | . ( |
DO MM YY
. . .  A m k
DORNASE ALFA (PULMOZYME) DOSAGE " - u
Start date: ][ - % :Y Y
Dose: I I 1 I I mg 0  ampoule domase alfa = 2.5 mg) Number of doses per day:
Subsequent dosage adjustment ( spec ify ):.
m l * ADVERSE DRUG REACTION.
^)nset of
reaction: 00 „ „  YY
Describe reaction (including relevant medical history, tests, and laboratory data).
Reaction resolved? Q  Yes d Date of 
resolution:
Change In domase alfa (Putmozyme) therapy ! I No change
[check one): ZZ _
J Reduced dose |_J Interrupted
J Increased dose M  Discontinued
Date of dose 
change:
Please list with dosages, dates, routes and indications
Causal relationship (drug reaction): □  Remote □  Possible
Have you reported this ADR to the CSM/NDAB? Q  Yes d  No
] Probable 
Date of report:
DO JTOP
To physician: Please return the top copy of this completed form to the Drug Surveillance
Department, Roche Products Ltd., In the reply-paid envelope provided. g '1
Physician's signature:. Date:
Appendix A
Response letter from Data Protection Commissioner
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D a t a
P r o t e c t i o n
M s Ju d ith  Strobl,
Research Fellow ,
Prescribing Research G roup,
Dept, o f  Pharm acology and Therapeutics, 
The  In firm ary ,
The U n ive rs ity  o f  L iverpoo l,
70 Pem broke Place,
L ive rpoo l L69 3GF.
O u r R ef: G 0 3 1 2 /IM  
17th M arch 2000
Dear M s Strobl,
T hank you  fo r y o u r le tter o f  16 /2 /00 . As I understand it  you  have tw o  questions:
1) Is patient consent needed to use coded or anonymised data fo r yo u r research ?
2) I f  “ in te rna l”  staff from  w ith in  the participating CF u n its /N H S  Trusts w h ich  supplied the 
anonymised data to  the E R C F  database “ de-anonymise”  the data in  order to validate i t  w ith in  
the T rust and given that on ly those staff w ill have access to any data in  a patient identifiable 
form at is i t  necessary to  obtain ind iv idua l patient consent to this use o f  the data ?
The  Data P ro tection  A c t 1998 defines personal data as, “ ...data w h ich  relate to a liv in g  
ind iv idua l w ho  can be identified  from  those data, o r from  those data and other in form ation  
w h ich  is in  the possession of, o r is like ly  to come in to  the possession o f  the data con tro lle r....” .
The First P rinc ip le  o f  the Data Protection A ct 1998 requires, amongst other things, that a data 
contro lle r, e.g a N H S  Trust, shall process personal data fa irly. Fairness includes ensuring that 
data subjects i.e. patients in  this case, have an understanding o f  the purposes fo r w h ich  their 
personal data are to  be processed, the like ly  consequences o f  such processing and, more 
particularly, w he ther particular disclosures o f  their personal data can be envisaged.
I t  is the Data P ro tection  Com m issioner’s v iew  that even “ anonymised”  personal data w ill 
remain personal data to  those w ho  on ly  have the encoded in fo rm a tion  extracted from  it, as 
w e ll as to  w hoever holds the encoding key, provided the key remains in  existence. The fact 
that at some fu tu re  p o in t apparently “ anonymised”  data held by a particular person could be 
“ re -iden tified ”  means that the data w ill still constitute personal data w h ils t held in  an 
“ anonym ised”  fo rm  by that person. In  such a scenario we take the v iew  that there has not 
been true anonym isation but rather something more akin to  “ pseudonymisation”  o f  what 
remains personal data subject to  the Act.
I t  appears from  the in fo rm a tion  you  have provided that the encoded data on the E R C F  
database is still personal data as defined by the A ct because the key is still in  the possession o f  
the CF u n its /N H S  Trusts w h ich  supplied the personal data.
T h e  O ff ic e  o f  th e  D ata  P ro te c tio n  C o m m is s io n e r  
W ych tfe  House, W ater Lane, W ih u s lo w . C hesh ire  SKV SAP T e lephone: 0 I (AS 5-15700 fa cs im ile : 0 I (On 5245 I 
__________________ e -m a il: n ia il( fljd a ta p m te itio n .p ;o v ,u k  H o m e  Page: w w w .d a ta p ro te c tio n .g o v .u k
D a ta  
P r o t e c t io n
H aving  said that I  should stress that from  the po in t o f  v iew  o f  the Data Protection 
Com m issioner this does no t mean that such personal data cannot be processed in  compliance 
w ith  the Act. W h ils t it  may be very d ifficu lt to  ever tru ly  anonymise data i t  is comparatively 
easy to ensure that w hat is, in  effect, pseudonymised personal data, is processed fa irly and 
law fu lly.
T o  do this you w ill  need to  ensure that you have a w e ll constructed security p ro toco l in  place 
between yourselves and the CF un its /N H S  Trusts w h ich  ensures the pseudonym ity o f  the 
personal data and prevents anyone, other than the appropriate staff w ith in  the CF un its /N H S  
Trusts, from  having access to the encoding key.
In  addition, in  order to com p ly  w ith  the First Princip le o f  the Data Protection A c t 1998, the 
Trusts should have arrangements in  place to in fo rm  patients o f  the like ly  uses o f  the ir personal 
data, inc lud ing  the fact that it  may be disclosed fo r research purposes, and to deal w ith  any 
objections from  patients. T he  provision o f  in form ation  to  patients in  this way is not 
something that the Data Protection A c t 1998 has introduced fo r the first tim e but is something 
that the Trusts should already have been doing in  order to  com ply w ith  the 1984 Data 
Protection Act.
H ow ever, the proper p rovis ion o f  patient in form ation  has no t always been treated as a p rio r ity  
in  some N H S  units. T he  Data Protection A c t 1998 brings this issue in to  sharper focus, 
placing as i t  does, m ore stringent legal requirements on data controllers to provide specific 
in fo rm ation  to data subjects and to ensure that they are able to  s ign ify the ir agreement to the ir 
personal data being processed. I f  any o f  the six N H S  Trusts partic ipating in  your research do 
no t curren tly  have adequate arrangements in  place fo r the proper p rovis ion o f  patient 
in fo rm a tion  then they should introduce these as soon as possible.
W e recognise the practical d ifficulties o f  do ing this fo r patients whose personal data is already 
on the database and w ou ld  n o t expect the Trusts to try  and obta in consent in  retrospect. 
H ow ever in  the event o f  a request from  a data subject whose personal data is already on the 
database, the Data P rotection Commissioner reserves the righ t to  assess w hether o r no t the ir 
personal data has beeen processed in  compliance w ith  the Act.
I hope you  find  m y response o f  value, i f  you w ish to discuss the m atter in  more detail you can 
reach me on 01625 545712.
YiOurs sincerely.
Ian M ille r, 
Com pliance O fficer.
Appendix A
Formulae for predicted lung function used in the study
Conventions: “ * ” = multiplication ; " A “ = (raise to) power
"Dundee” (UK CFF) formulae
per website www.cystic-fibrosis.org.uk 
For FE\A:
Age under 18 years (height in m)
(“From Polgar, Pulmonary Function Testing in Children “) 
Male: 0.812 * HeightA 2.77 
Female: 0.788 * HeightA 2.73
18 and above (height in cm)
(“From Reuben M Cherniak, Pulmonary Function Testing “) 
Male: 0.04525 * Height - 0.03509 * Age - 2.59946 
Female: 0.04071 * Height - 0.02147 * Age - 2.56958.
For FVC:
Age less than 18 years (height in m)
(“From Polgar, Pulmonary Function Testing in Children “) 
Male: 1.004 * HeightA 2.72 
Female: 0.946 * HeightA 2,61
18 and above (height in cm):
(“From Reuben M Cherniak, Pulmonary Function Testing “) 
Male: (0.06584 * Height - 0.02954) * Age) -  5.12451 
Female: (0.05557 * Height) -  (0.00793 * Age) -  4.89036.
“Knudson” formulae
Source: Knudson et al (1983) Changes in the normal expiratory flow volume 
curve with growth and ageing, American Review of Respiratory Disease, 127 
725 - 734
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For FEVi:
Heights in centimetres 
Males
Ages 6 but less than 12 
Age 12 but less than 25 
Age 25 and over
Females
Ages 6 but less than 11 
Age 11 but less than 20 
Age 20 and over
(0.0348*height) — 2.8142 
(0.0519*height) + (age*0.0636) 
(0.0665*height) + (age*0.0292)
(0.0336*height)-2.7578 
(0.035 l*height) + (age*0.0694) 
(0.0309*height) + (age*0.0201)
For FVC:
Heights in centimetres
Males
Ages 6 but less than 12 
Age 12 but less than 25 
Age 25 and over
Females
Ages 6 but less than 11 
Age 11 but less than 20 
Age 20 and over
(0.0409*height) -  3.3756 
(0.0590*height) + (age*0.0739) 
(0.0844*height) + (age*0.0298)
(0.0430*height) -  3.7486 
(0.0416*height) + (age*0.0699) 
(0.0427*height) + (age*0.0174)
6.1181
6.5147
3.7622
1.4050
6.8865
8.7818
4.4470
2.9001
422 Use of Databases in Drug Effectiveness Studies
Appendix A
Sample forms for sample-DQR
Cost-Effectiveness of rhDNase Study Group
Data Quality Review 
Section II/l: Demographic Data
Patient ID:
Current treatment centre:
Section 1: Demographic Data 
Data item Current entry Corrections and Comments
xxx
xxx
Sex
Date o f  b irth  (month and year)
Year o f  CF diagnosis
Has patient been genotyped? 
Chromosome 1 mutation 
Chromosome 2 mutation
X X X
X X X
X X X
X X X
X X X
X X X
Enrolment date
D iscontinuation date 
Reason fo r discontinuation
XX X
X X X
X X X
Comments:
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Appendix B
Further Baseline Data
The following baseline data presentation is limited to the 999 patients in 
the study sample (see Figure 4.2 for selection of sample).
Age, sex
The sample is reasonably well balanced in terms of sex and age groupings, 
with a slightly larger proportion of males across all age groups, 
particularly the adult group (Table A.3).
Table A.3: Sex and age at enrolment
Age at enrolment Male Female Total
<6 years 88 8.8% 65 6.5% 153 15.3%
6 to <13 years 136 13.6% 129 12.9% 265 26.6%
13 to <18 years 111 11.1% 98 9.8% 209 20.9%
18 years and over 206 20.6% 165 16.5% 371 37.2%
Total 541 54.2% 457 45.8% 998 100.0%
Enrolment date of one male patient unknown.
Genotype
Only 729 patients could be clearly categorised according to genotype. 
Centres 1 and 5 - children's and adult centres in the same conurbation - 
showed a markedly higher proportion of patients with less severe 
genotypes (Table A.4). Patients with less severe genotypes showed higher 
lung function on enrolment (Table A.5) and were much less likely to use 
dornase alfa (Table A.6).
Table A.4: Severity of genotype by enrolment centre
Enrolment centre A (severe) B (less severe) Total
1 104 93% 8 7% 112
2 62 97% 2 3% 64
3 128 97% 4 3% 132
4 108 98% 2 2% 110
5 59 89% 7 11% 66
6 154 96% 7 4% 161
7 82 98% 2 2% 84
Total 697 96% 32 4% 729
Table A.5: Severity of genotype by sex and lung function on
enrolment
Sex FEV, (% pred.) A (severe) B (less severe) Total
Male < 40 70 97% 2 3% 72
40 - (69.9 105 97% 3 3% 108
70+ 150 94% 10 6% 160
All male 325 96% 15 4% 340
Female < 40 44 96% 2 4% 46
40 - 169.9 100 96% 4 4% 104
70+ 118 94% 8 6% 126
All female 262 95% 14 5% 276
Total 587 95% 29 5% 616
Table A.6: Dornase alfa use by severity of genotype
Any dornase alfa use recorded Genotype category
A (severe) B (less severe)
No 373 53.5% 27 84.4%
Yes 324 46.5% 5 15.6%
Total 697 100.0% 32 100.0%
Diabetes
Diabetes was diagnosed or treatment of diabetes (insulin or oral anti­
diabetic drugs) was recorded in a total of 147 (14.7%) patients. Diabetics 
in the sample were more likely to be female (Table A.7), have poor lung 
function on enrolment (Table A.8), and have been receiving dornase alfa, 
compared to non-diabetics (Table A.9).
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Table A. 7: Diabetes by sex
Sex No record of diabetes Diabetes* Total
Male 476 87.8% 66 12.2% 542
Female 376 82.3% 81 17.7% 457
Total 852 85.3% 147 14.7% 999
‘ Diagnosis or treatment of diabetes recorded.
Table A.8: Diabetes by lung function on enrolment
FEVi (%pred) No record of diabetes Diabetes* Total
< 40 119 68.0% 56 32.0% 175
40 - 69.9 242 84.3% 45 15.7% 287
70+ 333 89.5% 39 10.5% 372
Total 694 83.2% 140 16.8% 834
‘ Diagnosis or treatment of diabetes recorded.
Table A.9: Diabetes by dornase alfa use
Any dornase alfa use recorded No record of 
diabetes
Diabetes*
No 499 58.6% 53 36.1%
Yes 353 41.4% 94 63.9%
Total 852 100.0% 147 100.0%
‘ Diagnosis or treatment of diabetes recorded.
Microbiological colonisation on enrolment
Enrolment reports of 904 patients contained culture reports. In some of 
these patients, the relevant culture may have been taken some weeks or 
months before the actual enrolment date; hence this is not to be treated 
as strict point prevalence.
There are differences in reported colonisation rates on enrolment for all 
recorded micro-organisms between individual centres (see Table A.10). 
For example, rates of colonisation with B.cepacia vary between 2.8% and 
4.8% in children's centres and as much as 8.1% and 25.6% in adult centres. 
Rates for Pseudomonas or Xanthomonas vary between 41.8% and 75.2% 
and 73.8% and 82.5% respectively. These large variations may put into 
question the completeness of recording of these variables, and again 
demonstrate the importance of between-centre variations.
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Table À. 10: Microbiological colonisation on enrolment by enrolment 
centre
Enrolment
centre
Patients with some 
colonisation reported
No colonisation 
reported
Patients with 
microbiology report
1 123 98.4% 2 1.6% 125
2 88 89.8% 10 10.2% 98
3 109 81.3% 25 18.7% 134
4 122 85.9% 20 14.1% 142
5 79 96.3% 3 3.7% 82
6 161 98.8% 2 1.2% 163
7 144 90.0% 16 10.0% 160
Total 826 91.4% 78 8.6% 904
Dornase aifa use
A total of 447 patients (44.7%) were reported ever to have received 
dornase alfa. The majority of patients were apparently commenced on 
treatment during 1994 and 1995. Children's centres appear to use 
dornase alfa less frequently than adult centres, but this may be partly due 
to the fact that some patients in the sample were too young during part of 
the follow-up period (Table A.11).
Twenty seven per cent of dornase alfa users have received the drug for a 
period of less than one year in total, regardless of interruptions, 4.4% (19 
patients) for 14 or fewer days. For 105 patients (24% of dornase users) the 
cumulative treatment duration was 4 years or more. Nearly all patients 
were on 2.5 mg daily for most of their treatment period.
For 68 patients (15.2% of dornase users), the first available spirometry 
results post-dated the first treatment initiation date. For the remainder 
of patients, the first spirometry either coincided with the first treatment 
initiation date, predated it, or the dates were missing.
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Table A. 11 : Dornase therapy by enrolment centre
Enrolment
centre
Continuous use Intermittent use No use Total
(100%)
Start before Start on or Start before Start on or
enrolment after enrolment after
enrolment enrolment
1 32 24.6% 1 .8% 11 8.5% 86 66.2% 130
2 14 13.9% 10 9.9% 12 11.9% 3 3.0% 62 61.4% 101
3 17 10.8% 28 17.8% 7 4.5% 6 3.8% 99 63.1% 157
4 17 11.9% 15 10.5% 1 .7% 24 16.8% 86 60.1% 143
5 2 2.3% 10 11.6% 9 10.5% 25 29.1% 40 46.5% 86
6 32 15.0% 47 22.0% 9 4.2% 28 13.1% 98 45.8% 214
7 28 16.8% 45 26.9% 5 3.0% 9 5.4% 80 47.9% 167
Total 110 11.0% 187 18.7% 44 4.4% 106 10.6% 551 55.2% 998
Table A. 12 presents the colonisation of patients on enrolment broken 
down by dornase alfa use group. Clearly, any dornase alfa user group 
showed higher rates of colonisation with Pseudomonas, particularly those 
treated before enrolment. This corresponds well with the notion that at 
least in some centres a colonisation with Pseudomonas was amongst the 
criteria for selection for treatment with dornase alfa. Similarly, 
colonisation with 6. cepacia was far higher in the dornase alfa treated 
groups. This trend was not visible for all micro-organisms.
Table A. 12: Per cent of patients with colonisation reported on
enrolment by dornase alfa use group, (n=904 with 
microbiological cultures reported on enrolment report)
Dornase alfa use 
category
N Pseudomonas,
Xanthomonas B. cepacia S. aureus Haemophilus
Any
colonisation
No use 492 56.1% 4.1% 32.3% 23.2% 87.0%
Continuous use - start 
before enrolment
89 88.8% 13.5% 39.3% 16.9% 97.8%
Continuous use - start 
on or after enrolment
185 78.9% 16.2% 32.4% 16.8% 96.8%
Intermittent use - start 
before enrolment
39 87.2% 17.9% 38.5% 33.3% 97.4%
Intermittent use - start 
on or after enrolment
99 79.8% 24.2% 23.2% 19.2% 94.9%
Total 904 67.9% 10.3% 32.3% 21.2% 91.4%
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The main reported reasons for discontinuation of dornase therapy were 
lack of effectiveness, but also an intended short treatment period, most 
likely during a hospital stay (Table A. 13).
Table À. 13: Reported reasons for discontinuation of dornase alfa
Reason Occurrences 
(number and %)
Lack of effectiveness stated 60 28%
Planned as short-term use (e.g. In hospital) 52 24%
Compliance /  patient choice 43 20%
Any symptoms mentioned 31 14%
External reason 12 6%
Trial stated as reason for discontinuation 7 3%
Death 7 3%
Dose change 4 2%
Other 4 2%
Unknown reason 3 1%
Total 218 100%
Note: Patients may appear more than once, n=149.
432 Use of Databases in Drug Effectiveness Studies
Use of Databases in Drug Effectiveness Studies 433
Further Outcome Data
Outcome: Exacerbations
Table A. 14 presents a subset of the main study sample with at least one 
year's observations available (n=857), as computations from short periods 
of observations are unstable, and high numbers of exacerbations over a 
short period may indicate problems of acute rather then chronic disease 
stage.
After annual rates had been computed and ranked, the data were 
dichotomised (into two equal parts). Dichotomisation was carried out 
separately for males and females to avoid possible confounding by sex.
The dichotomised data showed no difference between children and adults, 
possibly indicating that exacerbations were not related to the progression 
of the disease. Although hardly surprising, the association of 
dichotomised exacerbation data with death is statistically significant 
(p<0.001) and the rates for the death cases about 50% higher than 
survivors. The numbers are too small to seek general conclusions on 
increases in rate over time in the death cases.
Table A.15 illustrates a six-fold categorisation of rates of exacerbation - 
for convenience; the bands indicate the number of calendar quarters per 
year a "typical" patient was affected. The numbers show a continuum. 
The "no recorded dornase alfa group” had a high proportion of patients in 
the “no exacerbation” category, but still sizable numbers of patients in 
the highest categories.
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The data are difficult to interpret. It is worth pointing out that the 
frequency of exacerbations reported varied between centres, and under­
reporting in some of them seemed highly likely. In addition, the definition 
of the variable was problematic to say the least, given that three different 
points in the database indicated exacerbations, and the timely overlap 
between episodes was very unclear. Based on advice from clinicians, one 
week was considered the minimum time to separate two distinct episodes. 
Observed variations may have arisen at least in part due to differential 
impact of this definitional rule, or reporting differences between centres. 
This demonstrates that in ESDs, inconsistent reporting of outcomes and 
poor definition of key outcome variables can jeopardise any meaningful 
analysis.
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Table A. 14: Summary of individual annualised exacerbation rates by 
sex, initial age group and dornase alfa user group: also 
dichotomised by broad age group (< 18/18+), and diabetes 
status and categorical division (n= 857 with at least one 
year of observations) (7,867 exacerbations).
Rates computed as (n exacerbations) /  (n years of observation to nearest quarter)_______
Mean exacerbation rates
Initial five-year age 5<10 10<15 15<20 20<25 25<30 30<35 35+ all
group
Male 2.52 2.01 2.20 2.63 2.51 2.46 2.60 2.40
Sex Female 2.60 2.53 3.01 2.72 2.85 2.60 2.76 2.72
All 2.55 2.32 2.60 2.66 2.72 2.51 2.67 2.55
n 262 150 181 138 65 41 20 857
Use of dornase alfa
Continuous Some None
Starting Starting on Starting Starting on all
before or after before or after
enrolment enrolment enrolment enrolment
Group number 1 2 3 4 5
Male 2.71 3.01 2.33 2.77 2.11 2.40
Sex Female 3.32 2.92 3.42 3.42 2.26 2.72
All 3.03 2.96 2.86 3.06 2.17 2.55
n 72 186 37 103 459 857
Dichotomised data Age Diabetes
(including "0")
<18 18+ No Yes
Ranking by Low 275 154 365 64
annual High 260 168 358 70
rate All 535 322 695 134
T-test for 
significance of 
imbalance in 
dichotomised data
Male: p=0.32 
Female: p=0.21
p=0.57, and no difference 
controlled for age and sex
Exacerbations in relation to deaths - dichotomised data
Ranking by 
annual rate
Low
High
All
Survivors
417
364
781
Deaths
12
64
76
All
429
428
857
p<0.001 for male, 
female, and overall.
Exacerbations in relation to deaths
Survivors Deaths All
Mean Male 2.28 3.70 2.40
exacerbation Female 2.53 4.50 2.72
rates All 2.40 4.10 2.55
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Table A. 15: Categorical division of annual rates of exacerbations and 
dornase alfa use group classification (n= 857 with at least 
one year of observations) (7,867 exacerbations).
Use of dornase alfa Totals
Continuous Some None
Starting Starting on Starting Starting on all m f
before or after before or after
enrolment enrolment enrolment enrolment
Group 1 2 3 4 5
number
Categorized rates per annum
0 - none 6 16 2 1 95 120 73 47
<=1 12 28 5 10 99 154 81 73
1<2 8 32 8 20 74 142 73 69
2<3 14 26 7 18 65 130 67 63
3<4 9 37 5 30 60 141 77 64
4+ 23 47 10 24 66 170 75 95
N 72 186 37 103 459 857 446 411
Outcome: Body mass index -  cohort over time
Cross-sectional analyses could be misleading as to the effect of ageing in 
individuals. The cohort enrolled in 1994 or 1995, who had been under 
observation for five or six years, was analysed for change in the BMI 
percentiles, standardized against the Child Growth Foundation 1990 
references (“imputed” height calculations were used).
Although the groups were of mixed age, the composition of any particular 
group did not change, and for the initial analyses means by sex and 
dornase alfa use group were tabulated for inspection for any marked 
secular change (Table A. 16). Of course, individuals are also ageing over 
time, and a separate analysis by sex and initial five-year age group is 
given in Table A. 17, to see if there are any marked differences in the 
trends for different birth cohorts.
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Table À. 16: Six-year cohort - Body Mass Index percentiles by sex, 
observation year, and dornase alfa groups, adjusted to 
1990 Child Growth Foundation Data (n= 571)
Use of dornase alfa All n -
observations
Continuous Some None
Starting Starting Starting Starting
before on or before on or
enrolment after enrolment after
enrolment enrolment
Group 1 2 3 4 5
number
Sex mi 17 57 14 49 161 298
f 22 81 13 37 120 273
Totals 39 138 27 86 281 571
Males
Year 1 30.0 27.0 41.9 28.4 45.2 37.9 297
Year 2 28.3 28,6 44.1 30.2 45.5 38.7 297
Year 3 33.4 29.0 43.4 31.6 44.1 38.6 293
Year 4 31.4 29.1 39.0 30.2 43.8 37.9 295
Years 27.8 29.8 36.2 31.2 44.2 38.0 292
Year 6 33.0 33.1 31.2 36.2 43.5 39.2 216
All years 30.5 29.3 39.7 31.0 44.4 38.3 1690
Females
Year 1 26.9 34.6 35.8 36.2 46.6 39.5 269
Year 2 27.2 32.7 34.9 37.5 48.3 39.9 272
Year 3 26.2 31.4 34.2 40.6 47.1 39.3 273
Year 4 26.0 29.9 34.4 38.9 47.3 38.7 262
Year 5 21.8 29.3 31.1 41.4 46.6 38.0 270
Year 6 24.8 25.3 40.5 37.8 42.4 35.5 185
All years 25.5 30.8 34.8 38.8 46.6 38.7 1531
Males and females
Yearl 28.3 31.5 39.0 31.7 45.8 38.7 566
Year 2 27.7 31.0 39.6 33.3 46.7 39.2 569
Year 3 29.2 30.4 38.8 35.5 45.4 38.9 566
Year 4 28.4 29.5 36.8 33.8 45.3 38.2 557
Year 5 24.4 29.5 33.8 35.6 45.2 38.0 562
Year 6 28.7 28.9 35.4 36.9 43.0 37.5 401
All years 27.7 30.2 37.3 34.3 45.4 38.5 3221
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Table A. 17: Six-year cohort - Body Mass Index percentiles by sex, 
observation year and initial age groups, adjusted to 1990 
Child Growth Foundation Data (n= 571)
Age (years)
5<10 1O<15 15<20 20<25 25<30 30<35 35+ all n -observations
Sex m 
f
Totals
76
58
134
51
66
117
62
60
122
65
44
109
20
28
48
18
10
28
6
7
13
298
273
571
Males
Year 1 52.7 42.8 35.0 30.8 18.5 20.6 35.4 37.9 297
Year 2 52.1 43.0 35.5 32.0 22.7 22.7 36.5 38.7 297
Year 3 51.3 42.3 33.6 33.8 24.4 24.3 39.2 38.6 293
Year 4 49.8 42.9 31.2 35.0 23.6 22.8 39.8 37.9 295
Year 5 48.5 44.1 28.7 38.8 26.5 20.4 33.1 38.0 292
Year 6 49.9 47.5 28.0 38.9 34.2 10.9 47.0 39.2 216
All years 50.8 43.5 32.2 34.8 24.6 20.7 38.4 38.3 1690
Females
Year 1 48.6 37.0 44.2 34.2 31.6 32.4 25.3 39.5 269
Year 2 46.8 40.9 41.1 34.9 34.3 33.7 26.3 39.9 272
Year 3 43.9 41.4 39.6 32.8 36.3 39.0 30.6 39.3 273
Year 4 40.6 40.2 38.2 36.1 37.5 42.5 28.7 38.7 262
Year 5 37.2 41.6 34.5 38.2 37.9 46.8 29.3 38.0 270
Year 6 31.6 37.7 31.9 38.1 40.3 51.4 17.0 35.5 185
All years 42.1 
Males and females
39.9 38.6 35.6 36.3 40.0 26.6 38.7 1531
Year 1 51.0 39.6 39.5 32.2 26.2 24.8 29.9 38.7 566
Year 2 49.8 41.8 38.3 33.2 29.4 26.6 31.0 39.2 569
Year 3 48.1 41.8 36.6 33.4 31.3 29.5 34.6 38.9 566
Year 4 45.8 41.4 34.5 35.4 31.6 29.9 33.8 38.2 557
Year 5 43.7 42.6 31.5 38.6 33.2 29.9 30.9 38.0 562
Year 6 42.4 41.9 29.9 38.6 38.0 22.2 32.0 37.5 401
All years 47.0 41.5 35.4 35.1 31.4 27.5 32.0 38.5 3221
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B Appendix B: Material relating to review of 
ESDs
• Table B.1 Data sources used in the ESDs, and number of 
patients in both
• Table B.2: Effectiveness outcomes in ESDs
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Appendix B
Table B.2: Effectiveness outcomes in ESDs
First author Year Effectiveness outcomes Category*
Benvegnu L. 1998 (1) Worsening of stage of cirrhosis (Child's classification), (2) 
development of HCC, (3) death or liver transplantation
C
Berman S. 1997 Rates of unresponsive acute otitis media; adverse drug reaction; 
costs, prescribing
C
Bowman L. 2000 Occurrence of another antibiotic treatment within 24 days of first 
dose;
average cost adjusted for age and sex
D
Butterworth J. 1998 Duration of intubation, length of stay C
Chew D. 2001 Death, myocardial infarction M
Choi H. 2002 Mortality; cardiovascular and non-cardiovascular mortality M
Eggleston A. 1996 Success rates = reflux medication prescribed for <=3 months; 
relapse rates in 6 months in successfully treated patients.
D
Fedson D. 1993 Discharge with pneumonia and influenza and all respiratory 
conditions; hospital deaths with same; all deaths due to 
respiratory diseases and all causes
C
Gable C. 1990 Pneumonia incidence rate ratio of pre- and post-vaccination 
periods in vaccinated and non-vaccinated groups
C
Garcia L. 1999 Upper gastrointestinal bleeding c
Ghani A. 2001 Time taken for HIV-1 RNA to fall below detectable levels c
Giralt S. 2000 Leukaemia-free survival (i.e. in complete remission) c
Goldstein R. 1996 Cardiac mortality;
Non-fatal myocardial infarction, unstable angina
M
Graham N. 1991 Progression to AIDS C
Heudebert G. 1993 Percentage difference between the mean basal LDL-C level and 
the mean of all LDL-C measurements for the same patient during 
drug therapy
C
Huang X. 1999 “Cure" rate (i.e. no further treatment with one of three drugs 
within 30 days after the initial treatment)
D
IBMTR 1989 Relapse (i.e. reappearance of medullary or extramedullary 
leukaemia)
C
Johnson C. 1999 Change of FEVi (^predicted) from baseline to 12-month follow-up C
Krumholz H. 1998 30-day mortality;
in-hospital haemorrhage, in-hospital transfusion, in-hospital 
stroke, 1 -year mortality.
M
Krumholz H. 1995 30-day mortality;
use of aspirin within first 2 hospital days
M
Krumholz H. 2001 Mortality within 1 year of discharge M
Kuhn L. 2000 Death or diagnosis with a category C disease within the first year 
of life
M
Lawrenson R. 2001 Treatment failure (further antibiotic within 28 days) D
LundgrenJ 1994 Mortality; 
use of zidovudine
M
McDougall R. 1994 Disease activity, functional class, mortality C
Moore R. 1991 Survival M
Nichol K. 1994 Rate of hospitalisation for influenza and complications of 
influenza, including pneumonia, all acute and chronic respiratory 
conditions, and congestive heart failure, and its effect on 
mortality;
C
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costs of hospitalisation
Nichol K. 1999a Hospitalisations for pneumonia and influenza, for all respiratory 
conditions; and death from all causes;
outpatient visits for pneumonia and influenza and all respiratory 
conditions
C
Nichol K. 1999b Hospitalisations for pneumonia (including influenza); 
death from all causes, hospitalisation costs
C
Nordin J. 2001 Hospitalisations for pneumonia and influenza; 
deaths from all causes
C
Peterson L. 1999 In-hospital mortality;
In-hospital mortality + nonfatal stroke
M
Pethica B. 1998 Mean prescribed daily inhaled corticosteroid dose D
Price D. 1998 Peak expiratory flow, drug requirements, consultations and 
attendances
C
Rabinowitz J. 2001 Rehospitalisation C
Rahme E. 2002 AMI discharge diagnosis C
Sebaldt R. 1999 Changes within groups from baseline and differences between 
groups in bone mineral density of lumbar spine, femoral neck, and 
trochanter
C
Sernyak M. 2001 Psychiatric inpatient days C
Solomon D. 2002 AMI C
Tiefenbrunn A. 1998 In-hospital mortality; M
In-hospital mortality + nonfatal stroke
van Staa T. 1998 Number of patients with a fracture (not number of fractures!) C
Weintraub J. 2001 Caries-related services involving the occlusal surface of 
permanent first molars (CRSOs); 
cumulative expenditure
C
Ziegelstein RC.2001 Mortality M
* C=climcal outcome; D=drug-related outcome; M=mortality outcome
Use of Databases in Drug Effectiveness Studies 445
Appendix C
C Appendix C: Material relating to comparison 
case studies
a. Items assessed by quality assessment instruments and checklists 
for non-randomised studies
b. Quality Assessment Schedule for ESDs
c. Guide to Quality Assessment Schedule for ESDs
d. Quality of ESDs used for case studies
e. Data extraction sheet for review cases studies
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Table C.1: Items assessed by quality assessment
checklists for non-randomised studies
instruments and
For CRD 4 and Newcastle/Ottawa:
Times New Roman 
Arial Narrow 
Bold
studies
B ra d  Le uj H-flud
- suggestions for cohort studies
-  suggestions for case-control studies
- suggestions for both cohort and case control
- suggestions for case series (CRD 4 only)
Zaza et al. (2000) Centre for Reviews 
and Dissemination 
Version 4 (NHS Centre 
for Reviews and 
Dissemination 2001)
Newcastle-Ottawa 
Scale (Wells et al. 
2003)
Downs & Black (1997) 
with amendments and 
suggestions by MacLehose 
et al. (2000)
Description of 
population 
Description of 
intervention 
Sampling - frame
Description of groups
Representative sample 
of relevant population?
Controls randomly 
selected from source 
of population of cases?
Screening criteria 
for eligibility
Case definition explicit
Criteria for inclusion 
explicit?
Representativeness 
of cases?
Selection of 
controls
Representativeness 
of exposed cohort
Selection of non­
exposed group
Case definition 
adequate?
Definition of 
controls
Patient characteristics 
clearly described 
Interventions /  exposure of 
interest clearly described 
Proportion ineligible
Proportion refusing to 
participate
Staff, places, and facilities 
representative of majority 
of patients?
Inclusion / exclusion 
criteria clearly described.
Patients in different groups 
from same population?
Inclusion /  exclusion 
criteria clearly stated
Unit of analysis 
population entire 
population or 
probability sample 
Selection bias 
issues
Exposure variables 
- valid
Proportion followed up
Demonstration that 
outcome not 
present at start of 
study
Method and 
blinding of 
exposure_________
Measurement of 
intervention /  exposure 
valid?
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Zaza et al. (2000)
Exposure variables 
- reliable
Outcome and 
other independent 
variables - valid
Outcome and 
other independent 
variables - reliable
Analysis
Centre for Reviews Newcastle-Ottawa
and Dissemination Scale (Wells et al.
Version 4 (MHS Centre 2003) 
for Reviews and 
Dissemination 2001)
Intervention /  
treatment reliably 
ascertained?
Interventions and 
exposures assessed in 
the same way across 
groups
Disease state of cases 
reliably assessed and 
validated
Outcome assessment Assessment of
blind to exposure outcome - method
status? and blinding
Outcomes assessed by 
objective criteria or 
blinding used?
Description of 
distribution of 
prognostic factors
Adequate adjustment 
for effect of 
confounding factors
Appropriate statistical 
analysis used? 
(matched or 
unmatched)
If comparisons of sub­
series, was description 
of series and 
distribution of 
prognostic factors 
sufficient?
Comparability of 
cases and controls 
(cohorts) on the 
basis of the design 
or analysis
Is it possible that over­
matching has occurred 
and factors related to 
exposure were_______
Downs St Black (1997) 
with amendments and 
suggestions by MacLehose 
et al. (2000)
Attempt made to blind 
patients?
Attempt made to blind 
assessors?
Attempt made to blind 
those performing 
intervention?
Outcome measures valid 
and reliable?
Main confounding variables 
valid and reliable?
95% Cl and/or actual 
probability values for main 
outcomes reported?
Estimates of random 
variability of main 
outcomes (7).
If any results based on 
“data dredging" - is this 
made clear?
Statistical tests legitimate?
Adequate adjustment for 
confounding in analyses?
Intention to treat?
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Zaza et al. (2000)
Interpretation of 
results - % 
completed
Interpretation of 
results -
comparability of 
groups
Interpretation of 
results - control to 
limit bias 
Biases addressed 
and un-addressed
Reporting
Centre for Reviews 
and Dissemination 
Version 4 (NHS Centre 
for Reviews and 
Dissemination 2001) 
matched for?
Dropout rates and 
reasons similar across 
groups?
Response rates and 
reasons similar across 
groups?
Newcastle-Ottawa 
Scale (Wells et al. 
2003)
Non-response rate 
in both groups
Groups comparable on 
all important 
confounding factors
Comparable with 
respect to confounding 
factors?
Individuals entered at 
similar point in their 
disease progression? 
How was response rate 
defined?
Follow-up long enough 
for outcomes to occur?
Follow-up long enough 
for events to occur?
Follow-up long 
enough for 
outcomes to occur?
Adequacy of 
follow-up
Dose-response
relationship
demonstrated
Downs ft Black (1997) 
with amendments and 
suggestions by MacLehose 
et al. (2000)
Numbers lost to follow-up 
described?
Proportion in each group 
completing treatment?
How many subjects lost to 
follow-up?
Comparisons made, in case 
of substantial losses to 
follow-up?
Distribution of confounders 
clearly described for each 
group
Patients in different groups 
recruited over same period 
of time?
Patients randomised?
Effects of patients’ 
preferences and 
expectations on outcomes 
considered?
Any planned analyses 
subject to bias?
Follow-up duration same in 
all groups?
Clear description of: 
Hypothesis/aim/objective, 
main outcome, main 
findings
Interventions appropriate? 
Power calculation 
reported?
Primary outcome 
identified?
All possible adverse events 
reported?_______________
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QUALITY ASSESSMENT SCHEDULE 
FOR ESDs 
Version 18 December 2002
TO BE USED WITH ACCOMPANYING GUIDE.
I. INTERNAL VALIDITY Source*
1 ) Was the exposure /  intervention variable: 
Valid
Reliable (consistent and reproducible)?
yes
□
□
no unsure
□  □  
□  □
N/a
□  Z-m
□
2) Were the outcome and other independent (or predictor) variables: 
Valid
Reliable (consistent and reproducible)?
□
□
□
□
□
□ D Z
3) Were outcome assessors aware of the study objectives? □ □ □ □
4) Were those administering or prescribing treatment aware of the study 
objectives?
5) In case-control studies, has the disease state of cases been reliably 
assessed and validated?
6) Was the duration of follow-up the same for all groups being compared?
□
□
Yes
□
□
□
No­
accounted
for
□
□  0
□  □
No, not 
accounte 
d for
I—| Mac-m
7) Proportion of patients in intervention group lost to follow-up
(prospective study) or excluded from analysis (retrospective study) is 
<5%.
yes
□
no unsure 
□  0
N/a
□
8) Proportion of patients in control group lost to follow-up (prospective 
study) or excluded from analysis (retrospective study) is <5%.
D □ □ □
9) If substantial losses to follow-up occurred (i.e. >5%) was a comparison 
made of the characteristics of those lost to follow-up and those followed 
up?
□ □ □ D  Mac-m
10) Are patients in the study group naïve to the drug or free of use for a 
significant timespan before the treatment period in question? □ □ □ □
11 ) Did the authors assess whether the units of analyses were comparable 
prior to exposure to the intervention? □ □ □ □  z
12) Did the authors correct for controllable variables or institute study 
procedures to limit bias appropriately (e.g., randomisation, restriction, 
matching, stratification, or statistical adjustment)?
□ □ □ ° Z - m
13) Did the authors identify and discuss potential biases or
unmeasured/contextual confounders that may account for or influence 
the observed results?
□ □ □ ° Z - m
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14) If yes, did they explicitly state how they assessed these potential 
confounders and biases?
15) List biases /  confounders not identified and discussed by authors: 
II. EXTERNAL VALIDITY
1 ) Did the authors clearly describe the data source from where the study 
population was drawn?
2) Did the authors clearly define the screening criteria for study eligibility?
3) What proportion of subjects in the database were ineligible to 
participate?
4) What proportion of subjects who were eligible were excluded from the
□ □
yes no
□ □
□ □
0 0 Z-m
unsure N/a
0 0 Z-m
0 0 Z-m
% Mac-m
Mac-m
analysis?
5) Were the staff, places, and facilities where the patients were treated, 
representative of the treatment the majority of patients receive?
(D D □□□□ (0) Mac-
6) Is it likely that patients also receive relevant care from alternative 
sources?
yes
□
no
□
unsure
□
N/a
□  (MF)
7) Was the population that served as the unit of analysis the entire eligible 
population or a probability sample at the point of observations? □ □ □ □  Z
8) Were the patients in different intervention groups (trials and cohort 
studies) or the cases and controls (case-control studies) recruited from 
the same population?
□ □ □ Mac
9) Were the patients in the different treatment group (trials and cohort 
studies) or the cases and controls (case-control studies) recruited over 
the same period of time?
□ □ □ ^  Mac
10) Are there other selection bias issues not identified above? 
Describe: □ □ □ □ z
yes
III. DATA PROCESSING
Access and Confidentiality
1) Is there any indication of any of the authors being involved with the 
running of the database or registry? D
2) Is there any indication that a Research Ethics Committee or
Instituational Review Board or similar body has approved the research D
study?
3) Is there any indication that patients have given informed consent to the 
research study? 0
no unsure N/a 
0 0 0
0
0
0
0
0
0
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Source*
4) Are individuals’ data records identifiable through a code or record ID 
number (regardless of whether the researchers can decode the 
information or not)?
5) Are any safeguards on confidentiality or data protection reported?
Routine data collection and processing procedures
6) Is any routine data validation of variables reported?
7) Has any verification against alternative sources of data been reported 
on any data in the database or registry (either for the current or 
previous studies)?
8) Does or did routine processing include manual copying /  entry of data?
9) Is the aim of the database or registry congruous with the aim of the 
study?
10) Number of centres involved in the database /  registry:
11 ) Are centre variations in clinical or reporting practices likely?
Assessment of data quality including validation
12) Does the paper report that the included data have been assessed for 
consistency, accuracy, and completeness (either by database operators 
or researchers)?
13) Do the researchers report having undertaken any assessment of data 
quality?
Individual variables
14) Are the inclusion and exclusion criteria directly measured in the 
database or registry or any linked data source?
15) Are the main outcome and exposure /  intervention of interest directly 
measured in the database or registry or any linked data source?
16) Are the identified predictors and confounders directly measured in the 
database or registry or any linked data source?
17) If “no” to any of the previous three questions, have all used algorithms 
been validated?
yes
yes
yes
□ □ □ □
□ □ □ □
no unsure N/a
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □
Not
îportedO
□ □ □ □
no unsure N/a
□ □ □ □
□ □ □ □
no unsure N/a
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □
IV. ANALYSIS
1) Are estimates of the random variability of the main outcomes clearly 
described for each group of patients to be compared? □ □ □ □Mac-m
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2) Did the authors conduct appropriate statistical testing by:
i) Conducting statistical testing (when appropriate)?
ii) Reporting which statistical tests were used?
ii) Controlling for design effects in the statistical model?
iv) Controlling for repeated measures in populations that were followed 
over time?
v) Controlling for differential exposure to the intervention?
vi) Using a model designed to handle multi-level data when they included 
group-level and individual covariates in the model?
vii) Allowing for important centre differences in the analysis?
Missing or incomplete data
3) Have patients with incomplete data been excluded?
4) Have statistical adjustments been used for missing data?
Multilevel data
5) Have any measures of the overall adequacy of the statistical model been 
reported?
6) Have any sensitivity analyses been performed?
no unsure N/a
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □
no unsure N/a
□ □ □ □
□ □ □ □
no unsure N/a
□ □ □ □
□ □ □ □
(MF)
(MF)
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V. REPORTING
yes no unsure N/a Source
1 ) Was the study population well described?
□ □ □
Z-m
□
2) Was the intervention well described (what, how, who, where)?
□ □ □
Z-m
□
3) Have the numbers of patients lost to follow-up been described?
□ □ □ Q  Mac
4) Was a power calculation reported or at least mentioned?
□ □ □ □
5) Are the main findings of the study clearly described?
□ □ □
Mac-m
□
6) Have any explicit considerations of alternative explanations of 
the findings been presented? □ □ □ □  <MF)
7) Are conclusions going beyond capabilities of the database or 
study design? □ □ □ □  (MF)
*(MF) = question based on ideas by Motheral Et Fair man 1997, Z =  question from  Zaza 2000, 
Mac = question from  MacLehose 2000 (based on Downs f t  Black 1997), m  =  modified
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GUIDE TO 
QUALITY ASSESSMENT SCHEDULE 
FOR ESDs 
Version 18 December 2002
I. INTERNAL VALIDITY
1) Were the exposure /  intervention variables valid measures of the intervention under study?
The author should have reported one or more of the following:
Clear definition of the exposure variable.
Measurement of exposure in different ways. E xam ple: consistency decks f ir  self reports; use o f 
corroborating respondents; programme or organisational record searches compared to self-reports.
Citations or discussion as to why the use of these measures is valid. E xam ple : the authors considered 
eiidence fivm sim la r studies, or azailable standards o f measurement.
Other
Were the exposure /  intervention variables reliable (consistent and reproducible) measures of the 
intervention under study?
The author should have reported one or more of the following:
Measures o f internal consistency. Exanple C ronbach S a lpha; co n firm a to ry  fa c to r analysis. 
Measurement of exposure in different ways. E xam ple: seeabous.
Inter-rater reliability checks (if exposure was determined by an observer.) E xam ple : percent 
agreement, kappa
Citations or discussions as to why the use of these measures is reliable. E xam ple : seeahoæ.
Other.
2) Were the outcome and other independent (or predictor) variables valid measures of the outcome 
of interest?
The author should have reported one or more of the following:
Clear definition of the outcome variable.
Measurement of the outcome in different ways. E xam ple : Correlational analysis between measured 
outcomes to demonstrate oomergent (La, 2 or more measures reflect dre same underlying jmxess) or dksrgpnt v tlid ily  
(i.e ., 2 or more measures reflect cHjfirent dimensions). A  n example o f the firm er is that 5 items ansdfefficacy 
correlate h ig fly m th each other, an example o f the latter is that self-efficacy measures do not correlate highly u ith  
attitude measures.
Citations or discussion as to why the use of these measures is valid. E xam ple : seeabous.
Other. E xam ple : I f  authors fa il to blind obserœts/iruerdewsrs to treatment is. comparison group, when 
applicable, the answer to h is question should be ‘ho”.
Were the outcome and other independent (or predictor) variables reliable (consistent and 
reproducible) measures of the outcome of interest?
The author should have reported one or more of the following:
Measures of internal consistency. E xam ple: seeabous.
Measurement of outcome in different ways. E xam ple: seeabous.
Considered consistency of coding, scoring or categorisation between observers (e.g., inter-rater 
reliability checks) or between different outcome measures. E xam ple: percent agreement, kappa 
Considered how setting and sampling of study population might affect reliability.
Citations or discussion as to why the use of these measures is reliable. E xam ple : seeabous,
3) Were outcome assessors aware c f the study objectives?
4) Were those administering or prescribing treatment avare cfthe study objectives?
5) Was the duration offillom up the same f ir  a ll groups being compared?
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h) Proportion <fpatients m nuenendm ^v^ lost to follam i^ (prasperti^  study) crexdtdedjkmandysù 
(retrœpectrœ study} is <5%.
7) Proportion o f patients in antral group lost to fMow up (prospective smdy) or excluded from analysis (retrospectke 
study) is <5%.
8) Ifsuktandal losses to fidlow up occurred (Le. >5%) vas a comparison rmde cfthe characteristics cfthoselcstto 
foHwup and those fillouedup?
For retrospective studies, interpret “ lost to follow-up”  as meaning refusal by eligible 
cases/intervention subjects or controls to take part.
9) Are patients in the study goupmtve to the drugorfvx cfuse fo ra  sig ijkant tinvspan before the tmttrrent 
period in question?
10) D id the authors assess vhether the units ( f  analyses were comparable prior to exposure to the intervention  ^ For 
example, they should have assessed likely confounding via report of p- values and confidence 
intervals fo r the descriptive variables of age and sex or other key individual/community 
characteristics.
11) D id the authors oorrea fo r aontwllahle vzriahles or institute study procedures to lim it bias appropriately (eg, 
randormation, restriction, matching, stratification, or statistical adjustment)?
Considering the study design, were appropriate methods fo r controlling confounding variables and 
limiting potential biases used? Confounding can be addressed by appropriate use of 
randomisation, restriction, matching, stratification, or multivariable methods. Sometimes use of a 
single method may be inadequate. Some biases con be limited by institution or data collection or 
study procedures that support validity o f the study (e.g. training and/or blinding of interviewers or 
observers, interviewers and observers are different from  intervention iraplementers etc.)
Exam ple: Ifbetueengmup differences persist after randomisation or matching, statistical control should also hate 
been used
12) D id the authors identify and discuss potential biases or unmeasured/contextual corfounders that rray account fo r 
or influence the observed results?
13) I f  yes, did they explicitly state how they assessed these potential confbunders and biases?
14) L ist biases /  ccnfounders not identified and discussed by authors:
It. EXTERNAL VALIDITY 
Representativeness and Applicability
1) D id he authors dearly describe the data source fromvhere the study population wzs dravn?
A  clear description o f the data source should include its size, characteristics of included population, 
geographic area, and time period covered.
2) D id the authors specify the screening criteria fa r study d ighility (if applicable)?
3) W hatpnjportim cf subjects in the database were indigjhfe to participate?
“ Ineligible”  are those who do not meet the inclusion criteria. Answer 0% fo r case-control studies 
where the cases and controls would not be approached if they were ineligible.
4) M iat proportion o f subjects who were eligible were excluded from the analysis?
For case-control studies answer 0%. The refusal to  participate in case-control studies gives rise to 
problems of selection bias, not external validity/generalisabilrty.
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5) Wem the staff, places, andfacilities inhere the patients were treated, representative o f the treatment the majority o f 
patients receive?
For the question to be answered “ representative”  the reader should be confident that the findings 
of the study would apply in a range of different settings (e.g. teaching hospitals and district general 
hospital). Score on a scale between 1 (box furthest to the left) and 0, w ith 1 being representative, 0 
being not representative.
6) Is i t  likely that patients also receive relevant care from alternative sources?
Relevant care here means care or treatment similar to the intervention or which may significantly 
affect the outcome.
7) Was the population that sened as the unit o f analysis the entire digble population or a probability sample a t the 
point o f observations?
I f  the sample contains the entire eligible population or a probability sample, answer “ yes”  
otherwise “ no” .
8) Were the patients in  àfferent intervention groups ( trials and cohort studies) or the cases and controls (Ttse-contrxl 
studies) rm uitedfrom  the same population?
For example, patients fo r all comparison groups should be selected from  the same hospitals. The 
question should be answered “ can’t tell”  fo r cohort studies where there is no information 
concerning the source of patients included in the study. I t  should be considered that fo r some 
case-control studies that the use of the same local population fo r cases and controls maybe 
inappropriate. A  subjective judgement has to be made in the instance of case-control studies, as on 
occasion the use of the same local population fo r controls as well as cases may be inappropriate.
9) Were the patients in  the different treatment group (trials and cohort studies) or the cases and controls (case-control 
studies) recruited over the same period o f tine?
For a study which does not specify the time period over which patients were recruited, the question 
should be answered “ unsure” . Also, if the data collection period stretches over several years, 
consider whether this might have an impact on period or cohort effects.
10) A re there other selection bias issues not identified alxne?
This might include a very low participation rate (or a high refulsal rate), an all-volunteer sample (as 
opposed to a convenience sample selected by the investigators), an inappropirate control or 
comparison group, or extremely restricted sampling inappropriate fo r measuring the effectiveness 
o f the intervention being studied.
III. DATA PROCESSING 
Access and Confidentiality
1) Is there any indication o f any o f the authors being involved with the running o f the database or registry?
I f  there is no indication of any organisational or personal involvement, answer “ no” . Such 
indications may appear in the addresses and affiliations of authors or references to the database or 
registry. I f  operations of the database are narrated in the first person (“we” ), assume that there was 
involvement.
2) Is there any indication that a Research Ethics Committee or Instituational Review Board or similar body has 
approved the research study?
In  case of GPKD studies answer “ yes” ; these studies are approved by a specific ethics committee.
3) Is there any indication that patients have given informed consent to the research study?
I f  consent is mentioned, answer “ yes” .
4) Are individuals’ data records identifiable through a code or record ID  number (regardless of whether the 
researchers can decode the information or not)?
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For longitudinal data sources, answer “ yes” .
5) Ate any safeguards on confidentiality or data protection reported?
Examples are any references to measures in order to comply w ith relevant regulations, 
references to data security and protection o f patient identity.
Routine data collection and processing procedures
6) Is any routine data validation o f variables reported?
Any checking procedures applied routinely to  the data, e.g. checks fo r consistency, 
completeness, etc.
7) Is any routine testing o f reliability ofmeasurments reported?
8) Has any verification against alternative sources o f data been reported on any data in the database or registry 
(cither fo r  the current or previous studies)?
Alternative sources of data maybe other databases, patient records, etc.
9) Does or did routine processing include manual copying/entry o f data?
Routine processing here means the procedures involved in gathering and maintaining the data 
fo r/in  the database or registry, not extracting or processing them fo r the study.
10) Number of centres involved in the database/registry:
10) Are centre variations in clinical or reporting practices likely?
Answer “ yes” , if there is no comment on standardised reporting procedures or if treatment 
choice is not influenced centrally but entirely dependent on local clinicians.
Specify which differences may exist.
Assessment of data quality including validation
11) Does the paper report that the included data have been assessed fo r consistency, accuracy, and completeness 
(either by database operators or researchers)?
12) Do the resectnhers report Ixizing undertaken any assessment c f data quality?
Individual variables
14) - 16)
D irectly measured means not having been derived through assumptions involving other 
variables, e.g. exacerbations have been recorded as such, rather than derived from  temperature 
readings and culture tests.
17) I f  "no" to any of the previous three questions, have all used algorithms been validated?
Testing o f algorithms may involve validation against other sources o f information.
IV. ANALYSIS
1) Arc estimates of the random variability o f the main ou tcom es clearly described fo r each group ofpatients to 
be compared?
In  non-parametric data the interquartile range o f results should be reported In  parametric data
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the standard error, standard deviation, or confidence intervals should be reported. For binary 
outcomes, confidence intervals should be reported fo r each group. For case-control studies, 
confidence intervals should be reported fo r the proportions of cases and controls who are exposed.
2) Check “ yes” , "no” , or “ not applicable”  fo r each of the following:
D id  the authors conduct appropriate analysis by
Conducting statistical testing (when appropriate)?
Reporting which statistical tests were used?
Controlling fo r design effects in the statistical model?
Examples:
The study population w is sampled using conplex stratified sampling, haimer, the authors did not control 
For the sampling method in  the analysis.
The answer should be ‘'no”  i f  the study had a matched desist but an unmatched analysis.
Controlling fo r repeated measures in the analysis, fo r study designs in which the same population 
was followed w ith repeated measurements over time?
Accounting fo r different levels of exposure in segments o f the study population in the analysis?
I f  the authors analysed group-level and individual-level covariates in the same statistical model, was 
the model designed to handle multi-level data?
Where centre differences may Impinge on analysed variables, did the analysis use multi-level 
methods?
M issing or incomplete data
3) H aw  patients w th incomplete data been excluded?
4) Haw statistical adjustments been used fo r missing data?
Multi-level data
5) Haw any measures o f the owrall adequacy o f the statistical model been -reported (e.g. R2 in multiple 
regression analyses)?
6) Have any sensitivity analyses been performed?
Sensitivity analyses of impact o f methodological decisions such as criteria fo r selection of 
patients, treatment patterns, or diagnosis proxy variables.
V. REPORTING
1) Was the study population (i.e. the intervention and comparison population) well described?
The study population should be described by time (e.g., when the study population received the 
intervention), place, and person. Information about “person”  should include at least age (for all 
studies) and should include other relevant characteristics of participants that are key to a particular 
study (e.g., SES, gender, other). Important potential confounding factors should also be described.
2) Was the intervention well described?
The intervention should be described in terms of what was done, how it was delivered, who was 
targeted, and where it was done.
3) Haw  the numbers o f patients lost to fdlaw up been described?
Loss to follow-up should be interpreted as “ refusal to  take part by eligible subjects”  fo r case- 
control and retrospective cohort studies.
4) Was a poiw r calculation-reported or a t least mentioned?
5) Are the main findings o f the study clearly described?
Simple outcome data (including denominators and numerators) should be reported fo r all major
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findings so that the reader can check the major analyses and conclusions. (This question does not 
cover statistical tests, which are considered above).
6) Hate any explicit considerations cfaltematke explanations o f the findng beenpmerted*
7) A tv  conclusions gang beyond capabilities c f the database or study desigi
460 Use of Databases in Drug Effectiveness Studies
Appendix C
Quality of ESDs included as case studies
The quality assessment form for ESDs could not be used on Eggleston et ai. 
1996, because the published abstract contained very limited information on 
which to base the assessment. Specific issues which may impinge on the 
validity of this study, beyond those common to ESDs, are:
1. There is no indication of how far back records have been checked for 
previous diagnoses of GORD;
2. Random sampling has been undertaken before study eligibility has been 
assessed; this restricts the sample size unnecessarily;
3. Outcome assessment is based on GORD treatment variables (assessment 
of “relapse” after 6 months is not defined).
The results of the quality assessment of the other ESDs are presented in Table 
C.2 below.
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Table C.2: Quality assessment of ESDs (except Eggleston)
McDOUGALL SEBALDT TIEFEN-
BRUNN
VAN
STAA
1, INTERNAL VALIDITY
1 ) Was the exposure /  intervention variable:
Valid No No No Possibl
Reliable (consistent and reproducible)?
2) Were the outcome and other independent (or predictor) 
variables:
No No No No
Valid No No Some Yes
Reliable (consistent and reproducible)? No Yes,
calibrated
regularly
No No
3) Were outcome assessors aware of the study objectives? No Unsure Probably
not
No
4) Were those administering or prescribing treatment aware of the 
study objectives?
No Unsure No No
5) In case-control studies, has the disease state of cases been 
reliably assessed and validated?
N/a N/a N/a N/a
6) Was the duration of follow-up the same for all groups being 
compared?
No? Yes Yes Yes
7) Proportion of patients in intervention group lost to follow-up 
(prospective study) or excluded from analysis (retrospective study) 
is <5%.
No Yes No Yes
8) Proportion of patients in control group lost to follow-up 
(prospective study) or excluded from analysis (retrospective study) 
is <5%.
No (Complete 
follow-up 
only for one 
of the 
outcomes)
No Yes
9) If substantial losses occurred (i.e. >5%) was a comparison made N/a 
of the characteristics of those lost to follow-up and those followed 
up?
10) Are patients in the study group naïve to the drug or free of use Yes 
for a significant time span before the treatment period in 
question?
N/a N/a No
Not Not 
reported, but reported, 
most likely but most 
likely
Unsure
11 ) Did the authors assess whether the units of analyses were 
comparable prior to exposure to the intervention?
Yes Yes Yes Yes
12) Did the authors correct for controllable variables or institute 
study procedures to limit bias appropriately (e.g., randomisation, 
restriction, matching, stratification, or statistical adjustment)?
Yes No (BMD 
baseline 
differences 
not adjusted 
for)
Yes Yes
13) Did the authors identify and discuss potential biases or 
unmeasured/contextual confounders that may account for or 
influence the observed results?
Yes No Yes Yes
14) If yes, did they explicitly state how they assessed these 
potential confounders and biases?
Yes N/a Yes Yes
15) List biases /  confounders not identified and discussed by 
authors:
N/a Gender 
differences 
not tested; 
attrition in
Centre Dose an 
difference duratior 
s not of 
accounted treatme
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McDOUGALL SEBALDT TIEFEN- VAN
BRUNN STAA
controls not for; t not
explained or taken
tested; into
single-centre account
study - not
clear who
assessed
outcomes
and knew
about study
objectives.
II. EXTERNAL VALIDITY
Representativeness and Applicability
1) Did the authors clearly describe the data source from where the Yes 
study population was drawn?
2) Did the authors clearly define the screening criteria for study 
eligibility?
No
3) What proportion of subjects in the database was ineligible to 
participate?
4) What proportion of subjects who were eligible was excluded 
from the analysis?
5) Were the staff, places, and facilities where the patients were 
treated, representative of the treatment the majority of patients 
receive? (0 - 0.25 - 0.5 - 0.75 - 1)
6) Is it likely that patients also receive relevant care from 
alternative sources?
Unclear
Unclear
0.5
Unknown
7) Was the population that served as the unit of analysis the entire Unclear 
eligible population or a probability sample at the point of 
observations?
8) Were the patients in different intervention groups (trials and 
cohort studies) or the cases and controls (case-control studies) 
recruited from the same population?
9) Were the patients in the different treatment group (trials and 
cohort studies) or the cases and controls (case-control studies) 
recruited over the same period of time?
10) Are there other selection bias issues not otherwise addressed? N/a
Yes
No
No, but there No, but Yes 
is a there is a
reference reference 
No: exclusion Yes Yes
criteria not 
clear (e.g. 
which drugs 
were
permitted?); 
unclear what 
is
"ambulatory"
Unknown Unknown 99.5%
Apparently
0%
Apparently All
0%
Unknown Unknown
etidronat 
e takers 
should be 
included 
Yes
Unknown
Yes
No Unknown
(inpatient
data only)
Yes Yes
Yes
Unsure
Yes
Yes
Timing is not N/a 
addressed; 
control 
patients 
seem to be
Yes
Yes
N/a
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McDOUGALL SEBALDT
largely 
refusers of 
etidronate
TIEFEN-
BRUNN
VAN
STAA
DATA PROCESSING
Access and Confidentiality
1 ) Is there any indication of any of the authors being involved with Yes 
the running of the database or registry?
2) Is there any indication that a Research Ethics Committee or 
Institutional Review Board or similar body has approved the 
research study?
3) Is there any indication that patients have given informed 
consent to the research study?
4) Are individuals' data records identifiable through a code or 
record ID number (regardless of whether the researchers can 
decode the information or not)?
5) Are any safeguards on confidentiality or data protection 
reported?
No
No
Yes
No
No
No
No
No
Not
No
(Yes)
No
Most likely, Most likely, t Yes
since this is since this is necessarily
single-centre single-centre
No No No
Routine data collection and processing procedures
6) Is any routine data validation reported? No
7) Has any verification against alternative sources of data been No 
reported on any data in the database or registry (either for the 
current or previous studies)?
8) Does or did routine processing include manual copying /  entry ofMost likely 
data?
9) Is the aim of the database or registry congruous with the aim of Yes 
the study?
10) Number of centres involved in database /  registry: 1
11 ) Are centre variations in clinical or reporting practices likely? N/a
Assessment of data quality including validation
12) Does the paper report that the included data have been No 
assessed for consistency, accuracy, and completeness (either by 
database operators or researchers)?
13) Do the researchers report having undertaken any assessment of No 
data quality?
No
No
Unsure
Yes
1
N/a
No
No
No
No
Unsure
Unsure
No
No
No
Yes
Yes
Unsure
No
Unknown 550 
Yes Yes
No
No
Individual variables
14) Are the inclusion and exclusion criteria directly measured in Yes 
the database or registry or any linked data source?
15) Are the main outcome and exposure /  intervention of interest Yes 
directly measured in the database or registry or any linked data 
source?
16) Are the identified predictors and confounders directly Yes 
measured in the database or registry or any linked data source?
17) If "no" to any of the previous three questions, have all used N/a 
algorithms been validated?
Yes
Yes
Yes
N/a
Yes
Yes
Yes
N/a
Yes
Yes
Yes
N/a
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McDOUGALL SEBALDT TIEFEN- VAN
BRUNN STAA
IV. ANALYSIS
1) Are estimates of the random variability of the main outcomes No Yes Yes No
clearly described for each group of patients to be compared? 
2) Did the authors conduct appropriate statistical testing by: 
i) Conducting statistical testing (when appropriate)? Yes Yes Yes Yes
ii) Reporting which statistical tests were used? Yes Yes Yes Yes
iii) Controlling for design effects in the statistical model? Yes Yes N/a Matching
iv) Controlling for repeated measures in populations that were No No N/a No
followed over time?
v) Controlling for differential exposure to the intervention (or No Yes No Partly
checking that it makes no difference)?
vi) Using a model designed to handle multi-level data when theyN/a N/a N/a N/a
included group-level and individual covariates in the model? 
vii) Allowing for important centre differences in the analysis? N/a N/a No No
Missing or incomplete data
3) Have patients with incomplete data been excluded? Yes No exclusions No No
4) Have statistical adjustments been used for missing data? No
reported
Unsure
exclusions
reported
No
exclusion
s
reported
No
Multi-level data
5) Have any measures of the overall adequacy of the statistical N/a N/a Yes No
model been reported?
6) Have any sensitivity analyses been performed? Yes No No Yes
V. REPORTING
1) Was the study population well described? Yes No Yes Yes
2) Was the intervention well described (what, how, who, where, No Yes No No
how long/much)?
3) Have the numbers of patients lost to follow-up been described? Yes Yes N/a Yes
4) Was a power calculation reported? No No No No
5) Are the main findings of the study clearly described? Yes Yes Yes CIs
6) Have any explicit considerations of alternative explanations of No No Yes
missing
Yes
the findings been presented?
7) Are conclusions going beyond capabilities of the database or No Unsure No No
study design?
Use of Databases in Drug Effectiveness Studies 465
DATA EXTRACTION FORM
VERSION 13 Jan. 03 
including alterations following pilot
Study ID
Reviewer:
Date:
PART 1 : GENERAL INFORMATION
First author: 
publication cr report:
Year of
Title of publication or report:
Source of information: Journal article
Published or conference abstrac 
Unpublished study
Detailed source (Journal, Conference, including detailed reference to 
source):
Affiliation (of first author) and contact address:
Countries participating:
Number of centres contributing data: 
Stated main aim of the study:
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PART 2: PATIENT CHARACTERISTICS and SETTING
POPULATION CHARACTERISTICS
2.1 Source population and study setting (for each group):
2.2 Calendar years during which data included in study was collected:
STUDY SAMPLE
2.2 Specific study inclusion criteria: 
Gender:
Age:
Others:
2.3 Specific study exclusion criteria: 
Gender: Age:
Others:
2.4 Specific treatment and control conditions, including planned daily dose 
(mg):
Treatment group A
Treatment group B
Treatment group C
Treatment group D
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2.5 Specific characteristics of sample at baseline:
Treatment 
group A
Treatment 
group B
Treatment 
group C
TOTAL Significant
difference?
*
Number recruited:
Male/Female
numbers:
Mean (SD)/ median 
(range)** age in years:
Other characteristics 
reported:
* if “yes”, record p-value ** underline which is entered
2.6 Duration of follow-up reported
Planned (RCT only)
Mean (SD)
Median (range)
Minimum
Maximum
PART 3: INTERVENTION / "EXPOSURE”
3.1 Actual daily dose of drug, if different from planned regimen (in mg):
Treatment group A Treatment group B Treatment group
3.2 Duration of drug treatment (observational studies only):
Treatment group A Treatment group B Treatment group
Mean (±SE/SD)
Median (range)
Minimum
Maximum
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3.3 Continuity of treatment and compliance:
YES NO UNCLEAR N/A
Are ALL patients in all groups treated 
continuously?
Has compliance with treatment been 
assessed?
PART 4: OUTCOME MEASURES
Which outcome measures are available?
Outcome measures: HOW measured?
(definition of measure, 
instruments, person 
taking it, validity and 
reliability information)
WHEN measured? Same in 
all
groups?
At
baseline?
Post-baseline 
measurements 
(in weeks):
PRIMARY OUTCOME:
OTHER OUTCOMES:
PART 5: ANALYSIS
YES NO UNCLEAR N/A
5.1 Intention to treat analysis used?
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5.2 Number of patients included in study and excluded from analysis in each 
group: __________ ________________________________ _____________
Treatment 
group A
Treatment 
group B
Treatment
group
TOTAL
No. %
Included at 
beginning of study:
100%
Drop-outs before
follow-up
measurements
Number of patients 
at final assessment
5.3 How is attrition dealt with in the analysis?
5.4 Reported reasons for dropouts
List in order of priority:
Treatment group A Treatment group B Treatment group
5.5 Main analysis methods
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5.6 Variables controlled for in analysis:
Primary outcome analysis:
Variables controlled for: How was variable 
identified for 
control?*
Method of control:**
* e.g. bi-variate analysis, literature review, etc.
** e.g. restriction, randomisation, stratification, matching, multivariate 
analysis
Other outcome analysis:
Variables controlled for: How was variable 
identified for 
control?*
Method of control:**
* e.g. bi-variate analysis, literature review, etc.
** e.g. restriction, randomisation, stratification, matching, multivariate 
analysis
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PART 6: RESULTS
THIS ENTIRE SECTION HAD TO BE ALTERED SIGNIFICANTLY TO ACCOMMODATE 
SIMPLY THE OUTCOMES REPORTED IN A SPECIFIC OBSERVATIONAL STUDY - 
DIFFERENT FOR EACH CASE STUDY!
6.1 Mean (SD)* dose of corticosteroid use during study (mg):
Treatment group A Treatment group B Treatment group
‘ indicate if other measure is reported (e.g. median
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6.2 Lumbar spine bone mineral density
YEARS FROM BASELINE:
Group A Group B P-
value:
Difference between groups:
P-
value:
Mean(SD/SE)* 
percentage 
change from 
baseline
Mean ±SD
Other:
Mean (SD/SE)* 
absolute 
change from 
baseline 
(8/cm2)
YEARS FROM BASELINE:
Group Group P-
value:
Difference between groups:
P-
value:
Mean(SD/SE)* 
percentage 
change from 
baseline
Mean±SD
Other:
Mean (SD/SE)* 
absolute 
change from 
baseline 
(8/cm2)
YEARS FROM BASELINE:
Group Group P-
value:
Difference between groups:
P-
value:
Mean (SD/SE)* 
percentage 
change from 
baseline
Mean ±SD
Other:
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Mean (SD/SE)* 
absolute 
change from 
baseline
(g/cm2)_______ |_________ [
"underline which is reported
6.3 Femoral neck bone mineral density
YEARS FROM BASELINE:
Group A Group B P-
value:
Difference between groups:
P-
value:
Mean (SD/SE)* 
percentage 
change from 
baseline
Mean ± SD
Other:
Mean (SD/SE)* 
absolute 
change from 
baseline 
(g/cm2)
YEARS FROM BASELINE:
Group Group P-
value:
Difference between groups:
P-
value:
Mean(SDZSE)* 
percentage 
change from 
baseline
Mean ± SD
Other:
Mean (SD/SE)* 
absolute 
change from 
baseline 
(g/cm2)
YEARS FROM BASELINE:
Group Group P-
value:
Difference between groups:
P-
value:
/ccrx*.... Mean ± SD
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percentage 
change from 
baseline
Other:
Mean (SD/SE)* 
absolute 
change from 
baseline 
(g/cm2)
•underline which is reported
6.4 Trochanter bone mineral density
YEARS FROM BASELINE:
Group A Group B P-
value:
Difference between groups:
P-
value:
Mean (SD/SE)* 
percentage 
change from 
baseline
Mean±SD
Other:
Mean (SD/SE)* 
absolute 
change from 
baseline 
(g/cm2)
YEARS FROM BASELINE:
Group Group P-
value:
Difference between groups:
P-
value:
Mean (SD/SE)* 
percentage 
change from 
baseline
Mean±SD
Other:
Mean (SD/SE)* 
absolute 
change from 
baseline 
(g/cm2)
YEARS FROM BASELINE:
Group Group P-
value:
Difference between groups:
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P-
value:
Mean(SDZSE)* 
percentage 
change from 
baseline
Mean ± SD
Other:
Mean (SD/SE)* 
absolute 
change from 
baseline 
(g/cm2)
•underline which is reported
6.6 Fractures
YEARS FROM BASELINE:
Group A Group B P-
value:
Difference between groups:
Number of 
patients (%) 
experiencin 
g fractures
P-
value:
Relative risk±Cl
Odds ratio±CI
Mean (SD/SE)* 
number of 
fractures per 
patient
Mean ± SD
Other:
YEARS FROM BASELINE:
Group A Group B P-
value:
Difference between groups:
Number of 
patients (%) 
experiencin 
g fractures
P-
value:
Relative risk±CI
Odds ratio±CI
Mean (SD/SE)* 
number of 
fractures per 
patient
Mean ± SD
Other:
YEARS FROM BASELINE:
Group A Group B P-
value:
Difference between groups:
Number of 
patients (%)
P-
value:
Relative risk±CI
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experiencin 
g fractures
Odds ratio±CI
Mean (SD/SE)* 
number of 
fractures per 
patient
Mean ±SD
Other:
"underline whichever 
NOTES
is reported
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